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Abstract 
Consumption of flavanones has been associated with a reduction in risk of 
developing CVD, however flavanone bioavailability varies greatly in the population. 
The thesis aim was to investigate variations in absorption, as assessed by urinary 
excretion and, for the first time, the effect of commercially-available citrus supplements 
on CVD risk biomarkers.  
In study 1, 15 participants consumed orange juice (OJ; 500 ml: 8 mg naringenin, 42 
mg hesperidin/100 ml) and/or soya-nuts (25g): 30 mg daidzein, 57 mg genistein/100 g). 
Urine was collected at 0, 0-4, 4-8, 8-12, 12-24 and 24-36 hr on each of three separate 
occasions; saliva was collected hourly (0-8 and 24 hr) after co-ingestion of OJ and soya-
nuts. Daidzein was excreted to a greater extent than genistein (27-28% of dose ingested 
compared to 16-19%), whilst naringenin was excreted to a greater extent than hesperetin 
(9% vs 2.5-3%). There was a strong positive correlation between excretion of daidzein 
and genistein (r=0.72, p<0.01), and for hesperetin and naringenin (r=0.72, p< 0.01). 
Moreover, the amount of naringenin, and daidzein or genistein were correlated when co-
ingested (r=0.73, p<0.01; r=0.49, p=0.05). No flavonoid was detected in saliva at any 
time point. 
In study 2, 23 overweight participants ingested citrus supplements (114 mg 
hesperidin) or a placebo daily for 28 days in a randomised, cross-over intervention. 
Urinary excretion (24 hr) was analysed by LC-MS to determine flavanone metabolite 
concentration at day-1 or day-28. Hesperetin-3ʹ-O-glucuronide, hesperetin-3ʹ-O-sulfate 
and hesperetin-7-O-glucuronide were quantified. Supplement flavanones had similar 
bioavailability to OJ, and there was no cumulative increase in excretion over 28 days. 
There was a non-significant decrease in blood pressure and fasting blood glucose after 
supplementation compared to placebo, however pulse amplitude tonometry was not 
affected. Augmentation index was reduced after supplementation compared to baseline. 
v 
 
Although results from this thesis showed no significant change in CVD risk biomarkers, 
more work should verify the protective mechanism of hesperetin metabolites at different 
doses on vascular health. 
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Chapter 1: Introduction and Background 
1.1 Introduction 
Flavonoids are naturally occurring phytochemicals or secondary metabolites 
from plants. They are absorbed from food, metabolised, circulate in the bloodstream, 
and are excreted in the urine. Epidemiological studies have suggested that high intake of 
fruit; vegetables and particularly soy food reduce the risk of chronic diseases such as 
cardiovascular diseases and cancers. The gut microflora plays a significant role in the 
metabolism and absorption of some flavonoids. This role leads to a large inter-individual 
variation in the amount absorbed and excreted in urine.  
Cardiovascular disease (CVD) is the leading cause of deaths in the Western 
world. Established risk factors include high LDL cholesterol, high blood pressure and 
diabetes. Poor blood vessel health is considered a predictor of future CVD risk, but can 
be reversed. Several different measurements can be used to determine blood vessel 
health; such as blood pressure (BP), and newer techniques which measure blood flow 
through the arteries after a blood pressure cuff restricts blood flow for a few minutes in 
one arm. 
Literature review aimed to focus on the importance of bioavailability of the 
flavonoids flavanone and isoflavone and the effect of diet rich in flavanone in 
cardiovascular disease (CVD) risk. The research strategy focused on using the 
University of Leeds library system, Web of Science, Medline and EMBASE (both on 
Ovid.com), google scholar and PubMed database were searched between July 2010 and 
December 2014. The following search words were used: studies that investigated the 
bioavailability of flavanone and isoflavone their absorption and excretion OR the effect 
of food matrix and dose ingested. Biological samples were used to investigate the 
bioavailability absorption and excretions in (plasma, urine and saliva) were included. 
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Moreover, an advance search was carried out in the Phenol-Explorer database 
(http://phenol-explorer.eu/content) to retrieve mean content values for flavanone and 
isoflavone contained in orange juice and soya nut. The flavonoid content in the orange 
juice, soya nut and citrus supplement was considered as the mean after the experimental 
food samples were analyzed using HPLC.  
Studies investigated the impact of orange juice and citrus fruit on CVD risk factors 
were included. The studies were included only if they were randomized (with either a 
parallel or crossover design); had flavonoid intervention, recruited healthy and 
overweight adults participants. We focused our primary outcomes on risk factors that 
have strong relationship with CVD eg. systolic and diastolic blood pressure. As 
endothelial function is measured as flow-mediated dilation (FMD), and Endo-PAT , 
which are the predictor of CVD events and which correlate with the CVD risk factors 
such as blood glucose as secondary outcome. All languages were included in the search, 
however only papers with English abstracts were used for the review. Non-English 
language articles were translated when possible.  
The chapter will begin by introducing flavonoids classification, structural 
characteristics, dietary intake of flavonoids and their major food sources. Then, the 
absorption and metabolism of flavonoids and factors affecting their bioavailability was 
highlighted. One aim of the thesis was to investigate the the impact of citrus flavanones 
on cardiovascular risk factors, therefore search about endothelial cell function and blood 
flow related to dietary flavanones was conducted.  
1.2 Overview of flavonoids   
Polyphenols are the products of secondary metabolism of plants. They are 
compounds that can be widely found in high amounts in foods such as; fruits, 
vegetables, tea, cocoa, soya, wine (Nielsen et al., 2002, Ito et al., 2005) and nuts (Loke 
et al., 2009), dry legumes and cereals (Han et al., 2007). Polyphenols are available in 
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dietary sources predominantly as two main classes, phenolic acids and flavonoids 
(Crozier et al., 2009, Manach et al., 2004). The focus of this thesis is on flavonoids, 
which can be further sub-divided into different classes based on the structure groups 
around the phenolic rings (Crozier et al., 2009).  Flavonoids have a structure that 
consists of two phenolic rings A and B bound together with an oxygenated heterocycle 
ring C, with several hydroxyl groups attached to any/all of the rings. The basic structure 
is the flavonoid skeleton figure 1.1.  
 
Figure 1.1: Chemical structure of the basic flavonoid structure. The rings A, B and C 
may have hydroxyl groups substitutions at any of the numbered positions, see table 1.1 
for examples. 
 
 
The division is dependent on what their molecular structure and substitution to 
functional groups in ring A and B. These can provide different sub-classes, such as 
flavonols, flavones, isoflavones, flavanones, anthocyanidins, flavanols and 
proanthocyanidins. 
The majority of flavonoids occur naturally as glycosides rather than aglycones 
(Del Rio et al., 2013). There are over 9000 different flavonoids (Thilakarathna and 
Rupasinghe 2013) as a result of the combination between the flavonoid aglycones and 
monosaccharides. The most common monosaccharides are D-glucose and L-rhamnose 
which bind the different hydroxyl groups of the flavonoid aglycones. The glycosides are 
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usually O-glycosides, which bind to the sugar moiety at the C-3 or C-7 position (Erlund, 
2004). 
Table 1.1 shows the structure of the major classes of flavonoids and respective 
common dietary sources. Flavones, such as apigenin occur at high levels in parsley and 
celery (Linseisen and Rohrmann 2007). The richest source of flavonols in the diet is 
onion, which contains quercetin up to 1.2 g/kg fresh weight. Flavonols are also found in 
tea, which is an excellent source of flavanols/catechins found to be as high as 45 mg/L 
(Manach et al., 2004). Moreover, high amounts of catechins are found in many kinds of 
plant-based foods, such as dark chocolate: 41.5 mg of (-) epicatechin and 11.9 mg of (+) 
catechin per 100g and red wine: up to 300 mg/L (Manach et al., 2004). Anthocyanins 
are the coloured pigments rich in berry fruits and red wine. 
The sub-class of flavanones, which lack a double bond from position C2-3 in the 
C ring, are found almost exclusively in citrus fruits. The concentration of flavanones in 
the juice of these fruits can reach several hundred milligrams on a per-litre basis 
(Tomás‐Barberán and Clifford, 2000). Orange juice is reported to contain between 200 
and 600 mg hesperidin/L and 15–85 mg narirutin/L. The main flavonoids in orange and 
mandarins come from hesperidin (hesperetin-7-rutinoside) and narirutin (naringenin-7-
rutinoside). On the other hand, the main flavanone in grapefruit is naringin (naringenin-
7-neohesperoside) with lower amounts of narirutin (Kawaii et al., 1999). Naringenin is 
also found in low levels in other fruits such as tomatoes and other tomato-based 
products. With regards to tomatoes as a specific example, naringenin chalcone can also 
be found particularly within the skin of the tomato, but during the processing from fruit 
to tomato ketchup this is converted into naringenin (Krause and Galensa, 1991).  
Legumes and specifically soy foods are the main source of the isoflavone sub-
class. Isoflavones have the B-ring attached at position C3 on the C-ring, instead of C2 as 
with all the other flavonoid classes. Daidzein and genistein are the main isoflavones in 
soya products. The amounts of isoflavones contained in soybeans and their products is 
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estimated between 580 – 3800 mg/kg fresh weight, with lower amounts, between 30 – 
175 mg/L, found in soymilk (Manach et al., 2004).  
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Table 1.1: Classification and sources of some dietary flavonoids 
Flavonoids 
subclasses 
Dietary 
flavonoids 
 
Chemical structure 
Source (example) 
Flavanones naringenin 
eriodictyol 
hesperetin  
citrus fruits and juices (e.g. 
orange, grapefruit, lemon), 
peppermint 
Isoflavones 
(Flavans) 
genistein 
daidzein 
 
soyabean and soya 
products 
 
Flavonols 
myricetin, 
querecetin, 
kaempferol, 
isorhamnetin 
 
onions, tomatoes, tea 
(green, black), broccoli, 
apple 
Flavones 
 
 
apigenin 
luteolin 
 
celery, peppers, parsley, 
herbal tea 
Flavanols 
(Flavan-3-ols) 
catechin, 
epicatechin, 
 
red wine, tea (green), 
chocolate (dark, milk), 
cocoa, apples 
5
7
3'
4'
5'
O
R
O
OR
RO
R
R
O
R
OH
OH
5
7
3'
4'
5'
OH
O
R
O
OR
RO
R
R
5
7
3'
4'
5'
O
R
O
OR
RO
R
R
5
7
3'
4'
5'
R
O
OH
OR
RO
R
R
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Anthocyanidins cyanidin, 
malvidin 
 
cherry, red grapes, 
blueberries, red wine, 
strawberries 
Phenolic acids caffeic acid 
chlorogenic 
acid 
 
blueberry, cranberry, 
orange, apple, lettuce, 
spinach, coffee, tea, coffee 
Adapted from  (Pérez-Jiménez et a., 2010a) and (Crozier et al., 2009). 
 
1.3 Flavonoid intake 
It has been estimated that in developed countries an average of 1-2 g/day of 
polyphenols may be consumed, largely provided from fruit and beverages such as tea, 
wine, coffee and fruit juices (Rothwell et al., 2012). This level of dietary intake is much 
higher than the intake of vitamin C, E and other antioxidant compounds (Scalbert and 
Williamson, 2000, Jan et al., 2010). The average intake of flavonoids appears to be 
between 65 – 250 mg/d (Manach et al., 2004). In the US, the daily intake of flavonoids 
between 1999-2002 was calculated at 189 mg/d, and flavan-3-ols constituted the 
majority of this amount (Forester and Waterhouse, 2009). The intake of flavonols ranged 
from 13 – 64 mg/d in Germany; the flavone intakes were lower at 1-2 mg/d (Erdman et 
al., 2007). A study in France reported that a total of 337 polyphenols were consumed 
including 258 polyphenols consumed by at least one half of the subjects and 98 
polyphenols consumed in an amount > 1mg/d. Intake of individual polyphenols 
consumed were determined and the mean total of polyphenol intake was 1193 ± 510 
mg/d or 820 ± 335 mg/d expressed as aglycone equivalents. Flavanone intake was 26 ± 
29 mg/d mainly from oranges and orange juice (Pérez-Jiménez et al., 2011). 
5
7
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O
+
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RO
R
R
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Food frequency questionnaire (FFQ) is one of the common methods used to estimate 
flavonoid intake of the population (Tresserra-Rimbau et al., 2013). For example, an FFQ 
was used in a large cohort study carried out in Greece to estimate the polyphenol content 
of foods consumed by adults. It was suggested that the intake of polyphenol came 
mainly from the common diet such as olive oil, vegetables and wine that constitute the 
main diet in the Mediterranean basin (Dilis and Trichopoulou, 2010).  
It is very difficult to accurately measure the amount of flavonoid intake. This is 
due to the huge structural diversity in flavonoid classification and to the variation in 
content within foods. Moreover, the differences in content within similar food items 
results from the differences in growing environment, growing stage, storage, processing 
condition and the lack of standardised controlled analytical methods (Scalbert and 
Williamson, 2000). 
The dietary intake of flavonoids is often estimated using the USDA flavonoids 
database or Phenol-Explorer database. Phenol-Explorer database holds data on 502 
polyphenols contained in 452 foods and it has been developed and updated to be the 
most complete database currently available (Pérez-Jiménez et al., 2011, Tresserra-
Rimbau et al., 2013) .  
A large cohort study was conducted in 23 centres throughout 10 European 
countries. The aim of the project was to compare the total flavonoid dietary intakes 
between Mediterranean (MED) and non-MED countries participating in the European 
Prospective Investigation into Cancer and Nutrition (EPIC) study. The results showed no 
significant differences between MED countries (370.2 mg/d) and non-MED countries 
(373.7 mg/d) in the total mean flavonoid intake. However, the main differences were in 
flavonoid class intakes and food sources. The main contributors in the non-MED 
countries were proanthocyanidins (48%) and flavan-3-ol (24.9%), and the main food 
sources were tea (25.7%) and fruits (32.8%); in the MED countries the most abundant 
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contributor was proanthocyanidins (59%) and fruits, wine, and tea were the main food 
sources (55%), (16.7%) and (6.8%), respectively (Zamora-Ros et al., 2013). 
Beking and Vieira (2011) relied on data from the international FAO Food 
Balance Sheets (FBS) to report the flavonoid intake among the populations of the UK 
and Republic of Ireland. Twenty-three flavonoids from five groups (anthocyanidins, 
flavonols, flavanols, flavanones, and flavones) were analysed. The results showed that 
the daily flavonoid intake (all five groups) was 182 mg and 177 mg for the UK and 
Ireland, respectively. In both cases, anthocyanidins and flavanols were the highest 
contributor for about 65% of total consumption. Combined intake of flavones, 
flavanones, and flavonols was 60 mg/day in the UK and 69 mg/day in Ireland (Beking 
and Vieira, 2011).  
A study in China evaluated the intake of soya food and soya isoflavones. FFQ 
was the main tool in this study which recruited 1188 subjects. Results of the study 
revealed that the intake of soya isoflavones by Chinese rural adult women was much 
higher compared to women in western countries (Liu et al., 2004). The dietary intake of 
soya foods and isoflavones in the UK diet was <1 mg for both men and women 
(Mulligan et al., 2006). However, in soya consumers daily intake was higher at 8.6 mg, 
7.5 mg in women and men, respectively. Bread and bread rolls were the main source for 
the intake (62.5% and 53%, respectively). 
Data in table 1.2 shows the variation in the consumption and intake of flavonoids 
among different countries. This variation was explained by Scalbert and Williamson 
(2000) as the result of the dietary habits and preferences of the population involved in 
the study, as well as the differences in estimation from FFQ and database information.  
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1.4 Bioavailability of dietary flavonoids  
1.4.1 Absorption and metabolism of flavonoids 
Bioavailability has numerous definitions depending on the field of study. The 
most suitable one used in nutritional studies is “the fraction of the consumed ingredient 
that appears in the blood circulation” (Erdman et al., 2007). The process of 
bioavailability is complicated as it includes ingestion, absorption, metabolism and 
excretion (Thilakarathna and Rupasinghe, 2013). The capability of flavonoids to be 
absorbed from the digestive tract depends on certain factors including the food matrix, 
the chemical structure of the flavonoid and the type of the conjugated sugar, which 
affect the rate and extent of small intestinal absorption (Terao et al., 2008), large 
intestinal fermentation and transit time, and dietary habits (Bao and Fenwick 2004, 
Larkin et al., 2008, Thilakarathna and Rupasinghe, 2013). 
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Table 1.2: Estimated daily dietary intake of flavonoids by adults in different countries. 
Population 
Estimated dietary intake 
(mg/d) 
Major food 
source of 
flavonoids 
and PP 
Number of 
subjects and 
age 
References 
Spanish 
Total flavonoids,  443 ± 218 
Total phenolic acids, 304 ± 
156 
Coffee, fruits, 
olives & olive 
oil, oranges 
N= 7200 
55 – 80 y 
(Tresserra-
Rimbau et al., 
2013) 
French 
820 ± 335 aglycone 
equivalents 
Coffee, fruits, 
tea, wine, 
oranges 
N=4942 
45 – 60 y 
(Pérez-
Jiménez et 
al., 2011) 
European 
countries 
Total flavonoids,  
Mediterranean, 370.2 
Non-Mediterranean,  373.7 
Tea , fruits, 
wine 
N=521448 
21 – 83 y 
(Zamora-Ros 
et al., 2013) 
Spanish Total flavonoids,  313 
Apples, red 
wine, fruits, 
oranges 
N=40683 
35 – 64 y 
(Zamora-Ros 
et al., 2010) 
Greek 
Total flavonoids   ̴92 
Flavanones, 27, isoflavones, 
< 1 
Onion, citrus 
fruits, apples, 
tea, wine 
N=28572 
51y for men, 
54y for women 
(Dilis and 
Trichopoulou, 
2010) 
Australian 
Total flavonoids,  454 
Flavanones, 7 
Tea, wine, 
onion, apples, 
oranges 
N=13858 
>18 y 
(Johannot and 
Somerset, 
2006) 
American 
Total flavonoids,  189.7 
Flavanone, 7.6%, Isoflavones 
0.6% 
Tea, wine, 
legumes, 
citrus fruits 
8809 
>19 y 
(Chun et al., 
2007) 
British and 
Irish 
Total flavonoids,   
182 for UK  
177  for  Ireland 
NA NA 
(Beking and 
Vieira, 2011) 
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Hydrolysis and metabolism of flavonoids in the mouth will be limited. Some in 
vitro studies have suggested that some flavonoid glycosides can be hydrolysed by the β-
glucosidase and esterase activity from oral bacteria after incubation with saliva (Yang et 
al.,. 1999, Walle et al., 2005). However the short time they remain in the mouth suggests 
that early absorption is limited. The stomach may contribute to the absorption of some 
flavonoids that could be partly present in diet as aglycone, but not in their relative 
glycoside form (Crespy et al., 2002). Flavonols, isoflavones, flavones and anthocyanins 
are usually found in the glycoside form linked with different sugars such as glucose, 
galactose, arabinose, xylose, rhamnose and glucuronic acid (Scalbert and Williamson, 
2000). 
Flavonoid glycosides will arrive to the small intestine and here hydrolysis, 
absorption and metabolism are more important. The small intestine has a large surface 
and a longer residential time, and there are an abundance of enzymes. Some dietary 
flavonoid glycosides are deglycosylated by lactase phlorizin hydrolyase (LPH) present 
in the brush-border of the small intestine lumen (Day et al., 2000). For example, Day et 
al. (2003) incubated quercetin-3-O-glucoside and quercetin-4ʹ-O-glucoside with an 
inhibitor of SGLT1 and an inhibitor of the lactase domain of LPH using a rat everted-
jejunum model. The results provided evidence that deglycosylation by LPH and 
subsequent diffusion of the aglycone is the major route of absorption for quercetin 
metabolism in vivo (Day et al., 2000). Only glucoside conjugates appear to be 
hydrolysed by LPH (Németh et al., 2003), and these flavonoids will be absorbed in the 
small intestine. 
If the flavonoid is not a substrate of LPH, it will not be absorbed in the small 
intestine, but will continue to the large intestine where it will be deglycosylated by the 
action of microbial enzymes (Hollman, 2004; Thilakarathna and Rupasinghe, 2013). 
Both ways release the aglycone which is hydrophobic enough to pass through the 
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membrane of enterocyte by passive diffusion. The more efficient bioavailability of a 
flavonoid glucoside form was shown compared to the rhamnoglucoside form; 
Bredsdorff et al., (2010) reported that hesperetin and naringenin absorption were 
increased in humans by conversion from rutinoside (the natural form in orange juice) to 
the glucoside after commercial orange juice was treated with an α-rhamnosidase 
enzyme. 
The resulting aglycone will transport across the enterocyte of the small intestine 
or the colon and subsequently reach the liver. Flavonoids will undergo phase II 
metabolism in both the enterocyte and the liver. Aglycones will be metabolized by UDP-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs) and catechol-O-
methyltransferase (COMT; if an available catechol group is present) into, 
glucuronidated, sulfated and methylated metabolites, respectively (Manach et al., 2003, 
Matsumoto et al. 2004, Mullen et al., 2008, Brett et al., 2009,  Brand et al., 2010). These 
metabolites will then be distributed throughout the plasma, and will be excreted either 
through the urine or the bile. Significant amounts can be found in biological fluids such 
as plasma and urine (Matsumoto et al., 2004, Bredsdorff et al., 2010). 
The metabolites that are excreted from the bile can also be hydrolysed again to 
their corresponding aglycone by the action of colon microflora enzymes, setting up 
enterohepatic circulation (Yuan et al., 2007). The aglycone may also undergo further 
hydrolysis by the microflora to phenolic acids (Mullen et al., 2008) which may also be 
absorbed and further conjugated. The absorption and metabolism processes are 
summarised in figure 1.2. 
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Figure 1.2: Metabolism of flavonoid glycosides in vivo. Flavonoids glycosides may be 
hydrolysed by lactase phlorizin hydrolyse (LPH) and the aglycone diffuses into 
enterocyte. Flavonoids which are not absorbed in the small intestinal will be hydrolysed 
by the microflora in the colon and released as aglycone form. 
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1.4.2 Bioavailability studies of flavanones and isoflavones  
Human intervention studies on the flavanones hesperetin and naringenin, and the 
isoflavones daidzein and genistein are the most relevant flavonoids to be discussed in 
this thesis. The level of variability in the bioavailability of different sub-class of 
flavonoids is reported to vary greatly in vivo. The review by Manach et al. (2005) 
summarized the bioavailability of flavonoids on different sub-classes based on the data 
of 97 human studies conducted by that time. The review used several bioavailability 
measures, including the maximal plasma concentration (Cmax), area under the plasma 
concentration time curve (AUC), time to reach Cmax (Tmax), elimination half-life, and 
relative urinary excretion and the data is presented in Table 1.3. Overall the plasma 
concentrations of total metabolites ranged between 0.1-1.5 µmol/L for flavanones, and 
0.4-4.5 µmol/L for isoflavones, after an intake of 50 mg of aglycone equivalent. The 
Tmax was similar for all these compounds, averaging at 5.4 hr. An enormous inter-
individual variation in relative urinary excretion was shown, ranging between 1-30% 
and 7-62% of the ingested dose for flavanones and isoflavones respectively. In a review 
by Perez-Jimenez et al. (2010a) the recovery range for flavanones naringenin and 
hesperetin was 1.4 – 33% and 0.7 – 14%, respectively.  
After orange and grapefruit juice were ingested (8 ml/kg of body weight), the 
concentration of both compounds as aglycones in plasma and urine was measured. The 
relative concentration of these compounds as excreted in the urine was 30 and 1.1% for 
naringenin from grapefruit and orange juice, respectively, and 5.3% for hesperetin from 
orange juice (Erlund et al., 2001). This study shows the food matrix and source of the 
compound is also of importance. Another study was on six healthy participants and they 
ingested 135 mg of hesperetin and naringenin (aglycone) orally. The result showed that 
the concentration in plasma reached a peak 4 and 3.5 hr for hesperetin and naringenin 
respectively. The mean values of relative cumulative urinary excretion as % of ingested 
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dose, were 3.2 ± 0.4 and 5.81 ± 0.8% for hesperetin and naringenin, respectively 
(Kanaze et al., 2006). Therefore there appears to be similarity in absorption and 
excretion behaviour from a non-food source. 
In a cross-over study, 150 and 300 ml of blood orange juice (BOJ) were consumed by 
seven healthy females. The Tmax in plasma was reached in 5.1 hr after BOJ was ingested. 
The Cmax of hesperetin was 43.4 and 79.8 ng/ml after 150 and 300 ml consumed, 
respectively, and for naringenin the Cmax was 16.4 and 34.0 ng/ml respectively (Gardana 
et al., 2007). This shows dose response in the same individuals. 
Data were obtained on hesperidin and narirutin metabolites after ingestion of 0.5 
and 1 L orange juice contain 444 mg/L hesperidin and 96.4 mg/L narirutin. The relative 
urinary excretion was 4.1 and 6.4% for hesperetin after 0.5 and 1L OJ consumed, and 
7.1 and 7.8 % for naringenin as well. The circulating form of hesperetin was 13% 
sulfoglucuronides and 87% glucuronides (Manach et al., 2003).  
The urinary excretion after five different beverages consumed was investigated. 
Commercial orange juice (29.2 – 70.3 mg flavanones/100 ml) was compared to 
experimental orange beverages enhanced by 110.2 mg/100 ml flavanones. The study 
reported that the solubility of the flavanones, particularly hesperidin is the key factor for 
the bioavailability of flavanones. Relative urinary excretion ranged from 0.5-5.4% for 
naringenin and 1.0-8.9% for hesperetin. There was a large inter-individual variation 
observed in the excretion of flavanones compounds. However, this variation was 
consistent for all participants after the consumption of different drinks. This could be 
interpreted by the fact that bioavailability is dependent on the occurrence of microflora 
in the colon of each individual (Vallejo et al., 2010). 
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Table 1.3: Pharmacokinetic data of flavanones and isoflavones from 97 bioavailability studies * 
 
Tmax Cmax AUC Urinary excretion Elimination half-life 
Mean Range Mean Range Mean Range Mean Range Mean Range 
hr µmol/L µmol hr/L % of intake hr 
Daidzin 6.3 ± 0.6 4.0–9.0 1.92 ± 0.25 0.36–3.14 21.4 ±6.5 2.7–38.6 42.3 ± 3.0 21.4–62.0 5.3 ± 0.8 3.4–8.0 
Daidzein 4.9 ± 1.0 3.0–6.6 1.57 ± 0.52 0.76–3.00 12.2 ± 2.9 7.5–17.4 27.5  8.5 ± 0.8 7.7–9.3 
Genistin 6.5 ± 0.6 4.4–9.3 1.84 ± 0.27 0.46–4.04 23.7 ± 6.7 6.2–45.1 15.6 ± 1.8 6.8–29.7 7.8 ± 0.7 5.7–10.1 
Genistein 4.1 ± 0.6 3.0–5.2 2.56 ± 1.00 1.26–4.50 19.8 ± 6.5 10.4–32 8.6  7.1 ± 0.3 6.8–7.5 
Hesperidin 5.5 ± 0.1 5.4–5.8 0.46 ±0.21 0.21–0.87 2.7 ± 0.7 1.9–4.1 8.6 ± 4.0 3–24.4 2.2  
Naringin 5.0 ± 0.2 4.6–5.5 0.50 ± 0.33 0.13–1.50 3.7 ± 1.5 0.9–7.0 8.8 ± 3.17 1.1–30.2 2.1 ± 0.4 1.3–2.7 
*All data were converted to correspond to a supply of 50 mg a glycone equivalent. Tmax, time to reach Cmax AUC, area under 
the plasma concentration-time curve reproduced from (Manach et al., 2005).
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The effect of food matrix on bioavailability and metabolism of flavanones was 
studied after orange juice (250 ml) was given with or without full fat yoghurt (150 ml). 
Pharmacokinetic of orange juice hesperetin–7–O-glucuronide and an unidentified 
hesperetin-o-glucuronide was detected after orange juice was consumed. The 
concentration of the metabolites reached a peak (Cmax) of 924 nmol/L, 4.4 hr (Tmax) after 
orange juice was ingested and has reached a peak (Cmax) 661 nmol/L, and 5.5 hr (Tmax) 
after orange juice with yogurt have been consumed. The level of flavanone metabolites 
excreted 0-5 hr after OJ consumed were significantly decreased by yogurt, however this 
was not true over the full 0-24 hr urine collection period. Excretion of hesperetin as 
percentage of intake was 6.3% without and 6.4% with yogurt. Naringenin excretion was 
17.7% without yogurt combination and 15.7% with yogurt combination (Mullen et al., 
2008). 
The excretion level of phenolic acids was 62 µmol when OJ was ingested, but 
only 6.7 µmol and 9.3 µmol after ingestion of water and yoghurt, respectively. However, 
yogurt has a noticeable impact to slowing of the bulk of the meal reaching the large 
intestine and therefore effecting the excretion of phenolic acids resulting from the 
degradation of flavanones by the microflora in the colon (Roowi et al., 2009). The 
resulting phenolic acids such as 3-hydroxyphenylacetic acid, 3-hydroxyphenyl 
hydracrylic acid, 3-methoxy-4-hydroxy phenylhydracrylic acid, dihydroferulic acid and 
3-hydroxyl-hippuric acid, corresponded to 37% of the hesperetin-7-O-rutinoside ingested 
when the OJ was ingested individually (Roowi et al., 2009). 
In an attempt to improve the bioavailability of hesperidin, a double-blind, 
randomised, cross-over study was conducted. Sixteen participants consumed three 
different orange juices (1) with natural hesperetin (low-dose), (2) with orange juice (low 
dose) treated with hesperidinase enzyme, and (3) orange juice (high dose) fortified to 
provide 3 times more hesperidin than naturally present. The Cmax of hesperetin after OJ 
(2) was 4-fold higher (2.6 mmol/L) compound with the low dose OJ(1) and 1.5-fold 
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compared to high dose OJ(3). The Tmax was earlier (0.6 hr) after consuming hesperetin-7-
glucoside OJ(2) compared with 7.0 hr for the low-dose OJ (1) and 7.4 hr for the high-
dose OJ(3). The study concluded that bioavailability was improved by enzymatic 
conversion of hesperidin to hesperetin-7-glucoside which changed the absorption site of 
the compound (Nielsen et al., 2006). A study by Hubauzit et al. (2009) also reported that 
hesperetin-7-glucoside was more bioavailable than hesperidin, and the relative urinary 
excretion was increased from 2.4 to 3.6% by increase the dose between 0.25 and 0.5% 
hesperidin. Some human intervention studies after dietary intake of orange juice are 
shown in table 1.4. 
The effect of single and repeated intakes of orange on flavanone absorption in 
humans was investigated. The level of hesperetin in the plasma increased after the 
consumption of 400 g of processed orange juice. The maximum level in plasma for 
hesperetin was 148 nmol/L, while 15 nmol/L for naringenin. After multiple-doses daily, 
there was significant increase compared to the baseline with 7 and 14 days after ingestion 
of 200 g orange. The concentration was undetectable in day one. After 7 and 14 days 
plasma levels of hesperetin were increased to 94 and 91 nmol/l respectively, and the 
concentration of naringenin increased to 3 and 2 nmol/l. This is an indication that levels 
of hesperetin and naringenin in plasma had an accumulative effect.  However hesperetin 
and naringenin plasma levels showed no change from day 7 to 14 after orange fruits were 
consumed daily (De Pascual-Teresa et al., 2007).  
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Table 1.4: Human intervention studies, recovery of hesperetin and naringenin after dietary intake of orange juice 
Study design Source of 
flavanones 
Dose ingested (mg) Durati
on 
(hr) 
Urinary 
excretion 
recovery 
(%) 
Cmax 
(nM) 
T max  
(hr) 
References  
Single dose 
N= 8 (M/F) 
26 ± 5y 
OJ 8 ml/kg 24 H=5.3 
N=1.1 
H= 2.2µmol/l 
N=0.6 µmol/l 
- (Erlund et 
al., 2001) 
Single dose 
N=6 (M/F) 
25 ± 3.9 y 
Oral capsule  (H)135 mg 
(N) 135 
24 H=3.26  
N=5.81 
- H=4.0 
N=3.5 
(Kanaze et 
al., 2006) 
Single dose 
N=7 (F) 
25.7 ± 1y 
Blood OJ  150 ml and 300ml 
(H) 51 -102 mg 
(N) 6-12 mg 
24 - H= 43 – 79 ng/ml 
N= 16.4 – 34 ng/ml 
H= 5.3 – 
5.3  
N = 5.0 
(Gardana et 
al., 2007) 
Cross-over OJ 0.5 L 24 H=4.1 – 6.4 H=0.46 – 1.28 H=5.4 – 5.8 (Manach et 
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N =5  
25 ± 1y 
1L 
H = 444 mg/L 
N = 96.4 mg/L 
N=7.1 – 
7.87 
µmol/L 
N=0.06 – 0.2 
µmol/L 
N=4.6-5.0 al., 2003) 
Single dose 
N=10 (M) 
Mixture juice 28 mg/L 
Each compound 
48 H=14.2 
N=22.6 
H=0.25µmol/L 
N=0.18µmol 
H=4.9 
N=3.6 
(Krogholm 
et al., 2010) 
Cross over 
N=10 (M/F) 
OJ 29.2 – 70.3 mg/100ml 12 H=5.4 
N=2.6 
H=324 (nM) 
N=37(nM) 
H=4.6 
N=4.7 
(Vallejo et 
al., 2010) 
Cross over 
N=8  
21 – 50y 
OJ 250 ml 
H=168 µmol 
N=12 µmol 
24 7 OJ =922 nmol/L 
OJ with yogurt = 
661 nmol/L 
OJ=4.4 
OJ W=5.1  
 
(Mullen et 
al., 2008) 
Single dose 
N=10 (M/F) 
19 – 51y 
Polyphenol rich 
beverage 
350 ml 
H=45 µmol 
24 12 168 nmol/L 3.7 (Borges et 
al., 2010) 
Cross over OJ low dose H - 24 4.06 0.48 7.0 (Nielsen et 
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N=16 (M/F) 
36 ±7y 
OJ h-7-gly 
OJ high dose H 
14.40 
8.90 
2.6 
1.0 
0.6 
7.4 
al., 2006) 
Cross over 
N=20 (F/M) 
49y 
Orange fruit 
OJ 
150 g fresh fruit (79.7 
H, 11.8 N) 
300 g OJ (71.8H, 9.4 N) 
48 H=4.5 
N=12.5 
H=4.6 
N=10.2 
28 µg/L 
23 µg/L 
30 µg/L 
14.3 µg/L 
7.0 
5.8 
6.2 
4.46 
(Brett et al., 
2009b) 
OJ: Orange juice, (H) Hesperetin, (N) Naringenin
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Isoflavones are the most well-absorbed dietary flavonoids with urinary excretion 
of metabolites typically 20 - 50% of the intake. The mean relative urinary excretion of 
isoflavones is 42% and 15.6% for daidzein and genistein, respectively (Manach et al., 
2005). The bioavailability of isoflavones was reported by Watanabe et al. (1998). In 
their study seven male participants were given a 60 g of Kinoko (baked soybeans 
powder, containing 103 µmol/L daidzein and 112 µmol genistein. It reported that the 
plasma concentration of daidzein and genistein peaked at 1.5 ± 0.34 µmol/L and 2.4 
µmol/L, respectively. The mean recovery rate of daidzein in urine was 35.8% and 17.6% 
for genistein. A randomized, double blind crossover study in seven men aged between 
22-30 y was conducted to measure the pharmacokinetics of the isoflavones after 
ingestion of pure daidzein in both aglycone and glucoside form. After consumption of 1 
mg (aglycone equivalent)/kg body weight of pure daidzein or pure daidzein-7-O-
glucoside, blood and urine samples were collected. The cumulative recovery over 24 hr 
averaged 11.6% for daidzein and 38.9% after ingestion of daidzein glucoside (Rüfer et 
al., 2008).  
In another similar study, 19 healthy women were recruited and divided to 4 
groups and asked to ingest standard 50 mg doses of daidzein, genistein, daidzin and 
genistin. The peak plasma concentration Tmax of pure daidzein and genistein were 
reached in an average time of 5.2 and 6.6 hr, respectively, earlier than their 
corresponding glycosides where the Tmax was delayed to 9.3 and 9.0 hr, respectively. 
The Cmax was 0.76 and 1.5 µmol/L for daidzein and daidzin, respectively, and 1.26 and 
1.22 µmol/L for genistein and genistin (Setchell et al., 2001). 
The bioavailability of isoflavones from different soy-based foods was 
investigated with Isogen, soymilk, and fermented soybeans. The urinary recovery rates 
of daidzein and genistein were 42% and 17% after isogen, 46% and 23% after fermented 
soybeans, and 33% and 22% for the soymilk group. This study concluded that soy based 
food contain high amount of isoflavones aglycone such as fermented soy food are more 
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effective for maintaining high plasma isoflavone concentration (Chang and Choue, 
2013).  
A similar study investigated the effects of soymilk-based beverages containing 
different types of isoflavones on their bioavailability. Three different kind of soymilk 
(untreated soymilk, β-glucosidase-treated soymilk (ETS), and fermented soymilk (FSM) 
were ingested. The Cmax reached 0.94 µmol/L at 6.0 hr for soymilk. However, the 
concentration was reached more quickly for ETS and FSM at 1.0 hr of (1.75 and 2.05 
µmol//L), respectively. Moreover, the urinary excretion of isoflavones was significantly 
higher after ingestion of ETS and FSM compared with untreated soymilk up to 8 hr after 
consumption. The percentage of daidzein and genistein recovered in the urine after 
ingested was 37.3 and 20.2% for soymilk and 46 and 30% for ETS and 46.3 and 28.0 % 
for FSM. The aglycones isoflavone were reported to be absorbed faster and in greater 
amounts than their glucosides (Kano et al., 2006).  
The bioavailability of isoflavones after single consumption of fermented (Fsoy) 
and non-fermented soybeans (soy) products was investigated. The urinary recovery of 
total isoflavones was higher in the Fsoy group after 2 hr compared with that in the soy 
group with recovery rates 48% and 37% in 48 hr, respectively. The results demonstrated 
that the aglycone-rich Fsoy group were absorbed faster and in greater amounts 
compared with those consume glucoside-rich soy (Okabe et al., 2011).  
The pharmacokinetics of isoflavones in 10 healthy women was measured among 
participants who were asked to ingest 10, 20 and 40 g of soy nuts containing (9.8, 19.6 
and 39.2 mg genistein and 6.6, 13.2 and 26.4 mg daidzein). The mean fraction of the 
isoflavones excreted in the urine was decreased with the increase of the intake. The 
excretion was expressed (as %) of the dose ingested was 63.2%, 84.4% and 44.0% 
respectively for daidzein and 25.2%, 23.4% and 15.8% for genistein. The result showed 
that daidzein and genistein were absorbed at range from 2-8 hr after ingestion, with 
means for daidzein and genistein of 6.1 hr and 5.0 hr, respectively (Setchell et al., 
25 
 
2003a). Table 1.5 shows human intervention studies, recovery of daidzein and genistein 
after dietary intake of soy-based food products. 
The effect of the matrix (supplements or foods) on urinary recovery of 
isoflavones was reviewed by Perez-Jimerez et al. (2010a). There was no difference 
between acute and chronic isoflavone studies in urinary excretion, and the recovery 
range for isoflavones were 8.3-60% and 1.7-47% for daidzein and genistein, 
respectively. Food matrix and processing might be good factor which affect the 
absorption of isoflavones in human. Three different food products (fruit juice, chocolate 
bar and cookies) were prepared and 455 mg isoflavone rich extract was added to each 
product before processing. Different aglycone levels of isoflavone in the plasma were 
reported but they were not affected by the different food matrix. The urinary excretion 
of daidzein was similar for all three foods consumed with total urinary recovery of 33-
34% of dose ingested. However, urinary recovery of genistein was lower following 
consumption of juice compared with the other two foods, peak genistein levels were 
reached in plasma earlier after ingestion of a liquid matrix compared to solid matrix (De 
Pascual-Teresa et al., 2006). In a randomized crossover study, consumption of soy-
bread or soya-beverage for 3 weeks was investigated. These foods contained 2 g soy 
protein with 99 and 93 g isoflavone aglycone equivalents /day respectively. Women 
excreted more metabolites after the bread intervention than men. However, the excretion 
of isoflavones was the same and no differences was reported after the soy beverage was 
consumed by men and women. It was suggested that food matrix significantly affects 
soy isoflavone absorption, particularly in women (Ahn-Jarvis et al., 2012).  
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Table 1.5: Human intervention studies, recovery of daidzein and genistein after dietary intake of soy-based food products 
Study design Source of flavanones Dose ingested (mg) 
Duration  
(hr) 
Urinary 
excretion 
recovery (%) 
Cmax 
(µmol/L) 
T max 
(hr) 
References 
Single dose 
N=7 (M) 
33.3 y 
Backed  soybean 
powder 
60 g of kinako 
103 µmol (D) 
112 µmol (G) 
72 
D = 35.8 
G= 17.6 
D= 1.56 
G = 2.44  
6 
(Watanabe 
et al., 
1998) 
Crossover 
N=7 (M) 
22-30 y 
Pure daidzein (D) 
Pure daidzein 
glucoside (DG) 
3.9 µmol/kg body 
weight for both 
24 
D= 11.6 
DG = 38.9 
D= 0.48 
DG = 2.5  
D= 8.3 
DG = 9.1 
(Rüfer et 
al., 2008) 
Single dose 
N=19 (F) 
≥ 18 y 
Pure daidzein, 
diadzin, genistein, 
genistin 
50 mg each 
compound 
24 - 
(D= 0.76 , DG= 1.5 
(G = 1.26, G=1.22) 
(6.6 , 9.0) 
(5.2, 9.3 ) 
(Setchell 
et al., 
2001) 
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Single dose 
N=6 (M) 
37 y 
Soybean flour-based 
0.84 g flour/kg body 
weight 
27 and 3.6 µmol/kg 
body weight 
35 
D = 62 
G= 22 
D= 3.14 
G = 7.42 
D = 7.4 
G = 8.4 
(King and 
Bursill 
1998) 
Single dose 
N = 26 (F) 
25.4 y 
Isogen 
Fermented soybeans 
(FS) 
Soymilk 
 
64.8 isoflavones 
81.8 isogen 
43.8 FS 
600ml soymilk 
24 
Isogen 
(D=42,G=17) 
FS (D=46, 
G=23) 
Soymilk(D=33, 
G=22) 
Isogen 
(D=230,G=160 
ng/ml) 
FS (D=244, G=195 
ng/ml) 
Soymilk (D=211, 
G=231 ng/ml) 
Isogen (D=3.7,G=4.) 
FS (D=2.8, G=3.5) 
Soymilk (D=3.7, G=4.8) 
(Chang 
and Choue 
2013) 
Single dose 
N=12 (M/F) 
33.9 y 
3 soymilk 
Untreated 
Treated (ESM) 
Fermented (FSM) 
Untreated (D=130 , 
G= 116) 
ESM (D= 7, G= 5) 
FSM (D = 5 , G 
=15) 
48  
Untreated (D=0.47 , 
G= 0.41 µmol/L) 
ESM (D= 0.82, 
G=0.87) 
FSM (D =0.95 , G= 
1.02) 
Untreated (D=6 , G=5.9) 
ESM (D= 1.0, G=1.1) 
FSM (D =1.0 , G =1.0) 
(Kano et 
al., 2006) 
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Crossover 
N=12 (F) 
49 – 65 y 
F soy 
Soy 
Isoflavones 
95 µmol per 23g, for 
both 
48 
48 
37 
F soy ( D= 1.51, G= 
1.04) 
Soy (D= 0.9, G= 0.73 
) 
F soy ( D=1.0, G= 2.09) 
Soy (D= 3.9, G= 5.0) 
(Okabe et 
al., 2011) 
Single dose 
N=10 (F) 
≥ 18 y 
Soy nuts 
10,20,40g contain 
D=( 6.6,13.2, 26.4 
mg) 
G=(9.8,19.6, 39.2 
mg) 
120 
D= (63, 54, 
44%) 
G= (25, 13, 
15%) 
D=(428, 843, 1691 
nmol/L) 
G=(585, 1222, 2209 
nmol/L) 
D=(5.8,6.4, 6.0) 
G=(4.9,4.0, 6.0) 
(Setchell 
et al., 
2003a) 
N=12 (F) 
64 y 
Cereal bars and 
yoghurt 
100 mg isoflavones 
D= 118 µmol 
G= 241 µmol 
36 
D = 66 % 
G= 48 % 
 
D= (1.68 day 1 to 
2.27/ day 30 ) 
G= (3.8 day 1 to 5.3/ 
day 30) 
2 peaks for both 2  and 6 
(Vedrine 
et al., 
2006) 
 (D) Daidzein, (G) genistein
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1.4.3 Gut microflora and absorption of flavonoids  
The gut microflora plays an important role in metabolism, degradation and 
bioavailability of many flavonoids (Aura et al., 2008). Flavonoids that reach the 
colon are subject to breakdown to lower molecular weight compounds. These 
microbial metabolites may contribute to the biological effects of dietary flavonoids 
(Manach et al., 2005; Williamson and Clifford 2010). It has been estimated that 5-
10% of the total polyphenol intake is absorbed in the small intestine, and between 
90-95% of the total polyphenols consumed will reach the large intestine. Conjugated 
compounds excreted back through the bile into the small intestine are subjected to 
breakdown by the enzymatic activity of gut microflora to low-molecular weight 
compounds (Cardona et al., 2013). Figure 1.3 shows a proposed pathway for the 
breakdown of hesperetin-7-O-rutinoside in humans.  
Effects of the intestinal microflora on absorption of hesperidin were assessed 
after intestinal microflora was treated with antibiotics. Hesperetin concentrations in 
non-antibiotic-exposed and pseudo-germ-free rats were 0.58 and 0.20 μg/ml, 
respectively, and areas under the curve (AUC) values were 6.3 and 2.8 μg-h/ml, 
respectively. AUC and C max was significantly higher in normal compared to pseudo-
germ-free rats. These results have concluded that pharmacokinetic differences 
between non-antibiotic-exposed and pseudo-germ-free rats may be attributed to 
differing hesperidin uptake, as well as changing in metabolic activities of intestinal 
microflora (Jin et al., 2010). 
Metabolism of isoflavones and flavanones is mediated by both gut microflora 
and considerable inter-individual variations in the excretion of isoflavones and their 
metabolites among different individuals have been reported. This variation is 
recognized to be due to the gut microflora differences that are responsible for the 
hydrolysis of isoflavones (Rafii et al., 2003, Setchell et al., 2003a, Tamura et al., 
2007). Daidzein, an isoflavone found in soya, may be metabolized and converted by 
gut microflora to equol (7-hydroxy-3-[4-hydroxyphenyl]-chroman), 
dihydroxydaidzein, O-desmethylangolensin (O-DMD), or 4-hydroxy equol (Yuan et 
al., 2007), and likewise dihydrogenistein may be converted from genistein (Pérez-
Jiménez et al.,  2010a). Only individuals that have the appropriate microflora are 
able to produce equol, estimated to be approximately 30% of the Western population. 
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Equol has several biological activities relating to human health, and therefore the 
ability to produce this may be advantageous (Cardona et al., 2013). The production 
of equol might be influenced by particular dietary habits that stimulate/suppress 
individual microflora composition (Yuan et al., 2007).  
 Hesperetin-7-O-rutinoside 
 
aglycone + sugar 
 
 
 Hesperetin 
 
 
3- methoxy-4-hydroxy 
phenylhydracrylic acid 
 
 
 3-hydroxyphenyl 
hydracrylic acid 
 
dihydroferulic acid 3- hydroxyl-hippuric acid 
 
3-hydroxyphenylacetic 
acid 
 
Figure 1.3: Proposed pathway for the breakdown of hesperetin-7-O-rutinoside in 
humans. Most conversions are the probably mediated by colonic microflora. 
Adapted from (Del Rio et al., 2010). 
 
1.5 Cardiovascular disease (CVD)  
Cardiovascular disease (CVD) is a common term that is employed to describe 
diseases of the heart and blood vessels. In Europe, CVD is categorized as the main 
cause of mortality accounting for about four million deaths per year, nearly half of all 
deaths (48%) each year in Europe (Allender et al., 2008; Chong et al., 2010). Many 
environmental and genetic factors can cause this chronic and multi-factorial disease. 
H2O 
H2O H2O 
H2O 
H2O 
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Well-known environmental factors which cause and/or enhance the CVD risk are 
high saturated fat consumption, hypertension, diabetes mellitus (DM), 
hyperlipidemia, physical inactivity and smoking (Huang, 2009, Vauzour et al., 
2010). Some of these risk factors can be controlled or modified, for example lifestyle 
modification; changing dietary habit and physical activity behaviour both led to 
decreasing CVD risk (Chong et al., 2010), or if appropriate by pharmacological 
treatment (Kahn et al., 2005, Huang 2009). Many studies have studied the 
relationship between diets rich in fruit and vegetables and decreasing CVD 
incidence. Fruits and vegetables contain many compounds that may have cardio-
protective effects such as, folate, vitamin and non-nutrient phytochemicals, such as 
flavonoids and carotenoids (Chong et al., 2010).  
 
1.5.1 Endothelial cell function 
Endothelial cells are arranged in a single layer known as the endothelium, 
separating the vascular lumen from the smooth muscle cells of the vessels. The 
endothelium is a semi-permeable barrier which helps in water and nutrient exchange 
between the blood and the vessel wall (Celermajer, 1997). Endothelial cells play a 
fundamental role in the regulation of vascular tone and homeostasis (Bonetti et al., 
2003). Responding to different hemodynamic and hormonal factors, the endothelium 
releases various vasoactive mediators to maintain vascular tone (Celermajer, 1997, 
Hinderliter and Caughey, 2003), namely nitric oxide (NO) as a vasodilator and 
endothelin-1 (ET-1) as a vasoconstrictor (Widlansky et al., 2003, Shenouda and Vita 
2007).  
NO derived from endothelial cells is a strong vasodilator, and plays a crucial 
role in modulating both vascular tone and BP (Vallance and Chan, 2001, Moncada 
and Higgs, 2006). NO may play a crucial role in regulatory of atherosclerosis 
development, including restricting the activation of platelet aggregation, adhesion of 
leukocytes to the endothelial surface, synthesis of pro-inflammatory cytokines and 
vascular smooth muscle cell growth (Widlansky et al., 2003, Rush et al., 2005, Esper 
et al., 2006).  
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NO is produced after the amino acid from L-arginine is oxidised (also producing L-
citrulline), catalysed by endothelial nitric oxide synthase (eNOS) which can be found 
in caveolae (invaginations in cell membranes), in the presence of many cofactors 
including oxygen, tetrahydrobiopterin (BH4) and nicotinamide adenine dinucleotide 
phosphate (NADPH), flavan adenine dinucleotide (FAD), flavan mono nucleotide 
(FMN), and one heam group. The enzyme eNOS is activated to produce NO either 
by increase in blood flow (hyperaemia), which results in the increase of shear stress 
subsequently increasing intracellular Ca
2+
 (Davignon and Ganz, 2004), or by 
alteration in a number of chemical factors, such as histamine, bradykinin, 
acetylcholine (Moncada and Higgs, 1993, Kone et al. 2003, Fonseca et al., 2004, 
Kawashima and Yokoyama, 2004, Stuehr and Griffith, 2006). 
From the endothelial cells, NO will diffuse across the cell membrane into the 
smooth muscle cells in the vascular wall, where it activates guanylate cyclase 
resulting in an increase in cyclic guanosine 3,5-monophosphate (cGMP) level. This 
leads to smooth muscle cell relaxation (Vallance and Chan, 2001), as shown in figure 
1.4. 
 
 
Figure 1.4: Vasoactive mediator effects on endothelial cells. Taken from Tousoulis et 
al., (2005). 
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Low levels of NO bioavailability are recognised as an important factor in 
dysfunction of endothelial cells (Malek et al., 1999, Vita and Keaney 2002). 
Alterations in normal function of endothelial cells play a fundamental role in 
pathogenesis of CVD. Thus atherosclerotic plaque formation, thrombosis, 
inflammation and vasoconstriction are all known as dysfunction of endothelial cells 
(Widlansky et al., 2003, Bonetti et al., 2003, Huang and Vita, 2006; Shenouda and 
Vita, 2007). Cardiovascular risk factors which raise vascular production of reactive 
oxygen species (ROS), and decrease the endothelial nitric oxide availability are 
shown in Figure 1.5. These include: reduced eNOS activity due to increased ADMA 
levels (an endogenous eNOS inhibitor), resulting from redox-sensitive inhibition of 
DDAH; eNOS “uncoupling” due to increased oxidation of the cofactor BH4; and 
inactivation of NO by reaction with superoxide resulting in peroxynitrite (ONOO‾) 
(Landmesser et al., 2004). In fact NO bioavailability can be effected by many 
reasons such as decreased expression of eNOS, by altered activation of eNOS, or 
reduced level of eNOS cofactors (Venugopal et al., 2002, Förstermann and Münzel, 
2006), as well as increased synthesis of ROS from oxidative stress (Barua et al., 
2003, Mudau et al., 2012). 
 
 
Figure 1.5: The major cardiovascular risk factors increase endothelial dysfunction 
through decreasing the endothelial NO availability, reproduced from (Landmesser et 
al., 2004). 
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When there is deficiency in the enzyme cofactors or L-arginine, eNOS can 
raise the superoxide anion (O2
-
) and oxygen radical production. The O2
-
 in the 
absence of antioxidant defence mechanisms will react with NO to form peroxynitrite 
(ONOO
-
) or hydrogen peroxide (H2O2) decreasing NO bioavailability (Vanhoutte, 
2003, Spieker et al., 2006). 
Dysfunction of endothelial cells is an early contributor to atherosclerosis 
(Bonetti et al., 2003). It can therefore be an indicator for probable vascular 
complications (Anderson, 2004, Esper et al., 2006,). Endothelial cell dysfunction is 
considered as an independent vascular risk factor that can be treated by medication, 
abstinent smoking, and increased physical activity. In addition to improving food 
habits and the healthy dietary food consumption rich in flavonoid compounds tends 
to reverse endothelial cell dysfunction, and thus reduce the CVD risk. 
1.5.2 Atherosclerosis  
Atherosclerosis is a potentially serious condition whereby arteries become 
clogged up by fatty substances known as plaques or atheroma (Martini et al., 2012). 
Atherosclerosis is a chronic vascular disease which entails thickening and 
toughening of arterial walls and narrowing of arterial lumen. As a result, blood flow 
and thus oxygen and nutrient supply to the body’s tissues is diminished. 
Atherosclerosis is mainly observed in large and medium-sized arteries. 
Atherosclerosis pathogenesis requires several factors, such as vascular inflammation, 
endothelial dysfunction, and vascular cell and immune system interaction (Napoli et 
al., 2006).  
Atherosclerosis pathogenesis (theroma formation) comprises many steps as 
shown in figure 1.6. Firstly, low-density lipoprotein (LDL) accumulates within the 
intima layer where it is oxidized and modified. This gives rise to the release of 
leukocyte adhesion molecules by endothelial cells, which results in macrophages in 
the intima engulfing the modified LDL (De Winther and Hofker, 2000) eventually 
forming lipid-containing macrophages foam cells. It is the accumulation of foam 
cells which leads to fatty streaks. The fatty streak is covered by a cap of both smooth 
muscle cells and collagen matrix which forms the plaque. As the plaque grows, the 
blood vessel lumen narrows restricting the flow. The plaque might also rupture 
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which is of particular importance since it plays a crucial role in causing of ischaemic 
heart disease.  
 
1.6 Dietary flavonoids and cardiovascular disease  
1.6.1 Dietary flavonoids and CVD 
As a diet high in fruit and vegetables has been linked to reducing the risk of 
chronic related diseases this has encouraged many researchers to investigate the 
possible protective effects of flavonoids. The association between flavonoid intake 
and health benefit can be measured through different approaches such as 
epidemiological studies, animal studies, cell culture models, and randomized cross-
over intervention studies. Dietary intake of flavonoid-rich foods, or foods rich in 
specific flavonoid sub-classes such as anthocyanins and flavanones, were correlated 
with lower risk of death from CVD in large prospective cohort studies (e.g. Mink et 
al., 2007, McCullough et al., 2012). Several studies have also found that even a small 
quantity of foods that are rich in flavonoids may reduce certain CVD risk factors, 
shown in a meta-analysis of studies (Hooper et al., 2008). The role of flavonoid-rich 
foods on CVD has been reviewed by many (e.g. Manach et al., 2005; Erdman et al., 
2007). 
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Figure 1.6: Foam cell formation in atherosclerosis. In hypercholesterolemia patients, 
excess LDL infiltrates the artery and is retained in the intima, particularly at sites of 
hemodynamic strain. Oxidative and enzymatic modifications lead to the release of in 
the modified LDL particles are taken up by scavenger receptors of macrophages, 
which evolve into foam cells, reproduced from (Hansson, 2005). 
 
Flavonoids are found to possess both antioxidant and pro-oxidant effects. This gives 
them the ability to enhance the normal cell survival and suppress the risk of tumour 
cell proliferation (Jan et al., 2004). A prior study reported that the level of 
antioxidant capacity in plasma increased after the consumption of various 
polyphenol-rich foods (Manach et al., 2004). The study also showed that some of the 
polyphenol metabolites retain antioxidant activity. Thus it is considered that 
excessive consumption of flavonoids from food supplements should not be 
recommended (Halliwell, 2007). Polyphenols may affect the bioavailability of 
carcinogenic and toxic compounds by inhibiting/enhancing the enzymes implicated 
in their metabolic pathways, such as sulfotransferase, UDP- glucuronosyltransferase 
and cytochrome P450 isoforms (Manach et al., 2005).  
A randomized, placebo controlled double-blind crossover study to examine 
the effect of chocolate on lipid parameters, weight and glycaemic control was 
conducted among subjects with T2DM. The subjects (42-71 years) consumed 45 g 
chocolate with or without high flavonoid content for eight weeks crossover after four 
Coronary artery  
Retention  
LDL-Cholesterol   
Endothelium   
Activation  
Uptake   
Microphag
e 
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weeks washout time. After the ingestion of chocolate-rich in flavonoids, a significant 
increase in HDL cholesterol and a reduction in total cholesterol to HDL-C level were 
reported (Mellor et al., 2010).  
 
1.6.2 Citrus flavanones and CVD 
Some studies showed an inverse relationship between citrus consumption and 
the risk of CVD (Knekt et al. 2002, Chanet et al. 2012b). Although citrus fruits are 
the major dietary sources of flavanones, few epidemiological studies have studied the 
direct correlation between flavanone intake and CVD prevention. Flavanone intake, 
but not the total flavonoid intake, has been reported to be inversely related to the risk 
of stroke (Cassidy et al., 2012). The main effects of flavanones/orange juice, and 
some other flavonoids, on CVD risk have been reported by Coelho et al. (2013), 
these effects include: decreasing blood pressure, improving lipid profiles, antioxidant 
and anti-inflammatory effects, and improving the function of endothelial cells (Egert 
et al., 2009).  
Interestingly, orange juice consumption is correlated with better diet quality 
and nutrient adequacy. The results of recent study have shown that people who 
consumed 210 ml/day had lower total cholesterol level, LDL cholesterol and body 
mass index (BMI) compared with <50 ml/day. Moreover, the risk of being obese and 
having metabolic syndrome amongst those people decreased by 21% and 36%, 
respectively (O’Neil et al., 2012). 
Hypercholesterolemia, which can lead to atherosclerosis, is one of the risk 
factors for CVD developing. A number of other potential impacts of citrus flavanone 
have been demonstrated in the case of lipid metabolism. It has been reported that 
flavanones can regulate apolipoprotein B secretion by HepG2 cells—potentially via 
cholesterol ester synthesis inhibition (Borradaile et al., 1999, Kurowska et al., 2004). 
One study showed that grapefruit intake decreased plasma TG levels in patients with 
CVD (Gorinstein et al., 2006). Another study showed that the ingestion of 750 mL 
for 4 weeks, but not of 250 or 500 mL, increased HDL-cholesterol, and decreased the 
LDL:HDL cholesterol ratio (Kurowska et al., 2000). 
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Other studies demonstrated that flavanones can lower blood cholesterol 
concentration (Jung et al., 2003). Naringin supplements lowered the plasma total 
cholesterol (TC) and LDL-cholesterol, but not plasma triglyceride (TG) and high 
density lipoprotein (HDL)-cholesterol in hypercholesterolemic subjects (Jung et al., 
2003). However, when healthy overweight men aged between 50-65 years, 
consumed 500 ml orange juice containing hesperidin (292 mg) for one month, there 
was not any significant alteration in the level of TC, LDL-C, HDL-C and TG 
(Morand et al., 2011). Moreover, pure flavanone compounds ingested did not show 
any lowering effect on plasma TC and LDL-C levels (Demonty et al., 2010).  
Worldwide, hypertension is categorised as one of the major public health 
problems (Medina- Remón et al., 2011), with high BP shown to be one of the major   
risk factors of CVD. Differences in BP measurements by 20/10 mmHg above 115/75 
mmHg were correlated with raised CVD risk by two-fold, for people aged between 
40 and 70 years (Liu et al., 2014b). Evidence from nutritional studies suggested that 
consumption of fruit and vegetables is negatively correlated with high BP (Alonso et 
al., 2004, Mancia et al., 2013). Furthermore, intake of healthier foods such as the 
Mediterranean food pattern decreases the risk and the prevalence of high BP 
(Kokkinos et al., 2005).  
Fruit consumption may lower the risk of CVD through a BP reducing effect. 
Cross sectional data was used to quantify association of raw fruit and fruit juice 
intake with BP in different countries. BP was measured 8 times in 4 visits, four 24-h 
dietary recalls and two-24 hours urine samples were collected. The results concluded 
that diastolic BP was positively associated with consumption of fruit and fruit juice; 
moreover, there was positive association between citrus fruit consumption and 
diastolic BP in western regions (Savica et al., 2010; Griep et al., 2013). A meta-
analysis on the effect of fruit juice on serum cholesterol and BP assessed a total of 
618 participants from 19 studies. The study showed that fruit juice had a significant 
effect on decreasing DBP, but had no effect on blood lipid parameters such as, TC, 
HDL-C, LDL-C or SBP (Liu et al., 2013a).   
The effect of regular consumption of pasteurized orange juice on the 
nutritional status, biochemical profile, and arterial BP in healthy men and women 
was studied. Twenty one healthy women aged 20-35 years and 20 healthy men aged 
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21-44 years, were recruited to consume pasteurized orange juice (500 mL/d and 750 
mL/d) for 8 weeks. Total cholesterol and LDL-C significantly decreased after the 
consumption of orange juice in both men and women, and a rise in HDL-C level was 
abserved exclusively in women. FBS, DBP, and TG concentration were reduced in 
men after the consumption of orange juice. The study reported that regular 
consumption of pasteurized orange juice may decrease the risk of developing 
atherosclerosis, and raise the nutritional quality of their diets (Basile et al., 2010).  
To evaluate the antihypertensive effect of juice among patients with stage I 
hypertension, a double-blind, cross-over study was conducted in 12 patients and 
sweetie fruit juice, which is a hybrid between grapefruit and pummelo and contains a 
high level of flavonoids (mainly naringin and narirutin) (Reshef et al., 2005). For a 
5-week period, each participant consumed high-flavonoid sweetie juice and low-
flavonoid sweetie juice. A tendency toward reduced DBP and SBP was seen with 
both low and high sweetie juice. However, a significant reduce in DBP was reported 
only in the group consuming high flavonoid sweetie juice (-3.7 mm Hg; p=0.04). 
Consistent with this study, a randomized, controlled, crossover study 
investigated the effects of orange juice and hesperidin on microvascular reactivity, 
BP, and CVD risk biomarkers through both postprandial and chronic intervention in 
24 healthy, overweight men (age 50–65 y) (Morand et al., 2011). Participants 
consumed 500 mL orange juice, 500 mL control drink plus hesperidin (CDH), or 500 
mL control drinks plus placebo (CDP) daily in three 4-wk periods.  The study 
concluded that DBP was significantly decreased after four weeks consumption of 
orange juice or CDH compared to CDP. In addition, both orange juice and CDH 
consumption significantly enhanced postprandial microvascular endothelial 
reactivity compared with CDP when measured at the peak of plasma hesperetin 
concentration (Morand et al., 2011). 
Dysfunction of endothelial cells is a predictor for CVD events. Twenty two 
healthy participants were recruited in a single blind randomized crossover controlled 
study. The two groups consumed either commercial orange juice or fresh orange 
juice for the first four weeks and then switched to the second phase. The impacts of 
commercial and fresh orange juice on endothelial cell function and physiological 
characteristics in healthy humans was evaluated. Functionality of endothelial cells by 
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measuring flow-mediated dilation was evaluated alongside with serum lipids and 
inflammatory markers, such as adhesion molecule 1 (VCAM-1), E-selectin, high-
sensitivity C-reactive protein, and interleukin-6. The results did not reveal any 
alteration in FMD (Asgary et al., 2014). 
Some studies have examined the effect of consumption of hesperidin on 
vascular function and BP among spontaneously hypertensive rats. Following a single 
oral dose of 50 mg/kg hesperidin, SBP was reduced in SHR; data have suggested that 
the hypertensive effect of hesperetin is associated with NO mediated vasodilatation, 
which may explain the mechanism of lowering BP (Yamamoto et al., 2008b). 
Moreover hesperetin induced an increase in endothelium-dependent vasorelaxation 
of aortic ring (Yamamoto et al., 2008a). 
The estrogenic activities of naringenin and hesperetin were evaluated to 
verify whether they affect endothelial NO production. These were investigated via 
estrogen receptor activation. The results indicate that naringenin activated both 
estrogen receptor-α and estrogen receptor-β, whereas hesperetin activated estrogen 
receptor-α only (Liu et al., 2008). Hesperetin has been shown to increase NO release 
from endothelial cells in a dose-dependent manner. The results showed that 
hesperetin exerts an anti-atherogenic activity via affecting estrogen receptor-
mediated expression of eNOS and NO generation (Liu et al., 2008).  
Naringenin was reported to have a vasorelaxant effect via activation of Ca
2+
 
channels in monocytes (Saponara et al., 2006). A cell culture-based study was 
conducted to investigate the cellular and molecular mechanisms implicated in the 
role of flavanone in the decrease of CVD risk. The study reported that an inhibition 
effect of hesperetin and naringenin metabolites (hesperetin-3′-O-glucuronide, 
hesperetin-3′-O-sulphate and naringenin-4′-O-glucuronide) on the monocyte 
adhesion to tumour necrosis factor-α (TNFα) activated human endothelial cells by a 
gene expression effect (Chanet et al., 2012a). Figure 1.7 shows the possible effects of 
citrus flavonoids on CVD risk factors. 
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Figure 1.7: Possible effects of citrus flavonoids on CVD risk factors. Direction of 
arrows indicates effect. Reproduced from ( Mulvihill et al., 2012). 
 
1.6.3 Dietary flavonoids and obesity  
Worldwide, obesity is becoming an epidemic problem in both developed and 
developing states (Prentice, 2006; Velasquez and Bhathena, 2007). About one billion 
adults are considered overweight (Murthy et al., 2009) and the rate at which it 
progressing is increasing rapidly across all aged groups (Velasquez and Bhathena, 
2007).  It has been reported that 24.5% of adults and 13.9% of children in the UK are 
obese (BMI ≥ 30 kg/m2), and in the event that no action is taken, it is assessed that 
47% of males and 36% of females will be categorised as obese by 2025 (Shepherd, 
2010). Obesity is defined as the fat tissue aggregation to excess and to a degree that 
damages both physical and psycho-social wellbeing and health (James, 2004). 
Obesity has been shown to be associated with a number of diseases such as 
dyslipidemia, hypertension, stroke, metabolic syndrome and type 2 diabetes mellitus 
(T2DM), (Prentice, 2006; Velasquez and Bhathena, 2007; Meydani and Hasan, 2010; 
Ärnlöv et al., 2010; Huang et al., 1998; Nguyen et al., 2008; Ding et al., 2012).  
Many studies have shown that whole plant foods, dairy products, dietary fibre 
and functional foods such as probiotics and prebiotics, and certain phytochemicals, 
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can play a protective role against obesity and their related diseases (Tuohy et al., 
2009). The regular consumption of fruit and vegetable was found to be correlated 
with body weight reduction (Vioque et al., 2008). Furthermore, fruit and vegetables 
with high amounts of phytochemical and phenolic compounds have been shown to 
have anti-obesity and lipid-lowering effects and may help achieve body weight (Pal 
et al., 2004, Nagasako-Akazome et al., 2007, Vioque et al., 2008, Hsu and Yen, 
2008). Animal studies have also reported that consumption of foods/supplements rich 
in flavonoids can change lipid and energy metabolism and may help weight loss and 
prevent weight gain.  The potential effect of these flavonoids may be explained 
through several mechanisms: inhibition of fat absorption from the gut, increased 
glucose absorption by skeletal muscles, inhibition of anabolic pathways, stimulation 
of catabolic pathways in adipose tissues, liver and other tissues, angiogenesis in 
adipose tissues, inhibition of differentiation of pre-adipocytes to adipocytes, 
stimulation of apoptosis of mature adipocytes, and reducing of chronic inflammation 
correlated with adiposity (Meydani and Hasan, 2010). 
 
1.6.4 Dietary flavonoids and metabolic syndrome  
Metabolic syndrome is characterized by a number of metabolic abnormalities 
including hyperglycaemia (impaired fasting glucose), abdominal obesity, 
hypertension and dyslipidaemia (Alberti et al., 2009). Metabolic syndrome is 
correlated with developing T2DM, CVD, and all-cause mortality and is considered a 
highly prevalent health problem across the world (Yang et al., 2012). The prevalence 
was estimated in the general population from 1.2% to 22.6% with rates of up to 60% 
observed in the overweight and obese (Tailor et al., 2010). The unified diagnostic 
criterion for metabolic syndrome is having at least three of the following five 
abnormalities: serum TG level of 1.69 mmol/L or greater; HDL- cholesterol level 
lower than 1.03 mmol/L in men and lower than 1.29 mmol/L in women, waist 
circumference of 102 cm (40 inches) or greater in men and 88 cm (35 inches) or 
greater in women; BP of 135/85 mmHg or greater; or fasting blood glucose of 5.5 
mmol/L or greater (Alberti et al., 2009, Mitchell et al., 2013). 
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Recently, there has been an increased interest in the various ways dietary 
polyphenols may influence carbohydrate metabolism. The beneficial effect of 
polyphenols consumption on glucose metabolism has been observed by number of 
human studies and the possible mechanism of action includes activation of insulin 
receptors and glucose uptake in the insulin-sensitive tissue, inhibition of 
carbohydrate digestion and absorption of glucose in the intestine, increased insulin 
secretion from the pancreatic β-cells, modulation of glucose release from the liver 
and intracellular signalling pathways and gene expression (Hanhineva et al., 2010; 
Williamson, 2013).  
The correlation to total fruits and vegetables intake and decreasing risk of 
developing DM remains unclear. Some epidemiological studies have supported the 
positive effect of flavonoid-rich foods against the development of T2DM 
(Williamson, 2013, Liu et al., 2013b, Liu et al., 2014a). A recent study evaluated 
whether dietary intakes of flavonoids i.e., flavanols, flavones, flavanones, flavan-3-
ols and anthocyanins are associated with the risk of T2DM in US adults. A total of 
70359 participants who were free of T2DM, CVD, and cancer at baseline were 
involved in this study. The results concluded that higher ingestion of anthocyanin-
rich fruit was associated with a lower rate of T2DM (Wedick et al., 2012). These 
results are also in agreement with a large prospective case cohort study a cross 
European countries. The results reported significant inverse correlation between 
flavan-3-ols, proanthocyanidins and myricetin and risk of T2DM (Zamora-Ros et al., 
2013). Another study investigated the association between dietary polyphenol intake 
including flavonoids and metabolic syndrome. The study was conducted in Iran on 
2618 adults aged 19-84 years. Results of the study reported a relationship between 
high intake of flavonoids and lower incidence of WC, low HDL-cholesterol, 
hyperglycaemia, hypertriglyceridemia, BP and metabolic syndrome (Sohrab et al., 
2013).  
Some flavonoid-rich foods have been shown to significantly decrease fasting 
blood glucose, SBP and DBP among human subjects with metabolic syndrome 
(Egert et al., 2009, Almoosawi et al., 2010, Khurana et al., 2013) or with 
hypertension (Edwards et al., 2007). However, fasting glucose, insulinemia, total 
cholesterol, LDL cholesterol, HDL-cholesterol, and triglycerides were not 
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significantly different after consumption of 500 ml of orange juice (Morand et al., 
2011). Also a meta-analysis study reported that fruit juice may have no overall effect 
on fasting blood glucose and insulin concentrations (Wang et al., 2014). To confirm 
the positive implications of flavonoids on reducing the risk of metabolic syndrome 
and T2DM, more human studies with well-defined controlled diets and design are 
required. 
The overall aims of this thesis were to investigate the bioavailability of citrus 
flavanones, specifically to consider intra- and inter-individual variation in excretion, 
and to consider the impact of citrus flavanones on cardiovascular health by assessing 
cardiovascular disease risk biomarkers after an intervention. The hypothesis is that 
flavanones improve cardiovascular disease risk biomarkers.  
Many previous studies have investigated the absorption and excretion of 
flavonoids after a flavonoid-free period followed by an acute dose of a single 
food/beverage containing a specific flavonoid of interest. It is possible that co-
ingestion of foods containing different flavonoids may affect the absorption and 
excretion, but this has not previously been investigated in humans. From cell culture 
studies there is some indication that absorption and metabolism of one flavonoid may 
be affected by another flavonoid using similar pathways of absorption. This study 
will monitor flavonoids excretion in 36 hr urine after single or co- ingestion of soya 
nuts and orange juice in 10-15 volunteers consuming a habitual diet. 
Urine and blood are normally used to monitor the absorption of flavonoids 
from the diet, but saliva is a useful biological fluid that can represent exposure to 
some dietary compounds (e.g. caffeine). To the best of our knowledge, secretion of 
flavonoids into saliva after the ingestion of food has not previously been 
investigated. Due to improved analytical capability, it should now be possible to 
monitor salivary secretion to see if there is a significant pathway in humans. Saliva 
will therefore be collected concurrent with urine samples when orange juice and soya 
nuts are co-ingested by volunteers any salivary content correlated with the urinary 
content. 
Flavonoids are compounds found in plant-based foods, and are associated 
with a reduced risk of CVD. From the previous studies, there is strong evidence that 
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orange juice and citrus foods which have higher amount of citrus flavonoids 
improved cardiovascular risk factors such as BP and blood vessel health. The 
absorption of citrus flavonoids occurs in the colon after bacteria breakdown of the 
precursor forms found in food. After flavonoids are absorbed into the blood they are 
modified by liver enzymes before they are excreted in the urine. A large range of 
citrus flavonoid have been found excreted in urine, ranging anywhere from 0-57% of 
the dose. Variation in the potential health effect may reflect the level of the citrus 
flavonoid absorbed. However, this is not often considered in human studies. 
 This study is a 4-week double-blinded, randomized, cross-over intervention 
trial using a commercially-available citrus supplement and a placebo control. It aims 
to determine whether citrus supplements reduce blood pressure and improve blood 
vessel health after 4 weeks. Furthermore, it aims to determine if there is a 
relationship between the absorption of flavonoids (as measured by urinary excretion) 
and changes in blood pressure or blood vessel health. For the first time, blood flow in 
fingertips is monitored before and after the consumption of citrus supplement using 
Endo-PAT technique. An improvement in blood pressure and/or blood flow should 
provide evidence that blood vessel health has improved through short-term (4 week) 
use of a citrus flavonoid supplement. Moreover, to our knowledge, this is the first 
time the excretion of hesperetin conjugates is measured in urine after the 
consumption of citrus supplement as tablets. 
1.7 Thesis objectives  
The overall aims of this thesis were to investigate the bioavailability of citrus 
flavanones, specifically to consider intra- and inter-individual variation in excretion, 
and to consider the impact of citrus flavanones on cardiovascular health by assessing 
cardiovascular disease risk biomarkers after an intervention. The hypothesis is that 
flavanones improve cardiovascular disease risk biomarkers 
 
The specific objectives for this thesis were: 
1- Determine the inter- and intra- variation in concentration of isoflavone and 
flavanones excreted in urine.  
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2- Evaluation of excretion of flavanones and isoflavones in saliva to assess 
whether saliva can be used as a non-invasive biological fluid for monitoring 
flavonoid intake.  
3- Investigate the effect of co-ingestion of isoflavones and flavanones on 
excretion in urine. 
4- Investigate the effect of acute or chronic exposure to flavanones on changes 
to metabolites excreted in urine. 
5- Determine whether citrus bioflavonoid supplements reduce blood pressure 
after a 4 week placebo controlled cross-over intervention. 
6- Investigate whether citrus bioflavonoid supplements affect endothelial 
function by measuring pulse amplitude tonometry (PAT) index after a 4 week 
placebo-controlled, cross-over intervention 
7- Determine if there is a potential relationship between absorption of hesperidin 
(as measured by urinary excretion) and changes in blood pressure or blood 
vessel function (PAT index). 
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Chapter 2: Materials And Methods 
2.1 Introduction  
The general methods used throughout the thesis are described in detail in this 
chapter. More specific information and experimental details are described in the 
methodology section of the relevant chapter. 
2.2 Material 
2.2.1 Solvents 
Several solvents and acids were used throughout the study and the following 
were purchased from Fisher Scientific, (Loughborough, UK) and from Sigma 
Aldrich (Gillingham, Dorset, UK): acetonitrile, methanol, ethanol and ethyl acetate 
(all HPLC grade); acetone, acetic acid glacial, formic acid, L-ascorbic acid (99%), 
and dimethyl sulfoxide (DMSO) (all analytical grade). Purified water (≥ 18.2 MΏ cm 
at 25 ºC) was obtained from a Millipore Direct-Q 5 purified system (Millipore UK 
Ltd, Hertfordshire, UK) and was used throughout the experiments in this project for 
both analytical purposes and the HPLC mobile phase. Water and acetonitrile (LC-
MS grade) were purchased from VWR International (Leicestershire, UK). 
 
2.2.2 Flavonoid standards 
All flavonoid standards used in this study were purchased from Extrasynthase 
(Genay, France). These include the following list: daidzin, daidzein, genistin, 
genistein, narirutin, naringenin, hesperidin, hesperetin, apigenin, taxifolin, and rutin.  
All standards were of HPLC purity (above 97 %). Hesperetin-3′-O-glucuronides and 
7-O-glucuronides were kindly donated by Dr Denis Barron (Nestlé Research Centre, 
Switzerland). Hesperetin-3′-O-sulfate was kindly donated by Christine Morand 
(INRA, France). 
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2.2.3 Enzymes 
All enzymes used were purchased from Sigma Aldrich (Dorset, UK) and 
stored at 4˚C or -20˚C until use. Hesperidinase (EC 3.2.1.40) from Aspergillus niger; 
the enzyme has both α-L-rhamnosidase and β–D–glucosidase activities and was 
stored at 4˚C; each unit of enzyme is able to liberate 1 µmol of glucose from 
hesperidin/min at pH 3.8 and 40˚C. Cellulase (EC 3.2.14) from Aspergillus niger was 
stored at 4˚C; one unit of enzyme will liberate 1 µmol glucose from cellulose/ hr at 
pH 5 and 37˚C. Sulfatase was from Aerobacter aerogenes Type II (EC B.1.61) and 
was stored at -20˚C; one unit will hydrolyse 1 µmole of p-nitrophenyl sulphate/min 
at pH 7.1 and 37˚C. β-Glucuronidase from Escherichia coli Type IX-A (EC 3.2.1.31) 
was stored at -20˚C; one unit will liberate 1 µg of phenolphthalein from 
phenolphthalein glucuronide/ hr at 37˚C. 
2.2.4 Buffers  
The following buffer was used throughout the study: sodium phosphate buffer 
(0.2 M, pH 7; monobasic sodium phosphate (0.2 M) and dibasic sodium phosphate 
(anhydrous). The buffer salts were purchased from Sigma (Gillingham, Dorset, UK). 
 
2.3 HPLC Analysis 
2.3.1 HPLC equipment 
All high performance liquid chromatography (HPLC) analysis was performed 
on an Agilent 1200 SL system (Agilent Technologies, Dorset, UK) which comprised 
of a binary pump (model G1312B), that was optimised to cope with the repid 
resolution (up to 600 bars pressure), an in-line vacuum degasser (G1379B), and a 
photodiode array UV-VIS detector (model G1315C) with dual-lamp (deuterium and 
tungsten) design for high sensitivity with a wavelength range of 190–950 nm. The 
column temperature was held constant (35ºC) using model G1316 column heater. A 
high performance auto sampler SL (100-vial sampler tray) for high speed sample 
injection with lowest carryover was used. Data acquisition and analysis was done by 
ChemStation software under windows XP software. The mobile phases were 
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degassed in glass bottles using an ultrasonic waterbath (15 min; Clifton, Nickle-
Electro, Oldmixon Crescent, UK) prior to HPLC analysis. A Zorbax Eclipse plus 
C18 micro-bore column (internal diameter 1.8 µm, 4.6 x 50 mm; Agilent 
Technologies, Dorset, UK) was used for all HPLC and LC-MS analysis. Prior to the 
analysis, any air bubbles from the solvent lines were flushed out by pumping both 
solvent lines individually at a flow rate of 5 ml/min for at least 5 min each. Solvent 
was then pumped through the system under the initial method conditions to allow the 
system and to come to the stable pressure and equilibration based of each method 
used. 
 
2.3.2 HPLC consumables 
The HPLC consumables used throughout this study were purchased from 
Chromos Express (Macclesfield, UK): 2 ml crimp top glass vials (12x32 mm), 11 
mm aluminium crimp caps with butyl/PTFE septa, 17 mm PTFE syringe filter (0.2 
µm pore size). Crimp top sample vials, 0.3 ml crimp top fixed insert amber glass 
vials (Fisher Scientific Ltd, Leicestershire, UK) were used when the sample volume 
was less than 1 ml to ensure accurate sampling by the auto sampler. Vials were 
capped by using a hand crimper until fully secure. 
 
2.3.3 Chromatographic conditions 
2.3.3.1 Method A for food samples (Glycoside Method) 
This method was used to analyse flavanones in orange juice and isoflavones 
in roasted soy nuts. An Agilent 1200 series rapid resolution HPLC system was used 
with the diode array detector scanning from 190 to 450 nm. A gradient of water-
formic acid (solvent A;100:0.1, v/v) and acetonitrile-formic acid (solvent B; 100:0.1, 
v/v) was applied using a flow rate of 0.5 ml/min. A 5 µl sample was injected on to 
the column and the gradient program was as follows: the initial composition 
consisted of 95% A and 5% B for 5 min, followed by a liner gradient to 10% B for 
15 min, 30% B for 5 min, and 90% B for 4 min, 5% B for 1 min and 5% B for 3 min 
50 
 
(Figure 2.1). The absorbance of eluted flavonoids were monitored at 260 nm for 
isoflavones and at 280 nm for flavanones. 
 
Figure 2.1: Solvent gradient throughout the HPLC run for method A. Solvent A is 
water + 0.1% formic acid, Solvent B is Acetonitrile + 0.1% formic acid). 
 
 
2.3.3.2 Method B for biological fluid samples (Aglycone Method) 
An Agilent 1200 series rapid resolution HPLC system was used to detect the 
flavonoids and analyse both saliva and urine samples. A gradient of water-formic 
acid (solvent A; 100:0.1, v:v) and methanol- formic acid (solvent B; 100:0.1, v:v) 
was applied using a flow rate and column temperature of 0.75 ml/min and 35ºC, 
respectively. The solvent gradient is shown in Fig. 2.2 and started at 30% solvent B, 
increasing to 40% (by 3 min), and to 70% by 15 min, and then to 95% (by 18 min). 
This was maintained for 5 min and then decreased back to 30% solvent B for 5 min 
post-run.  A sample (10 µl) was injected on to the column and the DAD scanned 
from 220 to 450 nm. Specific detection was carried out at 220, 260, 280, 310 nm for 
optimal sensitivity to each compound. The needle was washed with methanol 
between injections to prevent sample run-over. Blank water samples and two 
different concentrations of mixture of standard were run at intervals of approximately 
every 20 unknown samples as a quality control measure. 
(Solvent A) 
(Solvent B) 
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Figure 2.2: Solvent gradient throughout the HPLC run for method B. Solvent is 0.1% 
formic Acid, and solvent B is methanol containing 0.1% formic Acid. 
 
2.3.4 LC-MS Analysis of conjugated flavanones in urine and saliva samples  
The prepared samples were analyzed using LC-MS with the same C18 
column used as described above. The analysis was carried out on a LC-MS 
Shimadzu LC-2010 HT HPLC coupled with a LC-MS-2020 quadrupole mass 
spectrometer fitted with an electro spray ionisation source used in negative mode 
(Milton Keys, UK). The column temperature was maintained at 30°C, mass detector 
was set at -1.80 kV, DL temperature 250°C, and the nebulizing gas flow and drying 
gas flow were 1.50 and 15 L/min respectively. The mass spectrophotometer was set 
to assay for ions with 301, 303, 381, 477 and 609 m/z ratios, corresponding to 
hesperetin, taxifolin, hesperetin sulfate conjugates, hesperetin mono-glucuronide 
conjugates and rutin respectively. The injection volume was 10 µL and a flow rate of 
0.5 mL/min was used. Mobile phase A consisted of 0.1% formic acid in water and 
mobile phase B consisted in 0.1% formic acid in acetonitrile. Elution started at 5% 
solvent B and increased to10% after 5 min. From 5 to 20 min the gradient increased 
up to 40% and after 5 min reached 90%, which was kept for 4 min more. Then, after 
1 min the gradient dropped down up to 5% and the run finished at 33 min (Figure 
(Solve
nt A) 
(Solvent B) 
(Solvent A) 
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2.3). Pressure limits had a maximum of 370 bar and a minimum of 20 bars. The data 
files of the LC-MS were analyzed by Shimadzu Lab Solutions software. 
 
Figure 2.3 Solvent gradients throughout the LC-MS method. Solvent A is water + 
0.1% formic acid, Solvent B is Acetonitrile + 0.1% formic acid). 
 
 
2.4 Methods  for extraction of flavonoids from food samples 
2.4.1 Extraction of orange juice 
A method by Mullen et a.l, (2008) was used with some modification. Orange 
juice (5 ml) in triplicate was mixed with 80% methanol (5 ml), vortexed (2 min) and 
then centrifuged (5 min at 3000 g, 20°C). The supernatant was removed and an 
additional 5 ml of 80% methanol was added to the remaining pellet, and the 
procedure was repeated. The pellet was extracted three times, and supernatants were 
combined and filtered (0.2 µm PTFE filter) and then analysed by HPLC using 
method A. 
The flavonoids in the sample were also hydrolysed by enzymes. Sodium 
phosphate buffer (2 ml; pH 3.5) containing hesperidinase enzyme (0.02 U/ml) was 
added to 2 ml of orange juice. The mixture was incubated for 18 hr in a shaking 
water bath at 37°C and 100 rpm (Grant OLS 200,Grant Instruments, Ltd, UK). After 
incubation, methanol (80%, 8 ml) was added and the sample was centrifuged (5 min 
(Solvent B) 
(Solvent A) 
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at 3000 g, 20°C). The supernatant was taken, filtered through 0.2 µm PTFE filter and 
analysed by HPLC. Samples were analysed in triplicate with 5 µl injected, using the 
HPLC system, using method (A) (section 2.3.3.1). 
 
2.4.2 Extraction of soya nuts 
A method described by Liggins et al., (1998) was used, with some 
modifications, to determine the daidzein and genistein in soya nuts. Triplicate 
samples of freeze dried soya nuts (2.5 g) were mixed with methanol (5 ml, 80%), the 
mixture was then vortexed for 2 min and left to incubate at 37°C for 1 hr in a 
waterbath. The mixture was vortexed again for 1 min and centrifuged for 5 min at 
3000 g, 20°C. The same procedure was performed with the pellet, which was 
extracted another two times and the whole supernatant was combined and filtered 
through 0.2 µm PTFE filter before analysis by HPLC.  
For enzyme hydrolysis, 0.5 g freeze dried soya nuts samples (in triplicate) 
were weighed and 10 ml of freshly boiled water was added and left for 5 min with 
occasional stirring. A volume of acetate buffer (10 ml; pH 5) containing cellulase 
(100 U/ml) was added. The mixture was incubated for 18 hr in a shaking waterbath 
at 37°C. After incubation, 30 ml of 80% methanol was added and centrifuged for 5 
min at 3000 g, 20°C. The supernatant then was collected, and filtered through a 0.2 
µm PTFE filter prior to HPLC analysis, (section 2.3.3.1). 
2.4.3 Extraction of urine samples to assess flavonoid aglycones 
Upon arrival in the lab, the volumes of urine sample were measured. Aliquots 
(2 x 50 ml) were centrifuged at (2000 g, 4°C for 10 min) to remove insoluble 
materials and cellular debris, and then the supernatant was taken and stored at -20°C 
until analysed (Appendix . 14).  
Urine was defrosted and centrifuged for 5 min at (3000 g at 20 ˚C). A volume 
of apigenin solution (10 µl of 2 mg/ml) was added as internal standard to 1 ml 
portions of urine. Sodium phosphate buffer 150 µl (0.2 M at pH 7) enriched with 5 
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U/ml of β -glucuronidase and 0.03 U/ml of sulfatase was added to the urine sample. 
These samples were then incubated in a shaking water bath at 37°C and 100 rpm for 
2 hr. A portion of 1 ml ethyl acetate was added to each hydrolysed urine samples and 
vortexed for 2 min. The samples were centrifuged for 5 min (3000 g, 20˚C) and the 
supernatant removed. The washing procedure was repeated twice more, so that there 
was 3 ml of ethyl acetate supernatant extract pooled together. The sample was then 
dried using the centrifugal evaporator (Genevac EZ-2 MK2, Ipswich, UK), using the 
low boiling point program (40
o
C for 2 hr). 
The evaporated samples then were reconstituted in 1 ml of aqueous methanol 
solution (50% methanol, 50% 200 μM ascorbic acid solution (v/v)). The samples 
were then vortexed for 2 min and sonicated for 2 min. until the samples were fully 
dissolved, and then centrifuged at 3000 g for 10 min. The supernatant was filtered 
(0.2 μm PTFE filters) prior to HPLC analysis.  
 
2.4.4 Urine and saliva preparation to determine flavanone conjugates  
The protocol for urine and saliva preparation was based on the method 
developed by Sang et al., (2008) with some modification. The urine was defrosted 
and vortexed for 30 sec before sonication for 5 min. The urine was vortexed again 
for 30 sec and 200 μl was removed for analysis. This was mixed with 100 μl rutin as 
internal standard 1 (IS1, 4.5 μg/ml), 100 μl of ethanol and 800 μl of methanol. This 
solution was then placed in shaking waterbath at 50˚C, at 110 rpm for 10 min to 
achieve the solubilisation of the compounds. The mixture was then centrifuged for 10 
min at 17000 g. The supernatant was removed as the first extract (extract A) and the 
process was repeated for the pellet (extract B) using water in the place of urine. The 
primary and secondary extracts were then dried down using centrifugal evaporation 
(5 hr, 46˚C; HPLC program with the lamp off) to achieve the evaporation of the 
methanol and ethanol layer. The dried samples were stored at -20˚C until analysis. 
Methanol (70 μl) was added to extract B. This solution was then vortexed for 30 sec, 
sonicated and placed in a shaking waterbath for 10 min. A 50 μl sample of extract B 
was then taken and placed with extract A, and vortexed for 30 sec, sonicated and 
placed in a shaking waterbath for 10 min.  
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For analysis, 50 μl of taxifolin as internal standard 2 (IS 2, 4 µg/ml in 0.2% 
ascorbic acid) was added to the combined solution, vortexed for 30 sec, and 
sonicated for 5 min. The sample was centrifuged for 10 min at 17,000 g and the 
supernatant was placed into amber HPLC vials. The vials were well capped and 
placed in the fridge (5˚C) until the LC-MS run. Triplicates were prepared and 
analyses using the LC-MS method (section 2.3.4).The same procedure was used to 
extract saliva samples with some modification in the volume where 100 µl instead of 
200 µl, was taken. 
 
2.5 Calibration curves and limit of detection 
2.5.1 Methods 
Stock solutions (2 mg/ml) of all standards were prepared in DMSO in 
methanol (0.1% DMSO): the flavanones - hesperidin, narirutin, hesperetin, 
naringenin and the isoflavones - daidzin, genistin, daidzein, genistein, and apigenin, 
taxifolin and rutin used as internal standards. Stock solutions were sonicated for 2 
min until fully dissolved and stored at –20 °C until analysed. A serial dilution was 
prepared for each compound from 5 – 100 µg /ml. Samples were filtered (PTFE 0.2 
µm pore size) prior to HPLC analysis. 
Calibration curves were constructed for each standard at six concentrations in 
duplicate. Regression analysis was assessed to determine the linearity of calibration 
curves. The result showed that the peak area was linearly correlated with on-column 
amounts over the range of (20 – 393 µM), (18.5 – 370 µM), (16.5 – 331 µM), (18.3 – 
367 µM) and (18.5 -370 µM) for daidzein, genistein, hesperetin, naringenin and 
apigenin, respectively.  
There are several definitions which are used to define limit of detection 
(LOD) and limit of quantification (LOQ). In general, LOD is taken as the lowest 
concentration of an analyte in sample that can be detected, but not quantified. The 
LOQ is the lowest concentration of an analyte in a sample that can be determined 
with acceptable precision and accuracy under the stated condition of the test 
(Shrivastava and Gupta, 2011). 
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The method used to estimate the detection and quantification limit is based on 
calculation from the calibration line at low concentration using the equation below: 
LOD = F*SD/b 
LOQ = F*SD/b 
Where  
F: factor of 3.3 and 10 for LOD and LOQ, respectively 
SD: Standard deviation of intercept,  
b: Slope of the regression line 
The LOD and LOQ for each standard were established at their particular 
maximum UV wavelength when the signal to noise ratio of peak height was at 
three and ten respectively. Recovery, accuracy and selectivity of the standards 
were evaluated intra-day by performing triplicate injections for each 
concentration. The inter-day reproducibility test was carried out by analysing two 
injections on two different days. Each aliquot of these solutions were injected on 
to the HPLC system and calibration curves were done by plotting concentration 
against peak area of each compounds and then regression equation was calculated 
for each curve for each flavanone and isoflavone. Accuracy of HPLC methods 
was evaluated by analysing blank urine samples spiked and non-spiked by 
appropriate concentration of the target compounds. The recovery was calculated 
by comparing the detemined amounts of extracted urine with the known amounts 
added. Moreover, the areas of peaks and retention times were identified in human 
urine with and without enzymatic analysis to identify evidence of inference from 
the matrix or other analytes. Control samples were prepared for each urine sample 
in duplicate, replacing the enzyme-enriched buffer with non-enriched buffer. 
2.5.2 Results 
Calibration curves were performed for each standard at 6 concentrations in 
duplicate. The R
2
 was greater than 0.99 for each standard using the 
chromatographic conditions mentioned in the methods previously (section 
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2.3.3.1) and (section 2.3.3.2) for glucoside and aglycone form, respectively. The 
slopes of peak area aginst the concentration of the standard (µg/ml) were as 
follows: daidzein 46.2, genistein 43.1, hesperetin 25.2, naringenin 26.1, daidzin 
10.2, genistin 6.2, narirutin 13.3, hesperdin 13.3, apigenin 16.7, taxifolin 8.46 
µg/ml. The limits of detection and quantification for these methods for 
isoflavones and flavanones standards are presented in Table 2.1. The precision of 
the methods were tested by both intra-day and inter-day and coefficient of 
variation was below 3% and 4.5%, respectively. The accuarcy of intra-day and 
inter-day accuracy were demonstrated across the concentration range with 
relative error of less than 6%. Standard curve of flavanones and isoflavones are 
shown in figure 2.4 and 2.5. 
 
Table 2.1: Limit of detection and quantification of isoflavones and flavanones 
compounds. 
 Limit of detection (LOD) 
(µg/ml) 
Limit of quantification (LOQ) 
(µg/ml) 
daidzein 0.19 0.66 
genistein 0.34 1.12 
naringenin 0.35 0.74 
hesperetin 0.22 0.74 
Daidzin 0.91 3.01 
Genistin 1.04 3.4 
narirutin 0.68 2.27 
hesperidin 2.5 8.4 
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Figure 2.4 Standard curves: (A) daidzein, (B) genistein at 260 nm (C) hesperetin and 
(D) naringenin, 10 µl injected in the column at 280 nm, by using HPLC-DAD.  
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Figure 2.5 Standard curves of (A) Narirutin (B) Hesperidin at 280 nm and (C) 
daidzin (D) genistin, 5 µl injected in the column at 260 nm, by using HPLC-DAD.  
 
The identification of flavanoids in the food and biological samples were 
based on comparison of retention times to authentic standards, and the UV 
absorption spectral characteristics, as shown in figure 2.6. 
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Figure 2.6: UV absorption spectra of flavanone and isoflavone standards daidzein 
(A), genistein (B) at 270 nm, hesperetin (C), naringenin (D) at 280 nm. 
 
 
An HPLC chromatogram showing a mixture of flavanone and isoflavone 
aglycone standards is shown in Figure 2.7. The peaks of the flavanones and 
isoflavones were well separated at 6.8, 7.8, 8.4, 8.7 and 10 min for daidzein, 
naringenin, genistein, hesperetin and apigenin, respectively. An HPLC 
chromatogram of a mixture of flavanone and isoflavone glycosides standards are 
shown in Figure 2.8 The peaks are well separated at 11.1, 14.0, 15.4, 17.4 and 23.1 
min for daidzin, genistin, narirutin, hesperidin and apigenin, respectively. 
Daidzein (A) Genistin (B) 
Hesperetin (C) Naringenin (D) 
Wavelength (nm) Wavelength (nm) 
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Figure 2.7: Reversed –phase HPLC chromatogram of a mixture of aglycone 
standards. Peak identity: P1- daidzein, P2- naringenin, P3- genistein, P4- hesperetin, 
P5- apigenin. 
 
Figure 2.8: Reversed –phase HPLC chromatogram of a mixture of glycoside 
standards. Peak identity: P1- daidzin, P2- genistin, P3- narirutin, P4- hesperidin, P5- 
apigenin.  
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2.5.3 Verification and identification of flavanone and isoflavone peaks 
The identification of eluted flavonoids was determined based on the 
following methods:  
a) UV Absorption spectra. Most flavonoids have a distinct UV spectrum, 
which is very useful for determining compounds expected in samples. 
However it is difficult to identify the aglycone or conjugate, or very 
similar flavonoid subclasses using spectral characteristics. 
b) Retention times. Hydrophobic aglycone flavonoids will elute later in 
reserved-phased HPLC, and hydrophilic glycosides or conjugate 
metabolites will elute earlier. Therefore comparing the retention time 
of the reference standard compound with the eluted unknown, 
especially in combination with the UV spectrum can help identify the 
flavonoid. 
c) Spiking. The sample was spiked with a known amount of flavonoid 
standard to verify the change in peak area of the target flavonoids; the 
peak area was compared before and after spike. 
d) Mass. For some samples (hesperetin conjugate metabolites), LC-MS 
was used to identify the mass of the parent compound. Along with the 
retention time and the UV spectrum this will add to the evidence to 
identify the right flavonoid. see chapter 7for more details  
2.6 Data Analysis 
Chemstation and Post-Run (LC-MS run) analysis took place using Chemstation 
and Lab-Solutions software. These data (peak areas and chromatograms) were 
further analyzed after combined with already known data (amount of juice ingested 
by each subject, hesperidin concentration in orange juice, urine volumes before and 
after each treatment). The calculations and the statistical analysis were performed 
using IBM SPSS Statistics 22. The comparison between and among the subjects or 
the treatments, was achieved using the paired t-test and ANOVA test, whereas the 
means and standard deviations were calculated using descriptive statistics. 
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Chapter 3: The Effect Of Flavanone And Isoflavone Co-
Consumption On Salivary And Urinary Excretion In Humans 
 
3.1 Abstract  
Chapter 3 investigates the bioavailability of flavanones and isoflavones by 
measuring the urinary excretion after orange juice and soya were consumed 
separately or co-ingested. The hypothesis was that the intra-individual variation in 
excretion in these compounds would be similar despite the large inter-individual 
variation – i.e. a high isoflavone excretor will also be a high flavanone excretor. 
Furthermore, the excretion of isoflavones and flavanones in saliva was evaluated.  
Fifteen subjects (eight women and seven men) with a mean age of 31±6.1 y 
(range 22 – 44 y) were recruited, with a mean BMI of 20±3.6 kg/m2 (range 15 – 27 
kg/m
2
). After two days on a low flavonoid diet they consumed 25 g roasted soya nuts 
and/or 500 ml orange juice, on each of three separate days. Urine was collected in 
different fractions (0, 0-4, 4-8, 8-12, 12-24 and 24-36 hr) in each phase, and saliva 
was collected each 2 hr from 0-12 hr, then at 24 hr and 36 hr, but only in the co-
ingestion phase. Urine and saliva samples were analysed by HPLC-DAD for 
flavanones and isoflavones after enzyme hydrolysis. 
There was considerable inter-individual difference in urinary excretion of 
flavanones and isoflavones after single and co-ingestion of orange juice and soya 
nuts. Total urinary excretion (% dose ingested) of hesperetin, naringenin, daidzein 
and genistein was 2.5, 9.2, 27.1 and 19.2%, respectively, when the soya nuts and 
orange juice were ingested separately. When the compounds were co-ingested 
excretion (% dose ingested) was 3.0, 8.6, 28.1 and 16.8%. There was a strong 
positive correlation between urinary excretion of daidzein and genistein for both 
single and co-ingestion. Similar results were found with hesperetin and naringenin. 
Daidzein was excreted to a greater extent than genistein; naringenin was also 
excreted to a greater extent than hesperetin. The cumulative amount of naringenin, 
daidzein and genistein excreted in urine after a single or co-ingested dose was similar 
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for all compounds, but this was not the case for hesperetin which had a significantly 
higher average excretion between 8-12 hr. Flavanones and isoflavones were not 
detected in the saliva at any time point under the conditions used. 
In conclusion a large inter-individual variation in urinary excretion of 
flavanones and isoflavones was observed between subjects. The largest variability 
based on the recovery in urine after 36 hr was observed for daidzein which ranged 
between 7% - 65% of dose ingested. High and low excretors of these flavonoids 
seem to have consistent excretion behaviour for different flavonoids only when co-
ingested. Moreover, salivary flavonoid was not a reliable biomarker for citrus or soya 
intake. 
 
3.2 Introduction: 
Flavonoids are polyphenolic compounds that can be widely found in fruit and 
vegetables, whole grains and legumes. Consumption of flavonoid-rich foods is now 
generally accepted to be beneficial for health. Flavanones are a subclass of 
flavonoids found in considerable amounts in citrus fruits (Scalbert and Williamson, 
2000). Hesperetin and naringenin are present in foods as their respective glycosides; 
hesperidin (hesperetin-7-O-glucose-(1-6)-rhamnoside) and narirutin (naringenin-7-
O-glucose-(1-2)-rhamnoside (see Fig 1-5 chapter 1). The glycoside must be 
hydrolysed by the gut microflora before these compounds can be absorbed (Manach 
et al., 2003). Intestinal microflora, which are responsible for breaking down 
naringenin and hesperidin, vary among individuals. As a result, varying degrees of 
absorption occur (Erlund et al., 2002). There is a substantial inter-individual 
variation in bioavailability of flavanones (Brett et al., 2009) with differences in 
bioavailability attributed to the differences in composition and metabolism of enteric 
microflora populations between individuals (Nielsen et al., 2006, Spencer et al., 
2008). The consumption of flavanones has been associated with a reduction of the 
risk of cardiovascular disease as reviewed by Chanet et al., (2012b). 
Isoflavones are dietary phytoestrogenic compounds found widely in legumes (Del 
Rio et al., 2013). Soybeans are the main source of the isoflavones genistein and 
daidzein (Erlund, 2004). Considerable inter-individual variation in excretion of 
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daidzein and genistein has also been reported (King and Bursill, 1998). The main site 
of absorption is in the distal small intestine and colon after bacterial de-conjugation. 
This is despite the potential for early absorption of the mono-glucosides, daidzein-7-
O-glucoside (daidzin) and genistein-7-O-glucoside (genistin) after hydrolysis by 
lactase phlorizin hydrolase (Day et al., 2000b). This is probably a result of low 
affinity for the enzyme and the presence of malonyl and acetyl esters of daidzin and 
genistin in the food source (Wiseman et al., 2002). Furthermore, daidzein may be 
metabolised by gut bacteria to equol, and only some people (approximately 30% of 
the population) have the right bacterial microbiome to produce this estrogenic 
compound (Chanet et al., 2012, Del Rio et al., 2013). Epidemiological evidence has 
shown that the high consumption of soy foods by many Asian populations reduced 
the incidence of chronic diseases such as breast and prostate cancer, and CVD (Cao 
et al., 2010), with intervention trials indicating a reduction of blood pressure 
(Morand et al., 2011). 
Although there is a large volume of literature on flavanones and isoflavones 
in plasma and urine, very few studies reported the level of flavonoids in saliva. 
Saliva as a biological fluid contains a large number of biochemical compounds some 
of which may indicate health status (Thomas et al., 2009). To the best of our 
knowledge, only one study found isoflavones in saliva after food ingestion. In this 
study, 166 full term infants between birth and 1 year of age were recruited into soya 
formula, cow’s milk formula or breast milk groups. The study investigated the 
correlation between urinary, salivary and blood concentration of the isoflavones. 
Daidzein and genistein were undetectable in most blood and saliva samples from 
children fed breast milk or cow’s-milk formula. However, they were detected after 
soya milk formula. Both genistein and daidzein had the highest median concentration 
in the urine, followed by blood and then saliva (Cao et al., 2009).  
In another study  (Tsuchiya et al., 1997), catechins were determined in human 
saliva in the concentration range (0.05-25 µg/ml). However these salivary catechins 
were determined after a green tea extract solution was used to rinse the mouth. None 
of the catechins were detected in saliva before mouth-rinsing. However, significant 
amount were found after mouth-rinsing the oral cavity with green tea extract even 
after 1 hr. Catechins and theaflavins compounds, derived from tea, have been tested 
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for the delivery to the oral cavity after holding both green tea leaves (2 g) or brewed 
black tea (2 g) in the mouth for 2-5 min and thoroughly rinsing the mouth. 
Concentration of (2.2-131 µM) and (0.6-1.8 µM) of catechins and theaflavins, 
respectively, were observed in saliva in the first hr (Lee et al., 2004).  
Walle et al., (2005) investigated the hydrolysis of flavonoid glucosides by 
saliva β-glucosidase. Un-stimulated saliva was collected from 17 participates. 
Flavonoid glycosides were hydrolysed to their aglycone in the oral cavity and high 
inter-individual variability was found; up to 20-fold for genistein-7-glucoside. 
Another cross-over study was conducted with 10 non-smoking volunteers between 
19-61 years old. The result from a β-glucoside assay confirmed that whole and 
microflora-reduced saliva can hydrolyse black raspberry anthocyanins to their 
aglycone cyanidin (Mallery et al., 2011). Similarly, beta-glucuronidase activity in 
saliva in relationship to some clinical parameters was investigated and it was 
concluded that high salivary β-glucuronidase activity existed (Lamster et al., 2003). 
To the best of our knowledge, only one study to date conducted and compared the 
isoflavone concentrations between blood, saliva and urine (Cao et al., 2009). 
As saliva would make an excellent non-invasive biological fluid to study 
flavonoid exposure, it is important to assess if flavonoids can be detected easily. As 
one study has found evidence of isoflavones in saliva, it was useful to use 
isoflavones as a positive control when assessing potential flavanone secretion in the 
saliva. Furthermore, soya isoflavones and citrus flavanones have the following 
related characteristics which make them interesting to study:  
(i) They are limited in the distribution across foods. 
(ii) They are predominantly absorbed in the large intestine. 
(iii) There is a wide variation in amounts excreted between individuals. 
(iv) They both have a reasonable level of excreted compounds in urine (as % 
of dose), compared to other flavonoid sub-classes, which suggests they are 
more resistant to ring fission by gut bacteria, 
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(v) They have both been shown to reduce blood pressure in intervention 
trials. 
3.3 Aims of the study 
The purpose of this study is to assess the variation in excretion of flavanones 
and isoflavones in volunteers. The hypothesis is that the intra-individual variation in 
excretion in these compounds is similar despite the large inter-individual variation – 
i.e. a high isoflavone excretor will also be a high flavanone excretor. 
 
The main aims are as follows: 
 To investigate the pattern of isoflavone and flavanone excretion after single 
or co-ingestion of flavonoid-rich foods containing these compounds. 
  To assess any correlation between excretion of isoflavones and flavanones. 
 To determine the possibility of using saliva as a non-invasive biological fluid 
to monitor flavonoid intake from food.  
3.4 Materials and Methods 
For a detailed description of the materials, see chapter 2. Orange juice 
(Tropicana100% Orange Juice, “Not from Concentrate”), and sachets of dry-roasted 
soya nuts (25 g; Food Doctor, London, UK) were purchased from Morrison’s 
supermarket between January 2011 and August 2011.  
 
3.4.1 Human study design 
The human study was designed as a cross-over, randomised (day 1 and 2), 
intervention using roasted soya nuts and fresh orange juice. The proposal was 
reviewed and approved by the MEEC Faculty Research Ethics Committee, 
University of Leeds, at its virtual meeting on 16
th
 August 2010; Ethics reference 
number MEEC 10-001 (see Appendix 1). Healthy volunteers who responded to the 
posted flyers/circular email were invited to read the study information sheet (see 
Appendix 2) and the study protocol was fully explained to each subject prior to the 
start of the study. Having given their verbal and written informed consent (see 
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Appendix 3), participants were asked to fill in a basic health questionnaire recording 
age, gender, height, weight, medical and surgical history, medications taken to 
ensure the suitability of the volunteers for study inclusion (Appendix 4). 
All subjects recruited were students (both male and female) from different 
Faculties (University of Leeds, UK) who fulfilled the following criteria: the 
volunteers were healthy, non-smokers, no use of vitamins or food supplements in the 
previous 3 months, no known history of allergy to soya or citrus fruit, no prescribed 
medication or antibiotics in the recent 3 months prior to study, no extreme diet (e.g 
vegan), no exercise regimes requiring significant dietary changes, they had normal 
body mass index (BMI) between 19 – 27 kg/m2 , were not pregnant or breast feeding 
and aged between 20 – 65 y. 
3.4.2 Study Protocol 
The study consisted of 3 separate days. Each  study day had a minimum of 24 
hr between them. Participants were encouraged to consume their normal diets prior 
to the study. However, participants were asked not to consume citrus fruits and 
juices, and soya products (or supplements containing these) for 48 hr prior to, and for 
the duration of the study day. Participants were given a list of food to be avoided or 
allowed (table 3.1). Participants were randomized by dividing into groups A and B. 
Group A was assigned to start with ingestion of orange juice as the first phase, while 
group B in this period ingested roasted soya nuts. In the second phase, Group A 
switched to soya and Group B switched to orange juice. Finally in the third phase all 
participants consumed soya nuts and orange juice together. The three phases were 
separated by a washout period of 24 hr at least. The protocol is summarised in the 
follow diagram Figure 3.1. 
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Table 3.1: List of foods to avoid 
Food items to avoid 
Soya beans (fresh, dried roasted nuts, flakes, flour, etc) bread containing soya flour  
Soya milk or drinks 
Tofu, Tempeh, Miso, Natt ,  Aburaage 
Soy-based desserts and yogurts containing phytoestrogens 
Soy sauce 
Soy protein Isolate 
Cereal bars and breakfast cereals for vegetarians 
Vegetarian Burgers and Nuggets and other vegetarian processed 
foods containing soya Citrus fruits in any form (fresh, canned or dried) 
Fruit juices, squashes and jams containing citrus fruits 
Tomato and tomato-based products (juice, paste, sauce, etc.) 
Red wine, Tea, coffee, onion ( items try to reduce as much as possible) 
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Figure 3.1: Intervention study 1 flowchart. 
 
3.4.3 Phase 1 and 2: single food ingestion 
Participants were provided with purpose-designed unisex urine collection 
containers and jug to be used for each study day. These were labelled by subject 
codes to maintain their anonymity. On the day of the study, participants were 
asked to void their bladder immediately on waking, and then have a glass of water 
(200-300 ml). Approximately an hour later (e.g. 8:00 am), the volunteers should 
again void their bladder and this time collect the urine sample in the baseline-
labelled bottle. Soon after the baseline urine collection, the volunteers were asked 
to consume either the orange juice (500 ml), or the sachet of soya nuts (25 g) and 
water (both which had been provided), depending on whether they were in group 
A or B. They were also invited to consume a slice of bread or toast with butter. 
The time of consumption was recorded and no other foods were consumed for the 
first hour. All other foods consumed during the day were recorded using the 
questionnaire (see appendix 5). Urine was collected in separate labelled bottles 
containing 1g/L ascorbic acid was added in six different fractions (0 – baseline, 0-
4, 4-8, 8-12, 12-24 and 24-36 hr), and the times recorded by the participant. All 
urine samples were returned to the School of Food Science and Nutrition. The 
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volume was measured and recorded for both baseline and all the 36 hr fractions. 
Urine samples were centrifuged (10 min, 2000 g, 4ºC) to remove insoluble 
materials and cellular debris (see appendix 6), and aliquots of the supernatant 
stored at -20°C until analysis. 
 
3.4.4 Phase 3: Co-ingestion of foods 
The volunteers were provided with 9 labelled salivette containers (Sarstedt, 
AG & Co., Germany) for the collection of saliva on the 3
rd
 study day and given 
instructions on how to use it (Walsh et al., 2006). After an overnight fast, the mouth 
was thoroughly rinsed with tap water, and then the un-stimulated whole saliva was 
collected on a cotton swab. Briefly the cotton swab was placed directly into the 
mouth by tipping the tube into the mouth and gently chewing and rolling the sponge 
around the mouth for 2 minutes before spitting it back into the tube (see Appendix 
7). The salivette samples were then kept in the fridge until transported to the lab next 
day. The volume of the spot saliva was recorded and then all samples were 
centrifuged (3000 g, 5 min, 4ºC) to remove any solid debris from the saliva samples, 
before a portion (500 – 2000 µl) of the supernatant was transferred to a new 
eppendorf tube and stored at -20ºC.  
Volunteers were asked to void their bladder immediately on waking, and then 
have a glass of water (200-300 ml). Approximately an hour later (e.g. 8:00 am), the 
volunteers should again void their bladder and this time collect the urine sample in 
the baseline-labelled bottle. A baseline saliva sample was collected at this time. Soon 
after the baseline urine collection, the volunteers asked to consume both the orange 
juice (500 ml) and a sachet of soya nuts (25 g) provided. The time of consumption 
was recorded and no food was consumed in the first hour after consumption of the 
foods. Urine was collected in separate labelled bottles for each time point, 0-4, 4-8, 
8-12, 12-24, 24-36 hr. Saliva also was collected in salivettes as described above, after 
rinsing the mouth with tap water, at approximately 0, 2, 4, 6, 8, 10, 12, 24 and 36 hr 
(time was recorded). All other foods consumed during the day were recorded. 
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3.5 Sample analysis 
Upon arrival in the lab, the volumes of urine sample were measured and 2X 
50-ml aliquots were taken using ameasuring cylinder. Urine aliquots are then 
centrifuged at 2000 g, 4°C for 10 min to remove insoluble materials and cellular 
debris, then the supernatant was taken and samples were then stored at -20 °C until 
analysed (see Appendix 6). Urine samples were defrosted and centrfuged for 5 min 
at 3000 g at 20°C, and treated as follows prior the analysis by HPLC-DAD. The 
HPLC method used to measure the concentration of flavanones and isoflavones as 
aglycone in urine was previously described in chapter 2.  
 
3.5.1 Extraction and hydrolysis of food flavonoids 
Orange juice and soya nut samples (both in triplicate) were analysed with and 
without enzyme hydrolysis of the flavonoids, as described in sections 2.4.1 and 2.4.2, 
respectively. The extracted samples were analysed by HPLC using the methods 
described in 2.3.3.1 and 2.3.3.2 for glycosides and aglycones, respectively. 
3.5.2 Extraction and hydrolysis of urine samples 
Urine samples (in triplicate) were analysed with enzyme hydrolysis of the 
flavonoids, as described in 2.4.3, and analysed using the aglycone method as 
described in section 2.3.3.2). 
 
3.5.3 Extraction and hydrolysis of saliva samples 
Defrosted saliva samples were vortexed for 30 sec, and 100 µl of saliva was 
added to 5 µl of apigenin solution (2 mg/ml) and 20 µl of sodium phosphate buffer 
(0.2 M, pH 7) enriched with 5 U/ml of β-glucuronidase and 0.03 U/ml of sulfatase 
(details in section 2.2.3). These samples were then incubated in a shaking water bath 
at 37°C and 100 r.p.m for 2 hr. 
Ethyl acetate (0.5 ml) was added to each hydrolysed saliva sample and 
vortexed for 2 min, followed by centrifugation (10 min, 17000 g, 20˚C). The 
supernatant was removed and the precipitate was extracted twice more, ending up 
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with 1.5 ml of ethyl acetate supernatant. This sample was then placed in the 
centrifugal evaporator, using the low boiling point program at 40
°
C for 1 hr. 
The dried samples were reconstituted in 100 µl of aqueous methanol solution 
(50% methanol; 50% 200 μM ascorbic acid solution, v/v). The samples were 
vortexed for 2 min, and sonicated for 2 min until the samples were fully dissolved in 
the solution then 90 µl of supernatant was placed in HPLC vials for analysis. 
Samples were analysed by HPLC (see section 2.3.3.2) and by LCMS analysis 
(section 2.3.4). 
 
3.5.4 Protein assay 
The Bradford Coomassie-binding colorimetric method was used to determine 
total protein content in the saliva samples. Bovine serum albumin (BSA) and 
Bradford reagent were purchased from Sigma (Poole, UK). Stock solutions of BSA 
were made between 100-1500 µg/ml and saliva samples (in duplicate) were diluted 
1:5 in buffer Aliquots (5 µl) of BSA standards and saliva samples were pipetted into 
a 96-well plate along with 250 µl Coomassie reagents. The plate was mixed on a 
plate shaker for 30 sec, incubated at room temperature for 10 min, and the 
absorbance read at 595 nm using a multi-well microplate reader (Multiskan FC, 
Thermo Scientific, China). The protein content of the saliva sample was calculated 
by subtracting the blank reagent value from the saliva sample reading. The protein 
content of extracted saliva samples was also monitored to confirm that all protein 
was precipitated by this process. 
3.5.5 Recovery of flavonoids compounds from different matrices 
Before analysing the biological samples (urine and saliva) from the human 
intervention study 1, the recovery of hesperetin, naringenin, genistein, daidzein and 
apigenin were confirmed by using blank baseline urine and saliva samples. The 
procedure could then be identified to allow for a good recovery of the compounds 
investigated. Two procedures have been used: free form of flavanones (ethyl acetate 
extraction) (see section 2.4.3) and one for hesperetin conjugates (present after 
precipitation of proteins using methanol and ethanol extraction). As the conjugated 
(sulfate or glucuronide) derivatives of isoflavones and flavanones were not available 
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commercially, the conjugates were not quantified by LC-MS in this study; however 
an assessment of the conjugate for was tentatively made by LCMS at m/z ratios 
relating to the conjugate form expected. Furthermore, to ensure that flavanones and 
isoflavones were recoverable from the saliva matrix various control experiments 
were carried out, as outlined in Table 3.2. 
Table 3.2: Control experiments to determine potential recovery of flavonoids from 
saliva matrix. 
Matrix Spiked 
compounds 
Reaction Rationale 
Water daidzein + 
genistein 
water Control – standards without interference 
of matrix 
Water daidzein + 
genistein 
hydrolysing 
enzymes 
Recovery control – recovery of standards 
after enzyme hydrolysis without 
interference of matrix 
Water water hydrolysing 
enzymes 
Control - potential interfering compounds 
in enzyme mixture 
Blank saliva water hydrolysing 
enzymes 
Control - potential interfering compounds 
in enzyme mixture and saliva 
Blank saliva water water Control - potential interfering compounds 
in saliva 
Blank saliva daidzein + 
genistein 
water Control – identification of aglycones with 
interference of saliva matrix 
Blank saliva daidzein + 
genistein 
hydrolysing 
enzymes 
Recovery control – identification of 
aglycones with interference of saliva 
matrix and enzymes, and recovery after 
enzyme hydrolysis 
Water (75%) urine (subject 4, 
12 hr) (25%) 
water Control – identification of metabolites 
without interference of saliva matrix 
Blank saliva urine (subject 4, water Evidence of conjugates after extraction 
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(75%) 12 hr) (25%) from saliva matrix 
Active saliva water water Sample analysis for presence of 
conjugates 
Active saliva water hydrolysing 
enzymes 
Sample analysis for presence of aglycones 
after hydrolysis 
3.6 Statistical analysis 
The results were expressed as mean ± SE unless otherwise stated. For each 
flavonoids compounds detected and quantified, the maximum observed urine 
concentration (urinary Cmax and time to reach urinary Cmax (urinary Tmax) were 
determined by visual inspectation of volunteers urine concentration time profile. 
The relative bioavaliblity of flavanones and isoflavones was calculated as 
precentage form the total a mount of these compounds excreted in urine over 36 
hr divided by the amount consumed from the experimental food. Spearman’s rank 
correction coefficients were calculated to evaluate the relation between the single 
and co-ingestion consumption patterns. A potential period effect was tested by a 
two-sample t-test to compare differences between different treatments. Moreover, 
the average of excretion was compared between phase 1,2 and 3, with the 
significance level set to 5%. A wide range of sample sizes was observed in the 
previous studies used for this analysis and the smallest sample used was 3 
participants and the most common sample sizes were 5 – 20 participants to show 
important finding from this analysis. Therefore, sample size of 15 was the target for 
this study. All of the statstical analyses were preformed using the Statistical 
software (SPSS) for windows, version 22. 
3.7 Results 
3.7.1 Subjects 
Fifteen healthy subjects gave their consent and completed all three phases of 
the study. Their characteristics are shown in Table 3.3. The study was reviewed and 
approved by the MEEC Faculty Research Ethics Committee, Ethics reference 
number is (MEEC 10-001) University of Leeds. 
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Table 3.3: Participant Characteristics 
Characteristics Mean ± SD, range 
Number of subjects 15 
 Male 7 
Female 8 
Age 
 
31 ± 6.1 (22 – 44) 
Body mass index (kg/m2) 
 
20 ± 3.6 (15-27) 
  
3.7.2 Quantification of flavonoids in food samples 
The identification of flavanones and isoflavones in food and biological fluid 
samples was based on the retention time of the eluted sample with that of the 
respective standard compound, the specific absorption spectra maxima for each 
reference compound, and confirmation on spiking of the sample with the authentic 
standard. LC-MS analysis was also carried out on selected saliva and urinary 
samples. Chapter 4 thoroughly explains the analysis of the flavonoid content for each 
food sample using enzyme hydrolysis.  
Figure 3.2 shows a typical HPLC chromatogram of the orange juice used in 
the study. Narirutin and hesperidin were the main peaks identified (peaks 1 and 2), 
and the orange juice contained 80 mg/L and 420 mg/L of narirutin and hesperidin, 
respectively. Hesperetin and hesperetin-7-glucoside were not present in the sample 
above the limit of detection.  
As daidzein and genistein are present as glucosides and also esterified to 
malonyl and acetyl groups in soya nuts, enzyme hydrolysis was used to hydrolyse the 
different conjugates in order to quantify the total amount of daidzein and genistein in 
the sample under the conditions applied. A typical HPLC chromatogram of 
hydrolysed soya nuts is shown in Figure 3.3. In this figure, the main peaks at 260 
nm, with retention time of 6.95 and 8.67 min, were identified as peaks 1 and 2 and 
represent daidzein and genistein respectively. A third more minor peak eluted ~30 
seconds after daidzein. This is likely to be glycetin, as it is normally present in soya 
foods at approximately 10% of the total isoflavones. Nevertheless, we did not 
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attempt to quantify this compound for the present study. The amount of daidzein and 
genistein found in the soya nuts were 30 mg/100 g and 57 mg/100 g, respectively. 
 
 
 
Figure 3.2: HPLC chromatogram of orange juice monitored at 280 nm. Peaks are 
identified as (1) narirutin (2) hesperidin and (3) apigenin used as internal 
standard. HPLC method is described in section 2.2.3.2. 
 
Figure 3.3: HPLC chromatogram of hydrolysed soya nuts monitored at 260 nm. 
Peaks identified in samples are: (1) daidzein, (2) genistein and (3) apigenin as 
internal standard. HPLC method is described in section 2.2.3.1. 
 
 
3.7.3 Extraction and quantification of flavonoids in urine 
On the basis of the authentic standards in Chapter 2, the identification of 
flavanones and isoflavones were achieved using HPLC-DAD. Flavanones were 
absent from all baseline samples, indicating compliance with the avoidance diet. 
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However, small amounts of isoflavones were detected in the baseline urine for three 
subjects who consumed food with hidden soya a day before the study day. Therefore, 
we have deducted the amount found in the baseline from the total of daidzein and 
genistein excreted. The total concentration of isoflavones and flavanones was 
quantified in the urine after de-conjugation by β-glucuronidase and sulfatase, and 
was corrected based on the recovery rate of internal standard with extraction 
efficiency of 87%. To ensure the quality of the data, quality control samples were 
analysed at the beginning and the end of each batch. An example HPLC 
chromatogram from baseline and an active urine sample (after enzyme hydrolysis) 
from one subject, after co-ingestion of orange juice and soya nuts is illustrated in 
figure 3.3. Peaks 1, 2, 3, 4 and 5 were detected in urine and in comparison with the 
retention time of authentic standards and relative spectra, these five peaks can be 
assigned as daidzein, naringenin, genistein, hesperetin and apigenin, respectively.  
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Figure 3.4: Typical HPLC chromatogram of a hydrolysed urine sample. Sample was 
from subject 16 at 12-24 hr after ingestion of 25 g soya nuts with 500 ml 
orange juice; (A) before enzyme hydrolysis and (B) after enzyme hydrolysis. 
The peaks were identified as (1) daidzein, (2) naringenin, (3) genistein, (4) 
hesperetin, and (5) apigenin (as internal standard). 
 
Only flavanone and isoflavone aglycones were measured in the urine samples 
after de-conjugation by β-glucuronidase and sulfatase enzymes. The quantities of 
flavonoids excreted in each of the time fractions following single food or co-food 
ingestion are shown in Table 3.4. Figures 3.5 and 3.7 present this data for the 
flavanone and isoflavones, respectively, as bar charts for easy comparison. Figures 
3.6 and 3.8 provide the cumulative excretion for the flavanones and isoflavones, 
respectively, over the 36 hr period of urine collection. 
Very small amounts of flavanones were detected in the urine during the first 4 
hr after ingestion. There was a rapid but fairly steady increase of naringenin from 4-8 
hr and 8-12 hr, as shown by the linearity between these points in Figure 3.6A. 
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Similar amounts were excreted in the 12-24 hr fraction, but as this represented a 12 
hour collection, the rate of excretion was slowing down. Excretion levels 
subsequently decreased and after 24 hr the baseline levels were likely to be reached 
before 36 hr. Naringenin excretion showed no difference between single and co-
ingestion of orange juice with/without soya.  
Hesperetin excretion followed a similar pattern, with little excretion up to 4 hr, 
and then an increase up to 12 hr. Although not significantly different, hesperetin 
excretion after co-ingestion did appear to be affected, with an increased excretion 
rate between 8 and 12 hr there is no significant difference (p=0.3), leading overall to 
a 20% increase in hesperetin excretion (Figure 3.6B). 
Throughout the entire collection there was no significant difference in average 
daidzein or genistein excretion, after single or co-ingestion of soya with/without 
orange juice (Figure 3.8). Low levels of daidzein and genistein were excreted in 
urine for the first 4 hr, but the rate increased and was steady to 12 hr. Between 12-36  
hr the excretion rate remained steady for single ingested soya, but for co-ingested 
soya the isoflavone excretion reached baseline by 36 hr (seen by the plateau in 
Figure 3.8). 
Table 3.5 shows the fraction percent excreted in the urine over the 36 hr after 
single or co-ingestion of the foods. For the flavanones between 64 and 75% of total 
naringenin and hesperetin was excreted by 12 hr, with little difference after only 
orange juice or with soya nuts. On the other hand, only 52-54% of isoflavones were 
excreted by 12 hr when soya was ingested on its own, whereas 68% of both 
compounds were excreted by 12 hr when co-ingested with orange juice. 
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Table 3.4: Quantities of flavanones and isoflavones compounds (µmol) excreted in urine from 25 healthy volunteers 0 – 36 hr after ingestion of 
orange juice and soya nuts. 
Flavonoids ingested Amount excreted in urine µmol (36 hr)  Total 
0 0-4 4-8 8-12 12-24 24-36 
Naringenin (single dose) 0.0 ± 0.0 0.4 ± 0.1 2.1 ± 0.5 1.5 ± 0.4 1.8 ± 0.5 0.5 ± 0.1 6.4 ± 1.6 
Naringenin (Co-ingestion) 0.0 ± 0.0 0.3 ± 0.1 1.9 ± 0.5 2.1 ± 0.5 1.6 ± 0.4 0.1 ± 0.0 5.9 ± 1.5 
Hesperetin (single dose) 0.0 ± 0.0 0.6 ± 0.2 3.1 ± 0.8 2.5 ± 0.6 2.4 ± 0.6 0.3 ± 0.1 8.8 ± 2.3 
Hesperetin (Co-ingestion) 0.0 ± 0.0 0.3 ± 0.1 2.7 ± 0.7 5.0 ± 1.3 2.4 ± 0.6 0.2 ± 0.0 10.6 ± 2.7 
Daidzein (single dose) 0.0 ± 0.0 0.6 ± 0.2 4.2 ± 1.1 3.8 ± 1.0 4.6 ± 1.2 2.8 ± 0.7 16.0 ± 4.1 
Daidzein (Co-ingestion) 0.0 ± 0.0 1.5 ± 0.4 3.7 ± 1.0 4.1 ± 1.1 3.6 ± 0.9 0.9 ± 0.2 13.8 ± 3.6 
Genistein (single dose) 0.0 ± 0.0 0.6 ± 0.2 3.4 ± 0.9 2.5 ± 0.6 3.5 ± 0.9 2.7 ± 0.7 12.7 ± 3.3 
Genistein (Co-ingestion) 0.0 ± 0.0 1.1 ± 0.3 2.5 ± 0.6 3.4 ± 0.9 2.5 ± 0.6 0.9 ± 0.2 10.4 ± 2.7 
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Figure 3.5: Averaged urinary excretion profile and concentration of (A) naringenin 
and (B) hesperetin in 15 volunteers after consumption of orange juice with 
and without soya nut. 
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Figure 3.6: Cumulative urinary excretion of (A) naringenin and (B) hesperetin 
measured in urine collected up to 36 hr in healthy volunteers following 
consumption of orange juice with and without soya nut. Values are means ± SE 
(n=15). 
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Figure 3.7: Average urinary excretion profile and concentration of (A) daidzein and 
(B) genistein in 15 participants after consumption of soya nut with and 
without orange juice. 
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Figure 3.8: Cumulative urinary excretion of (A) daidzein and (B) genistein measured 
in urine collected up to 36 hr in healthy volunteers following consumption of 
soya nut with and without orange juice. Values are means ± SE (n=15). 
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Table 3.5: Fractional excretion of isoflavones and flavanones as (%) of total urinary 
excretion in healthy volunteers up to 36 hr after ingestion of orange juice and soya 
nut (n = 15). 
Collection 
time (hr) 
Fractional excretion (% of total excretion) 
N 1 N 2 H 1 H 2 D1 D 2 G 1 G 2 
0 0 0 0 0 0 0 0 0 
0-4 7 5 7 3 4 11 5 11 
4-8 33 32 35 25 26 27 27 24 
8-12 24 35 29 47 24 30 20 33 
12-24 28 27 27 23 29 26 28 24 
24-36 8 1 3 2 17 6 21 8 
N1 and N2 are values for naringenin after single and co-ingested foods respectively. 
Likewise H1 and H2 represent hesperetin; D1 and D2 represent daidzein; G1 and G2 
represent genistein. 
 
The total amount of isoflavones and flavanones detected in 36 hr urinary 
excretion from the 15 volunteers is presented in figure 3.9.  
 
 
 
Figure 3.9: Mean urinary excretion of flavanones and isoflavones 36 hr after 
consumption of orange juice and/or soya nuts as single or co-ingested dose. 
Data presented as mean ± SE, n = 15 subjects. 
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Figure 3.10: Mean urinary excretion of flavanones and isoflavones in male and 
females 36 hr after consumption of orange juice and/or soya nuts as single or co-
ingested dose. Data presented as mean ± SE, n = 15 subjects. † indicates significant 
difference between gender, p < 0.05. 
 
On the basis of gender, the mean urinary excretion of isoflavones and 
flavanones were compared between subjects. Figure 3.10 shows the excretion 
differences between males and females. It appears that while similar amounts where 
consumed, the urinary excretion of all compounds, except naringenin, tends to be 
higher among males compared to females. This higher excretion was statistically 
significant for naringenin and hesperetin when orange juice was co-ingested with 
soya nuts (p= 0.01; p= 0.05).  Table 3.6 shows the individual total excretion of 
flavonoids based on gender. 
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Table 3.6: Total urinary amount excreted of flavanones and isoflavones in males and 
females, over 36 hr urinary collections, after consumption of orange juice and/or 
soya nuts. 
Gender code N 1 N 2 H 1 H 2 D1 D 2 G 1 G 2 
  (µmol excreted in 36 hr) 
Female 2 2.9 2.0 4.6 3.4 6.9 9.8 2.3 5.1 
4 8.5 3.0 12.6 12.7 16.8 14.4 2.6 5.1 
5 4.2 6.2 5.1 7.5 17.9 18.3 24.1 8.3 
8 2.3 3.9 2.6 3.2 11.8 8.4 7.8 6.0 
9 24.4 1.0 11.1 2.5 9.9 23.4 9.9 22.1 
14 2.8 0.9 2.2 4.5 28.8 4.3 28.0 3.7 
15 7.7 2.2 22.8 2.7 12.0 4.0 5.2 3.0 
Female mean 7.5 2.7 8.7 5.2 14.9 11.8 11.4 7.6 
Female SE 1.9 0.7 2.3 1.3 3.8 3.0 2.9 2.0 
Male 1 6.6 11.2 6.1 9.2 13.3 18.2 10.9 19.0 
3 3.5 4.7 4.5 5.7 13.4 13.8 22.8 6.2 
6 0.4 5.5 0.3 22.2 5.1 5.2 3.2 1.6 
10 6.7 6.0 11.1 10.7 30.5 21.3 24.0 15.6 
11 6.3 19.8 11.6 44.7 25.2 23.3 19.4 30.1 
12 7.2 4.4 13.2 10.7 18.5 13.0 9.5 6.9 
13 0.8 8.3 0.5 13.5 21.1 19.9 11.2 13.8 
16 11.4 10.2 24.2 6.4 9.3 9.1 9.4 9.1 
Male mean 5.4 8.4 † 9.4 16.3 † 17.6 15.1 14.2 11.9 
Male SE 1.4 2.2 2.4 4.2 4.5 3.9 3.7 3.1 
Overall Mean 6.4 5.9 8.8 10.6 16.0 13.8 12.7 10.4 
Overall SE 1.6 1.5 2.3 2.7 4.1 3.6 3.3 2.7 
N1 and N2 are values for naringenin after single and co-ingested foods respectively. 
Likewise H1 and H2 represent hesperetin; D1 and D2 represent daidzein; G1 and G2 
represent genistein. Mean ± SE (N=15; †significantly different between male and 
female p= <0.05). 
 
The mean urinary isoflavones and flavanones excreted as percentage of 
ingested dose was calculated and is presented in table 3.7. There was very little 
difference in the percent excreted for any compound between single or co-ingestion 
of the food. Daidzein was recovered in the urine to a greater extent than genistein; by 
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1.4- 1.7-fold increase for single dose compared to co-ingestion, respectively. 
Naringenin was recovered in urine to a greater extent than hesperetin; by 3.7-fold 
and 2.8-fold when orange juice was ingested separately or co-ingested with soya 
nuts. 
 
Table 3.7: Percentage dose excreted in 36 hr for each flavonoid 
Flavonoid Single/co-ingested Average % of dose excreted (± SE, n=15) 
Daidzein Soya nuts 27 ± 7.0 
Daidzein Soya nuts + OJ 28 ± 7.2 
Genistein Soya nuts 19 ± 4.9 
Genistein Soya nuts + OJ 16 ± 4.3 
Naringenin OJ 9.2 ± 2.3 
Naringenin OJ + soya nuts 8.6 ± 2.2 
Hesperetin OJ 2.5 ± 0.6 
Hesperetin OJ + soya nuts 3.0 ± 0.7 
 
Figure 3.11 (A) and (B) demonstrate the inter-individual values 
corresponding to the percentage of total genistein and daidzein excreted in urine after 
soya nuts were consumed as single dose and co-ingested with orange juice. Figure 
3.12 (A) and (B) illustrates the similar urinary recovery inter-individual variability of 
the flavanones. The percent dose excreted for naringenin ranged from 0.6 – 35%, and 
1.3 – 28% for a single dose and co-ingestion, respectively. Hesperetin had a smaller 
range of 0.1 – 7.0%, and 0.7 – 13% respectively. The individual excretion profiles of 
naringenin and hesperetin after the consumption of orange juice separately and with 
soya are shown in figure 3.13 and figure 3.14, respectively. Likewise, figure 3.15 and 
figure 3.16 show daidzein and genistein after soya nuts alone or with orange juice, 
respectively. The large inter-individual variation in urinary excretion of isoflavones 
and flavanones is evident; range was between 1.6-30 µmol/36 hr for isoflavones and 
0.8-45 µmol/36 hr for flavanones.  
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Figure 3.11: Inter-individual variation in recovery of daidzein (A) and genistein (B) 
as percentage of administrated dose. Data presented as mean ± SE (n = 15). 
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Figure 3.12: Inter-individual variation in recovery of naringenin (A) and hesperetin 
(B) and naringenin as percentage of administrated dose. Data presented as 
mean ± SE (n = 15). 
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Figure 3.13: Naringenin excretion profiles of individual subjects. (A) Single dose of 
orange juice, (B) co-ingestion after consumption of orange juice with soya 
nuts. 
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Figure 3.14: Hesperetin excretion profiles of individual subjects. (A) Single dose of 
orange juice, (B) co-ingestion after consumption of orange juice with soya 
nuts. 
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Figure 3.15: Daidzein excretion profiles of individual subjects. (A) Single dose of 
soya nuts, (B) co-ingestion after consumption of soya nuts with orange juice. 
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Figure 3.16: Genistein excretion profiles of individual subjects. (A) Single dose of 
soya nuts, (B) co-ingestion after consumption of soya nuts with orange juice. 
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 Using the Spearman correlation coefficient, the correlation between the 
flavanones and isoflavones as percentage recovered in urine was investigated after 
orange juice and soya nuts were ingested separately. As can be seen from figure 
3.17, the urinary excretion of hesperetin was correlated with the amount of 
naringenin recovered in urine samples (r= 0.54; p= 0.03), as was the amount 
recovered for daidzein and genistein (r= 0.72; p = 0.002). Conversely, neither 
hesperetin nor naringenin were correlated with the amount of daidzein and genistein 
excreted in urine samples when orange juice and soya nuts were consumed 
separately.  
 The results indicate that the urinary recoveries (% of intake) of isoflavones 
and flavanones when orange juice and soya nuts were co-ingested were correlated 
more significantly than after single ingestion (Figure 3.18). There was a strong 
positive correlation between urinary excretion of hesperetin and naringenin (r= 0.72; 
p<0.0005), and between genistein and daidzein (r=0.72; p=0.002).  Moreover, 
urinary excretion of naringenin was strongly correlated with the excretion of 
genistein (r=0.73; p=0.002), and daidzein (r=0.49; p=0.05). Whereas, excretion of 
hesperetin was weakly correlated with the urinary excretion of genistein (r=0.50; 
p=0.05), and was not correlated at all with daidzein. 
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Figure 3.17: Correlation between (A) naringenin and hesperetin (B) naringenin and 
daidzein (C) naringenin and genistein (D) hesperetin and daidzein (E) 
hesperetin and genistein (F) daidzein and genistein on the percentage 
recovered in urine samples after experimental meals were separately ingested 
sing the Spearman correlation coefficient. Correlation is significant at the p 
=0.01 **, p = 0.05 *. 
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Figure 3.18: Correlation between (A) naringenin and hesperetin (B) naringenin and 
daidzein (C) naringenin and genistein (D) hesperetin and daidzein (E) 
hesperetin and genistein (F) daidzein and genistein on the percentage 
recovered in urine samples after experimental meals were co-ingested using 
the Spearman correlation coefficient. Correlation is significant at the p =0.01 
**, p = 0.05 *. 
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3.8 Analysis of flavonoids in saliva 
Saliva samples were collected form 15 volunteers during phase 3 of the study. 
The average total protein concentration in the saliva was 0.60 ± 0.03 mg/ml, which 
is similar to reported values (Lin and Chang, 1989). Three subjects who had 
excreted high levels of isoflavones and flavanones in their urine were chosen for 
further HPLC – DAD and LC-MS analysis. All saliva fractions between 0 – 36 hr 
were analysed by HPLC after enzyme hydrolysis for the presence of the hesperetin, 
naringenin, daidzein and genistein aglycones. Figure 3.19 shows the chromatograms 
for one set of the saliva samples. No flavonoid aglycones were detected in any of the 
samples analysed. In case the hydrolysis step resulted in lower concentrations of 
compounds in saliva, selected samples were also analysed prior to enzyme 
hydrolysis to monitor any potential peaks present. Figure 3.20 shows an 8 hr saliva 
sample with and without enzyme hydrolysis. Again, no peaks were detected in any 
of these samples. 
As a result of the non-detectable values for all compounds in saliva by HPLC, 
more analysis using LC-MS was carried out. This analysis is more sensitive and 
selective for specific mass ratios expected, but even so the compounds were still not 
detected. Selected saliva samples were analysed, alongside urine samples from the 
same individual, and saliva samples spiked with 25% “active” urine (containing the 
flavanone metabolites) to confirm detection of conjugates was feasible under the 
extraction conditions used. Figure 3.21 shows the chromatograms from these 
analyses. Two hesperetin mono-glucuronides and one hesperetin sulfate peak were 
present in the urine sample diluted in water (25/75) and were also present in the 
saliva sample spiked with the urine sample. The key finding here is that there was no 
real difference between water and saliva spiked with the same amount of urine. 
Based on this observation, it is unlikely that saliva is irreversibly binding to the 
compounds and preventing detection in the samples collected. 
Due to the non-detectable values of isoflavones and flavanones in the samples 
analysed, further analysis of all the saliva samples was not carried out. If there are 
hesperetin and isoflavone metabolites in saliva, they are not at levels suitable for use 
as a biomarker in future human studies. 
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Figure 3.19: Example set of HPLC chromatograms representing analysis of active 
saliva (subject 4) 0-36 hr after the ingestion of 500 ml orange juice and 25 g 
soya nuts. Peaks identified as (1) daidzein, (2) naringenin, (3) genistein, (4) 
hesperetin, and (5) apigenin as internal standard. The peaks were monitored 
at 280 nm. 
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Figure 3.20: Example HPLC chromatogram representing analysis of saliva (subject 
4) collected  8 hr after the ingestion of 25 g soya nuts and 500 ml orange juice. 
(A) Active (8 hr) saliva sample before enzyme hydrolysis (B) Active saliva 
spiked with aglycones (C) Active saliva sample after enzyme hydrolysis. The 
peaks are identified as (1) daidzein, (2) naringenin, (3) genistein, (4) 
hesperetin, and (5) apigenin as internal standard. The peaks were monitored at 
280 nm. 
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3.9 Quantification of hesperetin from urine after enzyme hydrolysis. 
To assess whether the enzyme hydrolysis was complete or not for the 
hesperetin metabolites, samples of urine were analyzed by LC-MS before and after 
enzyme hydrolysis. Different metabolites in urine were identified by their UV 
spectra (by diode array) and molecular mass (negatively charged precursor ions of 
interest [M-H]
-
). The percentage of remaining un-hydrolyzed flavanone from the 
original amount was calculated.  
Peak (1) in Figure 3.22 is the internal standard taxifolin (Rt = 13.0 min), 
detected at m/z 303. Peaks 2, 3, and 4 (Rt = 15.6, 15.8 and 16.8 min, respectively) 
were detected with an m/z of 477, 477 and 381, respectively, indicating that the 
presence of mono-glucuronide derivatives of hesperetin and the mono-sulfate. After 
hydrolysis (but not prior to enzyme action) another peak was observed, at Rt 20.3 
min. This peak had an m/z at 301, and is assigned as hesperetin aglycone. Further 
confirmation of this was based on the Rt of the authentic standard of hesperetin and 
the UV spectrum. The percentage of hesperetin conjugate that was hydrolysed by β-
glucuronidase and sulfatase enzymes was calculated and shown in table 3.7.  
 
Table 3.8: Enzyme efficiency of beta-glucuronidase and sulfatase on hesperetin 
metabolites. 
Metabolite RT 
(min) 
Percent remaining 
after hydrolysis* 
Approximate 
percent hydrolysed 
Hesperetin-7-O-
glucuronide 
15.6 17.4 ± 1.4 82% 
Hesperetin-3′-O-
glucuroinde 
15.8 12.3 ± 3.1 88% 
Hesperetin-3′-O-sulfate 16.8 39.1 ± 7.8 61% 
*Under conditions described in section 3.5.3. 
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Figure 3.21: LC-MS Chromatogram of a saliva and a urine sample (from subject 4) 
8 hr after the ingestion of 25 g soya nuts with 500 ml orange juice. (A) 
baseline (0 hr) urine sample, (B) active (8-12 hr) urine sample without enzyme 
hydrolysis (C) active (8-12 hr) urine sample after enzyme hydrolysis, (D) 
active (8 hr) saliva sample after hydrolysis. The peaks were identified as (1) 
taxifolin (internal standard) transition (m/z)
-
 303, (2) and (3) hesperetin–O-
glucuronides form (m/z)
- 
477, (4) hesperetin-O-sulfate form (m/z)
-
 381, (5) 
hesperetin (m/z)
- 
301. 
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3.10 Discussion:  
The purpose of this study was to investigate various aspects of bioavailability, 
as assessed by urinary excretion of flavanones and isoflavones in volunteers. Firstly, 
we wanted to assess if there was any influence of consuming the specific flavonoid-
rich foods together or independently, and secondly to assess if there was any 
correlation in the amount excreted of each flavonoid. Lastly, saliva taken at various 
time points was analysed after both soya nuts and orange juice were consumed to 
see if this biological fluid would reflect flavonoid absorption. Overall the 36 hr 
urinary excretion of four dietary flavonoids (hesperetin, naringenin, genistein and 
daidzein) was investigated in 15 healthy volunteers. 
Daidzein and genistein were absorbed quickly and appeared in urine within a 
few hours after ingestion of soya nuts. Moreover, daidzein was recovered to a larger 
extent in urine than genistein in all subjects; the average percent dose excreted was 
about 27-28% for daidzein compared to 16-19% for genistein. This finding is in 
accordance with previous studies ( Watanabe et al., 1998, King and Bursill, 1998, 
Richelle et al., 2002, Faughnan et al., 2004, Vedrine et al., 2006), and the data for 
these is presented in Figure 3.23. The overall range reported by Manach et al., 
(2005) is between 21.4 – 62% for daidzein and 6.8 – 29.7% for genistein. The lower 
urinary excretion of genistein compared to daidzein measured as % of dose intake is 
not due to lower systematic bioavailability and plasma levels (Setchell et al., 2003a), 
but is more likely to reflect the more pronounced biliary elimination route for 
genistein. This has been shown as the major route for genistein-7-O-β-glucuronide 
(represents the major metabolite of genistein) in rats (Zheng et al., 2004). The 
reason for this difference in pathways may be the lower molecular weight and the 
increased water solubility of daidzein compared to genistein which favours urinary 
excretion via the kidney (Tapiero et al., 2002). Moreover, the 5-OH group in 
genistein is assumed to be more susceptible to microflora degradation leading to 
lower overall urinary recovery (Zheng et al., 2004).  
The variation in urinary recovery of genistein and daidzein is reasonable 
across different studies,  likely due to different factors such as the design of the 
study, the form of isoflavones ingested (e.g. glycosides vs. aglycone), the food 
matrix and individual variation in microflora (Nielsen and Williamson, 2007). The 
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urinary recovery as % of dose after ingestion of tempeh (a fermented soya food high 
in aglycones) was higher than after soybean pieces (contain mainly glucosides) 
(Hutchins et al., 1995). It has been reported that the absorption of isoflavones as 
cumulative uptake is higher in solid matrices, even though the absorption is faster 
from liquid matrix (Cassidy et al., 2006, de Pascual-Teresa et al., 2006). Processing 
soya foods such as steamed, fermented and roasted, has been reported to change the 
portion of the various isoflavones species and had the lowest quantities of malonyl-
glycosides (Ahn-Jarvis et al., 2013). Recent studies (e.g.) reported that under heat 
(100 ºC) moist and dry conditions, isoflavones (genistein and their glycoside forms) 
are converted from malonyl-genistein to genistein (Chien et al., 2005). These 
changes have been also reported from malonyl-glycoside to acetyl-glycosides under 
dry and moist heating in soya flour and soya milk processing and this could explain 
the higher levels of aglycones in roasted soya foods products. 
 
Figure 3.22: Data from various studies showing the urinary recovery of isoflavones 
in urine from original dose ingested from different type of supplements. 
 
In the present study, the recovery of hesperetin in the urine was 2.5-3% 
based on the ingested dose of 500 ml orange juice; naringenin was recovered at a 
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2003, Kanaze et al., 2006, Gardana et al., 2007, Mullen et al., 2008)  as shown in 
figure 3.24. It has been suggested that this difference may be due to the structural 
differences where naringenin only has a 4ʹ-OH group but hesperetin has a 3ʹ-OH and 
4ʹ-methoxy group, which makes it less water soluble and also increases the 
molecular weight. Thus, like with genistein it may preferentially be excreted via the 
bile. The structural changes may also partly influence the absorption of the 
flavonoid (Manach et al., 2003, Mullen et al., 2008,), such as differences in colon 
microflora that mediated degradation of hesperetin and naringenin. However, there 
was no difference in the bioavailability of flavanones either after the consumption of 
orange juice or fruits (Brett et al., 2009). In another study, the bioavailability of 
naringenin was reported to differ after ingestion of orange juice and grapefruit juice 
which suggest that this difference was determined by the type of juice (Erlund et al., 
2001). However, other factors that could also contribute include differences in the 
affinities of enzymes cleaving neohesperosides and rutinosides, or the dose-
dependent renal clearance (Erlund et al., 2001). Our result is within the range 
between (3 - 24.4%) for hesperidin and (1.1 – 30.2%) for naringenin that have been 
reported by Manach et al., (2005). 
 
Figure 3.23: Data from various studies showing the urinary recovery of flavanones 
in urine from original dose ingested from different type of supplements. 
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Food matrix and solubility of flavanones was reported to affect the 
absorption. Recent studies by Tomas-Navarro and colleagues (2013) have 
investigated the effect of processing on the flavanone bioavailability based on the 
processing effect on flavanone solubility and particle size of the cloud. The result 
revealed that high-pressure homogenized (HPH) juice showed better absorption and 
excretion rate compared to conventional pasteurized juice among higher excretor 
volunteers. This high absorption among higher excretor volunteers could be 
explained by the gut microbiotas which were active in releasing hesperetin from 
hesperidin. As a result, they take the benefit of small particle size of hesperidin in 
HPH juice with more availability to interact with the gut microbiota than in 
pasteurized juice (Tomás-Navarro et al., 2013). 
In the present study, a gender related trend in urinary excretion of 
isoflavones and flavanones was observed. Specifically, the mean urinary excretion 
of isoflavones and flavanones were higher in males compared to females. Several 
studies had reported no differences between males and females in the recovery of 
isoflavones in urine and plasma sample (Faughnan et al., 2004, Nielsen and 
Williamson, 2007). Similarly, the percentage of flavanones recovered in urine was 
not correlated with sex or BMI of the participants (Vallejo et al., 2010). In contrast, 
in a study to determine if there were any change in urinary recovery of isoflavones 
after three different soya foods were ingested (soya milk, textured vegetable protein 
(TVP) or tempeh), suggests that the absorption and excretion of genistein was higher 
in females compared with males. The absorption was also is influenced by the food 
matrix and chemical composition. In addition, metabolism of daidzein suggested to 
be altered by the chemical composition of the isoflavones ingested. (Faughnan et al., 
2004). In addition, genetic variation could influence the degree of absorption, 
metabolism and excretion of flavonoids. Several studies showed that ethnic 
background (or cultural food background) may have an influence on the metabolism 
of glucoside forms of isoflavones (Lampe et al., 1998, Zubik and Meydani, 2003). 
In this study, large inter-individual variation was observed between 
volunteers in the urinary excretion of flavanones and isoflavones. The largest 
variability based on the recovery in urine after 36 hr was observed in daidzein which 
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ranged between 7% - 65% of dose ingested. High and low excretors of these 
flavonoids seems to have consistent excretion behaviour for different flavonoids 
only when co-ingested, and was more prominent with naringenin than with 
hesperetin, as shown by the spearman correlation coefficients. This is possibly due 
to the similarity in the intestinal bacteria composition which leads to changes in 
metabolic activity of the colonic microflora due to different levels of α-
rhamanosidase and β-glucosidase activities. As a result of this there may be 
variation in the absorption of isoflavones and flavanones in the colon. This may also 
explain the delay to reach the urinary Cmax at 8-12 hr in co-ingestion phase 
compared to 4-8 hr when these compounds were consumed separately. 
In this study we hoped to investigate the concentration of flavonoids in saliva 
samples and to compare with urinary concentration to determine how reliable a 
saliva sample is as a biomarker for citrus and isoflavones consumption. No 
isoflavones or flavanones were detectable in the saliva. We expected the flavonoids 
might be available in saliva in conjugated form, therefore the hesperetin conjugate 
compound were tested using LC-MS, but this form was undetectable in saliva 
samples as well. These results are in contrast to the result obtained by Cao et al., 
(2009), who investigated the level of isoflavones in infants (birth to 1 year). 
Isoflavones were not detected after cow or breast milk, but recordable levels were 
determined in saliva samples after soya formula was given, although levels were 
higher in urine. It could be that the continuous intake of soya milk formula led to 
higher and constant levels of isoflavones in the circulation and therefore a detectable 
level in the saliva. Our study was a low dose given on a single occasion, and so if 
isoflavones are able to reach the saliva the levels were too low to be detected. 
Another study by Halm et al., (2007) reported that isoflavones are excreted 
in urine at higher level among children than adults, with total excretion rate of +32% 
higher (Halm et al., 2007). The higher urinary excretion level of flavonoids among 
children compared to adults also could be explained by the difference in microflora 
populated in the colon, which could be able to hydrolyse flavonoids more effectively 
to their aglycone form in children, however degrade the aglycones less efficiently 
(Halm et al., 2007). Released aglycones normally undergo ring fission leading to the 
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production of phenolic acids and hydroxycinnamates (Crozier et al., 2010, Del Rio 
et al., 2010).  
It should be noted that the salivary enzymes are capable of hydrolysing 
isoflavones and flavanones by the esterase and glucosidase activity from bacteria in 
the saliva. However, the activity may not be significant in physiological conditions. 
In practice, food will not normally stay in the mouth for more than 20-30 second. 
During the short stay of flavonoid glycoside in the mouth, the enzymes may 
continue to work through digestion, along the GI tract where PH changes greatly 
from 2-8. However, these enzymes in saliva were from a bacterial source as 
proposed by Walle et al., (2005), and the activity of these enzymes were 
significantly decreased when the mouth was rinsed by anti-bacterial solution before 
the collection of saliva. Furthermore, as a result of high concentration of nitric oxide 
produced by the stomach, most of the bacteria would be killed after reaching the 
stomach (Gladwin et al., 2005). For that reason, the activity of salivary enzymes will 
be limited, if their sources are from bacteria.  
From our results, it can be concluded that saliva as a non-invasive biological fluid is 
not a good tool to monitor flavonoid intake and not reliable biomarker for citrus and 
isoflavones consumption. 
Our result showed that the aglycone hesperetin yielded after enzyme 
hydrolysis of hesperetin conjugates from urine was incomplete. This is in agreement 
with Bredsdorff et al., (2010). Thus, to have a detailed description of isoflavones 
and flavanones absorption and metabolism, the analytical method employed must be 
highly sensitive and be able to identify the forms of metabolites in the biological 
fluids without any enzyme treatment of conjugates. It is recommend that further 
analysis using more sophisticated methods such as the LC-MS can reveal more 
accurately the concentration of these compounds. 
The current study was limited to only assessing the bioavailability of hesperetin 
and naringenin after consumption of orange juice and daidzein and genistein after 
consumption of soya nuts either separately or together. There is a need to investigate 
other foods which are commonly consumed together by the population for a better 
understanding of the flavonoid intake and bioavailability of these compounds, and if 
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interactions during absorption or metabolism by gut microflora occur. Ultimately a 
better understanding of inter-individual variability in bioavailability will be 
beneficial in assessing the ability of flavonoids in reducing the risk of chronic 
diseases. 
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Chapter 4: Quantification Of Flavonoid Contents In Orange Juice 
And Citrus Supplements 
 
4.1 Abstract  
The aim of this chapter was to assess the flavanone variability in commercially 
available orange juice, and orange drinks (being considered as a placebo-control), 
and citrus supplements, to determine the best options for carrying out a double-
blind, placebo-controlled, cross-over intervention human study (chapter 6). 
In this study the flavanone content of six selected brands of orange juice and 
orange juice drinks (< 3% from concentrate), and two citrus bioflavonoid tablets 
available in the UK market were extracted and analysed by HPLC. Hesperidin and 
narirutin were the major flavonoids detected. The orange drinks contained 2-5 
mg/100 ml hesperidin and 0.1-0.3 mg/100 ml narirutin, which were considerably 
lower than the orange juices which contained 39-49 mg/100 ml hesperidin and 3-5 
mg/100 ml narirutin. The supplements were analysed and were contained 55 
mg/tablet hesperidin for Solgar citrus bioflavonoids, and 22 mg/tablet for the Health 
Aid: Citrus Bioflavonoid. No flavonoids were detected in a placebo tablet.  
In conclusion, Solgar bioflavonoid supplements was analysed and had 
sufficient hesperidin levels of 55 mg/tablet, with 2 tablets equivalent to 200 ml 
orange juice, and so were selected as the experimental source to be used in study 2 
(chapter 6). These could be used more appropriately in a blinded intervention with a 
placebo control.  
4.2 Introduction  
There is an increasing support to the view that many phenolic secondary 
metabolites (polyphenols) found in plant-derived foods have some beneficial effects 
in the prevention of degenerative diseases (Del Rio et al., 2010, Khan and Dangles, 
2014). Besides, citrus fruit and juices are vastly consumed around the world. This 
consumption has considerably increased during the decade. The global production of 
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citrus fruit was estimated to be 82 million tons in 2009–2010. Of this total, orange - 
the most important citrus fruit - accounts for about 50 million tons (Khan and 
Dangles, 2014).  
Flavanones are a subgroup of flavonoids which are biologically active and 
have antioxidant activity (Brett et al., 2009). In general, most flavonoids are 
commonly present in plants in a conjugated form along with sugars, forming 
glycosides. Hesperidin is a predominant flavanone presented in high levels in citrus 
fruits, especially in oranges (Citrus sinensis) as hesperetin-7-O-rutinoside (Nielsen 
et al., 2006, Brett et al., 2009). The intake of hesperetin in the diet can be substantial 
from citrus fruits and juices. Flavanones are found almost exclusively in citrus fruits. 
The concentration of flavanones in the juice of these fruits can reach several 
hundred mg on a per-litre basis (Tomás‐Barberán and Clifford., 2000). An orange 
juice is reported to contain between 200 and 600 mg hesperidin/L and 15–85 mg 
narirutin/L. Additionally, a single glass of orange juice is expected  to contain 
between 40 and 140 mg flavanone glycosides (Manach et al., 2004). Mouly et al., 
(1998) reported that orange juice from concentrate contains 475 mg/L hesperidin. 
The same study also reported that pure orange juice contains on average a lower 
concentration of hesperidin, compared to orange juice from concentrate. Gil-
Izquierdo et al., (2002) reported that the concentration of hesperidin may also 
depend on the quality of the oranges used for preparing the juice. 
There are numerous factors that may influence the polyphenol content in 
orange juices. For instance, it has been reported in some studies that citrus 
flavanones exist in both juice serum and precipitated in the juice cloud (Silveira et 
al., 2014). Another factor is that orange juice processing methods are also an 
important factor affecting the total concentration and solubility of the citrus 
flavanones. The processing method may likely influence the levels of bioavailable 
compounds following juice consumption. It has been reported by a number of 
studies (Gil-Izquierdo et al., 2002, Bai et al., 2013) that total concentrations of 
hesperidin and narirutin and their content in the juice cloud are higher in 
commercially processed orange juice (POJ) compared to fresh squeezed orange juice 
(FOJ). Processing such as pasteurization and clarification that is used for 
commersial juices, can have an impact on flavonoids content for example the 
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flavonoid content of fresh fruit juices is much higher than the commercial one and 
the possible reason for that might be because of their precipitation or binding to the 
proteins that get degraded in the process of pasteurisation (Mahdavi  et al., 2010). 
It has also been documented that citrus fruits flavanones are present 
glycosides such as hesperetin-7-O-rutinoside (hesperidin) and naringenin-7-O-
rutinoside (narirutin) which contain both glucose and rhamnose sugars (Kawaii et 
al., 1999). The sugar moiety of flavonoids are proposed to be the major determinant 
of their absorption in human (Nielsen et al., 2006). The presence of sugar is very 
important, because it can influence the bioavailability. It is of major interest in the 
current investigation whether these compounds (like hesperidin) are bioavailable in 
the body. Many studies have been trying to identify flavonoid bioavailability during 
the last two decades ( Erlund et al., 2002, Brett et al., 2009, Bredsdorff et al., 2010). 
Once a food is consumed, it starts to undergo the digestion process in the body. This 
is followed by absorption, a process in which the digested compounds enter the 
inner organs in order to become either modified or further metabolized or excreted. 
The site of absorption depends on the glycosylated or esterified form of the 
compound. It also depends on which specific sugars or other prosthetic groups are 
attached to on it (Scalbert and Williamson, 2000).  
The increasing consumption of citrus around the world motivate researchers 
to investigate the most abundant citrus flavonoids, i.e. flavanones (Khan and 
Dangles, 2014). Many of these studies investigating the in vivo bioactivity of 
flavanones have used orange juice as intervention meal (Manach et al., 2003, 
Bredsdorff et al., 2010, Morand et al., 2011, Buscemi et al., 2012). Therefore, In 
order to assess any potential benefits, it is important to be aware of the composition 
of the biologically active compounds in commercially available orange juice and 
citrus tablets. In chapters 6 a human double-blind, placebo-controlled, cross-over 
intervention study on citrus flavanones and vascular health parameters has been 
designed and described. The aim of this study is to determine the concentration of 
flavanone in a commercially available orange juice and citrus supplements available 
in the UK market using HPLC technique. 
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The aims of this study are: 
 To determine the total content of flavanones in a selected orange juice and 
orange drinks for possible use in a human study. 
 To measure the concentration of hesperidin in citrus supplements for 
possible use in a human study. 
 To decide on the best available source of hesperidin to be adopted the 
planned human study. 
4.3 Materials  
For details of the chemicals and solvents used in this analysis see chapter 2.2 
for more information. All six orange juices were purchased from Morrison’s, Leeds, 
UK and Sainsbury’s, Leeds, UK between January 2011 and August 2011. Citrus 
supplements were purchased from online shops (Solgar vitamin and Herb, UK) 
between March 2013 and October 2013. Placebo tablets were purchased from 
(Fagron GmbH & Co. KG, Germany). 
4.3.1 Orange juice 
 Six commercial brands of orange juice and orange juice drinks were 
analysed to determine their flavanone content. All orange juices are orange juice 
from concentrate except orange juice (# 3 and 4) which are diluted orange juice with 
added sweeteners, and orange juice (#1) which is orange juice not from concentrate, 
details in Table 4.1. For each brand, 2 bottles from 2 different batches were 
purchased. Samples were prepared as described in chapter 2 (see section 2.4.1) and 
analysed using HPLC with diode array. 
4.3.2 Citrus and placebo supplements 
Two citrus supplements were analysed. The label information of these 
supplements is provided in Table 4.2. A further placebo supplement was also 
assessed for flavonoid content. For sample preparation, the tablet was crushed using 
a mortar and pestle. The powder (200 mg) was extracted with 5 ml of 80% methanol 
for three times. The combined sample was centrifuged for 15 min, and the 
supernatant dried in the centrifugal evaporator overnight. All samples were extracted 
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in triplicate. The dried samples were reconstituted with 5 ml of 80% methanol, and 
an aliquot (250 µl) has spiked with standards of hesperetin and naringenin (20 
µg/ml). The other two samples were spiked only with the internal standard apigenin 
(20 µg/ml). The samples were then analysed by HPLC using the method described 
in chapter 2 (section   2.3.31). 
Table 4.1: Analysed commercial orange juice and drinks 
 
 
 
Product code Manufacturer and product name Product labelled contents 
1 
Tropicana (purchased from 
Morrisons) 
Orange juice not from concentrate 
(100%) 
2 
Princes (purchased from 
Morrisons) 
Orange juice from concentrate 
(100%) 
3 Sainsbury’s orange juice drink 
Water, orange juice from concentrate 
(3%), citric acid, sodium citrate, 
flavourings, sucralose, beta-carotene.     
4 
Disney “Cars” orange juice drink 
(purchased from Morrisons) 
Natural mineral water, orange juice 
from concentrate (2%), citric acid, 
natural flavouring, pectin, sucralose, 
carotenes 
5 
Morrisons’ orange juice from 
concentrate 
Orange juice from concentrate 
(100%) 
6 
Sainsbury’s smooth orange juice 
from concentrate 
Orange juice from concentrate 
(100%) 
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Table 4.2: Information of the supplements 
Supplement A B C 
Brand: name Health Aid: Citrus 
Bioflavonoids 
Solgar: Citrus 
Bioflavonoids 
Complex 
Fagron: Placebo 
Tablet,Oval 
 
Weight per 
tablet/capsule 
1000 mg 1000 mg 770 mg 
Eating 
suggestion 
1 tablet/day with 
water 
1 tablet/day with 
food 
n/a 
Flavonoid 
claim per 
tablet 
Citrus 
Bioflavonoids 
(amounts not 
stated) 
Flavanones: 110 mg, 
Hesperidin: 70 mg,  
Eriocitrin: 40 mg 
none 
Other 
ingredients 
Bulking agent (di-
calcium 
phosphate), acacia 
gum,  
anti- caking 
agent,stearic acid, 
magnesium 
stearate 
Microcrystalline 
cellulose gum, 
vegetable stearic 
acid, 
hydroxypropylmethyl 
cellulose, vegetable 
glycerin 
Lactose 
monohydrate, 
magnesium stearate, 
microcrystalline 
cellulose 
 
4.3.3 Statistical analysis   
Samples were prepared in duplicate for the validation analysis. All results 
from the HPLC analysis are presented as mean ± standard deviation and results are 
expressed as mg/ 100 ml or mg / tablets. Individual compounds were confirmed by 
comparison with literature values of their relative retention times, order of elution, 
and the UV spectra (compared to pure hesperidin and narirutin standards). Orange 
juice sample means were compared using the Tukey test at the 5% probability level. 
Pearson correlation was also used to calculate the total flavonoid content (mg) and 
unit price (UK sterling). All of the statistical analyses were conducted using SPSS 
for Windows, software version 22. 
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4.4 Results  
4.4.1  Orange juice analysis 
 The flavanones are found mainly in the form of rutinoside conjugates in 
orange juice and citrus products. A small and large peak eluted after orange juice 
was analysed by HPLC (monitored at 280 nm) at retention times 14.9 and 16.1 min. 
This has a UV absorption spectra and retention times consistent with narirutin and 
hesperidin, respectively. Analysis of all various orange juices indicated the presence 
of these flavanones; typical chromatograms of flavanone content in six 
commercially orange juice form concentrate and orange drink drinks, using HPLC-
DAD detector monitored at 280 nm are shown in Figure 4.1.  
 Hesperidin was the highest percentage found in the analysis. It is followed 
by narirutin, the concentrations of which are shown in table 4.3. The samples were 
analysed in duplicate and all four pure orange juices made from concentrate had a 
similar total concentration. The concentration of hesperidin and narirutin ranged 
from 39.1 ± 0.2 to 48.9 ± 0.6 mg/100 ml, and 3.5 ± 0.1 to 5.1 ± 0.1, respectively. 
The three orange juices made from concentrates had the highest values of hesperidin 
and narirutin compared to the Tropicana orange juice and orange juice drink. On the 
other hand, the lowest amount of hesperidin and narirutin in orange juice drinks 
ranged between 2.0 ± 0.1 to 5.3 ± 0.1 mg/100 ml. This result was not surprising, 
because these orange drinks were diluted orange juice from concentrate containing 
only 2-3% juice. Brands with higher hesperidin content were found to have higher 
concentration of narirutin level.  
 Flavanone hesperidin and narirutin contents were significantly (P ≤ 0.05) 
higher in orange juice from concentrate 48.8 ± 5.02 mg/ 100 ml compared to orange 
juice drink 3.8 ± 1.8 mg/ 100 ml. The concentrations of flavanones were higher in 
orange juice from concentrate compared to orange juice drink as can be seen from 
Table 4.3. The concentration of flavanones in Morrisons’ orange juice from 
concentrate were higher by 24 and 12-fold compared to the orange juice drink 
number 3 and 4, respectively. 
 However, no significant difference was found in the content of hesperidin 
and narirutin among orange juice 2 and 5 (P = 0.28). Moreover, there was low 
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variation of hesperidin content in this study. CV was 3.9% compared to CV 8.3% 
for narirutin. The concentration of hesperidin content in orange juice from 
concentrate was higher by 12-fold compared to the level found in the orange juice 
drink. 
Table 4.3: Flavanones content in six commercial available brands of orange juices 
and drinks 
Product code Manufacture; brand Hesperidin 
mg /100 ml 
Narirutin 
mg /100 ml 
Total 
flavanone 
mg /100 
ml 
1 Tropicana 
(Morrisons) 
39.2 ± 0.2
a
 3.57 ± 0.1
a
 42.7 ± 0.3 
2 Princes (Morrisons) 46.9 ± 2.2
ab
 4.65 ± 0.1
abc
 51.7 ± 2.1 
3 Sainsbury’s orange 
juice drink 
5.3 ± 0.1
b
 0.26 ± 0.4
b
 5.5 ± 0.3 
4 Disney “Cars” orange 
juice drink 
(Morrisons) 
2.0 ± 0.1
c
 0.14 ± 0.1
ab
 2.1 ± 0.2 
5 Morrisons’ orange 
juice from 
concentrate 
48.9 ± 0.7
ab
 5.06 ± 0.1
ab
 53.9 ± 0.4 
6 Sainsbury’s smooth 
orange juice from 
concentrate 
42.7 ± 1.8
d
 4.35 ± 0.6
abc
 47.1 ± 1.6 
Data are mean ± SD (n=4). Means with in the column without the same letter (a, b 
and c) are significantly different (P ≤ 0:05; Tukey test). 
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Figure 4.1: Chromatograms of flavanone content in six commercially orange juice 
and drinks. Narirutin peak (1), hesperidin peak (2) and apigenin as IS peak 
(3), using HPLC-DAD detector monitored at 280 nm. For details of HPLC 
conditions see chapter 2 (section 2.3.3). 
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Figure 4.2: Pearson’s correlation between price and total flavanone content for 6 
commercial orange juice brand. 
 
 
In this study, price did not correlate well with the total flavanones content in 
orange juice. Orange juices were shown to have weak correlation (r= 0.24; P = 0.26) 
between price and total flavanones content figure 4.2. 
 
4.4.2 Supplement analysis 
Analysis of compounds in supplements using HPLC was performed using 
the methods described in chapter 2 (section 2.3.3.1). The mean weight of the 
supplements was 1.48 ± 0.1 g for citrus bioflavonoids and 0.78 ± 0.1 g for placebo 
supplements. Table 4.5 shows the flavonoid content in the selected supplements. A 
comparison was made between the result achieved after the analysis and the amount 
of flavonoid claimed by the manufacturer. Supplement B has the closest amount of 
hesperidin as compared to the claim (55 mg/tablet). On the other hand, supplement 
A had a significantly lower hesperidin content (21.8 mg/ tablets) compared to 
supplement B (55 mg/ tablets), although no claim was indicated on the label. Citrus 
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supplement contain ≈ 78% of the claimed by manufacture (70 mg hesperidin/tablet) 
compared to the amount of hesperidin found in the tablet (55 mg/tablet). For the 
placebo supplement no flavanone compounds were found in the tablets, as expected. 
 
Table 4.4: Flavanones content in the selected supplements. 
 Hesperidin 
mg /tablet 
Narirutin 
mg /tablet 
Total 
flavanone 
mg /tablet 
Health Aid: Citrus 
Bioflavonoids 
21.8 ± 2.1
a
 0.7 ± 0.55
a
 22.5 
Solgar: Citrus 
Bioflavonoids Complex 
55.4 ± 5.4
b
 1.8 ± 0.34
b
 57.2 
Fagron: Placebo 
Tablet,Oval 
0.0 ± 0.0 0.0 ± 0.0 0.0  
Average +/- S.D (n=4). Means with in the column without the same letter (a, b and 
c) are significantly different (P ≤ 0:05; Tukey test). 
 
4.5 Discussion: 
The aim of this chapter is to investigate a potentially good dietary source of 
flavanones to be used in the human intervention study. A considerable amount of 
literature has been published on quantification of flavanones in orange juice. The 
results were firstly compared with the amount found in the Phenol-explorer database 
for orange juice from concentrate (www.phenolexplorer.eu) (Rothwell et al., 2013). 
From this database the concentration of hesperidin ranged from 47.5 – 58.5 mg/100 
ml (mean of 52.68 mg/100 ml, n=220) and narirutin ranged between 5.22 – 7.08 
mg/100 ml (mean of 6.32 mg/100 ml, n=160). The amount of hesperidin and 
narirutin found by Manach et al., (2003) was 44.4 and 9.6 mg/100 ml, respectively. 
A study in Turkey found lower amounts of hesperidin (17.1 mg /100 ml) and 
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narirutin (3.99 mg/ 100 ml) (Kelebek et al., 2009). Mouly et al, (1998) reported that 
orange juice from concentrate contained 47.5 mg/100 ml hesperidin. Our results are 
in agreement with the results previously  reported values by Vanamala et al., (2006) 
where the total hesperidin and narirutin content in 13 made-from-concentrate orange 
juices were analysed and the concentration ranged from 32.9 ± 1.6 to 54.8 ± 3.4 mg/ 
100 ml  and 4.4 to 8.0 mg/100 ml, respectively. Vanamala et al., (2006) also 
reported that the concentration of flavanone was significantly higher in orang juice 
made from concentrate than not-from-concentrate orange juice (Vanamala et al., 
2006).  
The concentration of hesperidin and narirutin in the value-brand juice in this 
current study was higher compared to the Tropicana orange juice, which is 
considered a premium brand, and was used in study 1. This result supports the 
finding of  research carried out by Mouly et al., (1998), who reported that pure 
orange juice contained on average a lower concentration of hesperidin, compared to 
orange juice made from concentrate. The concentration of hesperidin may also 
depend on the quality of the oranges used for the juice. In this respect, the premium-
brand juice had a comparatively high concentration of hesperidin (Gil-Izquierdo et 
al., 2002), which is in disagreement with our finding. According to the label, orange 
juice drinks contain only 2-3% juice from concentrate. On the other hand, in juice 
made from concentrate the concentration of flavanones was 12 and 24-folds 
compared with orange juice drink analysed in this study. 
Mahdavi et al. (2010) have shown that the amount of polyphenol content 
found in fresh fruit juices is significantly higher than that found in commercial ones. 
They also stated that, because of their precipitation, the availability of the phenolic 
compounds is reduced. It was also shown that processes like pasteurization and 
clarification which are adopted in manufacturing commercial juices, may influence 
the polyphenol content (Mahdavi et al., 2010). However, in the juices used in the 
current study, the biggest hesperidin concentration was found in the value-brand 
orange juice, followed by the premium-brand and then by the orange juice drink. A 
possible reason for the lower apparent dose in different orange juices may be the 
variety of the oranges used in making the juice. It could also be due to the fact that 
hesperidin is binding to proteins that become degraded in pasteurisation (Mahdavi et 
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al., 2010). Hesperidin and narirutin are the major flavonoids in the orange juice. 
They occur as soluble in solution and precipitated in the juice cloud. A number of 
studies have reported that these distributions are influenced by commercial juice 
processing and storage techniques (Gil-Izquierdo et al., 2002, Gil-Izquierdo et al., 
2003, Bai et al., 2013). However, it is worth mentioning that the differences found 
in the flavanone content between different brands in this study may be explained by 
the variation in season and climate. Location may also influence the flavonoid 
content in orange juice. For example, naringin content of grapefruit juice from the 
same grove and trees fluctuated during the season and varied considerably between 
crop years (Albach et al., 1981). In addition, fruit harvested in earlier in the season 
reported to had better quality in terms of higher juice content, ascorbic acid, and 
flavonoids compared with that fruit harvested later in the season  (Bai et al., 2009). 
The aim of this study was to quantify the concentration flavanones in various 
orange juices and citrus supplements in order to better inform the choice for 
conducting a human intervention study. Only two citrus supplements were analysed 
in this study. The majority of citrus containing supplements available contain other 
added ingredients (e.g. vitamin C), which, if not controlled for, could affect the 
results in a human study. There was a large difference in the amount of flavanone 
between these supplements with “Solgar: Citrus Bioflavonoids Complex” containing 
the highest level. The placebo did not contain any flavonoid. In planning the second 
human intervention study (see chapters 6 and 7), we chose to use supplements 
instead of orange juice. Our choice was based on the following: 
 
(i) Tablets are easy to distribute, and do not take up large areas of storage over the 4 
week intervention (which would be required for 14 L of orange juice). 
(ii) Tablets make the blinding of the study easier. Although the juice drink contained 
considerably less flavanone than the juice, the drink contained added ingredients and 
the taste was very different. 
(iii) The juice-drink still contained flavanones which could have affected the study 
outcome for the control arm, but the placebo did not contain any flavonoids. 
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(iv) The tablets don’t contain additional vitamin C, and more importantly, or sugar 
found in natural orange juice (40 g per day if 500 ml was used), which could 
influence both the CVD risk factors, and the energy consumed over the 4 weeks. 
(v) The tablets contain approximately the same amount of flavanones that can be 
found in a 100 ml of orange juice.  
(vi) It is thought that it is the flavanone component of orange juice that has the 
impact on some of the CVD risk factors which are the main focus of the intervention 
study.  
(vii) To our knowledge, commercially-available health citrus supplements have not 
been used in previous studies. Therefore, it makes our study novel whilst adding to 
the evidence for citrus flavanone potential bioactivity. 
 
In conclusion, “Solgar Citrus Bioflavonoids Complex” supplements were 
chosen to be used in a double-blinded cross-over intervention study, with placebo 
tablets acting as the control arm. Two flavanone tablets, approximately 200-250 ml 
of orange juice, were given per day to be consumed with breakfast. All tablets could 
be allocated in advance in coded sealed containers, blinded to the researcher, and 
given to the volunteer on the first day of the study. See chapter 6 for more 
information about the study design. 
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Chapter 5 Pilot Study Of  Blood Pressure And Blood Glucose 
Measurements  
 
5.1 Abstract  
This study described in chapter 5 assessed the reproducibility of blood 
pressure measurements in healthy volunteers. Intra- and inter-operator reliability and 
repeatability were calculated at two different times, on three different days, in a 
sample of 7 subjects by the same researcher. Systolic and diastolic blood pressure 
(SBP, DBP) were measured in the morning vs afternoon. Data on visit-to-visit and 
within–visit BP variability were collected using a Panasonic (EW3152W) Blood 
Pressure Monitor and a Lloyds Blood Pressure Monitor (model LBPK1). Repeated 
measures analysis of variance (ANOVA) was used to assess the significance of the 
inter- and intra-operator variability. Reproducibility was assessed using the intra-
class correlation coefficient (ICC) and a repeated measures analysis of variance.  
The day-to-day variability was not significant and the operator showed 
excellent day-to-day reproducibility. The blood pressure measurements intra-session 
coefficient of variation at 2-hour intervals ranged between or between morning and 
afternoon session were (2.80 – 8.75%). The variability of the measurements 
measured on the same day (between morning sessions and afternoon session) was 
between 2.9 % and 11.8%. Reliability of blood pressure measurements made by the 
same operator was good to excellent (ICC = 0.6–0.90) for same day assessments 
morning and afternoon session, and good to excellent (ICC =0.24–0.95) when the 
measurements were taken in the morning of same day at 2-hour intervals. 
In conclusion, the current study has shown that reliable measurements were 
obtained and inter- and intra-operator variability was not significant. The inter- 
operator variation in blood pressure measurements was higher in morning and 
afternoon measurements compared to that in the morning of same day at 2-hour 
intervals. 
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5.2 Introduction  
In the intervention study 2, which will be presented in chapter 6, the results are 
based on repeatable measurements of blood glucose and blood pressure (BP) using 
standard equipment. For this reason, it was very important to validate the 
measurements for glucose and BP and to assess the operator variability in measuring 
blood pressure, in order to obtain accurate measurements and reliable results for a 
longer term intervention study. 
Hypertension is among the most important preventable causes of death around 
the world. It is also one of the most commonly treated conditions in primary care in 
the UK. It affects more than a quarter of all adults and over half of those are over 65 
years old (Krause et al., 2011). A significant relationship between high blood 
pressure (BP) and cardiovascular risk has been long-established. Furthermore, the 
treatment of hypertension has been shown to reduce systolic and diastolic blood 
pressure, and consequently reduce the risk of CVD.  
Reliable measurements of BP are important in monitoring hypertension 
accurately and in describing the nature of the risk (Altunkan et al., 2007). However 
the accuracy and reliability of BP monitors should be investigated according to the 
standards of accepted validation protocols (Altunkan et al., 2007). Blood pressure 
(BP) measurements based on repeated  measurements readings are generally used to 
make clinical decisions and to investigate the prognoses (Shin et al., 2012). In the 
UK, the National Institute for Health and Clinical Excellence (NICE) has recently 
produced guidelines and definitions of hypertension in adults (Krause et al., 2011). 
Previous studies have shown that there are a number of factors that need to be 
considered when measuring blood pressure. Factors that can cause error in 
measurement include: obtaining a measurement from an unsupported arm, lack of 
back support and crossed legs increase blood pressure, blood pressure measurement 
taken before bladder emptying, active listening or talking during blood pressure 
measurement. These factors can increase systolic blood pressure by 10 mm Hg or 
more (Handler, 2009). Previous studies have also shown that forearm BP 
measurements run 3.6/2.1 mmHg higher than upper arm generally. In addition, 
reading of BP decrease by  ≥ 20 mmHg systolic pressure when BP is measured 
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standing (Handler, 2009, Domiano et al., 2008). Finally, measurements taking with 
tight clothing pushed up on the arm or over clothing can result in a considerable 
effect (Handler, 2009). 
In a research setting on healthy volunteers, only small changes in blood 
pressure may occur after an intervention, therefore accurate operator technique is 
essential. The aim of this study was to ensure reliability of the BP monitoring using 
repeat measurements on volunteers at different times of day and over a period of 
time, to ensure that the best operator protocol was in place and that variability in 
measurement was reduced prior to the intervention study. 
Diabetes type II is an important healthcare problem. It was estimated that the 
prevalence of diabetes in 2010 was 4.3% (2.8 millions) in the UK with a dramatic of 
two-fold increase compared to 1996 (Clarke and Foster, 2012). Diabetes can be 
defined as a fasting blood glucose level of ≥ 7.0 mmol/L. Normal fasting blood 
glucose levels are in the range of 4-6 mmol/L, but as the body becomes more insulin 
resistant, the fasting blood glucose levels increase. A level of glucose between 6-7 
mmol/L is classified as impaired glucose tolerance, and is one of the indicators for 
metabolic syndrome. Both diabetes and metabolic syndrome are significant risk 
factors for CVD. 
In order to obtain reliable measurement results for clinical decisions, and 
nutrition research, the accuracy of the systems for self-monitoring of blood glucose 
is crucial. They play an important role in the management of diabetes, particularly in 
patients treated with insulin (Rheney and Kirk, 2000, Freckmann et al., 2010). 
Blood glucose meters must have sufficient accuracy to allow patients and physicians 
to monitor glycaemic control and then modify treatment accordingly (Freckmann et 
al., 2012). There is an internationally accepted standard defining the performance 
requirements for self-monitoring of blood glucose (SMBG) systems, e.g., 
concerning accuracy. The standard states that ≥95% of the measurement should fall 
within ±0.83 mmol/L of the results of the manufacturer’s measurement procedure at 
glucose concentrations <4.2 mmol/L and within ±15% at glucose concentrations 
>4.2 mmol/L (Freckmann et al., 2012). 
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A variety of factors can influence the performance and the accuracy of glucose 
meter result. Such factors as environmental factors, operator technique and patient 
factors (Tonyushkina and Nichols, 2009). The accuracy of blood glucose 
measurements can be altered and affected by substances that interfere with blood 
glucose measurements such as haematocrit (HCT), maltose, galactose, ascorbic acid 
and sodium (SKaron et al., 2008, Dimeski et al., 2010). As haematocrit has been 
shown that interfere glucose monitors are calibrated to provide accurate reading with 
a normal physiological range of values, typically 30 – 50% (Pfützner et al., 2013).  
In a research setting when only small changes in fasting blood glucose may be 
observed, accurate operator technique is vital. The aim of this study was to ensure 
reliability of the glucose monitor to be used over a period of time, and to ensure that 
the best operator protocol was in place to reduce errors in monitoring blood pressure 
and fasting blood glucose in volunteers. 
5.3 Materials and methods 
5.3.1 Subjects and study design: 
Two studies were conducted as part of Ethics reference (MEEC 12-025) that 
was approved by the Ethics of University of Leeds Committee. These two small 
projects were carried out in the human study room at the School of Food Science 
and Nutrition, Parkinson building. Participants were mainly recruited from students 
of the University of Leeds to validate the use of blood pressure devices in adult 
healthy participants.  
Seven healthy subjects (4 females and 3 males took part in the study I and 7 
males took part in study II. The inclusion criteria were as follows: the volunteers 
were healthy, non-smokers, no use of vitamins or food supplements in the previous 
2 months, no allergies, and no prescribed medication, no caffeine, high-fat foods, 
alcohol at least 2 hour before the measurements. All subjects had granted their 
informed consent form to participate in this pilot study. The subjects were instructed 
to refrain from exercise for at least 24 hours prior to taking the measurements. 
Subjects were allowed to consume their normal diet, but were asked not to ingest 
substances that might affect blood pressure such as caffeine, high-fat and nitrate- or 
flavonoid-rich foods for at least 24 hours prior to the measurements. Any individuals 
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with readings of systolic BP > 140 mm Hg or diastolic >90 mm Hg were omitted, 
because these were classified as mild hypertension (Krause et al., 2011).   
 
5.3.2 Method of the blood pressure measurements  
In study I the measurements were taken using a Panasonic (EW3152W) 
Blood Pressure Monitor (Matsushita Electric Works, China), with automated blood 
pressure cuff. In study 2, the test was performed using Lloyds Pharmacy (model 
LBPK1) Automatic Blood Pressure Monitor (Kinetik Medical Devices Ltd, Elstree, 
Herts, UK). Two cuff sizes were available: the standard adult cuff which is 
appropriate for arm circumferences measuring 22 to 32 cm, and the large adult cuff 
which is appropriate for circumferences of 32 to 40 cm. The device has been 
designed and validated for blood pressure self-measurements by British 
Hypertension Society. 
The protocol described by the manufacturers and the European Society of 
Hypertension (ESH) was followed with some modification based on O'Brien et al., 
(2010). The tests were performed with the same conditions in a low light and noise 
room with temperature controlled between 19 – 23ºC. Prior to measurements 
anthropometric data, such as height, weight and gender were collected, to allow time 
for subjects to relax. Subjects were also asked to remove tight or restrictive clothing. 
All subjects were relaxed in a sitting position (study 1), and a supine position (study 
2) with both arms resting on arm supports for at least 10 min, with the cuff placed on 
the upper non-dominant arm. They were asked not to do any activity that could 
affect the BP measurements such as exercise, activity, reading and talking. 
To determine the BP once subject fully relaxed, the start button was pressed 
to begin automatic inflation and the LCD screen automatically displayed the systolic 
and diastolic pressure reading after each measurement. The BP was recorded and the 
cuff deflated. BP was measured in triplicate with five minute intervals between the 
three consecutive measurements. The average of the last two readings only was used 
in the calculation.  
BP was monitored on three different days, separated by no more than 2 days, 
with two different sessions on each day, one in the morning between 9-11am and 
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one in the afternoon between 2-4 pm. The measurements were ideally taken at the 
same time, under the same conditions and in the same position each time and visit.  
 
5.3.3 System accuracy evaluation of blood glucose monitoring systems 
5.3.3.1 Materials and methods  
The materials used were glucose standard Solution (product code G 3285). 
Accu-Chek Aviv meter (Roche Diagnostics Ltd, West Sussex, UK), Accu-Chek test 
strip, and multi-click lancet device. A stock solution of D-glucose standard (8.33 
mmol/L) was prepared. This stock solution and the subsequent dilutions were 
prepared in Milli-Q water and vortexed before used. Different concentrations such 
as 1.39, 2.7, 5.5, 8.3 mmol/L were made. Testing was performed using the blood 
glucose monitoring system Accu-Chek Aviva. The measurement was taken in 
triplicate. Accu-Chek Aviva control solutions - low levels (ranged between 1.6 – 3.3 
mmol/L) and high levels (ranged between 14.1 – 19.1 mmol/L). The purpose of this 
study was to determine the repeatability and precision of the Accu-Chek Aviva 
blood glucose system carried out in the same location by the same operator, using 
the same equipment. The test strips were dosed with control solution and the process 
was repeated over six days for each assigned level of control solution.  
 
5.3.4 Protocol for measuring blood glucose using the Aviva Accu-Chek 
glucose meter  
The blood samples were collected based on the method described by the 
manufacture and with some modification (Zueger et al., 2012). The finger area 
where the sample would be taken from was first disinfected using a sterile wipe. The 
multi-click lancet was set with a new lancet drum and at a depth of 3 mm. The skin 
was pricked with pressing of the lancet. The first drop of blood was removed with a 
sterile tissue. All the measurements were carried out with one single subsequent 
drop from the same area. The drop was applied to the test strip inserted in the blood 
glucose monitor. The device was internally calibrated and directly reported the result 
as a plasma glucose value. The value was recorded and the test repeated on the same 
finger.  
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5.4 Statistical analysis  
The parameters investigated were age, height, weight, gender, BMI, systolic 
(SBP) and diastolic (DBP) blood pressure. In order to compare the reproducibility of 
three measurements, the standard deviation was used to compare the means between 
measurements. The following statistical methods were used to assess the 
reproducibility of the measurements and the difference from days (1 vs 2 and 3), and 
between morning and afternoon time. A paired t-test compared the mean of two 
sessions, to identify the difference between the results of test and re-test obtained 
(Stergiou et al., 1998). In addition, intraclass correlation coefficient (ICC) was 
calculated to measure the agreement between tests and re-tests results and to assess 
the variability that is caused by variation between the subjects and measurements 
error. The significant values of ICC have been defined as values of < 0.4, 0.5 – 0.75, 
and > 0.75, which correspond to poor, fair-to-good, and excellent agreement. The 
coefficient of variation (CV %) was calculated by dividing the SD by the mean 
values CV% = (SD/mean x 100). The alpha level was set at p< 0.05 for all statistical 
tests. The analysis of variance one-way ANOVA method allows the variability of 
the interaction between the sessions and days to be determined. Unless otherwise 
indicated, all the data reported are mean ± standard deviation. The measurements 
were done in triplicate in each session (three in the morning and three in the 
afternoon) and the results obtained were analysed based on the last two 
measurements. Calculations of blood glucose concentration were performed in 
mmol/L. All analyses were carried out using the Statistical Package for Social 
Science base 22 for windows (IBM SPSS Inc., Chicago, IL). 
5.5 Results 
5.5.1 Accuracy of blood pressure measurements study I, using Panasonic 
blood pressure monitor 
Descriptive statistical for all variable characteristics and demographic data of 
the study participants in the first visit are shown in table 5.1. Age, BMI, height, 
weight and blood pressure measurements were measured. A total of 7 participants 
were included in the study, 4 females and 3 males with a mean age of 25 years, and 
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an average BMI of 20.2 kg/m
2
 the group were all likely to be healthy and have 
normal BP values.  
 
Table 5.1: Baseline characteristic of the seven participants study I (Panasonic BP 
monitor). 
  
Age (y) 25±3.9 
Height (cm) 1.7±0.10 
Weight (kg) 96.4±13.5 
BMI kg/m2 20.2±3.6 
Systolic BP (mmHg) 112.7±8.4 
Diastolic BP (mmHg) 71.9±4.9 
Pulse ± 69.5±7.0 
  
                       All values are expressed as mean ± SD 
 
ANOVA analysis of variance was used to evaluate the reproducibility of 
measurements in the morning and afternoon. Tukey test was used to estimate the 
statistical differences. There were no significant differences among the 
measurements in the morning session or afternoon session for both SBP and DBP. 
The data shown in figures 5.1 and 5.2 show the results of SBP and DBP obtained on 
each session/day. The day-to-day variability was not significant and the operator 
showed excellent day-to-day reproducibility. 
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Figure 5.1: Systolic blood pressure reading (mm Hg), at the same time of day 
(morning and afternoon), and between different days. Result is expressed as 
mean ± SEM, significant within trials difference (p<0.05). 
 
 
Figure 5.2: Diastolic blood pressure reading (mm Hg), at the same time of day 
(morning and afternoon), and between different days. Result is expressed as mean ± 
SEM, significant within trials difference (p<0.05).  
 
Table 5.2 and 5.5 summarize the result of intraclass correlation coefficients 
(ICC), coefficient of variation and p-value from paired t-test. Reproducibility was 
defined as a non-significant paired t-test with an excellent intraclass correlation (> 
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0.7) within and between days. For SBP, the measurements were reproducible in day 
1, 2 and 3 ranged between (0.59 – 0.87). For DBP all of the measurements were 
reproducible with t-test were not significant and ICC was excellent and ranged 
between (0.71 – 0.76). The same results were obtained for pulse rate where ICC was 
ranged between good to excellent correlation (0.62 – 0.90). The p-value was > 0.05 
for all measurements of inter-day and intra-day and there was no statistical 
difference between measurements in the morning and afternoon in the same day and 
different days, and the probability of obtaining a different value within each day and 
between days was low. Therefore, the result confirms no difference within a single 
visit and between days and the result is reproducible. The variability of the 
measurements measured on the same day (between morning sessions and afternoon 
session) was between 2.9 % and 11.8%. 
 
Table 5.2: Mean and standard deviation of blood pressure measurements across 
three days morning and afternoon in healthy subjects. 
 Time point Day 1 Day 2 Day 3 
One way 
ANOVA “p 
Value” 
Systolic 
BP 
Morning session 113.8±8.6 113.0±6.1 112.6±8.6 0.95(NS) 
Afternoon session 111.4±7.4 115.4±9.7 115.10±2.2 0.54(NS) 
Diastolic 
BP 
Morning session 71.9±3.9 72.8±6.2 70.9±8.2 0.85(NS) 
Afternoon session 68.8±4.2 70.6±4.6 70.4±4.0 0.43(NS) 
Pulse 
Morning session 70.3±8.3 66.7±9.6 66.3±7.8 0.64(NS) 
Afternoon session 69.8±5.6 66.4±6.0 67.2±5.3 0.50(NS) 
Values are means ± SD unless otherwise indicated. All measurements were taken 
between 8:00 am – 12:00 pm morning session and 1:00 – 4:00 pm afternoon 
session.  P ≤ 0.05 vs visit one using Tukey post hoc test, NS not significant. 
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Table 5.3: Reliability of blood pressure measurements on the same days (day1) in 
healthy subjects. 
 Time point Mean ± SD CV% ICC 
Paired t-test P-
value 
Systolic BP 
Morning session 113.9±8.6 7.5 
0.78* 0.38 
Afternoon session 111.4±7.4 6.6 
Diastolic BP 
Morning session 71.9±4.0 5.5 
0.71* 0.05 
Afternoon session 69.0±4.2 6.1 
Pulse 
Morning session 70.3±8.3 11.8 
0.62 0.88 
Afternoon session 70.0±5.6 8.0 
Values are means± SD unless otherwise indicated. *p< 0.05, **p < 0.01.SD, 
standard deviation; CV, coefficient of variation; ICC, intraclass correlation 
coefficient, (0.5 – 0.6 moderate agreement,* 0.7-0.8 strong agreement, **> 0.8 
perfect agreement). 
Table 5.4: Reliability of blood pressure measurements on the same days (day 2) in 
healthy subjects. 
 Time point Mean ± SD CV% ICC 
Paired t-test P-
value 
Systolic BP 
Morning session 113.0±6.1 5.4 
0.78* 0.38 
Afternoon session 115.4±9.7 8.4 
Diastolic BP 
Morning session 73.0±6.2 8.5 
0.73* 0.28 
Afternoon session 70.6±4.6 6.6 
Pulse 
Morning session 66.7±9.6 14.4 
0.79* 0.92 
Afternoon session 66.4±6.0 9.1 
Values are means± SD unless otherwise indicated.  SD, standard deviation; CV, 
coefficient of variation; ICC, intraclass correlation coefficient  (0.5 – 0.6 
moderate agreement,* 0.7-0.8 strong agreement, **> 0.8 perfect agreement). 
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Table 5.5: Reliability of blood pressure measurements on the same days (day 3) in 
healthy subjects. 
 Time point Mean ± SD CV% ICC 
Paired t-test P-
value 
Systolic 
BP 
Morning session 112.6±7.6 7.6 
0.59 0.49 
Afternoon session 115.1±2.2 2.9 
Diastolic 
BP 
Morning session 71.0±8.2 11.6 
0.76* 0.83 
Afternoon session 71.7±3.2 4.4 
Pulse 
Morning session 66.3±7.8 11.8 
0.90** 0.56 
Afternoon session 67.2±5.3 7.9 
Values are means± SD unless otherwise indicated. SD, standard deviation; CV, 
coefficient of variation; ICC, intraclass correlation coefficient (0.5 – 0.6 
moderate agreement,* 0.7-0.8 strong agreement, **> 0.8 perfect agreement). 
5.6 Accuracy of blood pressure measurements study II, using Lloyds blood 
pressure monitor 
All 7 subjects completed the study. The baseline characteristics of the 
volunteers are presented in table 5.6. The mean age for all subjects was 39 years, 
with an average BMI 29.37 kg/m
2
.  
Table 5.6: Baseline characteristics of the 7 healthy participants study II (Lloyds BP 
monitor). 
  
Age (y) 39 ± 4.27 
Gender Male 
Room temp (ºC) 20.9 ± 0.8 
Height (m) 1.7 ± 0.05 
Weight (kg) 89.6 ± 13.5 
BMI (kg/m
2
) 29.4 ± 3.7 
Systolic PB (mm Hg) 117.2 ± 10.3 
Diastolic PB (mm Hg) 77.7 ± 4.5 
Pulse 70.9 ± 4.0 
          All values are expressed as mean ± SD 
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An analysis of variance (ANOVA) for repeated measurements was used to 
estimate the reproducibility of measurements of all parameters in 3 days. There were 
no significant difference among the three recordings in test and re-test of blood 
pressure measurements (figures 5.3 and 5.4). Table 5.7 shows the results of the 
repeated-measures ANOVA. The day-to-day variability was not significant and the 
operator showed excellent day-to-day reproducibility. The results of the paired t-test 
showed that there was no significant difference between the pairs of measurements 
obtained on the same day. According to the results obtained to compare the values 
of the mean from two repeated measurements test and re-test the result of systolic, 
the diastolic and pulse rate in three days, the p-value was > 0.05 and ranged between 
(0.26 – 0.86). Therefore, the differences between the two measurements within the 
days were not statistically significantly different at the 5% level of significance.  
 
Table 5.7: Mean and standard deviation of blood pressure measurements in three 
days test and re-test measurements in healthy subjects. 
 Time point Day 1 Day 2 Day 3 
One way 
ANOVA “p 
Value” 
Systolic 
BP 
Measurements 
1 
113.8±6.7 115.2±4.6 113.3±6.6 0.87 (NS) 
Measurements 
2 
113.7±4.6 115.1±4.6 113.0±6.2 0.74 (NS) 
Diastolic 
BP 
Measurements 
1 
77.7±4.5 79.4±3.8 77.7±4.9 0.73 (NS) 
Measurements 
2 
78.9±5.3 80.3±4.7 78.9±4.5 0.87 (NS) 
Pulse 
Measurements 
1 
70.8±3.9 96.4±1.8 68.4±3.2 0.43 (NS) 
Measurements 
2 
68.8±4.8 67.7±2.1 66.4±4.2 0.57(NS) 
Values are means ± SD unless otherwise indicated. All measures were collected 
between 8:00 am – 12:00 pm.  P≤0.05 vs visit one using Tukey post hoc test, 
NS not significant. 
 
The test and re-test of reliability and reproducibility was assessed with the 
intra-class correlation (ICC). The reliability of measurements for SBP, DBP, pulse 
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rate ranged between (0.87-0.95), (0.79-0.92) and (0.24-0.46), respectively. These 
values were within the acceptable ranges among 3 days according to Stanforth et al, 
(2000) which has consider CV of < 10% is good for most of the biological data 
(Stanforth et al., 2000) . These results were obtained between and within-subject 
variance. A second measure of variability was the coefficient of variation (CV %), 
the results were within acceptable range. Tables 5.8- 5.10 show the result, where 
variability of measurements using CV was stated and coefficient of variation for 
SBP, DBP and pulse rate ranged between 2.80 – 8.75%.  
 
 
Figure 5.3: Systolic rate reading (mm Hg), at the same time of day (test and re-test), 
and between different days. The results are expressed as mean ± SEM, significant 
within trials difference (p<0.05). 
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Figure 5.4: Diastolic reading (mm Hg), at the same time of day (test and re-test), and 
between different days. The results are expressed as mean ± SEM, significant 
within trials difference (p<0.05).  
 
Table 5.8: Reliability of blood pressure measurements on the same days (day1) at 2 - 
hour intervals in healthy subjects. 
 Time point Mean±SD CV% ICC 
Paired t-test P-
value 
Systolic 
BP 
Measurements 1 113.8±6.7 8.75 
0.95* 0.86 
Measurements 2 113.7±4.6 7.20 
Diastolic 
BP 
Measurements 1 77.7±4.5 5.75 
0.89* 0.33 
Measurements 2 78.9±5.3 6.66 
Pulse 
Measurements 1 70.8±3.9 5.61 
0.46 0.35 
Measurements 2 68.8±4.8 6.69 
Values are means± SD unless otherwise indicated, SD, standard deviation; CV, 
coefficient of variation; ICC, intraclass correlation coefficient (average 
measurements). (0.5 – 0.6 moderate agreement,* 0.7-0.8 strong agreement, 
**> 0.8 perfect agreement). 
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Table 5.9: Reliability of blood pressure measurements on the same days (day2) at 2 - 
hour intervals in healthy subjects. 
 Time point Mean±SD CV% ICC 
Paired t-test 
P-value 
Systolic BP 
Measurements 
1 
115.2±4.6 3.96 
0.87* 0.56 
Measurements 
2 
115.0±4.6 3.61 
Diastolic BP 
Measurements 
1 
79.4±3.8 4.88 
0.79* 0.42 
Measurements 
2 
80.3±4.6 5.84 
Pulse 
Measurements 
1 
69.4±1.7 2.80 
0.24 0.15 
Measurements 
2 
67.7±2.1 2.92 
Values are means± SD unless otherwise indicated, SD, standard deviation; CV, 
coefficient of variation; ICC, intraclass correlation coefficient, (0.5 – 0.6 
moderate agreement,* 0.7-0.8 strong agreement, **> 0.8 perfect agreement). 
 
The intra-operator variability in measurements of blood pressure measurement 
was assessed and figure 5.5 shows the measurements of SBP and DBP for each 
participant in two sessions on three different days. The results show that the CVs 
were between 0.5 – 7.4% for all measurements, which provides evidence of good 
operator variability. 
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Table 5.10: Reliability of blood pressure measurements on the same days (day3) at 2 
- hour intervals in healthy subjects. 
 Time point Mean±SD CV% ICC 
Paired t-test 
P-value 
Systolic BP 
Measurements 
1 
113.3±6.6 5.86 
0.95* 0.73 
Measurements 
2 
113.0±6.2 5.50 
Diastolic BP 
Measurements 
1 
77.7±4.9 6.37 
0.92* 0.29 
Measurements 
2 
78.9±4.4 6.08 
Pulse 
Measurements 
1 
68.4±3.2 4.62 
0.37 0.26 
Measurements 
2 
66.4±4.2 6.35 
Values are means± SD unless otherwise indicated, SD, standard deviation; CV, 
coefficient of variation; ICC, intraclass correlation coefficient. (0.5 – 0.6 
moderate agreement,* 0.7-0.8 strong agreement, **> 0.8 perfect agreement). 
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Figure 5.5: Blood pressure measurements among 7 participants in two sessions and 
three days. Systolic blood pressure (A). Diastolic blood pressure (B). 
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5.7 Accuracy and precision of the Accu-Chek Aviva blood glucose meter. 
The determination of control prepared glucose solutions were made on Accu 
Chek Aviva meter. The results obtained were linear within the range from 1.4 – 8 4 
mmol/L (Figure 5.5). The precision was good and the measurements are presented in 
Table 5.11. 
 
Figure 5.6: The concentration of standard glucose measured by Accu-Chek Aviva. 
 
The variation of the test was calculated by the coefficient of variation (CV %). 
The performance of a method based on CVs of 5% or less is generally an indication 
that the method is reliable. From the result obtained, it can be seen that the 
performance and accuracy of the Accu check Aviva gave CVs values of less than ≤ 
5%.  
Table 5.11: The accuracy of and performance of Accu Chek blood glucose meter. 
D-glucose standard 
conc. mmol/L 
Monitored glucose concentration 
(mmol/L)  
Mean SD CV% 
1.4 2.2 0.1 4.5 
2.8 3.9 0.1 1.8 
5.6 7.1 0.2 2.9 
8.0 9.8 0.2 2.2 
          Values are means ± SD (n=3) 
y = 1.2069x + 0.3208 
R² = 0.99 
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The accuracy of Accu-Chek Aviva blood glucose meter was tested six times 
on each of six different days with the manufacturers two control solutions, data 
shown in tables 5.12 and 5.13. The CV expresses the variation as a percentage of the 
mean. The precision of device was less than < 5%. Moreover, the intra-class 
correlation ICC was excellent. It ranged between 0.76 and 0.93 for low levels and 
high levels measurements of Accu-Chek Aviva control solutions, respectively. The 
results of the repeatability results using Accu-Chek Aviva control solutions and 
Accu-Chek Aviva blood glucose test strips. Result of the paired t-test shows that the 
difference was not statistically significant (p < 0.05). 
 
 
Table 5.12: Repeatability of Accu-Chek Aviva blood glucose meter at low 
concentration. 
 
Reading 
1 
Reading 
2 
Mean ± SD CV % ICC 
day 1 2.6 2.6 2.6 ± 0.0 0.0 
0.78* 
day 2 2.6 2.6 2.6 ± 0.0 0.0 
day 3 2.7 2.6 2.6  ± 0.1 2.7 
day 4 2.6 2.5 2.5 ± 0.1 2.8 
day 5 2.5 2.4 2.4 ± 0.1 2.9 
day 6 2.6 2.6 2.6 ± 0.0 0.0 
Mean 2.6 2.6 2.6 ± 0.0 1.4  
Control solution 1 ranged 1.6-3.3 mmol/l; ICC *p< 0.05, **p < 0.01. †paired t-test p 
< 0.05. 
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Table 5.13: Repeatability of Accu-Chek Aviva blood glucose meter at high 
concentration. 
 
Reading 
1 
Reading 
2 
Mean ± SD CV % ICC 
day 1 16.9 16.8 16.8 ± 0.1 0.4 
0.93* 
day 2 17.6 17.5 17.5 ± 0.1 0.4 
day 3 17.5 17.6 17.5 ± 0.1 0.4 
day 4 17.5 17.4 17.4 ± 0.1 0.4 
day 5 17.3 16.9 17.1 ± 0.1 1.7 
day 6 16.8 16.6 16.7 ± 0.1 0.8 
Mean 16.9 16.8 16.8 ± 0.1 0.7  
Control solution 2 ranged 14.1-19.1 mmol/l; *p< 0.05, **p < 0.01. †paired t-test p < 
0.05. 
 
5.8 Discussion 
After examining 7 different subjects on two different blood pressure 
monitoring devices, both were found to be reliable in measuring systolic and 
diastolic blood pressure. In the present study, we determined the within day 
variability of BP by repeating measurements on the same day, and the between day 
variability was evaluated by repeating the measurements on different days. Analysis 
of variance using one-way analysis gives the variability of the interaction between 
the sessions and days to be determined. The accuracy of the instrument was not 
affected by the three days in-use assessment. The results were not significant when 
using both monitors. The standard deviations of the device–observer discrepancies 
were well within the Advancement of Medical Instrumentation (AAMI) requirement 
of a standard deviation of  ≤ 8 mmHg (Bonso et al., 2008). The results obtained 
showed that there was low intra-operator variability, providing confidence in 
accurate measurements, and both the Lloyds BP Monitor and Panasonic EW3152W 
Blood Pressure Monitor were reliable.  
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Several studies showed that accuracy of blood glucose measurements vary 
largely between different blood glucose devices (Baumstark et al., 2012, Freckmann 
et al., 2012), and different test strip lots of the same blood glucose system 
(Baumstark et al., 2012). The Accu-Chek Aviva meter precision was acceptable and 
it met the accuracy requirement in comparison with the reference values 
recommended by the manufacture, which is in agreement with S.Karon et al., 
(2008). There was a difference between the standard glucose concentration and the 
glucose reading on the monitor, however the results were linear. This is likely to be 
as a result of internal calibration of the monitor which is calibrated to measure blood 
glucose, but to provide a plasma value reading that is also calibrated against 
interference from normal haematocrit values. Hence the absolute values obtained 
from the control glucose solutions were not relevant as long as linearity was 
observed. Ideally a hexokinase measurement would be made using a venous plasma 
sample, which would have low interference from collection of blood (which can 
occur from finger prick samples) and from matrix interference with maltose, 
galactose, haematocrit, ascorbic acid and sodium concentrations (S.Karon et al., 
2008, Dimeski et al., 2010, Freckmann et al., 2010, Pfützner et al., 2013). However 
this was impractical for the intervention study described in chapter 6, and the 
repeatability of the Accu-chek blood glucose monitor was deemed sufficient to 
determine impaired glucose tolerance from fasting blood glucose measurements, but 
would be unlikely to be accurate in detecting changes in fasting blood glucose after 
an intervention of <0.6-0.8 mmol/L (15%). 
In conclusion, the intra-operator variability in measuring blood pressure was 
good for both monitors, however the Lloyds upper-arm monitor was chosen as the 
results were dependable and repeatable.  Furthermore, the blood pressure cuff was 
comfortable in a sitting and lying position, which was essential for the intervention 
study in chapter 6, whereas the Panasonic BP monitor was easier to use in a sitting 
position. The Accu-Chek Aviva blood glucose monitor gave reliable and repeatable 
results when tested against glucose standards and control solutions provided by the 
manufacture. Both devices were accepted for use in the human intervention study 
described in chapter 6 as the operator variability was low. 
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Chapter 6: The Impact Of Oranges On Cardiovascular Health 
 
6.1 Abstract  
Cardiovascular disease (CVD) is the principal cause of death in the Western 
world. Established risk factors include high LDL cholesterol, high blood pressure 
(BP) and diabetes. Poor endothelial health is considered to be a predictor of future 
CVD risk. Previous studies have provided evidence that the consumption of orange 
juice improves cardiovascular risk factors such as BP and endothelial health. We 
tested the hypothesis that citrus bioflavonoid supplements improved BP and other 
CVD risk biomarkers in a double-blind, placebo-controlled, cross-over intervention 
study in overweight subjects. 
Twenty three volunteers (males and females, age 29-44 y) were recruited and 
assigned to a treatment in random order for a 4 week period, with a 4 week washout 
between phases. On each study day, participants had weight, height, waist 
circumference, and blood pressure measured. A finger-prick blood sample 
monitored fasting blood glucose level using an Aviva Accu-chek glucometer. Pulse 
amplitude tonometry (PAT; blood flow through fingertips) was also monitored using 
an Endo-PAT, before and after forearm blood flow was restricted using a blood 
pressure cuff for 5 min (hyperaemia).  
DBP, SBP and fasting blood glucose tended to be lower after 4 weeks 
consumption of citrus supplements compared to the placebo, however the data did 
not reach significance. Moreover, augmentation index (AI) significantly decreased 
when citrus supplement was ingested, compared to baseline, but no change was 
reported in the placebo intervention. There was no change in the reactive 
hyperaemia index (RHI) measured by the Endo-PAT.  
For the first time commercially-available citrus bioflavonoid supplements 
were assessed for their ability to affect vascular parameters. It can be concluded that 
in healthy overweight subjects citrus supplements tended to decrease SBP, DBP and 
fasting blood sugar, however further studies are warranted at different doses and for 
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longer duration to determine if hesperidin, as the main compound in the citrus 
tablets, could be linked to the beneficial effects of orange juice in reducing the risk 
of CVD. 
 
6.2 Introduction 
Cardiovascular disease (CVD) is the main cause of morbidity and mortality 
around the world. Epidemiological studies showed that there is an inverse 
relationship between eating high quantities of vegetables and fruits and reducing the 
risk of CVD. The actual role played by these compounds is unclear and still under 
investigation (Chanet et al., 2012b). Established risk factors of CVD include high 
LDL cholesterol, hypertension and diabetes, however, endothelial dysfunction has 
been defined  as “the ultimate risk of the risk factors” as it can be considered a 
summation of the integrated effects of CV risk factors (Lerman and Zeiher, 2005). 
Endothelial dysfunction can be identified by an impaired endothelium-dependent 
vasodilation response to changes in blood flow or other stimuli (Allan et al., 2013). 
Flow mediated dilation (FMD), pulse amplitude tonometry (PAT), and peripheral 
blood pressure (BP) can all be used to measure different aspects of underlying 
vascular dysfunction and are considered to be predictors of future CV risk 
(Tomiyama and Yamashina, 2010). Endothelial dysfunction is reversible (Inaba et 
al., 2010, Green et al., 2011). 
The endothelium is the inner lining of blood vessels. It allows blood to flow 
smoothly within them and actively maintains the physiological condition. Normal 
endothelial function helps to protects blood vessels from formation of 
atherosclerosis. The endothelium has been recognized as the key regulator of 
vascular homeostasis. Healthy endothelial cells produces a wide range of factors that 
regulate vascular tone, thrombus formation, adhesion of circulating blood cells to 
the vessel wall, smooth muscle cell proliferation, and vessel wall inflammation, 
which are the key mechanism of the atherosclerotic process.  
The effect on vascular tone is one of the most important functions of the 
endothelium, which is achieved by the production of several vasoactive compounds 
that relax the vessel (Poredos and Jezovnik, 2013). Nitric oxide (NO) is the most 
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important of these factors; it is an influential vasodilator, inhibits inflammatory 
activity, vascular smooth muscle cell proliferation and platelet adhesion and 
aggregation (Allan et al., 2013). Endothelial dysfunction occurs when the balance 
between NO production and its consumption is disrupted (Poredos and Jezovnik, 
2013). 
Many non-invasive methods designed for measuring endothelial function 
have been investigated. Two of the most commonly used are flow mediated 
dilatation (FMD) and peripheral artery tonometry (PAT) (Arrebola-Moreno et al., 
2012). Both methods depend on increasing hemodynamic shear stress during 
reactive hyperaemia to stimulate NO release; changes in blood flow or vessel 
diameter explains the change in smooth muscle tone in resistance or conduit arteries 
(Ganz and Vita, 2003).  
FMD is an ultrasound-based test and it is the most commonly used method to 
measure endothelial dysfunction. It measures alteration in conduit artery diameter 
stimulated by reactive hyperaemia (Corretti et al., 2002, Lekakis et al., 2011). The 
reactive hyperaemia phenomenon is a result of temporary arterial occlusion and then 
release which leads to increasing the  blood flow (hyperaemia) and causes an 
increase in shear stress on the vessel wall. This activates endothelial nitric oxide 
synthase (eNOS) which oxidises L-arginine to produce NO. The NO enters the 
smooth muscle cell causing relaxation and vasodilation (Felmeden and Lip, 2005, 
Arrebola-Moreno et al., 2012, Conraads, 2013, Allan et al., 2013). FMD is 
measured as the percentage of change in brachial artery diameter between baseline 
(before occlusion) to the maximum diameter immediately after release (Al-Qaisi et 
al., 2008). Figure 6.1 shows the setting and testing of FMD. Although the 
assessment of FMD is still one of the most widely used techniques to measure 
endothelial dysfunction, it requires good training and a high level of ultrasound 
experience in order to achieve replicable results (Conraads, 2013). Reports show 
that this technique has a considerable high intra- and inter- operator variability 
(Dhindsa et al., 2008). 
Digital peripheral arterial tonometry (PAT) is a relatively new and non-
invasive technique. It measures the peripheral microvascular endothelial function by 
measuring pulse wave amplitude during reactive hyperaemia. It has been developed 
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to avoid  the user-dependent measurement disadvantage of FMD (Conraads, 2013, 
Lumsden et al., 2013). The Endo-PAT system (Itamar, Isreal), works by using 
pneumatic fingertip probes to automatically measure digital arterial pulse wave 
response when reactive hyperaemia is induced (Lekakis et al., 2011), instead of the 
need for ultrasound. 
 
 
Figure 6.1: (A) Setting for flow-mediated dilation testing. The picture showing the 
ultrasound probe in a fixed position in the upper arm, and the blood pressure 
cuff on the lower forearm used to occlude blood flow. (B) Ultrasound image 
of brachial artery used to measure both the diameter changes and flow 
velocity. The red arrow shows the direction of blood flow through the vessel 
and the green arrows show the diameter which is the measurement taken 
before and after occlusion. Taken from Arrebola-Moreno et al., (2012). 
 
 
The Endo-PAT system is effectively an operator-independent device that is 
easy to use as it is computer controlled. The differences in technique are that Endo-
PAT measures microvascular endothelial function, whereas FMD measures 
endothelial function at level of large conduit artery. Both techniques, however, are 
correlated well in healthy participants (Conraads, 2013).   
The EndoPAT device has been approved by the Federal Drug Administration 
(FDA) and is commercially used to measure endothelial function in the USA 
(Hamburg and Benjamin, 2009). It consists of two probes placed on the index 
fingers of both hands to sense the change in blood volume in each arterial pulsation 
as shown in Figure 6.2. Using the pneumatic digital probes (figure 6.3) to sense the 
changes in pulsatile blood volume from the microvasculature of the fingertips, the 
peripheral arterial tone (PAT) can be measured.  
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Figure 6.2: Diagram of  Endo-PAT fingertip and inflatable cuff. (A) A thimble-like 
probe placed on the end of each index finger as shown in diagram. (B) A cuff 
is placed on one upper arm then inflated to supra systolic pressure to total 
occlusion, which on releases induce hyperaemia. (C) The air filled chamber 
senses changes in volume with each arterial pulsation. Reproduced from 
Hamburg and Benjamin., (2009). 
 
 
Figure 6.3: Cross-sectional view through the PAT finger probe. derived from 
Celermajer., (2008). 
 
Each endothelial function test includes three phases; namely: baseline, 
occlusion and hyperaemia. A relative index (the reactive hyperaemia index, RHI) is 
then calculated by monitoring the change in pulsatile blood volume between 
baseline and hyperaemia, and compared to the control blood flow in the non-
occluded arm. Endo-PAT score, or RHI, can be divided to 3 levels: RHI ≤ 1.67 
indicates the need for further medical assessment for endothelial dysfunction; a 
score between 1.68–2 indicates the endothelium is fine, and >2.1 is considered a 
C A 
B 
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good healthy endothelium. Figure 6.4 shows an example of the difference between 
low and high endothelial response measured by Endo-PAT 2000 device. 
 
 
Figure 6.4: Low (A) and high (B) endothelial responses monitored by Endo-PAT 
2000. The test has three phases: phase 1 (panel up to approx. 5 min) records 
the baseline, phase 2 (blue section) monitors occlusion during the cuff 
inflation, and phase 3 records the response after cuff release (hyperaemia). 
Probe 1 is test finger response, and probe 2 is the control finger response. 
 
There have been several studies on citrus flavanones on CVD risk factors, 
such as BP and FMD. Buscemi et al., (2012) showed that endothelial function, was 
significantly improved after was measured by flow-mediated dilation. Morand et al., 
(2011) also showed in healthy, moderately overweight, men that orange juice 
decreased diastolic blood pressure when regularly consumed, and post–prandial 
increased endothelium–dependent microvascular reactivity. At the time of this 
study, to the best of our knowledge, no intervention had been published using 
commercially-available citrus supplements to improve CVD risk factors and, 
A  
B  
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furthermore, Endo-PAT had not been used to investigate chronic changes in 
endothelial response after flavanone intake.  
 
6.3 Aims of the study 
The purpose of this study is to assess changes in various CV risk factors after 
a four week placebo-controlled, cross-over intervention study after volunteers have 
consumed citrus supplements or a placebo supplement, on a daily basis with 
breakfast. The hypothesis is that chronic intake of flavanones improves endothelial 
health by decreasing blood pressure and increasing reactive hyperaemia. 
 
The main aims were as follows: 
 To investigate the change in systolic and diastolic blood pressure before and 
after citrus supplementation for four weeks, and compare to any changes 
after a placebo for the same time. This was the primary objective and was 
used as a basis for power calculations for determining volunteer numbers. 
 To  assess any changes in reactive hyperaemia as measured by Endo-PAT in 
the same intervention study. 
 To assess any changes in fasting blood glucose, in the same intervention 
study.  
6.4 Material and methods 
This study was reviewed and granted permission by the MEEC Faculty 
Research Ethics Committee at its virtual meeting of 14
th
 March 2013, under the 
Ethics reference number (MEEC 12-025) University of Leeds (see Appendix 2 for 
the Ethics forms). The study is registered with clinical Trial under the clinical 
Trials.gov identifier (NCT01935362). 
6.4.1 Subjects 
The study advertised for volunteers by (i) emails sent using the University of 
Leeds distribution lists, (ii) poster adverts displayed around the University and 
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across Leeds, (iii) an advert on the School of Food Science and Nutrition website, 
(iv) an advert in “The Reporter” the University monthly magazine. The Inclusion 
criteria specified in the advert were to have no known cardiovascular disease or 
diabetes, to be between 30-60 y, to be heavier than average (Body mass index, BMI 
≥ 25 kg/m2), to be a non-smoker, and willing to consume orange juice supplements 
for 2 months. The recruitment for this study was open to everyone; male and female 
were equally eligible to participate in the study. 
 
The volunteers who responded positively to the adverts were invited to read 
the detailed study information sheet, and the study protocol in full was explained to 
each person. Having given their verbal and written informed consent, eligible 
participants were asked to fill in a basic health questionnaire recording age, gender, 
height, weight, medical and surgical history, medications taken and recent smoking 
status, to ensure the suitability for study inclusion.  
Participants were recruited if they:  
 
 had not taken any antibiotics in the 2 months prior to the study,  
 did not consume dietary or herbal supplements,  
 had not ever had any gastrointestinal tract surgery,  
 were not currently taking medication,  
 were happy to sign the informed consent form. 
 
Figure 6.5 shows a flowchart of the recruitment period; in total 23 volunteers 
were excluded because they failed to meet the criteria required to participate in the 
study, a further volunteer did not complete the study as they started taking 
medication for blood pressure midway through the intervention, invalidating their 
data. Finally, 23 subjects complete in the entire study.  
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Figure 6.5: Flowchart of the study recruitment. 
 
6.4.2 Design of the study 
 The study was designed as a 4-week double-blinded, randomized, cross-over 
intervention trial using a commercially-available orange juice supplement and a 
placebo control (Figure 6.6). The study lasted for 12 weeks and has 3 phases:  
 
Phase 1 - a commercially-available orange juice supplement or a placebo control 
was given daily for the first 4 weeks  
Phase 2 – a wash-out period of at least 4 weeks of no supplement  
Phase 3 – the other supplement, either citrus supplement or a placebo control 
depending on first phase, was given for 4 more weeks. 
 
 The amount of flavanone absorbed and excreted by each individual was 
measured by collecting 24 hr urine samples at the beginning and end of each phase 
(analysed in Chapter 7). The vascular health of the individuals was measured by 
collecting height, weight, waist circumference, fasting blood glucose, BP and PAT, 
at the start and end of each phase. 
• Responded to advert: posters, websites, magazine and email 
invitation, n =47 
Recrutment  
• Excluded, n= 23 
• Did not want to participate, n=12 
• Did not meet inclusion criteria during telephone and email screening, 
n= 8 
• Did not meet inclusion criteria during screening appointment, n= 3 
Screening  
• Participation in study, n = 24 
• Excluded during study due to medication, n= 1 
Eligible to participate 
•  Participants completing entire study, n= 23 
Volunteers finishing all phases of the study  
156 
 
 
 
Figure 6.6: Experimental design of the study for 12 weeks. A 4-week double-
blinded, randomized, cross-over intervention trial using a commercially-
available orange juice supplement and a placebo control. Wt is weight, ht is 
height, wc is waist circumference, PAT is pulse amplitude tonometry, BP is 
blood pressure. 
 
 The 24 participants were randomised into the different supplement groups, 
coded A and N, and blinded to the study manager. At least one week after the 
consent form had been signed the participant attended the first study day. They were 
asked to refrain for consuming citrus foods/beverages (table 6.1) for 2 days prior to 
this. On each study day, the participant would arrive at the human study room at 9 
am. They had been asked to fast from 9 pm the previous evening, drinking only 
water after this time. Height was measured using the Leicester height stand meter 
(Measure, Invicta plastics Ltd, UK); weight was recorded using a Marsden 
(MAR1047) weight scale, and waist circumference was determined with a Seca 200 
measuring tape.  
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Table 6.1: Food items need to be avoided 48 hours prior to each experimental 
session. 
Food items to avoid 
Citrus fruit in any form (fresh, canned or dried):  
e.g. oranges, tangerines, clementines, satsumas, grapefruit, lemons, limes 
Fruit juices, fruit squashes (cordials) and jam or marmalade containing citrus fruit 
 
 
6.4.3 Evaluation of fasting blood glucose 
Fasting blood glucose was monitored using a hand-held glucometer device, 
Accu-Chek Aviva (Roche Diagnostics; see chapter 5 for validation). Participants 
cleaned their fingers with an alcohol wipe prior to a finger-prick blood sample being 
taken using a single-use lancet. The Accu-Chek test strip would be placed adjacent 
to the blood droplet and allowed to soak into the strip. The blood glucose 
concentration was measured automatically and the value recorded. Triplicate 
measurements were taken on different fingers to improve reliability.  
 
6.4.4 Evaluation of blood pressure 
The participant was asked to remove tight or restrictive clothing and to relax 
in a comfortable chair, whilst they completed a citrus food habit questionnaire (see 
appendix 12). After sitting for 10 min, they were then ask to lie in a supine position 
on a bed with both arms resting on arm support pads to avoid muscular activities of 
the arms and fingers. A blood pressure cuff was placed on the upper left arm (see 
also 6.2.3 for set up of PAT) and then they were asked to continue to relax and 
refrain from talking. Measurement of blood pressure was calculated automatically 
using a portable blood pressure device (Lloyds Pharmacy Model (LBPK1) 
Automatic Blood Pressure Monitor measuring device, made by Kinetik medical 
devices Ltd, Elstree, Herts, UK). Blood pressure was measured in triplicate with at 
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least 5 min between each reading. The average of the last two readings were 
recorded for the study.  
 
6.4.5 Evaluation of peripheral arterial tonometry (PAT) 
The supine participant had a thimble-like sensor probe placed on the index 
finger of the hand undergoing hyperaemia testing (right hand), and a second PAT 
probe was placed on the control index finger (left hand). A blood pressure cuff was 
placed on the forearm, just below the elbow, of the right arm, but was left deflated. 
(See figure 6.2 for set up pictures, although in our study the blood pressure cuff was 
on the forearm). Once all was in position the sensor probes were inflated and the 
participant ask not to move their hands or fingers for the monitoring period. The 
Endo-PAT 2000 device was controlled by a laptop computer using Itamar EndoPAT 
software (version 2.0). The finger tip blood flow was continuously recorded from 
this point. After approximately 10 min in the relaxed state, the PAT baseline 
response was recorded for 5 min (i.e. PAT pre-occlusion). The radial artery was then 
occluded using the blood pressure cuff (220–240 mm Hg), for exactly 5 min. The 
pressure cuff was then released and the PAT response was monitored for a further 5 
min (i.e. PAT post-occlusion). The finger probes are then deflated and removed, and 
the reactive hyperaemia index (RHI) automatically calculated by PAT device 
(Hamburg et  al .,  2008, Hamburg & Benjamin.,  2009). 
The RHI is calculated as the ratio of the occluded arm’s mean pulse wave 
amplitude at 90–150 s post-deflation to the mean amplitude of the same arm at 
baseline divided by the same ratio from the control arm, the quotient of which is 
multiplied by a proprietary baseline correction factor (Itamar Medical Ltd), As 
follows: 
Equation 6.1:  
RHI = 
A/B
C/D
 x baseline correction factor 
Where A is the mean digital pulse volume during the reactive hyperaemia, B 
is the baseline mean digital pulse volume and C and D are the respective values 
obtained in the control arm. Figure 6.7 shows the typical recording from the Endo-
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PAT system and how estimation of peripheral arterial tonometry (PAT) ratio is 
calculated. 
 
 
 
Figure 6.7: Typical recordings from the Endo-PAT. Estimation of peripheral arterial 
tonometry (PAT) ratio after correction of the reactive hyperaemia index for the 
control arm. Probe 1 corresponds to the occluded arm and probe 2 to the control 
arm. The blue-coloured interval corresponds to the duration of occlusion in the test 
arm (John Lekakis et al., 2011). A, B, C, D refer to equation 6.1. 
 
After finishing the experiment (approximately 30 min), the participant was 
provided with breakfast and asked to take the first supplements of the study. They 
were also asked to fill in a brief pain assessment questionnaire (appendix 18) 
regarding their impression on the intensity of pain from the Endo-PAT set up. The 
Wong-Baker Face Pain Rating Scale, ranged from (0–5) was used (Newman et al., 
2005, Tierney et al.,  2009).  
 
6.4.6 Intervention 
The supplements used in this study were (i) active phase - Solgar Citrus 
Bioflavonoid Complex 1000 mg (providing 70 mg hesperidin per tablet; equivalent 
to approximately 300 ml orange juice); (ii) control phase – a placebo (Fargon, 
placebo tablet, Germany) that was manufactured to European Pharmacy standards. 
Participants were asked to consume their normal diets for the duration of the study, 
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with the exception of 2 days prior to each study day when citrus fruits and juices 
should be avoided (see table 6.1). They were asked to take two of the provided 
supplement (in a seal opaque container, blinded to the study manager), every day at 
breakfast (and before 11 am), starting on day 1 of each phase after the vascular 
measurements had been taken. Any remaining tablets should be returned on day 28 
of each phase. A supplementary questionnaire was provided so participants could 
write down any days missed, or deviations from the protocol. Urine was collected 
for 24 on day 1 and day 28. See appindex 11. 
 The participants were allowed at least 4 weeks without supplements before 
they were invited back for the third study day in phase 2. This was identical to the 
first study day, except the alternative supplement was given. 
6.5 Statistical analysis 
All statistical analyses were performed by using the statistical software 
package (IBM, SPSS statistics 21, Chicago, USA) and Origin Pro 8.6 software. 
Within-day reproducibility of the technique was determined by comparing the 
measurements during the three days. Between days reproducibility was evaluated by 
comparing the measurements obtained during the three days. A paired t-test was also 
used to check if there are any differences between the parameters at the beginning 
(baseline) and at the end of the 4-week period of treatment. Correlation coefficient 
was determined for PAT and blood pressure measurements with age, gender, and 
BMI, WC and blood glucose. in order to indicate the difference between these 
groups. A repeated measurement ANOVA has been used in order to determine any 
effect of time and treatments, and to trace any interaction between time and 
treatments on RHI and blood pressure measurements of the two supplements (citrus 
and placebo supplements ) from baseline ( day 1) to day 28. The alpha level was set 
at P< 0.05 for all statistical tests; all values are reported as mean +/- SD unless 
otherwise indicated. Based on a predicted reduction in diastolic blood pressure based 
on a previous study, and for a confidence level of <0.05, statistical power of >0.8, 
and to achieve an average reduction in diastolic blood pressure of 3.2 mmHg; 20 
participants are required. 
 
161 
 
6.6 Results 
The characteristics of the participants in the study are shown in Table 6.2. 
Subjects were predominantly male, older than the average student population, and 
had an average BMI of 30 kg/m
2
 (classed as obese). The study was targeted at 
recruiting older, heavier volunteers, as although cardiovascular disease is not 
present, these characteristic may suggest greater potential for early metabolic 
syndrome.  
Table 6.2: Baseline characteristics of study subjects 
Characteristics Mean ± SD Range 
Number of subjects 23 (19 male, 4 female) 
Age, y 37.0 ± 4.2 (29 – 44) 
Weight, Kg 87.3 ± 15.1 (66 – 134) 
Height, m 1.70 ± 0.07 (1.60 – 1.80) 
BMI, kg/m
2
 30.0 ± 4.4 (24.3 – 40.0) 
Waist circumference, cm 98.0 ± 9.3 (80 – 122) 
Values are means ± standard deviation (SD) 
Results from the Wong-Baker faces pain rating questionnaire given to 
participants to evaluate the discomfort and pain of the Endo-PAT procedure are 
shown in Figure 6.8. In total 65% of participants described the discomfort as little or 
no pain, whereas 35% rated their discomfort as some pain. None of the participants 
rated the discomfort at the top two levels of more intense pain. 
 
Figure 6.8: Assessment using Wong-Baker faces pain rating scale of the EndoPAT. 
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The cardiovascular risk factors monitored before and after the 28 day 
intervention are summarized in tables 6.3 and 6.4. Fasting blood glucose, systolic 
(SBP) and diastolic blood pressure (DBP) and Augmentation index (AI) all appeared 
to be reduced after 4 weeks of taking the citrus supplements, however only AI 
reached statistical significance in a paired t-test, with DBP not quite reaching 
significance. RHI, the index measuring the endothelial response to occlusion using 
the Endo-PAT was not affected at all. As expected, there was no difference between 
any of the parameters measured before and after the placebo intervention. 
 
Table 6.3: Summary of paired t-test, within treatments, before and after consuming 
citrus supplements for 4 weeks. 
Parameters citrus 
supplement 
baseline 
citrus 
supplement 
28 d 
P value 
(0.05) 
Paired difference 
Mean 95% 
confidence 
interval 
Lower Upper 
SBP (mm Hg) 115.0 ± 7.9 113.8 ± 7.2 0.19 1.2 -0.7 3.1 
DBP (mm Hg) 78.3 ± 6.7 76.9 ± 6.9 0.07 1.4 -0.5 3.2 
AI -3.1 ± 10.8 -4.7 ± 10.7 0.01* 1.7 0.3 3.0 
RHI "ratio" 1.9 ± 0.4 1.9 ± 0.5 0.81 - 0.0 - 0.2 0.2 
Fasting blood 
glucose (mmol/L) 
5.5 ± 0.5 5.1 ± 1.3 0.17 0.4 -0.2 1.0 
WC (cm) 98.6 ± 14.4 98.3 ± 14.5 0.14 0.1 -0.1 0.8 
BMI (kg/m
2
) 29.9 ± 4.4 29.9 ± 4.4 0.86 -0.0 -0.25 0.2 
SBP systolic blood pressure; DBP diastolic blood pressure; RHI reactive hyperaemia 
index; AI Augmentation Index; WC Waist circumference; BMI body mass index. 
Data are expressed as mean ± SEM (n = 23); means are significantly different at, * 
significantly different at P<0.05.  
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For the anthropometric measurements, participants in the citrus and placebo 
group had an average BMI of 30.0 ± 4.4 kg/m
2 
 at the baseline, and there was no 
difference in weight loss for all participants, or between males and female for either 
the citrus or placebo group. Similar results were obtained for waist circumference. 
As expected, there was no significant change in any anthropometric measures 
observed in both groups from baseline to post intervention, or between groups after 
controlling for baseline values. 
 
Table 6.4: Summary of paired t-test, within treatments, before and after consuming 
placebo supplements for 4 weeks. 
Parameters Placebo 
supplement 
baseline 
Placebo 
supplement 
28 d 
P value 
(0.05) 
Paired difference 
Mean 95% confidence 
interval 
Lower Upper 
Fasting blood 
glucose 
(mmol/L) 
5.4 ± 0.4 5.41 ± 0.5 0.8 0.0 -0.2 0.2 
SBP (mm Hg) 114.7± 7.1 115.5 ± 8.4 0.4 -0.8 -2.7 -1.2 
DBP (mm Hg) 77.5± 5.5 77.6 ± 6.3 0.9 -0.1 -1.9 1.7 
RHI "ratio" 2.0 ± 0.6 1.9 ± 0.4 0.6 - 0.1 - 0.2 0.3 
AI -5.6± 9.5 -4.8 ± 9.9 0.8 -0.3 -3.3 2.6 
WC (cm) 98.5± 8.8 98.2 ± 8.8 0.1 0.3 -0.1 0.7 
BMI (kg/m
2
) 29.9 ±4.3 29.9 ± 4.1 0.7 -0.0 -0.2 0.2 
SBP systolic blood pressure; DBP diastolic blood pressure; RHI reactive hyperaemia 
index ; AI Augmentation Index; WC Waist circumference; BMI body mass index. 
Data are expressed as mean± SEM (n = 23) 
 
Figure 6.9 shows the concentration of blood glucose before and after 
ingestion of supplements for 4 weeks. Although a decline in fasting blood glucose 
was observed, the large variation in response means this result was not significant 
with the number of participants in this study. The diastolic and systolic blood 
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pressure changes are shown in Figure 6.10 and 6.11, respectively. A non-significant 
(p =0.07) reduction in mean diastolic blood pressure pre- and post- citrus 
supplementation of -1.4 mmHg was observed, although for some individuals the 
decrease in DBP up to -11 mmHg. A trend in reduction of systolic blood pressure 
was also observed at -1.2 mmHg. No significant change in blood pressure was 
observed in the placebo group before and after the intervention with regard to 
systolic and diastolic blood pressure.  
 
 
 
Figure 6.9: Change in fasting blood glucose level before and after consumption of 
citrus and placebo supplements (suppl). Data are expressed as mean ± SEM 
(n = 23), (Red) citrus treatment, (Blue) placebo treatment, * between group 
comparisons significant at (P < 0.05). (V: visit). 
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Figure 6.10: Change in diastolic blood pressure before and after citrus bioflavonoid 
and placebo supplements. Data are expressed as mean ± SEM (n = 23); (Blue) 
citrus treatment, (Green) placebo treatment. *between group comparisons 
significant at (P < 0.05). (V: visit). 
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Figure 6.11: Change in systolic blood pressure before and after citrus bioflavonoid 
and placebo supplements (suppl). Data are expressed as mean ± SEM (n = 
23); between group comparisons significant at *P < 0.05, (Blue) citrus 
treatment, (Orange) placebo treatment. (V: visit). 
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Figure 6.12: Change in waist circumference (WC) before and after citrus 
bioflavonoid and placebo supplements (suppl). Data are expressed as mean ± 
SEM (n = 23); (Red) citrus treatment, (Blue) placebo treatment, between 
group comparisons significant at *P < 0.05. (V: visit). 
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Figure 6.13: Mean change in reactive hyperaemia index (RHI) before and after 
citrus bioflavonoid and placebo supplements (suppl) intervention. Data are 
expressed as mean ± SEM (n = 23); (Green) citrus treatment, (Blue) placebo 
treatment, between group comparisons significant at *P < 0.05; between 
baseline measurements significant at α P < 0.05. (V: visit). 
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index of 46% of the subjects increased (improved condition) after 4 weeks of citrus 
supplement compared to the baseline, however, the increase overall was not 
statistically significant. On the other hand, the RHI after the placebo 
supplementation for weeks decreased, but again was not significantly different in 
comparison to the baseline values. Furthermore there was a statistically not 
significant difference in the baseline values between the citrus group and the placebo 
group (p= 0.08), with the placebo group displaying higher (more favourable) 
endothelial function. As the participants were all randomised at the start of the study 
to receive either the placebo or the citrus supplement first, there should not have 
been a difference in the baseline measurements. 
The augmentation index (AIx) was derived from the digital pulse wave 
(automated output of the EndoPAT software). AIx expresses the (mathematically 
derived) augmentation of the central aortic pressure. Augmentation index (AI) as 
calculated from the pulse wave in the finger tips (Figure 6.14) displayed a clear 
marked decrease after citrus supplements intervention from -3.1±10.8 to -4.7±10.7, 
which was significant (p=0.01). As the decrease signifies improvement, it can be 
noted that chronic consumption of citrus consistently benefited digital augmentation 
index among 65% of the participants. The AI did not alter after placebo supplement 
intervention. However, just as with the RHI there was  significant difference (p = 
0.07) between the baseline values of citrus or placebo treatment, with the improved 
endothelial function represented in the placebo baseline. 
  
170 
 
 
 
 
Figure 6.14: Mean change in augmentation index (AI) before and after citrus 
bioflavonoid and placebo supplements (suppl) intervention. Data are 
expressed as mean± SEM (n = 23); (Green) citrus treatment, (Blue) placebo 
treatment; between group comparisons significant at *P < 0.05; between 
baseline measurements significant at P < 0.05. (V: visit). 
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6.7 Repeated measures ANOVA design 
 This is a statistical test that is used when the same subjects take part in all the 
conditions of an experiment (placebo-controlled, cross-over design). We assume that 
the relationship between pairs of experimental condition is similar (known as the 
assumption of sphericity) and sphericity is met when these variances are equal. The 
hypothesis that the variances of the difference between conditions are equal is 
measured by Mauchly’s test. Repeated measurement ANOVA used when there are 
repeated measurement on the same sampling units and the higher the F-value, the 
more likely the difference between samples are statistically different.  
 Table 6.5 summarises the descriptive and repeated-measures ANOVA results 
for all parameters assessed in four visits using 2 different supplements (citrus and 
placebo). According to the means ± SE, it can be concluded that some category 
means are different from each other. Mauchly’s test for these data was checked and 
the significance value was less than 0.05 are <0.005, 0.03, for fasting blood glucose, 
AI, respectively. The hypothesis that the variances differences between levels were 
significantly different is accepted.  
 The next stage is which of the means are significantly different by using test 
of within-subjects effects, where we can determine the F and p value that indicate 
whether these means differ significantly or not. The result obtained from the test of 
sphericity, can be used to accept or reject the null hypothesis for this analysis. We 
should use sphericity assumed correction when sphericity test p value was > 0.05, 
and we should use Greenhouse-Geisser correction when the sphericity test p values 
were < 0.05 as shown in table 6.5. Using this correction, none of the F values were 
significant.  
 We have conducted Hotelling’s Trace post-hoc tests to indicate significant 
differences between category means. These tests search for sources of the significant 
results by comparing two groups or two combinations of groups using t-tests; i.e. 
using paired-samples t-tests for a repeated-measures ANOVA’s post hoc tests. It can 
be concluded that all p values were > 0.05 which mean that there were no 
differences in the means between groups and within the same group. Therefore, it 
can be stated that the effect of supplements were the same. 
172 
 
Table 6.5: A summary of repeated measures one way ANOVA between 4 visits.  
 Citrus supplements 
(mean ± SE) 
Placebo  supplements 
(mean ± SE) 
M
a
u
ch
ly
's
 T
es
t 
 
F
-v
a
lu
e 
Tests of Within-Subjects 
Effects P-value 
Hotelling's 
test p-
value 
Visit 1 Visit 2 Visit 3 Visit 4 Sphericity 
Assumed 
Greenhoue-
Geisser 
 
Blood glucose 
mmol/L 
5.5±0.5 5.1±1.2 5.4±0.4 5.4±0.4 <0.005 - 0.29 0.48 
SBP (mm gh) 114.3±7.2 113.1±6.10 114.7±7.0 115.5±8.4 0.06 0.21 - 0.23 
DBP (mm gh) 78.8±6.0 76.9±6.9 77.5±5.6 77.6±6.3 0.25 0.38 - 0.36 
RHI "ratio" 1.90±0.4 1.92±0.4 2.03±0.5 1.97±0.4 0.34 0.51 - 0.40 
AI -3.06±10.8 -4.74±10.1 -5.15±9.4 -4.81±9.9 0.03 - 0.25 0.27 
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 Bivariate correlations of PAT index with parameters measured in this study 
among 23 participants are described in table 6.6.  Age and blood glucose level were 
significantly correlated, (r = 0.41, p=0.04). BMI and WC were strongly correlated, (r 
= 0.80, p < 0.01). Moreover, the correlation between diastolic blood pressure 
measurements and systolic blood pressure and augmentation index (AI) was 
significantly positively correlated (r = 0.54, p < 0.01) and (r = 0.06, p < 0.01), 
respectively. 
Moreover, correlation between the total amount of hesperetin conjugate 
(glucuronides and sulfates) present in urine samples over 24 hr post-intervention 
(see chapter 7) with vascular reactivity and function measurements showed an 
inverse, or weak, correlation. Both RHI and SBP were inversely correlated (r= -0.37, 
p=0.0.08) and (r = -0.12, p=0.57). Similarly, other measures of vascular reactivity 
and function, such as DBP change (r=0.12, p=0.55), blood glucose change (r=0.29, 
p=0.17), AI change (r=0.10, p=0.65), all measurements displayed low or non-
existent correlations with total urinary hesperetin metabolites after citrus 
bioflavonoids tablets were consumed for 4 wk. moreover, weak positive association 
was found when correlated with WC and BMI, (r=0.05, p=0.79), (r=0.16, p=0.45) 
respectively. as it can be seen in (figure 6.13). 
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Table 6.6: Adjusted Pearson’s correlations of changes in CVD risk factors among participants consumed citrus bioflavonoids tablets 
(n=23).  
 Age (y) BMI 
(kg/m2) 
WC Cm Blood 
glucose 
mmol/L 
DBP 
(mm Hg) 
SBP 
(mm Hg) 
Pulse rate 
beat/min 
RHI "ratio" AI 
Age (y)  -.043 (0.84) .077(0.72) 0.41(0.05)
*
 -0.21(0.33) -0.38(0.06) 0.23(0.30) 0.17(0.39) 0.011(.962) 
BMI (kg/m2) -.043(0.84)  0.80
**
(.00) .013(0.56) .332(0.35) .07(0.16) .35(0.09) .396(0.17) 0.24(0.26) 
WC Cm .077(0.72) 0.80
**
(0.00)  .18(0.40) 0.07(0.73) 0.05(0.80) 0.16(0.46) 0.21(0.33) 0.13(0.56) 
Blood glucose 
mmol/L 
0.41(0.05)
*
 .013(0.56) .18(0.40)  0.15(0.47) -0.14(0.51) 0.07(0.75) -0.28(0.19) 0.32(0.12) 
DBP(mm Hg) -0.21(0.33) .332(0.35) 0.07(0.73) 0.15(0.47)  0.54
**
 (<0.05) -0.15(0.47) -0.3(0.89) 0.63
**
 (<0.05) 
SBP (mm Hg) -0.38(0.06) 0.07(0.16) 0.05(0.80) -0.14(0.51) 0.54
**
 (<0.05)  0.22(0.30) 0.26(0.22) 0.28(0.18) 
Pulse rate 0.23(0.30) .35(0.09) 0.16(0.46) 0.07(0.75) -0.15(0.47) 0.22(0.30)  0.07(0.72) -0.02(0.93) 
RHI "ratio" 0.17(0.39) .396(0.17) 0.21(0.33) -0.28(0.19) -0.3(0.89) 0.26(0.22) 0.07(0.72)  0.03(0.87) 
AI 0.01(.962) 0.24(0.26) 0.13(0.56) 0.32(0.12) 0.63
**
 (<0.05) 0.28(0.18) -0.02(0.93) 0.03(0.87)  
Data presented as r (p-value) are represented in bold value. Abbreviation: BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; RHI, reactive hyperaemia index ; AI, Augmentation Index; WC, Waist circumference;  
*Correlation is significant at the 0.05 level (2-tailed), **Correlation is significant at the 0.01 level (2-tailed). 
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Figure 6.15: Correlation of change in endothelial function biomarkers with total 
hesperetin conjugates. Correlation of amount of metabolites (sum of 
hesperetin glucuronide and sulfate) excreted in urine in 24 hr after 4 weeks 
of citrus bioflavonoids tablets were ingested compared to the change 
observed in the parameters. Blood glucose (A), WC (B), SPB (C), DBP (D), 
RHI (E), AI (F). 
 
 
 
 
 
 
A B 
C D 
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6.8 Discussion 
The overall aim of this study was to investigate, for the first time, the effect of 
commercially available citrus bioflavonoid supplements on endothelial function by 
measuring changes in some CVD risk markers. The specific focus was on changes in 
BP, as this parameter has been shown in previous studies to be reduced by orange 
juice consumption and the data from these studies had been used in the power 
calculations to determine number of volunteers required. The secondary aim was to 
monitor changes in PAT after supplementation, using an Endo-PAT. Changes in 
endothelial function after orange juice consumption have previously been shown 
using FMD measurements, but the Endo-PAT has rarely been used in any type of 
intervention studies (Hamburg and Benjamin, 2009, Moerland et al., 2012, Allan et 
al., 2013), and this is the first study, to the best of our knowledge, to measure Endo-
PAT after flavavone intake.  
Although the evidence was weak, and not statistically significant, there was a 
trend towards a reduction in both systolic and diastolic BP after 4 weeks of citrus 
supplementation compared to the placebo. The reduction in SBP and DBP were by 
1.2 and 1.4 mmHg, respectively. Based on previous studies on citrus juices (Morand 
et al., 2011, Buscemi et al., 2012), DBP was significantly reduced by at least 3 
mmHg. It has been estimated that even if the blood pressure lowering effect is 
moderate, in persons aged 50 – 69 y with an SBP of 150 mmHg  and a DBP of 90 
mmHg, a 3-4 mmHg decrease in DBP would reduce the incidence of coronary artery 
disease by 20% (Law et al., 2009). Not all studies on flavanones have been 
consistent. For example, Rizza et al., (2011) found no change in blood pressure after 
three weeks consumption with 500 mg of hesperidin (Rizza et al., 2011). Orange 
and other juices also contain vitamin C, potassium, fibre, carotenoids, possibly 
anthocyanins, and also sugar. The supplements used in this study did not contain any 
of these additional compounds. These compounds might have contributed 
favourably (e.g. potassium) or negatively (e.g. sugar) to the blood pressure and 
endothelial effects. Larger trials, for a longer time periods, that monitor the 
influence of the non-flavonoid components as well, may be required to determine 
the effect of flavanones on BP. 
 177 
 
DBP is a good indicator for peripheral vessel resistance (Franklin, 2007), 
however changes in overall endothelial function after 4 weeks of citrus 
supplementation was assessed by measuring changes in reactive hyperaemia index 
(RHI) and augmentation index (AI) using an EndoPAT. RHI was not affected by the 
citrus intervention. AI did show a significant change between baseline and 4 weeks 
after supplements were taken, however the baseline measurements between the 
supplement and the placebo were also significantly different which could indicate 
the variability in this measurement is less reliable. All the volunteers had an RHI in 
the normal healthy range. 
A placebo-controlled crossover study involving participants with metabolic 
syndrome showed an improvement in FMD after three weeks consumption with 500 
mg of hesperidin, despite no change on blood pressure (Rizza et al., 2011). Morand 
et al., (2011) also reported that daily intake of 500 ml OJ for 4 weeks improved 
endothelial function significantly. In another study (Buscemi et al., 2012), FMD 
increased significantly (5.7% compared with 7.9%, p < 0.005) after one week of red 
orange juice (containing flavavones and anthocyanins) consumption in volunteers 
with increased CV risk. Recent studies on anthocyanin-rich juices have not find 
significant increases in FMD. A study conducted among 13 hypertensive men (39-
68 y) investigated the acute effects of pomegranate juice on blood pressure and 
endothelial function measuring the change in FMD. A significant reduction in both 
SBP and DBP were observed, but brachial artery FMD did not change significantly 
(Asgary et al., 2013). A study testing the effects of cranberry juice did show a 
decrease in pulse wave velocity, which is a measure of arterial stiffness, but the 
FMD, which measure the brachial artery, did not change (Dohadwala et al., 2011). 
Acute changes (2 hr) in FMD were significantly improved in healthy adults after 
intake of grape polyphenols (Li et al., 2013). 
The possible mechanisms by which the flavonoids-rich foods are lowering BP 
and improving FMD may involve a chronic increase in the production of NO by 
vascular endothelium (Grassi et al., 2009, Morand et al., 2011, Asgary and 
Keshvari, 2013). In addition, inhibitory effect on angiotensin-converting enzyme 
could be another mechanism responsible for the blood reducing effects of 
flavanones (Actis-Goretta et al., 2006, Morand et al., 2011).  Moreover, the study by 
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Rizza et al., (2011) reported that hesperetin treatment increased FMD and reduced 
circulating markers of inflammation. This has the vascular-protective actions that 
may explain the beneficial effects of citrus intake on CVD. The same study reported 
that hesperetin acutely stimulated phosphorylation of AMP kinase, and eNOS which 
mediate NO production by endothelial cells.  
The present study did not find a significant difference in fasting blood glucose 
levels after citrus supplement treatment (5.5 ± 0.5 mmol/L and 5.1 ± 1.2 mmol/L; p 
= 0.17). These findings are consistent with previous studies which showed that citrus 
flavonoids intake did not improve fasting blood glucose level after 500 ml orange 
juice daily for a 4 wk period (Morand et al., 2011). In addition, our results were 
consistent with the results obtained from a recently published study which recruited 
22 healthy volunteers and examined the effects of commercial fresh orange on 
endothelial function markers in healthy volunteers for 4 wk. The study concluded 
that fasting blood glucose did not change after treatments (Asgary et al., 2014). No 
significant differences were observed in fasting plasma glucose, and fasting plasma 
insulin concentrations  (Rizza et al., 2011).  
Hesperidin may have an important role in the modulation of gene expression 
and activities of hepatic glucose metabolic enzymes such as glucokinase and 
glucose-6-phosphatase. These enzymes are involved in the final step of catalysing 
the gluconeogenesis and glycolysis, and therefore can have a hypoglycaemic effect 
and play a role in regulating the homeostatic plasma glucose (Jung et al., 2006, de 
Oliveira et al., 2013). Moreover, isolated hesperidin in rats significantly increased 
the number of GLUT-2 and GLUT-4 carriers enhancing cellular signalling and 
glucose transport and consequently reducing insulin resistance (de Oliveira et al., 
2013). However, the mechanisms of how citrus flavanones may influence glucose 
control and insulin sensitivity in non-diabetic volunteers are unclear. One possible 
explanation is that participants have a fasting glucose concentration which fluctuates 
within the normal range, and hesperidin treatment does not affect the physiologic 
regulation of plasma glucose and insulin concentration under these parameters. 
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6.9 Limitations of the study 
 This study has certain limitations that need to be acknowledged. These are 
related to the size of the sample of participants, differences in health status of 
participants, food habits and physical activities of the participants, the length of the 
study and the dose of flavanones given, and the differences in the tablets and 
placebos given. This study did not recruit the same number of female and male (4 
females and 19 males) and the influence of gender could not be taken into account. 
It assumed that the sample size of 23 participants would be enough to determine a 
change in BP of >3 mmHg, but the majority of participants were normotensive and 
therefore may be less responsive to changes. The same is true for RHI, in that 
normal RHI may not be influenced and only if an individual has endothelial 
dysfunction can an improvement be shown. The small sample size could account for 
the lack of detecting significant difference in blood pressure measurements, as a 
small decrease was observed and perhaps a larger cohort would have provided more 
evidence. Furthermore, a larger and/or longer treatment could influence the blood 
pressure measurements as many intervention studies on blood pressure use 3 months 
or longer.  
 Changes in RHI using Endo-PAT has not been used in many previous 
intervention studies, and although it has been shown to correlate well with 
endothelial dysfunction and overall CV risk, it is unclear whether short-term 
changes will be monitored in an intervention study. Few studies have investigated 
intra-individual variation in response to RHI measurement, and we were not able to 
do this in the current study (see Chapter 5 validation of BP), due to the prohibitive 
cost of the probes required. FMD measurements in previous studies have been 
affected by flavanones and other flavonoids in both chronic and acute studies (see 
chapter 1), and so this does appear to be a more robust measurement of endothelial 
function, however it can be significantly affected by end-user variability. 
 Although the study was a double-blind study, with neither the researcher nor 
the participants aware of which supplements they had been given, there were 
dramatic differences in the size, shape and colour of the tablets. This was because 
both supplements were commercially available and therefore had not been matched, 
as they would be in a larger scale RCT. The citrus supplements were larger and 
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brown in colour and the placebo were small and white. The researcher was blinded 
as far as possible by providing opaque pre-labelled bottles that were given to the 
participants, and the participant was not directly aware of which tablet was which. 
However it could be stated that these differences could have influenced the design of 
the study by making it not a fully double-blind study.  
 
6.10 Summary 
 In summary, flavanones may reduce the risk of CVD, particularly by 
reducing the level of BP, vascular reactivity and fasting blood glucose, however in 
this study further supporting evidence for these affects were not found using 
commercially available citrus supplements in a 4 week intervention. We observed 
trends towards favourable changes in BP after the consumption of citrus 
supplements, but significance was not reached under the conditions of the study. The 
flavanone hesperidin could be responsible for the observed reduction, but it could be 
that other components of orange or citrus juices may contribute to the effects seen in 
other studies where significant reduction in blood pressure, or improvement in 
endothelial function were monitored.  
 More randomized controlled human studies are needed to evaluate the effects 
of hesperidin on blood glucose control, endothelial function and BP lowering effect. 
Before recommending that citrus bioflavonoid supplements are an option for people 
to promote CV health, long-term and high quality RCTs need to be conducted with 
more participants male and female from different age groups, especially those who 
are at high risk of CVD. Further studies are needed to identify the optimal dose of 
flavanones required to improve blood pressure, fasting glucose and endothelial 
health and additional parameters that could be influenced by flavanones. 
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Chapter 7: Bioavailability Of Hesperetin-Conjugate From Citrus 
Supplements 
 
7.1 Abstract  
The human study described in chapter 6 was also conducted to investigate the 
bioavailability, as measured by urinary excretion, of hesperidin from citrus 
supplements. The aim of this chapter was to identify and quantify metabolites of 
hesperetin excreted in urine after the acute 1 day and chronic 28 days ingestion of 
citrus bioflavonoids tablets by 23 participants. Urine was collected over 24 hr at the 
beginning and at the end of each phase after 4 weeks and hesperetin metabolites 
were quantified using LC-MS analysis.  
Three hesperetin metabolites were detected in substantial amounts in urine 
samples taken 1 day and 28 days after the intake of citrus supplements. The main 
urinary metabolite present was hesperetin-3′-O-glucuronide, with 10.0 ± 6.4 
µmol/24 hr and 8.5 ± 7.0 µmol/24 hr being excreted after 1 day and 28 days. 
Hesperetin-3′-O-sulfate was the second most abundant flavanone at 8.5 ± 5.2 and 8.3 
± 4.3 µmol/24 hr at 1 day and 28 days respectively. Hesperetin-7-O-glucuronide was 
also detected with an average of 4.1 ± 3.2 µmol and 3.1 ± 2.8 µmol/24 hr after 1 day 
and 28 days, respectively. 
The urinary excretion of hesperetin-O-glucuronide as a proportion of the dose 
ingested was 7.5 ± 3.4% and 6.2 ± 3.7% after 1 day and 28 days, respectively. The 
excretion of hesperetin-3′-O-sulfate was 4.51 ± 2.71% and 3.36 ± 2.24% after 1 day 
and 28 days, respectively. Daily supplementation of hesperidin over 28 days did not 
significantly change the amount of glucuronide excreted, although hesperetin-3′-O-
sulfate excretion significantly decreased after 28 days ingestion of citrus tablets (p < 
0.05). 
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Hesperetin metabolites appear to be more bioavailable from citrus tablets 
compared to the orange juice used in this study based on the dose ingested, although 
further studies would need to confirm this.  
 
7.2 Introduction 
Citrus fruits are rich sources of flavanones and are widely consumed as part of 
human diets (Brett et al., 2009, Turner and Burri, 2013). The regular consumption of 
orange juice has been associated with protective health benefits, such as reducing 
the incidence of cardiovascular disease (Morand et al., 2011, Chanet et al., 2012b), 
possibly improving endothelial function and reducing blood pressure (Morand et al., 
2011, Buscemi et al., 2012). 
In general, flavonoids, mainly glycosides, are present in plants as conjugated 
forms. Hesperidin is the major flavanone in orange fruit and juice. It is found as the 
7-O-rutinoside – hesperidin (Nielsen et al., 2006, Bredsdorff et al., 2010). The 
bioavailability of flavanones and the presence of their metabolites in biological 
fluids such as plasma and urine samples have been investigated using LC-MS (Brett 
et al., 2009, Bredsdorff et al., 2010, Yamamoto et al., 2013). After oral ingestion, 
hesperidin is expected to be hydrolysed in the colon by β-glycosidases derived from 
gut microflora. The hesperetin aglycone is then absorbed and metabolised by UDP- 
glucuronosyltransferase (UGTSs) and sulfotransferase (SULTs) to glucuronides and 
sulfates metabolites in the intestinal cells (Brand et al., 2010, Yamamoto et al., 
2013) or broken down by the colonic microbiota and produce phenolic acids 
catabolites (Roowi et al., 2009). These potentially bioactive compounds are 
distributed through the plasma around the body and a significant amount is excreted 
in the urine (Matsumoto et al., 2004). The main hesperetin conjugates are 
hesperetin-7-O-glucuronide, hesperetin-3′-O-glucuronide, hesperetin-di-glucuro- 
nides, hesperetin sulfa-glucuronides and hesperetin-3′-O-sulfate (Matsumoto et al., 
2004, Mullen et al., 2008, Bredsdorff et al., 2010). Hesperetin and its respective 
conjugates are shown in Figure 7.1. 
Biological samples such as urine and plasma collected from human 
intervention studies after the consumption of OJ, have been used to measure 
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hesperetin compounds after de-conjugation with sulfatase and β-glucuronidase prior 
to LC-MS analysis (Nielsen et al., 2006, Gardana et al., 2007). However, due to 
some inconsistencies in hydrolysis by sulfatase (Bredsdorff et al., 2010), and  a 
growing interest in improving the knowledge of the form that OJ flavanones and 
metabolites are present and involve the analysis of conjugated forms of citrus 
flavanones metabolites mainly (glucuronide and sulfate) relevant to free-form 
standards (Pereira-Caro et al., 2014). Free form standards usually generate standard 
curve for quantification of conjugates relative to their free forms. 
Hesperetin metabolites have been assayed by LC-MS as this technique is very 
sensitive and selective, and has a high throughout it is particularly sensitive when 
dealing with complex matrices and mixtures as the peaks of the compounds of 
interest may overlap each other (Brett et al., 2009, Bredsdorff et al., 2010, Di Donna 
et al., 2013), And cannot be separated by UV.  MS improves identification by 
monitoring at selected mass for expected compounds. 
The main aim of this study was to identify and quantify the metabolites of 
hesperidin from citrus supplement in humans using a 24 hr urinary collection, both 
in after an acute dose of 24 hr and after a 4 wk chronic intervention. Another aim 
was to compare the total urinary excretion from the OJ consumed in study 1 and the 
citrus supplement in study 2. 
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Table 7.1: Structure of hesperidin and hesperetin and their metabolites 
 
7.3 Materials and methods 
Urine from participants in study 2 (chapter 5) was analysed for levels of hesperetin 
conjugates. 
 
7.3.1 Materials 
For all common reagents and chemicals please see details in Chapter 2. Rutin 
(≥99%), hesperetin (>95%) and taxifolin (>90%) were purchased from 
Extrasynthèse (Genay, France). L-Ascorbic acid was purchased from Fisher 
Scientific (UK). Hesperetin-3’ and 7-glucuronides were kindly donated by Dr Denis 
Barron (Nestlé Research Centre, Switzerland). Hesperetin-3′-O-sulfate was donated 
by Christine Morand (INRA, France). 
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For details of the human intervention study, see method section in chapter 5. 
Urine was collected at several time points over 24 hr (baseline, 1 day and week 4) in 
designated bottles containing 1 g of ascorbic acid. The total volume of each urine 
sample was measured and recorded; samples were centrifuged at 3000 x g for 5 min 
at 4ºC to remove insoluble materials and cellular debris. Aliquots were stored at – 20 
C until analysed. One out of the 24 volunteers was excluded due to health and 
medication issues see study information design in chapter 5 for more details.  
 
7.3.2 Preparation of stock solutions 
A stock solution of rutin (4.5 µg/ml in methanol), to be used as internal 
standard 1(IS1) was aliquot and stored at -20°Cuntil used for sample preparation. 
Taxifolin to be used as internal standard 2 (IS2) was prepared on the day of analysis, 
at a final concentration of 5 μg/ml, using 0.2% ascorbic acid as solvent.  
Stock solutions of hesperetin, hesperetin-7-glucuronide and hesperetin-3′-
glucuronide were used to spike blank urine (baseline) in order to calculate the 
extraction efficiency and prepare the standard curve. Hesperetin, hesperetin-7-
glucuronide and hesperetin-3′-glucuronide were solubilised in methanol at a 
concentration of 1 mM. These solutions were then vortexed for 1 min, and sonicated 
for 5 min. The hesperetin-3′-O-sulfate stock solution was diluted with the 5% 
acetonitrile (ACN) as running solvent. 
For the standard curve all stock solutions were diluted to produce solutions at 
concentrations of 0.5, 0.6, 1, 2, 5, 10, 50 µg/ml. For each sample, 50 µl of 0.005 
mg/ml taxifolin (in 0.2% ascorbic acid) was included. The solutions were then 
filtered into vials for LC-MS analysis.  
7.4 Extraction of hesperetin conjugates from urine 
Urine samples were defrosted for 12 hr at 4˚C and 30 min at room temperature 
prior to extraction. Duplicate urine samples were extracted for each person at each 
time point. For each replicate of sample, 200 μl of urine was mixed with 100 μl of 
rutin-IS1 (4.5μg/ml), 100 μl of ethanol and 800 μl of methanol. This solution was 
then placed in a shaking water bath (GLS Aqua 12 Plus, Grant Instruments Ltd, UK; 
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50˚C, 110 rpm, 10 min) to achieve the solubilisation of the compounds. The 
mixtures were then centrifuged for 10 min at 17000 g (Eppendorf centrifuge, 
Thermo, IEC-Micro CL17, Germany). The supernatant was removed as the first 
extract (extract A) and the process was repeated for the pellet using methanol in the 
place of urine (extract B). The primary and secondary extracts were placed in the 
freezer at -20˚C until the day of the centrifugal evaporation  
The samples were dried using a centrifugal evaporator (Genevac EZ2plus 
Evaporation System, US). To achieve a complete drying, the samples underwent a 5 
hr HPLC program of drying with the lamp off to achieve the evaporation of 
methanol and ethanol layer. This was followed by an extra 2 hr and 15 min aqueous 
program at 65˚C to evaporate the remaining urine-water layer. If the samples were 
not dried after this session, an extra stage of 1.5 hr drying session was added in the 
aqueous program 65˚C. When the samples were completely dried, they were placed 
back in to freezer at -20˚C until their reconstitution.  
The dried samples were reconstituted prior to analysis on the LC-MS. 
Methanol (100 μl) was added to extract B. This solution was then vortexed for 1 
min, sonicated 2 min and placed in shaking waterbath for 10 min. Extract B was 
then added to the dried extract A and was vortexed, sonicated and placed in the 
shaking waterbath for 10 min. Then, 50 μl of 0.2% ascorbic acid containing 5 µg/ml 
taxifolin (IS2) was added to the combined solution and vortexed until the samples 
were fully dissolved in the solution. The sample was further centrifuged (10 min, 
17,000g) and the supernatant was filtered and placed in labeled HPLC vials (brown 
vials). The vials were well capped and stored at 4˚C until LC-MS analysis. 
7.5 LC-MS analysis 
The LC-MS analysis was carried out on a single quad LC-MS Shimadzu LC-
2010 HT HPLC coupled with a LCMS-2020 quadrupole mass spectrometer fitted 
with an electro spray ionisation source used in negative mode, detector -1.80 kV, DL 
temperature 250 °C, nebulizing gas flow and drying gas flow 1.50 and 15 L/min 
respectively (Milton Keys, UK). An eclipse XDB-C18 analytical column (4.6x50 
mm, 1.8 µM; Berkshire, UK) was used for the chromatographic separation and 
semi-preparative purification protocol, and it was maintained at 30 °C. The mass 
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spectrophotometer was set in negative mode to assay for ions at m/z: 301, 303, 381, 
477 and 609 m/z ratios, corresponding to hesperetin, taxifolin, hesperetin sulfate 
conjugates, hesperetin mono-glucuronides conjugates and rutin respectively. The 
injection volume was 10 µL at flow rate of 0.5 mL/min. A gradient of water-formic 
acid (Solvent A; 100:0.1, v:v) and acetonitrile-formic acid (Solvent B; 100:0.1, v:v) 
was applied. Elution started at 5% solvent B and increased to 10% after 5 min. From 
5 to 20 min the gradient increased up to 40% and after 5 min reached 90%, which 
was kept for 4 min more. Then, after 1 min the gradient dropped down to 5% and 
the run finished at 33 min. Pressure limits had a maximum of 370 bar and a 
minimum of 20 bar. The data files of LC-MS were analyzed by Shimadzu Lab-
Solutions software. 
7.6 Data analysis 
Post-Run (LC-MS run) analysis took place using Lab-Solutions software. 
These data (peak areas and chromatograms) were further analyzed after combined 
with already known data (amount of supplements ingested by each subject, 
hesperidin concentration in citrus  and placebo supplements, urine volumes before 
and after each treatment). The calculations and the statistical analysis were 
performed using SPSS 21.  The difference between 24 hr ingestion and 4wk 
ingestion was tested using paired t-test. The results were expressed as mean ± 
standard deviation (n=3) measurements obtained from urine samples from 23 
participants. Differences were considered to be significant at p < 0.05. 
7.7 Results 
7.7.1 Extraction efficiency experiments 
Recovery experiment was carried out in the urine samples during 
preparation. The samples are expecting to contain various compounds that could 
affect the chromatography performance and results. Urine samples were spiked with 
a known amount of available authentic standard and the percentage ratios between 
recovered after processing and expected concentration were calculated. Table 7.2 
shows the mean recovery value obtained for each compounds at three concentrations 
(5, 10 and 20 µg/ml) spiked in two independent replicates of blank urine (collected 
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before experimental supplements consumption). The results showed good recovery 
values for all compounds, which is in the range of 81.5 ± 9.3 to 100.7 ± 1.5%. The 
average extraction efficiencies of the six compounds tested were acceptably good 
and reliable for every spiking concentration with coefficient variation value ranged 
from 3.2 - 16% across the concentration range tested. Moderate recovery values 
were obtained for the hesperetin conjugates, which were approximately in the range 
between 81.5 ± 9.3 and 90.7 ± 3.0%.  From the results obtained can be concluded 
that the majority of flavanones tested had a high and moderate recovery percentage, 
therefore this method was suitable for the urine preparation step prior to LC-MS 
analysis. The data are summarised in Table 7.2. 
Table 7.2: Recovery rate of the compound 
Compounds Recovery (% of initial 
concentration) 
Coefficient 
variation (CV %) 
Rutin 95 ± 3.1 3.1 
Taxifolin 100 ± 1.5 1.6 
H-7-O-glucuronide 90  ± 3.0 4.3 
H-3′-O-glucuronide 89  ± 6.0 7.6 
H-3′-O-sulfate 81 ± 9.0 16.8 
Hesperetin 83 ± 1.9 3.2 
Concentrations of the internal standards (IS) were the same for all spiking samples. 
Values are mean ± SD (n=3). 
 
7.7.2 Identification of hesperetin metabolites in urinary excretion 
The urine of 23 participants was collected over 24 hr at four separate time 
points, two pre-supplementation (baseline) and two post-supplements (day one and 
28 days) for both citrus supplements (containing 188 µmol hesperetin equivalents to 
300 ml OJ) and placebo. Urine was tested for compliance to the study. As the diet 
was restricted for 24 hr before urine collection a significant increase of metabolites 
excreted in urine after supplementation compared to baseline was indicative of 
compliance the citrus supplement. 
 189 
 
Hesperetin conjugates were absent from all baseline urine samples except a 
small amount found in three volunteers (0.6, 0.7 and 1.0 µmol), indicating good 
compliance with the flavanone avoidance diet. Urine extracts before and after the 
consumption of the citrus supplements were analysed by LC-MS based on their 
mass (m/z ratio) and retention time. A comparison with the retention time and the 
peak of authentic standards, these three peaks appeared in the same mass window 
assigned as H-7-O-glcA, H-3′-O-glcA and H-3′-O-SO4, respectively. Representative 
example of chromatograms for the standards and mixture of all standards are shown 
in Figure 7.1 and 7.2. Rutin and taxifolin were identified at 609 and 303 m/z at a 
retention time of 11.4 and 12.2 min, respectively. Also H-7-O-glcA, H-3′-O-glcA 
and sulfate H-3′-O-sulfate were identified at RT 14.5, 14.7 and 16.9 min, 
respectively. The mono-glucuronides eluted at similar retention times, without 
complete resolution of the peaks. Typical mass spectra used in identifying hesperetin 
glucuronides and sulfates are shown in Figure 7.3. 
 
 
 
Figure 7.1: LC-MS chromatogram representing peaks of the mixed of standards. 
Peak (A) rutin; Peak (B) taxifolin; Peak (C) H-7-O-glcA; Peak (D) H-3′-O-glcA; 
Peak (E) H-3′-O-sulfate; Peak (F) hesperetin. 
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Urine extracts before and after the consumption of the two different 
supplements were analysed by LC-MS. A representative example of a 
chromatogram from subject 1 after the consumption of citrus supplements is shown 
in figure 7.4.  Figure 7.5 shows the profile of peaks after the placebo intervention. A 
significant quantifiable amount of both hesperetin glucuronides and the sulfate were 
present in the urine samples of all volunteers except volunteer 20 and 21 where the 
amount was after both acute and chronic collections indicating that these volunteers 
were lower excretors. 
  
 191 
 
 
 
 
Figure 7.2: LC-MS chromatograms representing peaks of the standards. (A) rutin, 
11.4 min; (B) taxifolin, 12.2 min; (C)  Hesperetin-7-O-glcA, 14.4 min; (D) 
Hesperetin-3′-O-glcA , 14.7 min; (E) Hesperetin-3′-O-sulfate, 16.9 min ; (F) 
hesperetin, 19.0 min. 
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Figure 7.3: A typical MS spectrum of hesperetin conjugate standards and standard 
compounds obtained in negative ion mode [M-H]-. (A) rutin; (B) taxifolin; (C) 
hesperetin-7-O-glcA; (D) hesperetin-3′-O-glcA; (E) hesperetin-3′-O-SO4; (F) 
hesperetin. 
300.0 325.0 350.0 375.0 400.0 425.0 450.0 475.0 500.0 525.0 550.0 575.0 600.0 625.0 m/z
0.0
1.0
2.0
3.0
4.0
Inten. (x100,000)
477.00
301.00 651.00
300.0 325.0 350.0 375.0 400.0 425.0 450.0 475.0 500.0 525.0 550.0 575.0 600.0 625.0 m/z
0.0
2.5
5.0
7.5
Inten. (x10,000)
477.00
301.00 651.00
175.0 200.0 225.0 250.0 275.0 300.0 325.0 350.0 375.0 400.0 425.0 450.0 475.0 500.0 525.0 550.0 575.0 600.0 625.0 m/z
0.0
1.0
2.0
3.0
4.0
Inten. (x1,000)
381.00
303.00
651.00152.00
300.0 325.0 350.0 375.0 400.0 425.0 450.0 475.0 500.0 525.0 550.0 575.0 600.0 625.0 m/z
0.00
0.25
0.50
0.75
1.00
Inten. (x100,000)
609.00
651.00301.00
175.0 200.0 225.0 250.0 275.0 300.0 325.0 350.0 375.0 400.0 425.0 450.0 475.0 500.0 525.0 550.0 575.0 600.0 625.0 m/z
0.0
0.5
1.0
1.5
2.0
2.5
Inten. (x100,000)
303.00
609.00477.00
651.00152.00
381.00
275.0 300.0 325.0 350.0 375.0 400.0 425.0 450.0 475.0 500.0 525.0 550.0 575.0 600.0 625.0 m/z
0.0
1.0
2.0
3.0
Inten. (x100,000)
301.00
463.00
651.00269.00
609.00
A 
 
B 
 
 C 
 
D 
 
E 
 
F 
 
Fragment ion (m/z) 
T
o
ta
l 
io
n
 c
o
u
n
ts
 (
x
1
0
5
) 
 193 
 
As shown in Figure 7.4 three main hesperetin conjugates: hesperetin-7-O-
glucuronide, hesperetin-3'-O-glucuronide and hesperetin-3′-O-sulfate. They were 
two mono-glucuronides peaks at 477 m/z. Hesperetin-7-O-glcA peak eluted first 
followed by a higher peak representing hesperetin-3'-O-glcA. Hesperetin-3′-O-
sulfate was identified at an m/z ratio of 381 with a retention time of 16.9 min. 
In some subjects (n= 5), very low amounts of hesperetin were present at 301 
m/z at retention time of 19 min same as authentic standard aglycone. There were 
also two unknown compounds which had an m/z of 651 at RT 4.2 and 7.8 min, 
respectively. These compounds have an m/z for hesperetin di-glucuronide, therefore 
it is possible that these are hesperetin 3′, 7-O-diglucuronide and hesperetin 5, 7-O-
diglucuronide based on the report by Bredsdorff et al., (2010). 
Some participants (n=7), consuming the placebo excreted trace amounts of 
hesperetin metabolites < 0.2 µmol as the diet was not controlled. However, after 
citrus supplementation resulted in a > 50 fold higher excretion of hesperetin 
glucuronides in comparison to placebo supplementation. 
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Figure 7.4: LC-MS chromatograms representing extracted urine samples from 
subject 1 after the consumption of citrus bioflavonoid supplements. (A) Baseline 
urine, (B) 1 day (C) urine after 28 days intervention. Internal standards are peaks 1, 
rutin; 2, taxifolin. Peaks 3 is hesperetin-7-O-glucuronide 4 is hesperetin-3'-O-
glucuronide and 5 is hesperetin-3′-O-sulfate (5).  
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Figure 7.5: LC-MS chromatograms representing active urine sample from subject 1 
after the consumption of placebo supplements. (A) Baseline urine, (B) 1 day (C) 
urine after 28 days intervention. Internal standards are peaks 1, rutin; 2, taxifolin. 
The three main metabolites of hesperidin: hesperetin-3′-O-sulfate, hesperetin-7-O-
glucuronid and hesperetin-3'-O-glucuronide were not found.  
 
 
0
20000
40000
60000
80000
0 5 10 15 20 25 30 35
A 
2 
0
10000
20000
30000
40000
50000
60000
70000
0 5 10 15 20 25 30 35
B 
2 
0
10000
20000
30000
40000
50000
60000
70000
80000
0 5 10 15 20 25 30 35
C 
2 
1 
1 
1 
A
b
so
lu
te
 I
n
te
n
si
ty
  
 
 196 
 
7.7.3 Quantification of hesperetin metabolites in urine 
The quantitative data of hesperetin metabolites excreted in urine over 24 hr 
at day 1 and day 28 is presented in Table 7.2 and Figure 7.6. Hesperetin-3′-O-glcA 
was the highest metabolite excreted followed by hesperetin-3′-O-sulfate and 
hesperetin-7-O-glcA was the lowest metabolite excreted. The proportion of sulphate 
to glucuronide metabolites was approximately 37.5:62.5. For all metabolites it 
appeared that the amount excreted in 24 hr was lower after 28 day than at 1day, 
however it was only significantly different (p<0.05) for hesperetin-3′-O-sulfate (see 
Table 7.3). Total hesperetin metabolites were also significantly different between 
day 1 and day 28 (p= < 0.01) (Fig. 7.6C).  
The inter-individual variation of excretion of each metabolite is shown in 
Figure 7.7. It was apparent that some of the volunteers had a considerably higher 
excretion of hesperetin than other volunteers. In the case of hesperetin-3′-O-sulfate, 
hesperetin-7-O-glucuronide and hesperetin-3′-O-glucuronide, volunteer 8 was the 
highest excretor, with 2-3 x the average % dose excreted for both glucuronides. 
Volunteers 20 and 21 were the lowest excretors, with levels close to zero or the limit 
of detection in some cases. The highest amount of hesperetin metabolites excreted 
by volunteer 8 was 2-fold and 3-fold higher the average amount excreted 22 µmol 
and 18 µmol after citrus supplements were consumed for 1 day and 28 days, 
respectively. Interestingly, nothing was excreted by subject 15 after 1 day exposure; 
however, after 28 days the amount excreted was 1.8-fold lower than the average 
amount excreted. 
Overall the total amount excreted ranged from 0-6.5% for hesperetin-7-O-
glcA, 0-17% for hesperetin-3′-O-glcA and 0-10% for hesperetin-3′-O-sulfate. The 
total excretion as a percentage of doses is shown in Figure 7.7, and shows the range 
of amount excreted was varied from  0 – 32 µmol (average 22 and 18 µmol for day 1 
and day 28 respectively). And the total excretion as percentage of dose ingested is 
shown in figuer 7.8. 
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Table 7.3: Quantification of hesperetin metabolites (µmol) excreted in urine from 23 healthy volunteers after consumption of citrus and 
placebo supplements. 
Hesperetin 
metabolites (µmol) 
Citrus supplement Placebo supplement 
 Baseline 1 day Day 28 Baseline 1 day Day 28 
H-7-O-glcA 0.02 ± 0.08 4.10 ± 3.15 3.13 ± 2.78 0.0 ± 0.0 0.00 ± 0.05 0.10 ± 0.26 
H-3′-O-glcA 0.01 ± 0.02 10.04 ± 6.42 8.53 ± 7.03 0.01 ± 0.05 0.11 ± 0.18 0.23 ± 0.32 
H-3′-O-sulfate 0.07 ± 0.12 8.49 ± 5.21 6.33 ± 4.26* 0.0 ± 0.0 0.06 ± 0.11 0.08 ± 0.23 
Total excreted 0.1 ± 0.04 22.63 ± 4.90 17.99 ± 4.69 0.01 ± 0.05 0.17± 0.11 0.41 ± 0.27 
All values are reported as mean ± SD (n=4). Asterisk (*) indicates that values are significantly different (p < 0.05) between day 1 and 
day 28. 188 µmol ingested.
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Figure 7.6: Excretion of hesperetin metabolites in urine after Day 1 and day 28 post 
consumption of (A) citrus bioflavonoid supplements, (B) placebo supplements, (C) 
comparison of total hesperetin metabolites excreted. Asterisk (*) indicates that values 
are significantly different (p < 0.05). 
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Table 7.4: P values for significance of hesperetin metabolites collected at different 
times. 
Intervention Compounds 
BL vs 1 
day 
Bl vs 28 
days 
1 day vs 28 
days 
BL 
(placebo) 
vs (Citrus 
supplement) 
Citrus 
supplement 
H-7-O-
glcA 
<0.01* <0.01* 0.17 0.28 
H-3ʹ-O-
glcA 
<0.01* <0.01* 0.27 0.91 
 H-3ʹ-O-
sulfate 
<0.01* <0.01* 0.03* 0.1 
BL = baseline. Samples were performed in technical duplicates, from 23 subjects. 
Asterisk (*) indicates that values are significantly different (p < 0.05). 
 
As it can be seen from figure 7.9 (A and B), the correlation between the 
hesperetin glucuronide metabolites as an amount excreted in urine was investigated 
using the spearman correlation coefficient. The urine excretion of the hesperetin 
metabolites were highly correlated in the basis of the amount recovered with p <0.01 
(0.89 in 1 day and 0.93 in 28 days intervention. The data was assessed to identify 
whether there was a relationship between the excretion of hesperetin-7-O-glcA and 
hesperetin-3ʹ-O-glcA. There was a high positive association (R > 0.89) between the 
excretion of the two hesperetin glucuronide conjugate after acute (day 1) and chronic 
supplementation over 28 days. As for the chronic dose, it appears that the association 
after the 28 day became stronger, although the concentration was less after 28 day 
intervention.  
The correlation between urine maximum concentration of hesperetin 
glucuronide and urinary excretion of hesperetin sulfate metabolites was also 
investigated and shown in figure 7.10. The correlation was statistically significant 
between the concentration of hesperetin-O-glucuronides in urine and the total 
amount of hesperetin -3-O-sulfate excretion in urine (r = 0.62, p = < 0.01, Pearson 
coefficient) in 24 hr excretion. The correlation was observed to be stronger after 
were consumed for 28 days (r = 0.80, p = < 0.01).  
 
 
 200 
 
 
 
 
Figure 7.7: Presents the amount excreted as percentage from the dose ingested for 
hesperetin-7-O-glucuronide (A), and hesperetin-3′-O-glucuronide (B), hesperetin-3′-
O-sulfate. 
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Figure 7.8: The total excretion as a percentage of doses ingested. Day 1 and 28 days 
after consumption of  the citrus supplements. 
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Figure 7.9: Correlation between excretion of  H-7-O-glcA and H-3ʹ-O-glcA in urine 
collected for 24 hr post-intervention of citrus supplements of 1 day (A), or after 28 
days supplementation (B). Correlation is significant at the * 0.05 and 0.01** level (2-
tailed). 
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Figure 7.10: Correlation between a) hesperetin-O-glucuronide and hesperetin -3′-O-
sulfate after 24 hr ingestion b) hesperetin-O-glucuronide and hesperetin -3′-O-sulfate 
after 28 days ingestion based on the amount recovered in urine samples using the 
Spearman correlation. Correlation is significant at the * 0.05 and 0.01** level (2-
tailed). 
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7.8 Comparison between bioavailability of orange juice and citrus supplement 
The total urinary excretion between the orange juice in study 1 (see chapter 3) 
and the citrus supplements in study 2 (described in this chapter 6) were compared. In 
study 1 the metabolites were hydrolysed by sulfatase and β-glucuronidase before 
analysis of the aglycone. As shown in chapter 4, these enzymes, and particularly the 
sulfatase, did not completely hydrolyse the metabolites. In this chapter the 
metabolites were therefore analysed individually and the total metabolites 
determined. However despite the differences in methodology and the different 
volunteers taking part, we wanted to compare the datasets to see if any comparisons 
could be made between the different sources of flavanones. 
Table 7.4 summarises the data from the two studies. Despite nearly a 2-fold 
increase in dose provided from the orange juice, and a longer (36 h) and therefore 
complete collection of hesperetin metabolites, the % dose excreted was only 9.3%. 
The percent excreted from the supplements was at least twice this value. The percent 
excreted from the supplements was 2.5x this value. However we know that the 
hydrolysis enzymes did not fully hydrolyse the conjugates in study 1 (see chapter 3). 
So assuming a partial (50%) hydrolysis of hesperetin-3′-O-sulphate and only a partial 
(80%) hydrolysis of the glucuronides then based on the ratio of conjugates at 
37.5:62.5 for sulphate:glucuronide respectively found in study 2 (this chapter), the 
following estimated calculation could be applied: 
% recovery from study 2 (day 1) = 22.6% 
37.5% of this is sulphate metabolites and 62.5% is glucuronide metabolites. 
> Therefore 22.6 x 37.5% = 8.475% is from sulphates 
> Therefore 22.6 x 62.5% = 14.125% is from glucuronides 
Assumption: If enzymes were only 50% efficient for sulphate metabolites and 80% 
efficient for glucuronide metabolites then, 
> 50% x 8.475 = 4.2% 
> 80% x 14.125 = 11.3% 
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TOTAL expected recovery in study 2, day 1, if enzyme hydrolysis had been used is 
15.5%. 
Hence based on the assumption of enzyme efficiency, the crude estimation in 
recovery of hesperetin was 15.5% in study 2 if enzyme hydrolysis had been used, 
compared to 9.3% determined in study 1. This suggests that the bioavailability is 
potentially higher after supplements than after fresh orange juice, and is certainly not 
worse. However, in order to verify this hypothesis a human intervention cross-over 
study would be required to ensure that the variables of excretion time, volunteer 
differences and enzyme activity were all fully taken into account.  
 
Table 7.5: Bioavailability of hesperidin between study1 ingested orange juice and 
study 2 ingested citrus tablets 
 Study 1 (orange juice) Study2(citrus supplements) 
No. of participants (M/F) 15 23 
Urine collection period (hr) 36 24 
Form of hesperidin 
measured 
Aglycone form after 
enzyme hydrolysis 
Hesperetin conjugates 
“glucuronide and sulfate” 
Dose ingested (µmol) 500 ml orange juice 
(344 µmol) 
2 citrus bioflavonoid 
tablets (188 µmol) 
Dose excreted in urine % 9.27 ± 8.09 (22.6 ± 4.9)
† 
(18 ± 4.7)
‡
 
(
†
Day 1; 
‡
28 Days) 
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7.9 Discussion 
A number of aims have been pursued in this study. The first aim was focussed 
on the bioavailability of hesperetin metabolites following consumption of citrus 
supplements. The second aim was to investigate whether or not there were 
differences between acute and chronic intake of supplements in the excretion of 
hesperetin metabolites. Finally, this study seeked to answer whether the hesperetin 
was more bioavailable from the supplement intake than from orange juice (compared 
to the results obtained in chapter 4 of this thesis). LC-MS analysis was chosen as the 
most appropriate method to identify and quantify the hesperetin metabolites in urine. 
The study examined the excretion profiles of the compounds the three main 
hesperetin metabolites in 23 subjects who followed  a single 1 day and chronic dose 
(28 days)of citrus supplements starting from a washed out point. For the first time, 
this study provided evidence to show that hesperidin was bioavailable in reasonable 
quantities following the consumption of citrus bioflavonoids supplements and 
apperaed as bioavailble as orange juice as a source of flavanones.  
We have identified and quantified three hesperetin metabolites hesperetin-7-O-
glcA, hesperetin-3ʹ-O-glcA and hesperetin-3′-O-sulfate. Our results are in agreement 
with recent studies that have identified these hesperetin metabolites in human urine 
after the consumption of orange juice (Matsumoto et al., 2004, Mullen et al., 2008, 
Brett et al., 2009, Bredsdorff et al., 2010,  Pereira-Caro et al., 2014).  
The quantification of metabolites in the present study was based on the 
corresponding metabolites of respective authentic synthesised standards, monitored 
by LC-MS. In the present study, hesperetin glucuronides were the most abundant 
metabolites recovered in the urine after 1 day and 28 days of citrus supplementation. 
This was consistent with the other studies, however in these studies hesperetin-7-O-
glucuronide was more abundant than hesperetin-3′-O-glucuronide, opposite to the 
finding in chapter 7. Hesperetin sulfate in other studies was also found to be the least 
excreted metabolite. Manach et al., (2003) found 87% of hesperetin as glucuronide, 
with 13% as sulfo-glucuronide, which was similar to the present study at 68% 
hesperetin glucuronide (di-glucuronides were observed but not quantified). The 
variation in positioning of the glucuronide may be as a result of variations in UDP-
glucuronosyl transferase activity in different individuals (Brand et al.,  2010). 
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In all studies that have considered flavavone excretion a large variation in 
metabolite excretion has been observed, highlighted by Brett et al., (2009) who 
showed 0-57% variation in excretion. The large inter-individual variation is likely to 
be a result of the difference in gut microflora which will alter the hydrolysis of the 
rutinoside sugar, allowing the aglycone hesperetin to be absorbed, and the extended 
breakdown of the flavavone into smaller phenolic acids (shown by Roowi et al, 
2009). Table 7.5 summarises the previous studies along with the results from this 
thesis. The percent dose recovered in the current studies is higher than many of the 
other studies; all carried out with orange juice, but is similar to the results of previous 
studies; Pereria-Caro et al., (2014), Borges et al., (2010) and Krogholm et al., 
(2010). Many of the studies monitored the aglycone after enzyme hydrolysis, which 
will have resulted in a lower recovery due to the poor ability of the sulfatase to 
deconjugate hesperetin-3′-O-sulfate (Bredsdorff et al.,  2010). 
The quantification of metabolites in our study was based on the corresponding 
metabolites of their respective authentic synthetic standards. The concentration of 
hesperetin-7-O-glcA was slightly lower than that of  H-3′-O-glcA. This result is in 
disagreement with the findings by Matsumoto et al., (2004). In this study, there was 
a significantly greater amount of hesperetin metabolites excreted after the 
consumption of citrus supplments as a single dose compared with that after a chronic 
consumption for 4 weeks. previous results reported by Bredsdorff et al., (2010), 
indicated that increasing the dose of hesperidin 3-fold affected the overall 
concentration, but not the profile of the conjugate formed after colonic absorption. A 
correlation test between the relative urine excretion %  of intake and the dose ingesed 
in (µmol) was done with our results and the results obtained from previous studies 
(table 7.6) and low correlation was found (r = 0.19; p < 0.51). 
This inter-individual difference in the ability of the enterocytes to hydrolyse 
glucosides, glucuronidate, sulfate or methylate flavonoids could lead to differences 
in metabolism of these compounds (Brett et al., 2009). It can be stated that a  
possible reason for our observation is that the participants recruited in this study had 
sulfotransferase enzymes that worked more effectively than the UDP 
glucuronosyltransferase (UDP) which catalyse the conjugation of flavanones with 
sulfate group and glucuronic acid (Scalbert and Williamson, 2000, Brand et al., 
 208 
 
2010, Bredsdorff et al., 2010). Another possible explanation is related to sulfate 
conjugates.  Because of their excellent response in negative ESI compared to 
aglycone, sulfate are more readily ionised and give higher values. Moreover, 
hesperetin-3ʹ-O-sulfate has been reported not to respond well to enzymatic 
hydrolysis with sulfatase (Bredsdorff et al., 2010).   
The excretions of flavanones between the two different treatments 1 day and 
28 days were compared. The consumption chronic dose of supplements up to 28 days 
did not statistically significantly change the amount of hesperetin-7-O-gluA and 
hesperetin-3′-O-glcA recovered in urine. However, the excretion of hesperetin-3′-O-
sulfate was significantly decreased after 28 days (p < 0.05). This lead to the 
conclusion that there is not a cumulative change in bioavailability however, the 
amount of hesperetin metabolites was statistically higher after 1 day ingestion 
compared with 28 days ingested.  
In conclusion, flavavones from citrus supplements are bioavailable and the 
amount excreted is at least equivalent, if not more than from orange juice. There is 
no evidence of accumulation of flavanone metabolites over time, and possibly a 
reduction in excretion over time due to changes in sulfation.  
Future work should focus on understanding the bioavailability of hesperidin 
by examining the influence of the environmental or genetic factors on the enzyme 
expression and activity. In this respect, a study of microflora composition would be a 
very promising approach. This could be achieved by taking faeces samples from 
individuals who underwent a hesperidin intervention treatment. Improving the 
method to determine the hesperidin metabolites will also help understand the fate and 
metabolism of these compounds more clearly. 
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Table 7.6: The relative urine excretion of hesperidin from different human studies 
Reference Source Ingested dose 
(µmol) 
Relative urine 
excretion, % 
of intake 
(Manach et al., 2003)** OJ
1
 363 hesperetin 
727 hesperetin 
4.13 ± 1.18 
6.41 ± 1.32 
(Nielsen et al., 2006)** OJ 98 hesperidin 
314 hesperidin 
4.06 ± 1.77 
8.9 ± 3.83 
(Erlund et al., 2001)** OJ 206 hesperetin 5.3  ± 3.1 
(Brett et al., 2009)* OJ 117 hesperetin 4.63 ± 3.05 
(Pereira-Caro et al., 
2014)* 
OJ 348 hesperetin 17.2 
(Borges et al., 2010)* P-R juice
2
 45 hesperidin 12 ± 1.6 
(Mullen et al., 2008)* OJ 168 hesperidin 7 
(Roowi et al., 2009)* OJ +Yoghurt 168 hesperidin 37 
(Krogholm et al., 2010)** Mix juice 52 hesperetin 14.2 ± 9.1 
Study 1**( chapter 3) OJ 344 hesperidin 9 ± 9.4 
10 ± 8.3 
Current study* (chapter 7) Citrus 
supplements 
188 hesperidin 22.6 ± 4.9 
17.9 ± 4.7 
1
OJ, orange juice; 
2
P-R, polyphenol-rich juice drink; Asterisk (*) indicates that 
sample was not hydrolysed; (**) indicates that samples were hydrolysed 
enzymatically and the aglycone measured.  
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Chapter 8: General Discussions And Future Perspectives 
8.1 Overview of thesis 
  The overall aims of this thesis were to investigate the absorption of citrus 
flavanones, specifically to consider intra- and inter-individual variation in 
excretion, and the impact of citrus flavanones on cardiovascular health by 
assessing cardiovascular disease risk biomarkers during an intervention. 
  Cardiovascular disease (CVD) is the major cause of death worldwide 
(WHO, 2015). Diet plays a significant role in both causation (e.g. increasing 
blood LDL levels, and blood pressure), and in reducing risk of CVD. Reduction 
in risk has been linked to an improvement in endothelial health, and recently 
there has been a lot of interest in whether flavonoids are associated with the 
beneficial effects on endothelial function of fruit and vegetable intake. Only 
certain flavonoids may improve CVD risk, and citrus flavanones have been a 
subclass of flavonoids that show potential in lowering blood pressure and 
improving endothelial health. Moreover, flavonoid bioavailability varies widely 
across populations, based primarily on the gut microflora composition, and 
bioavailability is key to the impact on health. 
  The work in this thesis was based on two human intervention studies. The 
first study (chapter 3) investigated the inter-individual variation and absorption of 
both flavanones and isoflavones by measuring urinary excretion, after they were 
consumed individually or co-ingested. In the second study (chapter 6 and 7), the 
absorption of flavanones was assessed by means of the urinary excretion after a 
single dose or after 28 days of taking a citrus flavonoid supplement. Moreover, a 
comparison was done between the amount of flavanone excreted after orange 
juice or citrus supplements were consumed. Saliva, as a potential non-invasive 
biomarker fluid of exposure, was also analysed to assess the absorption of 
isoflavone and flavanone after the study. The second study (chapter 6) was 
designed as a randomised, double-blind, placebo-controlled, cross-over 
intervention to investigate the effects of citrus flavanone supplements on CVD 
risk biomarkers, such as blood pressure (BP), and pulse amplitude tonometry 
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(PAT), after 28 days of daily intake. Augumentation index (AI), fasting blood 
glucose, waist circumference and weight were also monitored. 
The main findings of the thesis are summarised below: 
Outcome of intervention studies: 
 There was a trend towards decreasing systolic and diastolic blood pressure 
after 28 days of supplementation compared to placebo, but this was not 
statistically significant (p= 0.19) and (p= 0.07). 
 Changes in augmentation index were decreased significantly after 28 days 
of supplementation compared to baseline (p= 0.01), but not to placebo. 
 There was no difference in waist circumference, weight and reactive 
hyperaemia index (measurement of PAT) after 28 days of supplementation 
compared to placebo. 
Outcome of bioavailability studies: 
 The inter-individual variation in flavanone and isoflavone 36 hr urinary 
excretion which ranged from 0.6-35% and 5.4-65%, respectively. 
 There was little difference between urinary excretion of flavanones and 
isoflavones after single or co-ingestion of foods. 
 The percent dose excreted for daidzein and naringenin was higher than 
genistein and hesperetin, respectively. 
 Excretion of genistein and daidzein, and hesperetin and naringenin,  were 
correlated after single food or co-food ingestion. 
 Naringenin excretion was correlated to genistein and daidzein excretion 
only after co-food ingestion. 
 There was little difference in 24 hr urinary excretion of flavanones 
between 1 day and 28 days intake of citrus supplements. 
 The major metabolites excreted in the urine were hesperetin-3ʹ-O-
glucuronide > hesperetin-3ʹ-O-sulfate > hesperetin-7-O-glucuronide. 
 The major metabolites were always excreted in the same relative order for 
all individuals. 
 Genistein, daidzein, hesperetin and naringenin were not detected in saliva 
at any time point after foods were consumed. Which indicate that saliva 
was not suitable as biological fluid for assessment of exposure to 
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flavanones and isoflavones compounds. 
 Citrus bioflavonoid supplements appeared to be just as bioavailable, as 
measured by urinary excretion, as orange juice. 
8.2 General discussion and limitations of thesis 
  The first study compared excretion of flavonoids from orange juice and/or 
soya nuts when given seperately or co-ingested. Very few previous studies have 
investigated impact on absorption and excretion after different flavonoid-rich 
foods are co-ingestion. One study showed that after ingestion of three foods 
(grapefruit, soyamilk and onion), daidzein had a slower fecal disappearance rate 
but also an increased urinary recovery than genistein, naringenin, quercetin and 
hesperetin (Simons et al., 2009). The authors suggested this was a direct result of 
the lack of 5-hydroxyl group on daidzein compound compared to the other 
flavonoid moieties. The rate of degradation of flavonoids by gut microflora are 
different and affected by structural differences. For example human microflora 
degraded flavonoids with 4,7- and 4′-OH group more quickly than those 
flavonoids lacking any one of these hydroxyl groups. These results may explain 
why rapidly degraded flavonoids such as genistein may not be as bioavailable in 
the colon, because they have less time to be absorbed before being metabolised 
by gut microflora (Simons et al., 2009).  
Pearson correlations were performed based on the relative urinary excretion 
as percentage of intake. There was a strong correlation between daidzein and 
genistein and between hesperetin and naringenin when they were ingested 
individually. When co-ingested urinary excretions of naringenin was strongly 
correlated with the excretion of genistein (r=0.73; p=0.002), and daidzein (r=0.49; 
p=0.05). This suggests that similar mechanisms may affect the gut hydrolysis and 
subsequent absorption for these two classes of compound. From the inter-individual 
differences observed, many of the results obtained from individuals with high levels 
of urinary excretion of hesperetin also show a correspondingly high level of urinary 
excretion of daidzein.  
  The hesperetin metabolites excreted in urine after the ingestion of citrus 
supplements (2 tablets contain 188 µmol/hesperidin), were similar to other studies 
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(Nielsen et al., 2006, Bredsdorff et al., 2010, Brett et al., 2009). The observation 
that some of the volunteers may be better absorbers than others, may not only be 
a result of gut microflora differences, but also possibly due to particular 
polymorphisms for transporters or enzymes expression in the gastrointestinal tract 
(Manach et al., 2005), and/or in the liver and kidney. In a recent study (Brand et 
al., 2010) using an intestinal cell model, Caco-2 cells, showed that the co-
administration of hesperetin with specific flavonoids such as quercetin improved 
the transport of hesperetin metabolites to the basolateral side; in addition there 
was a decrease in the amount of metabolites formed. Some dietary flavonoids 
have been shown to be potent BCRP-transporter inhibitors. This could lead to a 
decrease in the apical efflux of hesperetin metabolites and an increase in the 
transport to the basolateral sides (Brand et al., 2010). Furthermore, competitition 
of the phase II conjugation enzymes upon co-exposure with quercetin and 
hesperetin may result in an increase in the transported aglycone.  
Study 1 monitored excretion in different time periods over 36 hr, whereas 
study 2 collected the total 24 hr sample. Flavanones are mainly excreted within 
24 hr, although isoflavones are circulating in the body for longer. This is also due 
to the enterohepatic circulation as a result of flavonoid metabolite excretion in the 
bile followed by β-glucuronidase activity of colon microflora releasing the 
aglycone allowing further absorption. Long collection times would also allow 
phenolic acid breakdown products of the flavonoids to be investigated which 
would give a broader view of absorption. Moreover, combining urinary excretion 
data with plasma measurements would provide complete understanding of 
bioavaliblity. Catabolite 3-hydroxyphenylacetic acid was identified in urine of some 
participants (n=8) by LCMS (data not shown). Further analysis of phenolic acids 
following the consumption of citrus food is required to fully understand the 
degradation by microflora and the complete bioavailability of flavanones. Further 
studies should investigate not only commonly co-consumed flavonoid-rich foods, 
and the impact of the food matrix, but also the competition between transporters, 
enzymes and bacterial metabolism in vitro. Bacterial breakdown products should 
also be followed in plasma and urine. 
A limitation of the study in chapter 3, and for many other researchers on 
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bioavailability of flavonoids, is the incomplete hydrolysis achievable with the 
deconjugating enzymes available. Different flavonoid subclasses, and different 
positions of conjugation all have different affinities for the enzymes, and especially 
in the case of hesperetin-3′-O-sulfate, only 50-60% was hydrolysed. Other 
researchers have reported this with flavanones and other sub-classes (Bredsdroff et 
al., 2010, Saha et al., 2012). LC-MS can improve identification by providing m/z of 
the parent ion, and a daughter ion providing unequivocal identification of the 
metabolites in analysis. For this thesis, LC-MS was used to quantify the metabolites 
from study 2 (chapter 6&7), using synthesized hesperetin metabolites from Denis 
Baron (Nestle Research Center, Lausanne, Switzerland) and Christine Morand 
(INRA, Clemond Ferrand, France). Thus, ideally future studies should be conducted 
using LC-MS/MS with the full range of standards for flavonoid metabolites to allow 
complete quantification of all compounds, without the need for enzyme hydrolysis.  
The total dietary intake of polyphenol is reported to be 1 g/d (Scalbert and 
Williamson, 2000) and polyphenol intake was negatively correlated with blood 
pressure in people who are at high risk of CVD (Medina-Remón et al., 2011). The 
beneficial effects of flavanones on cardiovascular health outcomes have been 
reported in many studies (Giles et al., 2005, Morand et al., 2011, Buscemi et al., 
2012b, Asgary et al., 2014). Hesperidin, which exists as a rich dietary source in 
citrus fruits, was suggested to contribute to reducing the incidence of CVD and 
particularly in reducing BP. The consumption of grapefruit was found to reduce SBP 
significantly compared with baseline (-3 ± 10.13 mm Hg, p=0.03; Dow et al., 2012). 
Moreover, evidence from a cross-sectional international study (INTERMAP) 
reported that citrus fruit consumption is clearly correlated with diastolic BP in 
western consumers (Griep et al., 2013). A meta-analysis study of 19 randomized 
controlled trials (RCT) has reported that a reduction of 2 mm Hg in DBP results in a 
reduction of incidence rates of coronary heart disease and hypertension by 
approximately 6% and 17%, respectively (Liu et al., 2013a). 
In chapter 6, the effects of hesperidin (from a commercially-available health 
supplement) on BP, on markers of endothelial function through measurements of 
PAT index, and on blood glucose were investigated. Our results were in accordance 
with those obtained by Morand et al., (2011), who showed that consumption of 500 
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ml orange juice for 4 wk decreased DBP in healthy subjects when compared with the 
control drink plus placebo group. Moreover, in a similar study investigating the 
effect of the consumption of high naringenin sweetie fruit on blood pressure reported 
that DBP was reduced after 5 wk consumption in hypertensive volunteers when 
compared with low naringenin juice (Reshef et al., 2005). The same observation that 
regular intake of OJ decreased SBP and DBP in young adult men was also reported 
(Bonifácio and César, 2009). On the other hand, a study conducted by BasiLe et al., 
(2010) to investigate the effect of intake of pasteurized OJ (500 ml and 750 ml/d) for 
8 wk, found SBP in both males and females did not change from baseline. However, 
DBP significantly reduced in male subjects (BasiLe et al., 2010). 
An animal study by Yamamoto et al., (2008b) studied the mechanism by 
which hesperidin lowered blood pressure in spontaneously hypertensive rats (SHR). 
They concluded that the major metabolite, hesperetin glucuronide had a significant 
hypotensive effect at 9–12 hr after administration of hesperidin. This effect of 
hesperetin was associated with nitric oxide-mediated vasodilation. Increasing the 
production of NO by the vascular endothelium is one possible mechanism of action 
by which these flavanones may lower BP (Grassi et al., 2009). Other mechanisms 
that could be responsible for lowering the BP include an inhibitory effect on 
angiotensin converting enzyme (ACE), which is a regulator of BP catalysing the 
conversion of angiotensin I to activated form angiotensin II. ACE can also degrade 
and inactivate the vasodilator bradykinin (Actis-Goretta et al., 2006, Moore et al., 
2009). 
It is important to examine the mechanism by which hesperetin metabolites 
and catabolites might exert a protective effect at physiological doses (Pereira-Caro et 
al., 2014). In this context, a recent study by Chanet et al., (2013), reported that 
hesperetin metabolites such as hesperetin-3ʹ-O-sulfate, hesperetin-3ʹ-O-glucuronide 
and naringenin-7-O-glucuronide significantly reduced monocyte adhesion to TNF-α-
stimulated endothelial cells and modulated the expression of related genes involved 
in atherogenesis. Also reported were that flavanone metabolites conjugated on the B-
ring were more efficient in decreasing cell adhesion compared with those conjugated 
on the A-ring, regardless of the nature of substituent glucuronide or sulfate.  
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Results from studies using orange juice suggested improvements in 
endothelial reactivity (Morand et al., 2011, Rizza et al., 2011). Hesperetin reported 
to play a crucial rule in BP regulation via activation and up-regulation of 
endothelium NO synthase (eNOS) which results in increased endothelial NO 
production (Liu et al., 2008).  Endothelial function was assessed in the present study 
(chapter 6) by using Endo-PAT, which is an alternative method of assessment of 
endothelial function, which obtains radial artery pressure waveforms of smooth 
muscle tone (Wilkinson et al., 2002). To the best of our knowledge, this is the first 
study to link ingestion of the effects of citrus tablets and a placebo to PAT index in a 
randomized, crossover, double-blind design. The results showed no significant effect 
on the PAT/ reactive hyperaemia index (RHI). Morand et al., (2011), demonstrated 
that the daily intake of 500 ml OJ for 4 wk improved endothelial function 
significantly, measured as the cutaneous acetylcholine micro-vascular reactivity by 
using Laser Doppler photometry. Moreover, hesperidin resulted in an improvement 
in the flow-mediated dilation of the brachial artery (Rizza et al., 2011).  
The findings of study 2 suggest there is no beneficial effect of short-term 
citrus hesperidin ingestion on markers of vascular health monitored by RHI. 
However, the augmentation index (AI, derived from the microvasculature and 
measured by the EndoPAT) improved significantly after citrus supplementation in 
65% of the participants by 1.67% decrease from -3.0 ± 10.8 to -4.7 ± 10.7 (p<0.01). 
Additionally, the improvements in AI observed in this study were correlated with 
increases in diastolic blood pressure but not in RHI (r= 0.63; p <0.005). It has been 
reported that augmentation index showed no correlation with Endo-PAT RHI in 100 
hypertensive patients (Yang et al., 2011), suggesting improved AI to be independent 
of microvasculature dilation. Further, in another study a decreased augmentation 
index after chocolate intake was not accompanied by a drop in PWV (Vlachopoulos 
et al., 2005).  
A different study recruited 186 patients to assess the relationship between AI 
obtained from peripheral arterial tonometry (PAT) with cardiovascular risk factors. 
The results showed that AI measured by PAT was found to be correlated with central 
aortic blood pressures (Patvardhan et al., 2011). Moreover, in the same study a 
correlation between age, heart rate, systolic blood pressure, mean arterial pressure, 
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pulse pressure, body weight and body mass index with AI were observed. Although, 
Yang et al. (2011) reported that age and sex were not correlated with AI in their 
study. The importance of the current study is that no previous assessments have been 
made of the relationship between citrus flavanone ingestion and arterial stiffness. 
However, these results should be considered with caution, due to the lower AI in the 
placebo group, which cannot be explained in the present study. Further investigations 
on this biomarker parameter may be worthwhile after a thorough validation of the 
measurement. This was a major limitation of the thesis as the probe costs were 
prohibitively high which meant a pre-study could not be conducted. 
The fasting blood glucose levels in study 2 were not significantly different 
between the citrus and placebo treatments, although there was a trend towards a 
decrease at the end of the citrus phase. These results are in agreement with the results 
observed by Asgary et al., (2014) where 22 healthy subjects consumed 500 mL OJ 
twice a day for 4 wk, and in accordance with the results by Morand et al., (2011), 
where no changes in blood glucose level were reported. However, another study 
observed a significant decrease in fasting glucose levels after daily consumption of 
750 ml OJ for 2 months in normo-lipidemic subjects (BasiLe et al., 2010). It is 
feasible that the length of time for the intervention, the dose of flavanone given, or 
the well-controlled normal fasting blood glucose levels of the current subjects was 
not sufficient to provide a positive outcome. Moreover, the study was designed to 
primarily test for a decrease in BP, therefore more subjects may be required and a 
more sensitive analytical method for measuring blood glucose would be of benefit. 
8.3 Future work  
Orange juice is a popular drink in developing and developed countries. 
Hesperidin (hesperetin-7-0-rhamnoglucoside) is the main flavanone that is present in 
oranges and in their juice. The bioavailability of hesperidin from orange juice is 
highly bioavailable compared to other flavonoid compounds. In addition, hesperidin 
is potentially important to CV health and therefore could be recommended as a good 
dietary source to improve a healthy lifestyle. It is essential to note that many of the 
aspects attributed to these effects are not fully understood. This is specifically due to 
the contributory impact of flavonoids and polyphenols, in the diet, that also may have 
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similar biological effect. Furthermore there could be interaction between flavanones 
and other nutrients present in orange juice (e.g. potassium, folate, vitamin C), or 
elsewhere in the diet (other B-vitamins, vitamin D), that synergistically improve 
endothelial function vascular health. The following directions could be pursued to 
provide more evidence on the effect of flavonoids and specifically flavanones on CV 
health. 
 Since glucuronidated and sulfated hesperetin were found in urine and plasma 
samples, well-designed studies are recommended to investigate the 
bioavailability of these compounds. 
 Based on inter individual variation of flavanone absorption through the 
percentage excretion of the amount ingested, it would be very important to 
correlate the observed changes in CVD risk factors parameters with the 
plasma concentrations of these compounds not only with urine excretion. The 
information about the amount of metabolites available in plasma after the 
consumption of orange juice is very useful for future studies attempting to 
assess the impacts of flavanones on human health. 
 Future studies should assess a dose response regarding absorption and in 
relation to CV health markers. Additionally, inflammation and endothelial 
dysfunction markers in plasma should be measured at the same time along 
with the concentration of hesperetin metabolites in plasma.  
 Future large-scale human intervention studies in hypertensive and/or 
hyperglycaemic participants should be performed, in order to determine the 
effect of orange juice/hesperidin supplementation on endothelial function 
markers in humans. 
 Ideally, participants should have a fully controlled and standardized 
environment and diet when conducting an intervention. 
 More intervention studies in different populations using isolated flavanones 
compounds are recommended in order to explain the effect of these 
compounds in humans.  
 Since the absorption mainly occurred in the large intestine, and the types of 
colonic microflora vary with individual, this will affect the absorption of 
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these compounds. Therefore, it will be worthwhile to assess the type of 
microflora populated in the colon to understand the bioavailability of 
hesperidin in humans and relate this to other flavonoid classes. 
 Interactions between flavanones and other flavonoids, and indeed flavonoids 
and other nutrients should be investigated in both model systems and further 
well designed interventions. 
8.4 Conclusion  
The data provided from this thesis contributes to the growing knowledge on 
flavonoids found in orange and soya, with specific emphasis on the bioavailability of 
flavanones in an acute or chronic intervention, and from a matrix of commercially-
available supplements and juice. The findings of this thesis provide good information 
about the forms of hesperetin metabolites using LCMS which verify the extensive 
modification in the human body after consumption of citrus-rich food before 
excreted in urine. Moreover, for the first time dietary health supplements were 
assessed for their ability to alter CVD risk factors. Although a significant decrease in 
blood pressure and fasting blood glucose were not found, there was a trend towards a 
reduction in these parameters in healthy overweight subjects, which does warrant 
further investigation both as a longer term study and in subjects who have higher 
blood pressure or metabolic syndrome. No changes in endothelial function were 
observed as measured by Endo-PAT, but this does not rule out potential changes in 
function, and should be further investigated by FMD or PWV in longer term studies. 
An extensive study on bioavailability of flavanones monitoring plasma 
concentrations as well as excretion levels of metabolites should determine the 
importance of absorption, metabolism and overall bioavailability on CVD risk. 
Although the results achieved in this thesis showed no significant change in CV risk 
biomarkers, more work is needed to verify the protective mechanism of hesperetin 
metabolites and the effects of different doses on the vascular protection in humans. 
 220 
 
Reference: 
 
ACTIS-GORETTA, L., OTTAVIANI, J. I. & FRAGA, C. G. 2006. Inhibition of 
angiotensin converting enzyme activity by flavanol-rich foods. Journal of 
Agricultural and Food Chemistry, 54, 229-234. 
AHN-JARVIS, J., CLINTON, S. K., RIEDL, K. M., VODOVOTZ, Y. & 
SCHWARTZ, S. J. 2012. Impact of food matrix on isoflavone metabolism 
and cardiovascular biomarkers in adults with hypercholesterolemia. Food & 
Function, 3, 1051-1058. 
AHN-JARVIS, J. H., RIEDL, K. M., SCHWARTZ, S. J. & VODOVOTZ, Y. 2013. 
Design and selection of soy breads used for evaluating isoflavone 
bioavailability in clinical trials. Journal of agricultural and food chemistry, 
61, 3111-3120. 
ALBACH, R. F., REDMAN, G. H. & CRUSE, R. R. 1981. Annual and seasonal 
changes in naringin concentration of Ruby Red grapefruit juice. Journal of 
Agricultural and Food Chemistry, 29, 808-811. 
ALBERTI, K., ECKEL, R. H., GRUNDY, S. M., ZIMMET, P. Z., CLEEMAN, J. I., 
DONATO, K. A., FRUCHART, J.-C., JAMES, W. P. T., LORIA, C. M. & 
SMITH JR, S. C. 2009. Joint Scientific Statement. Harmonizing the 
Metabolic Syndrome. Circulatio, 120, 1640-1645. 
ALLAN, R., DELANEY, C., MILLER, M. & SPARK, J. 2013. A comparison of 
flow-mediated dilatation and peripheral artery tonometry for measurement of 
endothelial function in healthy individuals and patients with peripheral 
arterial disease. European Journal of Vascular and Endovascular Surgery, 
45, 263-269. 
ALLENDER S, SCARBOROUGH P, PETO V, RAYNER M, LEAL J, LUENGO-
FERNANDEZ R AND GRAY A. 2008. European cardiovascular disease 
statistics.112. 
ALMOOSAWI, S., FYFE, L., HO, C. & AL-DUJAILI, E. 2010. The effect of 
polyphenol-rich dark chocolate on fasting capillary whole blood glucose, 
total cholesterol, blood pressure and glucocorticoids in healthy overweight 
and obese subjects. British Journal of Nutrition, 103, 842-850. 
ALONSO, A., DE LA FUENTE, C., MARTÍN-ARNAU, A. M., DE IRALA, J., 
ALFREDO MARTÍNEZ, J. & MARTÍNEZ-GONZÁLEZ, M. Á. 2004. Fruit 
and vegetable consumption is inversely associated with blood pressure in a 
Mediterranean population with a high vegetable-fat intake: the Seguimiento 
Universidad de Navarra (SUN) Study. British Journal of Nutrition, 92, 311-
319. 
 221 
 
AL-QAISI, M., KHARBANDA, R. K., MITTAL, T. K. & DONALD, A. E. 2008. 
Measurement of endothelial function and its clinical utility for cardiovascular 
risk. Vascular Health and Risk Management, 4, 647. 
ALTUNKAN, S., ILMAN, N., KAYATÜRK, N. & ALTUNKAN, E. 2007. 
Validation of the Omron M6 (HEM-7001-E) upper-arm blood pressure 
measuring device according to the International Protocol in adults and obese 
adults. Blood pressure monitoring, 12, 219-225. 
ANDERSON, T. J. 2004. Nitric oxide, atherosclerosis and the clinical relevance of 
endothelial dysfunction. The Role of Nitric Oxide in Heart Failure. Springer. 
55-70. 
ANTER, E., THOMAS, S. R., SCHULZ, E., SHAPIRA, O. M., VITA, J. A. & 
KEANEY, J. F. 2004. Activation of endothelial nitric-oxide synthase by the 
p38 MAPK in response to black tea polyphenols. Journal of Biological 
Chemistry, 279, 46637-46643. 
ÄRNLÖV, J., INGELSSON, E., SUNDSTRÖM, J. & LIND, L. 2010. Impact of 
body mass index and the metabolic syndrome on the risk of cardiovascular 
disease and death in middle-aged men. Circulation, 121, 230-236. 
ARREBOLA-MORENO, A. L., LACLAUSTRA, M. & KASKI, J. C. 2012. 
Noninvasive assessment of endothelial function in clinical practice. Revista 
Española de Cardiología (English Edition), 65, 80-90. 
ASGARY, S. & KESHVARI, M. 2013. Effects of citrus sinensis juice on blood 
pressure. ARYA Atherosclerosis, 9, 98-101. 
ASGARY, S., KESHVARI, M., AFSHANI, M. R., AMIRI, M., LAHER, I. & 
JAVANMARD, S. H. 2014. Effect of Fresh Orange Juice Intake on 
Physiological Characteristics in Healthy Volunteers. International Scholarly 
Research Notices, 2014, 1-7. 
ASGARY, S., KESHVARI, M., SAHEBKAR, A., HASHEMI, M. & RAFIEIAN-
KOPAEI, M. 2013. Clinical investigation of the acute effects of pomegranate 
juice on blood pressure and endothelial function in hypertensive individuals. 
ARYA Atherosclerosis, 9, 326. 
AURA, A.-M., MATTILA, I., SEPPÄNEN-LAAKSO, T., MIETTINEN, J., 
OKSMAN-CALDENTEY, K.-M. & OREŠIČ, M. 2008. Microbial 
metabolism of catechin stereoisomers by human faecal microbiota: 
comparison of targeted analysis and a non-targeted metabolomics method. 
Phytochemistry Letters, 1, 18-22. 
BAI, J., BALDWIN, E., PLOTTO, A., MANTHEY, J. A., MCCOLLUM, G., IREY, 
M. & LUZIO, G. 2009. Influence of harvest time on quality of 
‘Valencia’oranges and juice.  Proceedings of the Florida State Horticulture 
Society, 122, 308-315. 
BAI, J., MANTHEY, J. A., FORD, B. L., LUZIO, G., CAMERON, R. G., 
NARCISO, J. & BALDWIN, E. A. 2013. Effect of extraction, pasteurization 
and cold storage on flavonoids and other secondary metabolites in fresh 
orange juice. Journal of The Science of Food and Agriculture, 93, 2771-2781. 
 222 
 
BAO, Y. & FENWICK, R. 2004. Phytochemicals in Health and Disease, CRC Press. 
BARUA, R. S., AMBROSE, J. A., SRIVASTAVA, S., DEVOE, M. C. & EALES-
REYNOLDS, L.-J. 2003. Reactive oxygen species are involved in smoking-
induced dysfunction of nitric oxide biosynthesis and upregulation of 
endothelial nitric oxide synthase an in vitro demonstration in human coronary 
artery endothelial cells. Circulation, 107, 2342-2347. 
BASILE, L. G., LIMA, C. & CÉSAR, T. B. 2010. Daily intake of pasteurized orange 
juice decreases serum cholesterol, fasting glucose and diastolic blood 
pressure in adults.  Proceedings of the Florida State Horticultural Society, 
123, 228-233. 
BAUER, V. & SOTNÍKOVÁ, R. 2010. Nitric oxide--the endothelium-derived 
relaxing factor and its role in endothelial functions. General Physiology and 
Biophysics, 29, 319-340. 
BAUMSTARK, A., PLEUS, S., SCHMID, C., LINK, M., HAUG, C. & 
FRECKMANN, G. 2012. Lot-to-lot variability of test strips and accuracy 
assessment of systems for self-monitoring of blood glucose according to ISO 
15197. Journal Of Diabetes Science and Technology, 6, 1076-1086. 
BEKING, K. & VIEIRA, A. 2011. An assessment of dietary flavonoid intake in the 
UK and Ireland. International Journal of Food Sciences and Nutrition, 62, 
17-19. 
BONETTI, P. O., LERMAN, L. O. & LERMAN, A. 2003. Endothelial dysfunction a 
marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular 
Biology, 23, 168-175. 
BONIFÁCIO, N. P. & CÉSAR, T. B. 2009. Influência da ingestão crônica do suco 
de laranja na pressão arterial e na composição corporal. Revista Brasileira de 
Oftalmologia, 16, 76-81. 
BONSO, E., RAGAZZO, F. & PALATINI, P. 2008. Validation of A&D UA-85X 
device for blood pressure measurement. Blood Pressure Monitoring, 13, 339-
341. 
BORGES, G., MULLEN, W., MULLAN, A., LEAN, M. E., ROBERTS, S. A. & 
CROZIER, A. 2010. Bioavailability of multiple components following acute 
ingestion of a polyphenol‐rich juice drink. Molecular Nutrition & Food 
Research, 54, S268-S277. 
BORRADAILE, N. M., CARROLL, K. K. & KUROWSKA, E. M. 1999. Regulation 
of HepG2 cell apolipoprotein B metabolism by the citrus flavanones 
hesperetin and naringenin. Lipids, 34, 591-598. 
BRAND, W., BOERSMA, M. G., BIK, H., HOEK-VAN DEN HIL, E. F., 
VERVOORT, J., BARRON, D., MEINL, W., GLATT, H., WILLIAMSON, 
G. & VAN BLADEREN, P. J. 2010. Phase II metabolism of hesperetin by 
individual UDP-glucuronosyltransferases and sulfotransferases and rat and 
human tissue samples. Drug Metabolism and Disposition, 38, 617-625. 
BRAT, P., GEORGÉ, S., BELLAMY, A., DU CHAFFAUT, L., SCALBERT, A., 
MENNEN, L., ARNAULT, N. & AMIOT, M. J. 2006. Daily polyphenol 
 223 
 
intake in France from fruit and vegetables. The Journal of Nutrition, 136, 
2368-2373. 
BREDSDORFF, L., NIELSEN, I. L., RASMUSSEN, S. E., CORNETT, C., 
BARRON, D., BOUISSET, F., OFFORD, E. & WILLIAMSON, G. 2010. 
Absorption, conjugation and excretion of the flavanones, naringenin and 
hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. 
British Journal of Nutrition, 103, 1602-1609. 
BRETT, G. M., HOLLANDS, W., NEEDS, P. W., TEUCHER, B., DAINTY, J. R., 
DAVIS, B. D., BRODBELT, J. S. & KROON, P. A. 2009. Absorption, 
metabolism and excretion of flavanones from single portions of orange fruit 
and juice and effects of anthropometric variables and contraceptive pill use 
on flavanone excretion. British Journal of Nutrition, 101, 664-75. 
BREVIK, A., RASMUSSEN, S. E., DREVON, C. A. & ANDERSEN, L. F. 2004. 
Urinary excretion of flavonoids reflects even small changes in the dietary 
intake of fruits and vegetables. Cancer Epidemiology Biomarkers & 
Prevention, 13, 843-849. 
BUSCEMI, S., ROSAFIO, G., ARCOLEO, G., MATTINA, A., CANINO, B., 
MONTANA, M., VERGA, S. & RINI, G. 2012. Effects of red orange juice 
intake on endothelial function and inflammatory markers in adult subjects 
with increased cardiovascular risk. The American Journal of Clinical 
Nutrition, 95, 1089-95. 
CAI, H. & HARRISON, D. G. 2000. Endothelial dysfunction in cardiovascular 
diseases: the role of oxidant stress. Circulation Research, 87, 840-844. 
CAO, J., ZHANG, Y., CHEN, W. & ZHAO, X. 2010. The relationship between 
fasting plasma concentrations of selected flavonoids and their ordinary 
dietary intake. British Journal of Nutrition, 103, 249-255. 
CAO, Y., CALAFAT, A. M., DOERGE, D. R., UMBACH, D. M., BERNBAUM, J. 
C., TWADDLE, N. C., YE, X. & ROGAN, W. J. 2009. Isoflavones in urine, 
saliva, and blood of infants: data from a pilot study on the estrogenic activity 
of soy formula. Journal of Exposure Science and Environmental 
Epidemiology, 19, 223-234. 
CARDONA, F., ANDRÉS-LACUEVA, C., TULIPANI, S., TINAHONES, F. J. & 
QUEIPO-ORTUÑO, M. I. 2013. Benefits of polyphenols on gut microbiota 
and implications in human health. The Journal of Nutritional Biochemistry, 
24, 1415-1422. 
CASSIDY, A., BROWN, J. E., HAWDON, A., FAUGHNAN, M. S., KING, L. J., 
MILLWARD, J., ZIMMER-NECHEMIAS, L., WOLFE, B. & SETCHELL, 
K. D. 2006. Factors affecting the bioavailability of soy isoflavones in humans 
after ingestion of physiologically relevant levels from different soy foods. 
The Journal of nutrition, 136, 45-51. 
CASSIDY, A., RIMM, E. B., O'REILLY, É. J., LOGROSCINO, G., KAY, C., 
CHIUVE, S. E. & REXRODE, K. M. 2012. Dietary flavonoids and risk of 
stroke in women. Stroke, 43, 946-951. 
 224 
 
CELERMAJER, D. S. 1997. Endothelial dysfunction: does it matter? Is it reversible? 
Journal of the American College of Cardiology, 30, 325-333. 
CELERMAJER, D. S. 2008. Reliable endothelial function testing at our fingertips? 
Circulation, 117, 2428-2430. 
CELERMAJER, D. S., SORENSEN, K. E., SPIEGELHALTER, D. J., 
GEORGAKOPOULOS, D., ROBINSON, J. & DEANFIELD, J. E. 1994. 
Aging is associated with endothelial dysfunction in healthy men years before 
the age-related decline in women. Journal of the American College of 
Cardiology, 24, 471-476. 
CHANET, A., MILENKOVIC, D., DEVAL, C., POTIER, M., CONSTANS, J., 
MAZUR, A., BENNETAU-PELISSERO, C., MORAND, C. & BÉRARD, A. 
M. 2012a. Naringin, the major grapefruit flavonoid, specifically affects 
atherosclerosis development in diet-induced hypercholesterolemia in mice. 
The Journal of Nutritional Biochemistry, 23, 469-477. 
CHANET, A., MILENKOVIC, D., MANACH, C., MAZUR, A. & MORAND, C. 
2012b. Citrus flavanones: what is their role in cardiovascular protection? 
Journal of Agricultural and Food Chemistry, 60, 8809-8822. 
CHANG, Y. & CHOUE, R. 2013. Plasma pharmacokinetics and urinary excretion of 
isoflavones after ingestion of soy products with different aglycone/glucoside 
ratios in South Korean women. Nutrition Research and Practice, 7, 393-399. 
CHONG, M. F.-F., MACDONALD, R. & LOVEGROVE, J. A. 2010. Fruit 
polyphenols and CVD risk: a review of human intervention studies. British 
Journal of Nutrition, 104, S28-S39. 
CHUN, O. K., CHUNG, S. J. & SONG, W. O. 2007. Estimated dietary flavonoid 
intake and major food sources of US adults. The Journal of Nutrition, 137, 
1244-1252. 
CLARKE, S. & FOSTER, J. 2012. A history of blood glucose meters and their role 
in self-monitoring of diabetes mellitus. British Journal of Biomedical 
Science, 69, 83-93. 
COELHO, R. C., H. H. HERMSDORFF, et al. 2013. "Anti-inflammatory properties 
of orange juice: possible favorable molecular and metabolic effects." Plant 
Foods Hum Nutrition 68, 1-10. 
COLLABORATION, P. S. 2002. Age-specific relevance of usual blood pressure to 
vascular mortality: a meta-analysis of individual data for one million adults in 
61 prospective studies. Lancet, 360, 1903-1913. 
COLLINS, T. & CYBULSKY, M. I. 2001. NF-κB: pivotal mediator or innocent 
bystander in atherogenesis? The Journal of Clinical Investigation, 107, 255-
264. 
CONRAADS, V. M. 2013. Assessment of endothelial dysfunction in childhood 
obesity and clinical use. Oxidative Medicine and Cellular Longevity, 2013.1-
19. 
CORRETTI, M. C., ANDERSON, T. J., BENJAMIN, E. J., CELERMAJER, D., 
CHARBONNEAU, F., CREAGER, M. A., DEANFIELD, J., DREXLER, H., 
 225 
 
GERHARD-HERMAN, M. & HERRINGTON, D. 2002. Guidelines for the 
ultrasound assessment of endothelial-dependent flow-mediated vasodilation 
of the brachial artery: a report of the International Brachial Artery Reactivity 
Task Force. Journal of the American College of Cardiology, 39, 257-265. 
CRESPY, V., MORAND, C., BESSON, C., MANACH, C., DEMIGNE, C. & 
REMESY, C. 2002. Quercetin, but not its glycosides, is absorbed from the rat 
stomach. Journal of Agricultural and Food Chemistry, 50, 618-621. 
CROZIER, A., DEL RIO, D. & CLIFFORD, M. N. 2010. Bioavailability of dietary 
flavonoids and phenolic compounds. Molecular Aspects of Medicine, 31, 
446-467. 
CROZIER, A., JAGANATH, I. B. & CLIFFORD, M. N. 2009. Dietary phenolics: 
chemistry, bioavailability and effects on health. Natural Product Reports, 26, 
1001-1043. 
Davignon, J., & Ganz, P. 2004. Role of endothelial dysfunction in atherosclerosis. 
Circulation, 109, 111-127.   
DAY, A. J., BAO, Y., MORGAN, M. R. A & WILLIAMSON, G. 2000. Conjugation 
position of quercetin glucuronides and effect on biological activity. Free 
Radical Biology and Medicine, 29, 1234-1243. 
DAY, A. J., CAÑADA, F. J., Dı́AZ, J. C., KROON, P. A., MCLAUCHLAN, R., 
FAULDS, C. B., PLUMB, G. W., MORGAN, M. R.A & WILLIAMSON, G. 
2000. Dietary flavonoid and isoflavone glycosides are hydrolysed by the 
lactase site of lactase phlorizin hydrolase. FEBS Letters, 468, 166-170. 
DAY, A. J., DUPONT, M. S., RIDLEY, S., RHODES, M., RHODES, M. J.C., 
MORGAN, M. R.A & WILLIAMSON, G. 1998. Deglycosylation of 
flavonoid and isoflavonoid glycosides by human small intestine and liver β-
glucosidase activity. FEBS Letters, 436, 71-75. 
DAY, A. J., GEE, J. M., DUPONT, M. S., JOHNSON, I. T. & WILLIAMSON, G. 
2003. Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the 
rat small intestine: the role of lactase phlorizin hydrolase and the sodium-
dependent glucose transporter. Biochemical Pharmacology, 65, 1199-1206. 
DE CATERINA, R., LIBBY, P., PENG, H.-B., THANNICKAL, V. J., 
RAJAVASHISTH, T., GIMBRONE JR, M., SHIN, W. S. & LIAO, J. K. 
1995. Nitric oxide decreases cytokine-induced endothelial activation. Nitric 
oxide selectively reduces endothelial expression of adhesion molecules and 
proinflammatory cytokines. Journal of Clinical Investigation, 96, 60. 
DE OLIVEIRA, D. M., DOURADO, G. & CESAR, T. B. 2013. Hesperidin 
associated with continuous and interval swimming improved biochemical and 
oxidative biomarkers in rats. Journal of the International Society of Sports 
Nutrition, 10, 27. 
DE PASCUAL-TERESA, S., HALLUND, J., TALBOT, D., SCHROOT, J., 
WILLIAMS, C. M., BUGEL, S. & CASSIDY, A. 2006. Absorption of 
isoflavones in humans: effects of food matrix and processing. The Journal of 
Nutritional Biochemistry, 17, 257-264. 
 226 
 
DE PASCUAL-TERESA, S., SÁNCHEZ-MORENO, C., GRANADO, F., 
OLMEDILLA, B., DE ANCOS, B. & CANO, M. 2007. Short and mid-term 
bioavailability of flavanones from oranges in humans. Current Topics in 
Nutraceutical Research, 5, 129. 
DE WINTHER, M. P. & HOFKER, M. H. 2000. Scavenging new insights into 
atherogenesis. The Journal of Clinical Investigation, 105, 1039-1041. 
DEL RIO D, COSTA LG, LEAN MEJ AND CROZIER A. 2010. Polyphenols and 
health: What compounds are involved. Nutrition, Metabolism, And 
Cardiovascular Diseases. 20, 1-6. 
DEL RIO, D., RODRIGUEZ-MATEOS, A., SPENCER, J. P., TOGNOLINI, M., 
BORGES, G. & CROZIER, A. 2013. Dietary (poly) phenolics in human 
health: structures, bioavailability, and evidence of protective effects against 
chronic diseases. Antioxidants & Redox Signalling, 18, 1818-1892. 
DEMONTY, I., LIN, Y., ZEBREGS, Y. E., VERMEER, M. A., VAN DER KNAAP, 
H. C., JÄKEL, M. & TRAUTWEIN, E. A. 2010. The citrus flavonoids 
hesperidin and naringin do not affect serum cholesterol in moderately 
hypercholesterolemic men and women. The Journal of Nutrition, 140, 1615-
1620. 
DHINDSA, M., BARNES, J. N., DEVAN, A. E., SUGAWARA, J., & TANAKA, H. 
2011. "Comparison of augmentation index derived from multiple devices." 
Artery Research 5, 112-114. 
DHINDSA, M., SOMMERLAD, S. M., DEVAN, A. E., BARNES, J. N., 
SUGAWARA, J., LEY, O. & TANAKA, H. 2008. Interrelationships among 
noninvasive measures of postischemic macro-and microvascular reactivity. 
Journal of Applied Physiology, 105, 427-432. 
DI DONNA, L., TAVERNA, D., MAZZOTTI, F., BENABDELKAMEL, H., 
ATTYA, M., NAPOLI, A. & SINDONA, G. 2013. Comprehensive assay of 
flavanones in citrus juices and beverages by UHPLC–ESI-MS/MS and 
derivatization chemistry. Food Chemistry, 141, 2328-2333. 
DILIS, V. & TRICHOPOULOU, A. 2010. Antioxidant intakes and food sources in 
Greek adults. The Journal of Nutrition, 140, 1274-1279. 
DIMESKI, G., JONES, B., TILLEY, V., GREENSLADE, M. & RUSSELL, A. 
2010. Glucose meters: evaluation of the new formulation measuring strips 
from Roche (Accu-Chek) and Abbott (MediSense). Annals of Clinical 
Biochemistry, 47, 358-365. 
DING, X., FAN, S., LU, Y., ZHANG, Y., GU, M., ZHANG, L., LIU, G., GUO, L., 
JIANG, D. & LU, X. 2012. Citrus ichangensis peel extract exhibits anti-
metabolic disorder effects by the inhibition of PPAR and LXR signaling in 
high-fat diet-induced C57BL/6 mouse. Evidence-Based Complementary and 
Alternative Medicine, 2012.1-10. 
DIXON, Z. R., BURRI, B. J., CLIFFORD, A., FRANKEL, E. N., SCHNEEMAN, 
B. O., PARKS, E., ... & ERDMAN, J. W. 1994. Effects of a carotene-deficient 
diet on measures of oxidative susceptibility and superoxide dismutase activity 
in adult women. Free Radical Biology & Medicine, 17, 537-544. 
 227 
 
DOHADWALA, M. M., HOLBROOK, M., HAMBURG, N. M., SHENOUDA, S. 
M., CHUNG, W. B., TITAS, M., KLUGE, M. A., WANG, N., 
PALMISANO, J. & MILBURY, P. E. 2011. Effects of cranberry juice 
consumption on vascular function in patients with coronary artery disease. 
The American Journal of Clinical Nutrition, 93, 934-940. 
DOMIANO, K. L., HINCK, S. M., SAVINSKE, D. L. & HOPE, K. L. 2008. 
Comparison of upper arm and forearm blood pressure. Clinical Nursing 
Research, 17, 241-250. 
DOW, C. A., GOING, S. B., CHOW, H.-H. S., PATIL, B. S. & THOMSON, C. A. 
2012. The effects of daily consumption of grapefruit on body weight, lipids, 
and blood pressure in healthy, overweight adults. Metabolism, 61, 1026-1035. 
EDWARDS, R. L., LYON, T., LITWIN, S. E., RABOVSKY, A., SYMONS, J. D. & 
JALILI, T. 2007. Quercetin Reduces Blood Pressure in Hypertensive 
Subjects. The Journal of Nutrition, 137, 2405-2411. 
EGERT, S., BOSY-WESTPHAL, A., SEIBERL, J., KÜRBITZ, C., SETTLER, U., 
PLACHTA-DANIELZIK, S., WAGNER, A. E., FRANK, J., 
SCHREZENMEIR, J. & RIMBACH, G. 2009. Quercetin reduces systolic 
blood pressure and plasma oxidised low-density lipoprotein concentrations in 
overweight subjects with a high-cardiovascular disease risk phenotype: a 
double-blinded, placebo-controlled cross-over study. British Journal of 
Nutrition, 102, 1065-1074. 
ERDMAN, J. W., BALENTINE, D., ARAB, L., BEECHER, G., DWYER, J. T., 
FOLTS, J., HARNLY, J., HOLLMAN, P., KEEN, C. L. & MAZZA, G. 
2007. Flavonoids and heart health: Proceedings of the ilsi north america 
flavonoids workshop, May 31–June 1, 2005, Washington, DC. The Journal of 
Nutrition, 137, 718S-737S. 
ERLUND, I. 2004. Review of the flavonoids quercetin, hesperetin, and naringenin. 
Dietary sources, bioactivities, bioavailability, and epidemiology. Nutrition 
Research, 24, 851-874. 
ERLUND, I., MERIRINNE, E., ALFTHAN, G. & ARO, A. 2001. Plasma kinetics 
and urinary excretion of the flavanones naringenin and hesperetin in humans 
after ingestion of orange juice and grapefruit juice. The Journal of Nutrition, 
131, 235-241. 
ERLUND, I., SILASTE, M., ALFTHAN, G., RANTALA, M., KESÄNIEMI, Y. & 
ARO, A. 2002. Plasma concentrations of the flavonoids hesperetin, 
naringenin and quercetin in human subjects following their habitual diets, and 
diets high or low in fruit and vegetables. European Journal of Clinical 
Nutrition, 56, 891-898. 
ESCUDERO‐LÓPEZ, B., CALANI, L., FERNÁNDEZ‐PACHÓN, M. S., ORTEGA, 
Á., BRIGHENTI, F., CROZIER, A. & RIO, D. 2013. Absorption, 
metabolism, and excretion of fermented orange juice (poly) phenols in rats. 
BioFactors. 40, 327-335. 
 228 
 
ESPER, R. J., NORDABY, R. A., VILARIÑO, J. O., PARAGANO, A., 
CACHARRÓN, J. L. & MACHADO, R. A. 2006. Endothelial dysfunction: a 
comprehensive appraisal. Cardiovasc Diabetol, 5, 4-22. 
FAUGHNAN, M. S., HAWDON, A., AH-SINGH, E., BROWN, J., MILLWARD, 
D. & CASSIDY, A. 2004. Urinary isoflavone kinetics: the effect of age, 
gender, food matrix and chemical composition. British Journal of Nutrition, 
91, 567-574. 
FELMEDEN, D. C. & LIP, G. Y. 2005. Endothelial function and its assessment. 
Expert Opinion on Investigational Drugs.14,1319-36. 
FONSECA, V., DESOUZA, C., ASNANI, S. & JIALAL, I. 2004. Nontraditional 
risk factors for cardiovascular disease in diabetes. Endocrine Reviews, 25, 
153-175. 
FORESTER, S. C. & WATERHOUSE, A. L. 2009. Metabolites are key to 
understanding health effects of wine polyphenolics. The Journal of Nutrition, 
139, 1824S-1831S. 
FÖRSTERMANN, U. & MÜNZEL, T. 2006. Endothelial nitric oxide synthase in 
vascular disease from marvel to menace. Circulation, 113, 1708-1714. 
FRAGA, C. G., GALLEANO, M., VERSTRAETEN, S. V. & OTEIZA, P. I. 2010. 
Basic biochemical mechanisms behind the health benefits of polyphenols. 
Molecular Aspects of Medicine, 31, 435-445. 
FRANKLIN, S. S. 2007. The importance of diastolic blood pressure in predicting 
cardiovascular risk. Journal of the American Society of Hypertension, 1, 82-
93. 
FRECKMANN, G., BAUMSTARK, A., JENDRIKE, N., ZSCHORNACK, E., 
KOCHER, S., TSHIANANGA, J., HEISTER, F. & HAUG, C. 2010. System 
accuracy evaluation of 27 blood glucose monitoring systems according to 
DIN EN ISO 15197. Diabetes Technology & Therapeutics, 12, 221-231. 
FRECKMANN, G., SCHMID, C., BAUMSTARK, A., PLEUS, S., LINK, M. & 
HAUG, C. 2012. System accuracy evaluation of 43 blood glucose monitoring 
systems for self-monitoring of blood glucose according to DIN EN ISO 
15197. Journal of diabetes science and technology, 6, 1060-1075. 
GANZ, P. & VITA, J. A. 2003. Testing endothelial vasomotor function nitric oxide, 
a multipotent molecule. Circulation, 108, 2049-2053. 
GARDANA, C., GUARNIERI, S., RISO, P., SIMONETTI, P. & PORRINI, M. 
2007. Flavanone plasma pharmacokinetics from blood orange juice in human 
subjects. British Journal of Nutrition, 98, 165-172. 
GILES, T. D., BERK, B. C., BLACK, H. R., COHN, J. N., KOSTIS, J. B., IZZO, J. 
L. & WEBER, M. A. 2005. Expanding the definition and classification of 
hypertension. The Journal of Clinical Hypertension, 7, 505-512. 
GIL-IZQUIERDO, A., GIL, M. I. & FERRERES, F. 2002. Effect of processing 
techniques at industrial scale on orange juice antioxidant and beneficial 
 229 
 
health compounds. Journal of Agricultural and Food Chemistry, 50, 5107-
5114. 
GIL-IZQUIERDO, A., GIL, M. I., TOMÁS-BARBERÁN, F. A. & FERRERES, F. 
2003. Influence of industrial processing on orange juice flavanone solubility 
and transformation to chalcones under gastrointestinal conditions. Journal of 
Agricultural and Food Chemistry, 51, 3024-3028. 
GLADWIN, M. T., SCHECHTER, A. N., KIM-SHAPIRO, D. B., PATEL, R. P., 
HOGG, N., SHIVA, S., CANNON, R. O., KELM, M., WINK, D. A. & 
ESPEY, M. G. 2005. The emerging biology of the nitrite anion. Nature 
chemical biology, 1, 308-314. 
GORINSTEIN, S., CASPI, A., LIBMAN, I., LERNER, H. T., HUANG, D., 
LEONTOWICZ, H., LEONTOWICZ, M., TASHMA, Z., KATRICH, E. & 
FENG, S. 2006. Red grapefruit positively influences serum triglyceride level 
in patients suffering from coronary atherosclerosis: studies in vitro and in 
humans. Journal of Agricultural and Food Chemistry, 54, 1887-1892. 
GRASSI, D., DESIDERI, G., CROCE, G., TIBERTI, S., AGGIO, A. & FERRI, C. 
2009. Flavonoids, vascular function and cardiovascular protection. Current 
Pharmaceutical Design, 15, 1072-1084. 
GRASSI, D., DESIDERI, G., NECOZIONE, S., LIPPI, C., CASALE, R., 
PROPERZI, G., BLUMBERG, J. B. & FERRI, C. 2008. Blood pressure is 
reduced and insulin sensitivity increased in glucose-intolerant, hypertensive 
subjects after 15 days of consuming high-polyphenol dark chocolate. The 
Journal of Nutrition, 138, 1671-1676. 
GREEN, D. J., JONES, H., THIJSSEN, D., CABLE, N. & ATKINSON, G. 2011. 
Flow-Mediated Dilation and Cardiovascular Event Prediction Does Nitric 
Oxide Matter? Hypertension, 57, 363-369. 
GREEN, D. J., MAIORANA, A., O'DRISCOLL, G. & TAYLOR, R. 2004. Effect of 
exercise training on endothelium-derived nitric oxide function in humans. 
The Journal of Physiology, 561, 1-25. 
GRIEP, L. M. O., STAMLER, J., CHAN, Q., VAN HORN, L., STEFFEN, L. M., 
MIURA, K., UESHIMA, H., OKUDA, N., ZHAO, L. & DAVIGLUS, M. L. 
2013. Association of raw fruit and fruit juice consumption with blood 
pressure: the INTERMAP Study. The American Journal of Clinical Nutrition, 
97, 1083-1091. 
HABAUZIT, V., NIELSEN, I. L., GIL-IZQUIERDO, A., TRZECIAKIEWICZ, A., 
MORAND, C., CHEE, W., BARRON, D., LEBECQUE, P., DAVICCO, M. 
J., WILLIAMSON, G., OFFORD, E., COXAM, V. & HORCAJADA, M. N. 
2009. Increased bioavailability of hesperetin-7-glucoside compared with 
hesperidin results in more efficient prevention of bone loss in adult 
ovariectomised rats. British Journal of Nutrition, 102, 976-84. 
HALLIWELL, B. 2007. Dietary polyphenols: good, bad, or indifferent for your 
health? Cardiovascular research, 73, 341-347. 
 230 
 
HALM, B. M., ASHBURN, L. A. & FRANKE, A. A. 2007. Isoflavones from soya 
foods are more bioavailable in children than adults. British journal of 
nutrition, 98, 998-1005. 
HAMBURG, N. M., KEYES, M. J., LARSON, M. G., VASAN, R. S., SCHNABEL, 
R., PRYDE, M. M., MITCHELL, G. F., SHEFFY, J., VITA, J. A. & 
BENJAMIN, E. J. 2008. Cross-sectional relations of digital vascular function 
to cardiovascular risk factors in the Framingham Heart Study. Circulation, 
117, 2467-2474. 
HAMBURG, N., & BENJAMIN, E. 2009. Assessment of endothelial function using 
digital pulse amplitude tonometry. Trends in Cardiovascular Medicine, 19, 6-
11. 
HAN, X., SHEN, T. & LOU, H. 2007. Dietary polyphenols and their biological 
significance. International Journal of Molecular Sciences, 8, 950-988. 
HANDLER, J. 2009. The importance of accurate blood pressure measurement. The 
Permanente Journal, 13, 51. 
HANHINEVA, K., TÖRRÖNEN, R., BONDIA-PONS, I., PEKKINEN, J., 
KOLEHMAINEN, M., MYKKÄNEN, H. & POUTANEN, K. 2010. Impact 
of dietary polyphenols on carbohydrate metabolism. International Journal of 
Molecular Sciences, 11, 1365-1402. 
HANSSON, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. 
New England Journal of Medicine, 352, 1685-1695. 
HARRIS, K., KASSIS, A., MAJOR, G. & CHOU, C. J. 2012. Is the gut microbiota a 
new factor contributing to obesity and its metabolic disorders? Journal of 
Obesity, 2012, 1-14. 
HINDERLITER, A. L. & CAUGHEY, M. 2003. Assessing endothelial function as a 
risk factor for cardiovascular disease. Current atherosclerosis reports, 5, 506-
513. 
HOBBS, D. A., GEORGE, T. W. & LOVEGROVE, J. A. 2013. The effects of 
dietary nitrate on blood pressure and endothelial function: a review of human 
intervention studies. Nutrition Research Reviews, 26, 210-222. 
HOLLMAN, P. C. 2004. Absorption, bioavailability, and metabolism of flavonoids. 
Pharmaceutical Biology, 42, 74-83. 
HOOPER, L., KAY, C., ABDELHAMID, A., KROON, P. A., COHN, J. S., RIMM, 
E. B., & CASSIDY, A. 2012. Effects of chocolate, cocoa, and flavan-3-ols on 
cardiovascular health: a systematic review and meta-analysis of randomized 
trials. The American Journal of Clinical Nutrition, 95, 740-751. 
HOOPER, L., KROON, P. A., RIMM, E. B., COHN, J. S., HARVEY, I., LE 
CORNU, K. A., RYDER, J. J., HALL, W. L. & CASSIDY, A. 2008. 
Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of 
randomized controlled trials. The American Journal of Clinical Nutrition, 88, 
38-50. 
 231 
 
HSU, C. L. & YEN, G. C. 2008. Phenolic compounds: evidence for inhibitory effects 
against obesity and their underlying molecular signaling mechanisms. 
Molecular Nutrition & Food Research, 52, 53-61. 
HUANG, A. L. & VITA, J. A. 2006. Effects of systemic inflammation on 
endothelium-dependent vasodilation. Trends in Cardiovascular Medicine, 16, 
15-20. 
HUANG, P. L. 2009. A comprehensive definition for metabolic syndrome. Disease 
Models & Mechanisms, 2, 231-237. 
HUANG, Z., WILLETT, W. C., MANSON, J. E., ROSNER, B., STAMPFER, M. J., 
SPEIZER, F. E. & COLDITZ, G. A. 1998. Body weight, weight change, and 
risk for hypertension in women. Annals of Internal Medicine, 128, 81-88. 
INABA, Y., CHEN, J. A. & BERGMANN, S. R. 2010. Prediction of future 
cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a 
meta-analysis. The International Journal of Cardiovascular Imaging, 26, 
631-640. 
ISMAIL, N. A., RAGAB, S. H., ELBAKY, A. A., SHOEIB, A. R., ALHOSARY, Y. 
& FEKRY, D. 2010. Frequency of Firmicutes and Bacteroidetes in gut 
microbiota of obese and normal weight Egyptian children and adults. 
Archives of Medical Science, 7, 501-507. 
ITO, H., GONTHIER, M.-P., MANACH, C., MORAND, C., MENNEN, L., 
RÉMÉSY, C. & SCALBERT, A. 2005. Polyphenol levels in human urine 
after intake of six different polyphenol-rich beverages. British Journal of 
Nutrition, 94, 500-509. 
JAMES, P. T. 2004. Obesity: the worldwide epidemic. Clinics in Dermatology, 22, 
276-280. 
JAN, A. T., KAMLI, M. R., MURTAZA, I., SINGH, J. B., ALI, A. & HAQ, Q. 
2010. Dietary flavonoid quercetin and associated health benefits—an 
overview. Food Reviews International, 26, 302-317. 
JIN, M. J., KIM, U., KIM, I. S., KIM, Y., KIM, D.-H., HAN, S. B., KIM, D.-H., 
KWON, O.-S. & YOO, H. H. 2010. Effects of gut microflora on 
pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-
free rats. Journal of Toxicology and Environmental Health, Part A, 73, 1441-
1450. 
JOHANNOT, L. & SOMERSET, S. M. 2006. Age-related variations in flavonoid 
intake and sources in the Australian population. Public health nutrition, 9, 
1045-1054. 
LEKAKIS, J., ABRAHAM, P., BALBARINI, A., BLANN, A., BOULANGER, C. 
M., COCKCROFT, J., COSENTINO, F., DEANFIELD, J., GALLINO, A. & 
IKONOMIDIS, I.2011.Methods for evaluating endothelial function: a position 
statement from the European Society of Cardiology Working Group on 
Peripheral Circulation. European Journal of Cardiovascular Prevention & 
Rehabilitation, 18: 775- 789. 
JUNG, U. J., LEE, M.-K., PARK, Y. B., KANG, M. & CHOI, M.-S. 2006. Effect of 
citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA 
 232 
 
levels in type-2 diabetic mice. The International Journal of Biochemistry & 
Cell Biology, 38, 1134-1145. 
JUNG, U., KIM, H., LEE, J., LEE, M., KIM, H., PARK, E., KIM, H., JEONG, T. & 
CHOI, M. 2003. Naringin supplementation lowers plasma lipids and 
enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic 
subjects. Clinical Nutrition, 22, 561-568. 
KAHN, R., BUSE, J., FERRANNINI, E. & STERN, M. 2005. The metabolic 
syndrome: time for a critical appraisal Joint statement from the American 
Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care, 28, 2289-2304. 
KANAZE, F., BOUNARTZI, M., GEORGARAKIS, M. & NIOPAS, I. 2006. 
Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin 
after single oral administration in human subjects. European Journal of 
Clinical Nutrition, 61, 472-477. 
KANO, M., TAKAYANAGI, T., HARADA, K., SAWADA, S. & ISHIKAWA, F. 
2006. Bioavailability of Isoflavones after Ingestion of Soy Beverages in 
Healthy Adults. The Journal of Nutrition, 136, 2291-2296. 
KAWAI, M., HIRANO, T., HIGA, S., ARIMITSU, J., MARUTA, M., 
KUWAHARA, Y., OHKAWARA, T., HAGIHARA, K., YAMADORI, T. & 
SHIMA, Y. 2007. Flavonoids and related compounds as anti-allergic 
substances. Allergology International, 56, 113-123. 
KAWAII, S., TOMONO, Y., KATASE, E., OGAWA, K. & YANO, M. 1999. 
Quantitation of flavonoid constituents in citrus fruits. Journal of Agricultural 
and Food Chemistry, 47, 3565-3571. 
KAWASHIMA, S. & YOKOYAMA, M. 2004. Dysfunction of endothelial nitric 
oxide synthase and atherosclerosis. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 24, 998-1005. 
KELEBEK, H., SELLI, S., CANBAS, A. & CABAROGLU, T. 2009. HPLC 
determination of organic acids, sugars, phenolic compositions and antioxidant 
capacity of orange juice and orange wine made from a Turkish cv. Kozan. 
Microchemical Journal, 91, 187-192. 
KHAN, M. K. & DANGLES, O. 2014. A comprehensive review on flavanones, the 
major citrus polyphenols. Journal of Food Composition and Analysis, 33, 85-
104. 
KHURANA, S., VENKATARAMAN, K., HOLLINGSWORTH, A., PICHE, M. & 
TAI, T. 2013. Polyphenols: Benefits to the Cardiovascular System in Health 
and in Aging. Nutrients, 5, 3779-3827. 
KING, R. A. & BURSILL, D. B. 1998. Plasma and urinary kinetics of the 
isoflavones daidzein and genistein after a single soy meal in humans. The 
American Journal of Clinical Nutrition, 67, 867-872. 
KINGWELL, B. A. 2000. Nitric oxide-mediated metabolic regulation during 
exercise: effects of training in health and cardiovascular disease. The FASEB 
Journal, 14, 1685-1696. 
 233 
 
KNEKT, P., JARVINEN, R., REUNANEN, A., & MAATELA, J. 1996. Flavonoid 
intake and coronary mortality in Finland: a cohort study. British Medical 
Journal, 312, 478-481. 
KNEKT, P., KUMPULAINEN, J., JÄRVINEN, R., RISSANEN, H., 
HELIÖVAARA, M., REUNANEN, A., HAKULINEN, T. & AROMAA, A. 
2002. Flavonoid intake and risk of chronic diseases. The American Journal of 
Clinical Nutrition, 76, 560-568. 
KOKKINOS, P., PANAGIOTAKOS, D. B. & POLYCHRONOPOULOS, E. 2005. 
Dietary influences on blood pressure: the effect of the Mediterranean diet on 
the prevalence of hypertension. The Journal of Clinical Hypertension, 7, 165-
172. 
KONE, B. C., KUNCEWICZ, T., ZHANG, W. & YU, Z.-Y. 2003. Protein 
interactions with nitric oxide synthases: controlling the right time, the right 
place, and the right amount of nitric oxide. American Journal of Physiology-
Renal Physiology, 285, F178-F190. 
KRAUSE, M. & GALENSA, R. 1991. Analysis of enantiomeric flavanones in plant 
extracts by high-performance liquid chromatography on a cellulose triacetate 
based chiral stationary phase. Chromatographia, 32, 69-72. 
KRAUSE, T., LOVIBOND, K., CAULFIELD, M., MCCORMACK, T., 
WILLIAMS, B. & GROUP, G. D. 2011. Management of hypertension: 
summary of NICE guidance. British Medical Journal, 343, 1-6. 
KROGHOLM, K. S., BREDSDORFF, L., KNUTHSEN, P., HARALDSDOTTIR, J. 
& RASMUSSEN, S. E. 2010. Relative bioavailability of the flavonoids 
quercetin, hesperetin and naringenin given simultaneously through diet. Eur J 
Clin Nutr, 64, 432-435. 
KROGHOLM, K. S., HARALDSDÓTTIR, J., KNUTHSEN, P. & RASMUSSEN, S. 
E. 2004. Urinary total flavonoid excretion but not 4-pyridoxic acid or 
potassium can be used as a biomarker for the intake of fruits and vegetables. 
The Journal of Nutrition, 134, 445-451. 
KUMPULAINEN J, LEHTONEN M AND MATTILA P. 1999. Trolox equivalent 
antioxidant capacity of average flavonoids intake in Finland. Special 
Publication-Royal Society Of Chemistry, 240: 141-150. 
KUROWSKA, E. M. & MANTHEY, J. A. 2004. Hypolipidemic effects and 
absorption of citrus polymethoxylated flavones in hamsters with diet-induced 
hypercholesterolemia. Journal of Agricultural and Food Chemistry, 52, 2879-
2886. 
KUROWSKA, E. M., BORRADAILE, N. M., SPENCE, J. D., & CARROLL, K. K. 
2000. Hypocholesterolemic effects of dietary citrus juices in rabbits. Nutrition 
Research, 20, 121-129. 
KUROWSKA, E. M., SPENCE, J. D., JORDAN, J., WETMORE, S., FREEMAN, 
D. J., PICHÉ, L. A. & SERRATORE, P. 2000. HDL-cholesterol-raising 
effect of orange juice in subjects with hypercholesterolemia. The American 
Journal of Clinical Nutrition, 72, 1095-1100. 
 234 
 
LAMPE, J. W. 2003. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. 
The Journal of Nutrition, 133, 956S-964S. 
LAMPE, J. W., KARR, S. C., HUTCHINS, A. M. & SLAVIN, J. L. 1998. Urinary 
equol excretion with a soy challenge: influence of habitual diet. Experimental 
Biology and Medicine, 217, 335-339. 
LAMSTER, I. B., KAUFMAN, E., GRBIC, J. T., WINSTON, L. J., & SINGER, R. 
E. 2003. β-glucuronidase activity in saliva: relationship to clinical periodontal 
parameters. Journal of Periodontology, 74, 353-359. 
LANDBERG, R., SUN, Q., RIMM, E. B., CASSIDY, A., SCALBERT, A., 
MANTZOROS, C. S., HU, F. B. & VAN DAM, R. M. 2011. Selected dietary 
flavonoids are associated with markers of inflammation and endothelial 
dysfunction in US women. The Journal of Nutrition, 141, 618-625. 
LANDMESSER, U., HORNIG, B. & DREXLER, H. 2004. Endothelial function a 
critical determinant in atherosclerosis? Circulation, 109, II-27-II-33. 
LARKIN, T., PRICE, W. E. & ASTHEIMER, L. 2008. The key importance of soy 
isoflavone bioavailability to understanding health benefits. Critical Reviews 
in Food Science and Nutrition, 48, 538-552. 
LAW, M., MORRIS, J. & WALD, N. 2009. Use of blood pressure lowering drugs in 
the prevention of cardiovascular disease: meta-analysis of 147 randomised 
trials in the context of expectations from prospective epidemiological studies. 
British Medical Journal, 338:b1665. 
LEE, M.-J., LAMBERT, J. D., PRABHU, S., MENG, X., LU, H., MALIAKAL, P., 
HO, C.-T. & YANG, C. S. 2004. Delivery of tea polyphenols to the oral 
cavity by green tea leaves and black tea extract. Cancer Epidemiology 
Biomarkers & Prevention, 13, 132-137. 
LEKAKIS, J., ABRAHAM, P., BALBARINI, A., BLANN, A., BOULANGER, C. 
M., COCKCROFT, J. & VLACHOPOULOS, C. 2011. Methods for evaluating 
endothelial function: a position statement from the European Society of 
Cardiology Working Group on Peripheral Circulation. European Journal of 
Cardiovascular Prevention & Rehabilitation, 18, 775-789. 
LI, G., ZHANG, Y., MBUAGBAW, L., HOLBROOK, A., LEVINE, M. A. & 
THABANE, L. 2014. Effect of green tea supplementation on blood pressure 
among overweight and obese adults: a protocol for a systematic review. 
British Medical Journal open, 4, e004971. 
LI, S.-H., TIAN, H.-B., ZHAO, H.-J., CHEN, L.-H. & CUI, L.-Q. 2013. The Acute 
Effects of Grape Polyphenols Supplementation on Endothelial Function in 
Adults: Meta-Analyses of Controlled Trials. PloS one, 8, e69818. 
LIN, L. Y., & CHANG, C. C.1989. Determination of protein concentration in human 
saliva. The Kaohsiung Journal Of Medical Sciences, 5, 389-397. 
LIGGINS, J., BLUCK, L. J., COWARD, W. A., & BINGHAM, S. A. (1998). 
Extraction and quantification of daidzein and genistein in food. Analytical 
Biochemistry, 264, 1-7. 
 235 
 
LINSEISEN J AND ROHRMANN S. 2007. 3.2. Biomarkers of dietary polyphenol 
intake for studying diet-cancer relationships. This review has been prepared 
as part of ECNIS Work Package 9: Mechanisms of modulation of cancer by 
dietary factors: 1990. 
LIU, K., XING, A., CHEN, K., WANG, B., ZHOU, R., CHEN, S., XU, H. & MI, M. 
2013a. Effect of fruit juice on cholesterol and blood pressure in adults: a 
meta-analysis of 19 randomized controlled trials. PloS one, 8, e61420. 
LIU, K., ZHOU, R., WANG, B. & MI, M.-T. 2014a. Effect of resveratrol on glucose 
control and insulin sensitivity: a meta-analysis of 11 randomized controlled 
trials. The American Journal of Clinical Nutrition, 99, 1510-1519. 
LIU, K., ZHOU, R., WANG, B., CHEN, K., SHI, L.-Y., ZHU, J.-D. & MI, M.-T. 
2013b. Effect of green tea on glucose control and insulin sensitivity: a meta-
analysis of 17 randomized controlled trials. The American Journal of Clinical 
Nutrition, 98, 340-348. 
LIU, L., XU, D. M., & CHENG, Y. Y. 2008. Distinct effects of naringenin and 
hesperetin on nitric oxide production from endothelial cells. Journal of Agricultural 
and Food Chemistry, 56, 824-829. 
LIU, Y., MA, W., ZHANG, P., HE, S. & HUANG, D. 2014b. Effect of resveratrol 
on blood pressure: A meta-analysis of randomized controlled trials. Clinical 
Nutrition. 34, 27-34. 
LIU, Z., LI, W., SUN, J., LIU, C., ZENG, Q., HUANG, J., YU, B. & HUO, J. 2004. 
Intake of soy foods and soy isoflavones by rural adult women in China. Asia 
Pacific Journal of Clinical Nutrition, 13, 204-209. 
LOKE, W. M., JENNER, A. M., PROUDFOOT, J. M., MCKINLEY, A. J., 
HODGSON, J. M., HALLIWELL, B. & CROFT, K. D. 2009. A metabolite 
profiling approach to identify biomarkers of flavonoid intake in humans. The 
Journal of Nutrition, 139, 2309-2314. 
LUMSDEN, N. G., ANDREWS, K. L., BOBADILLA, M., MOORE, X. L., 
SAMPSON, A. K., SHAW, J. A., MIZRAHI, J., KAYE, D. M., DART, A. 
M. & CHIN-DUSTING, J. P. 2013. Endothelial dysfunction in patients with 
type 2 diabetes post acute coronary syndrome. Diabetes and Vascular 
Disease Research, 1479164113482593. 
MAGISTRONI, R., LIGABUE, G., LUPO, V., FURCI, L., LEONELLI, M., 
MANGANELLI, L.,& ALBERTAZZI, A. 2009. Proteomic analysis of urine 
from proteinuric patients shows a proteolitic activity directed against albumin. 
Nephrology Dialysis Transplantation, 24, 1672-1681. 
MAHDAVI, R., NIKNIAZ, Z., RAFRAF, M. & JOUYBAN, A. 2010. Determination 
and comparison of total polyphenol and vitamin C contents of natural fresh 
and commercial fruit juices. Pakistan Journal of Nutrition, 9, 968-972. 
MAKRIS, D. P., KALLITHRAKA, S. & KEFALAS, P. 2006. Flavonols in grapes, 
grape products and wines: Burden, profile and influential parameters. Journal 
of Food Composition and Analysis, 19, 396-404. 
 236 
 
MALEK, A. M., ALPER, S. L. & IZUMO, S. 1999. Hemodynamic shear stress and 
its role in atherosclerosis. The Journal of the American Medical Association, 
282, 2035-2042. 
MALLERY, S. R., BUDENDORF, D. E., LARSEN, M. P., PEI, P., TONG, M., 
HOLPUCH, A. S., LARSEN, P. E., STONER, G. D., FIELDS, H. W. & 
CHAN, K. K. 2011. Effects of human oral mucosal tissue, saliva, and oral 
microflora on intraoral metabolism and bioactivation of black raspberry 
anthocyanins. Cancer Prevention Research, 4, 1209-1221. 
MANACH, C., MORAND, C., GIL-IZQUIERDO, A., BOUTELOUP-DEMANGE, 
C. & REMESY, C. 2003. Bioavailability in humans of the flavanones 
hesperidin and narirutin after the ingestion of two doses of orange juice. 
European Journal of Clinical Nutrition, 57, 235-242. 
MANACH, C., SCALBERT, A., MORAND, C., RÉMÉSY, C. & JIMÉNEZ, L. 
2004. Polyphenols: food sources and bioavailability. The American Journal 
of Clinical Nutrition, 79, 727-747. 
MANACH, C., WILLIAMSON, G., MORAND, C., SCALBERT, A. & RÉMÉSY, 
C. 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review 
of 97 bioavailability studies. The American Journal of Clinical Nutrition, 81, 
230S-242S. 
MANCIA, G., FAGARD, R., NARKIEWICZ, K., REDON, J., ZANCHETTI, A., 
BÖHM, M., CHRISTIAENS, T., CIFKOVA, R., DE BACKER, G. & 
DOMINICZAK, A. 2013. 2013 ESH/ESC Guidelines for the management of 
arterial hypertension The Task Force for the management of arterial 
hypertension of the European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC). European Heart Journal, 34, 2159-
2219. 
MARTINI, F., NATH, J & BARTHOLOMEW, M. 2012. Fundamentals of anatomy 
and physiology. 9
th
 edition. Pearson Education. San Francisco. USA. 
MATSUMOTO, H., IKOMA, Y., SUGIURA, M., YANO, M. & HASEGAWA, Y. 
2004. Identification and quantification of the conjugated metabolites derived 
from orally administered hesperidin in rat plasma. Journal of agricultural and 
food chemistry, 52, 6653-9. 
MCCULLOUGH, M. L., PETERSON, J. J., PATEL, R., JACQUES, P. F., SHAH, 
R. & DWYER, J. T. 2012. Flavonoid intake and cardiovascular disease 
mortality in a prospective cohort of US adults. The American Journal of 
Clinical Nutrition, 95, 454-464. 
MEDINA-REMÓN, A., ZAMORA-ROS, R., ROTCHÉS-RIBALTA, M., ANDRES-
LACUEVA, C., MARTÍNEZ-GONZÁLEZ, M. A., COVAS, M. I., 
CORELLA, D., SALAS-SALVADÓ, J., GÓMEZ-GRACIA, E. & RUIZ-
GUTIÉRREZ, V. 2011. Total polyphenol excretion and blood pressure in 
subjects at high cardiovascular risk. Nutrition, Metabolism and 
Cardiovascular Diseases, 21, 323-331. 
 237 
 
MELLOR, D., SATHYAPALAN, T., KILPATRICK, E., BECKETT, S. & ATKIN, 
S. 2010. High‐cocoa polyphenol‐rich chocolate improves HDL cholesterol in 
Type 2 diabetes patients. Diabetic Medicine, 27, 1318-1321. 
MENNEN, L. I., SAPINHO, D., ITO, H., BERTRAIS, S., GALAN, P., 
HERCBERG, S. & SCALBERT, A. 2006. Urinary flavonoids and phenolic 
acids as biomarkers of intake for polyphenol-rich foods. British Journal of 
Nutrition, 96, 191-198. 
MENNEN, L., SAPINHO, D., ITO, H., GALAN, P., HERCBERG, S. & 
SCALBERT, A. 2007. Urinary excretion of 13 dietary flavonoids and 
phenolic acids in free-living healthy subjects–variability and possible use as 
biomarkers of polyphenol intake. European Journal of Clinical Nutrition, 62, 
519-525. 
MEYDANI, M. & HASAN, S. T. 2010. Dietary polyphenols and obesity. Nutrients, 
2, 737-751. 
MINK, P. J., SCRAFFORD, C. G., BARRAJ, L. M., HARNACK, L., HONG, C.-P., 
NETTLETON, J. A. & JACOBS, D. R. 2007. Flavonoid intake and 
cardiovascular disease mortality: a prospective study in postmenopausal 
women. The American Journal of Clinical Nutrition, 85, 895-909. 
MITCHELL, A. J., VANCAMPFORT, D., SWEERS, K., VAN WINKEL, R., YU, 
W. & DE HERT, M. 2013. Prevalence of metabolic syndrome and metabolic 
abnormalities in schizophrenia and related disorders—a systematic review 
and meta-analysis. Schizophrenia Bulletin, 39, 306-318. 
MOERLAND, M., KALES, A. J., SCHRIER, L., VAN DONGEN, M. G. J., 
BRADNOCK, D. & BURGGRAAF, J. 2012. Evaluation of the EndoPAT as 
a Tool to Assess Endothelial Function. International Journal of Vascular 
Medicine, 2012, 1-8. 
MOJŠIŁOVÊ, G. & KUCHTA, M. 2001. Dietary flavonoids and risk of coronary 
heart disease. Physiological Research, 50, 529-535. 
MÖLLER, M., SUSCHKE, U., NOLKEMPER, S., SCHNEELE, J., DISTL, M., 
SPORER, F., REICHLING, J. & WINK, M. 2006. Antibacterial, antiviral, 
antiproliferative and apoptosis‐inducing properties of Brackenridgea 
zanguebarica (Ochnaceae). Journal of Pharmacy and Pharmacology, 58, 
1131-1138. 
MONCADA, S. & HIGGS, A. 1993. The L-arginine-nitric oxide pathway. The New 
England Journal of Medicine, 329, 2002-2012. 
MONCADA, S. & HIGGS, E. 2006. Nitric oxide and the vascular endothelium. The 
Vascular Endothelium I. Springer Berlin Heidelberg. 176, 213-254. 
MOORE, R. J., JACKSON, K. G. & MINIHANE, A. M. 2009. Green tea (Camellia 
sinensis) catechins and vascular function. British Journal of Nutrition, 102, 
1790-1802. 
MORAND, C., DUBRAY, C., MILENKOVIC, D., LIOGER, D., MARTIN, J. F., 
SCALBERT, A. & MAZUR, A. 2011. Hesperidin contributes to the vascular 
 238 
 
protective effects of orange juice: a randomized crossover study in healthy 
volunteers. The American Journal of Clinical Nutrition, 93, 73-80. 
MORTENSEN, A., KULLING, S. E., SCHWARTZ, H., ROWLAND, I., RUEFER, 
C. E., RIMBACH, G., CASSIDY, A., MAGEE, P., MILLAR, J. & HALL, 
W. L. 2009. Analytical and compositional aspects of isoflavones in food and 
their biological effects. Molecular Nutrition & Food Research, 53, S266-
S309. 
MOULY, P., GAYDOU, E. M. & AUFFRAY, A. 1998. Simultaneous separation of 
flavanone glycosides and polymethoxylated flavones in citrus juices using 
liquid chromatography. Journal of Chromatography A, 800, 171-179. 
MUDAU, M., GENIS, A., LOCHNER, A. & STRIJDOM, H. 2012. Endothelial 
dysfunction: the early predictor of atherosclerosis: review article. 
Cardiovascular journal of Africa, 23, 222-231. 
MUDAU, M., GENIS, A., LOCHNER, A. & STRIJDOM, H. 2012. Endothelial 
dysfunction: the early predictor of atherosclerosis: review article. 
Cardiovascular Journal Of Africa, 23, 222-231. 
MULLEN, W., ARCHEVEQUE, M.-A., EDWARDS, C. A., MATSUMOTO, H. & 
CROZIER, A. 2008. Bioavailability and metabolism of orange juice 
flavanones in humans: impact of a full-fat yogurt. Journal of Agricultural and 
Food Chemistry, 56, 11157-11164. 
MULLIGAN, A., WELCH, A., MCTAGGART, A., BHANIANI, A. & BINGHAM, 
S. 2006. Intakes and sources of soya foods and isoflavones in a UK 
population cohort study (EPIC-Norfolk). European Journal of Clinical 
Nutrition, 61, 248-254. 
MULVIHILL, E., & W HUFF, M. 2012. Citrus flavonoids and the prevention of 
atherosclerosis. Cardiovascular & Haematological Disorders-Drug Targets 
(Formerly Current Drug Targets-Cardiovascular & Hematological Disorders), 
12, 84-91. 
MURTHY, N., MUKHERJEE, S., RAY, G. & RAY, A. 2009. Dietary factors and 
cancer chemoprevention: an overview of obesity-related malignancies. 
Journal of Postgraduate Medicine, 55, 45. 
NAGASAKO-AKAZOME, Y., KANDA, T., OHTAKE, Y., SHIMASAKI, H. & 
KOBAYASHI, T. 2007. Apple polyphenols influence cholesterol metabolism 
in healthy subjects with relatively high body mass index. Journal of Oleo 
Science, 56, 417-428. 
NAPOLI, C., LERMAN, L. O., DE NIGRIS, F., GOSSL, M., BALESTRIERI, M. L. 
& LERMAN, A. 2006. Rethinking primary prevention of atherosclerosis-
related diseases. Circulation, 114, 2517-2527. 
NÉMETH, K., PLUMB, G. W., BERRIN, J.-G., JUGE, N., JACOB, R., NAIM, H. 
Y., WILLIAMSON, G., SWALLOW, D. M. & KROON, P. A. 2003. 
Deglycosylation by small intestinal epithelial cell β-glucosidases is a critical 
step in the absorption and metabolism of dietary flavonoid glycosides in 
humans. European Journal of Nutrition, 42, 29-42. 
 239 
 
NEWMAN, C. J., LOLEKHA, R., LIMKITTIKUL, K., LUANGXAY, K., 
CHOTPITAYASUNONDH, T., & CHANTHAVANICH, P. 2005. A 
comparison of pain scales in Thai children. Archives of Disease in Childhood, 
90, 269-270. 
NGUYEN, N. T., MAGNO, C. P., LANE, K. T., HINOJOSA, M. W. & LANE, J. S. 
2008. Association of hypertension, diabetes, dyslipidemia, and metabolic 
syndrome with obesity: findings from the National Health and Nutrition 
Examination Survey, 1999 to 2004. Journal of the American College of 
Surgeons, 207, 928-934. 
NIELSEN, I. L. F. & WILLIAMSON, G. 2007. Review of the factors affecting 
bioavailability of soy isoflavones in humans. Nutrition and Cancer, 57, 1-10. 
NIELSEN, I. L. F., CHEE, W. S., POULSEN, L., OFFORD-CAVIN, E., 
RASMUSSEN, S. E., FREDERIKSEN, H., ENSLEN, M., BARRON, D., 
HORCAJADA, M.-N. & WILLIAMSON, G. 2006. Bioavailability is 
improved by enzymatic modification of the citrus flavonoid hesperidin in 
humans: a randomized, double-blind, crossover trial. The Journal of 
Nutrition, 136, 404-408. 
NIELSEN, S. E., FREESE, R., KLEEMOLA, P. & MUTANEN, M. 2002. 
Flavonoids in human urine as biomarkers for intake of fruits and vegetables. 
Cancer Epidemiology Biomarkers & Prevention, 11, 459-466. 
NIJVELDT, R. J., VAN NOOD, E., VAN HOORN, D. E., BOELENS, P. G., VAN 
NORREN, K. & VAN LEEUWEN, P. A. 2001. Flavonoids: a review of 
probable mechanisms of action and potential applications. The American 
Journal of Clinical Nutrition, 74, 418-425. 
O’NEIL, C. E., NICKLAS, T. A., RAMPERSAUD, G. C., & FULGONI 3RD, V. L. 
(2012). 100% orange juice consumption is associated with better diet quality, 
improved nutrient adequacy, decreased risk for obesity, and improved 
biomarkers of health in adults: National Health and Nutrition Examination 
Survey, 2003–2006. Nutrition Journal, 11, 107. 
OKABE, Y., SHIMAZU, T. & TANIMOTO, H. 2011. Higher bioavailability of 
isoflavones after a single ingestion of aglycone‐rich fermented soybeans 
compared with glucoside‐rich non‐fermented soybeans in Japanese 
postmenopausal women. Journal of the Science of Food and Agriculture, 91, 
658-663. 
ØRGAARD, A., & JENSEN, L. 2008. The effects of soy isoflavones on obesity. 
Experimental Biology and Medicine, 233, 1066-1080. 
PAL, S., NAISSIDES, M. & MAMO, J. 2004. Polyphenolics and fat absorption. 
International Journal of Obesity, 28, 324-326. 
PATVARDHAN, E., HEFFERNAN, K. S., RUAN, J., HESSION, M., WARNER, 
P., KARAS, R. H. & KUVIN, J. T. 2011. Augmentation index derived from 
peripheral arterial tonometry correlates with cardiovascular risk factors. 
Cardiology Research and Practice, 2011. 
PEREIRA-CARO, G., BORGES, G., VAN DER HOOFT, J., CLIFFORD, M. N., 
DEL RIO, D., LEAN, M. E., ROBERTS, S. A., KELLERHALS, M. B. & 
 240 
 
CROZIER, A. 2014a. Orange juice (poly) phenols are highly bioavailable in 
humans. The American Journal of Clinical Nutrition, 100, 1378-1384. 
PÉREZ-JIMÉNEZ, J., FEZEU, L., TOUVIER, M., ARNAULT, N., MANACH, C., 
HERCBERG, S., GALAN, P. & SCALBERT, A. 2011. Dietary intake of 337 
polyphenols in French adults. The American Journal of Clinical Nutrition, 93, 
1220-1228. 
PEREZ-JIMENEZ, J., HUBERT, J., HOOPER, L., CASSIDY, A., MANACH, C., 
WILLIAMSON, G. & SCALBERT, A. 2010a. Urinary metabolites as 
biomarkers of polyphenol intake in humans: a systematic review. The 
American Journal of Clinical Nutrition, 92, 801-809. 
PÉREZ-JIMÉNEZ, J., NEVEU, V., VOS, F. & SCALBERT, A. 2010b. Systematic 
analysis of the content of 502 polyphenols in 452 foods and beverages: an 
application of the phenol-explorer database. Journal of Agricultural and 
Food Chemistry, 58, 4959-4969. 
PFÜTZNER, A., SCHIPPER, C., RAMLJAK, S., FLACKE, F., SIEBER, J., 
FORST, T. & MUSHOLT, P. B. 2013. Determination of hematocrit 
interference in blood samples derived from patients with different blood 
glucose concentrations. Journal of Diabetes Science and Technology, 7, 170-
178. 
PHENOLEEXPLORER. 2015. Phenol Explorer 3.5. [Online]. Available: 
http://phenol-explorer.eu/compounds 
POREDOS, P. & JEZOVNIK, M. K. 2013. Testing endothelial function and its 
clinical relevance. Journal of Atherosclerosis and Thrombosis, 20, 1-8. 
PRENTICE, A. M. 2006. The emerging epidemic of obesity in developing countries. 
International Journal of Epidemiology, 35, 93-99. 
RAFII, F., DAVIS, C., PARK, M., HEINZE, T. M. & BEGER, R. D. 2003. 
Variations in metabolism of the soy isoflavonoid daidzein by human 
intestinal microfloras from different individuals. Archives of Microbiology, 
180, 11-16. 
RESHEF, N., HAYARI, Y., GOREN, C., BOAZ, M., MADAR, Z. & KNOBLER, 
H. 2005. Antihypertensive Effect of Sweetie Fruit in Patients With Stage I 
Hypertension*. American Journal of Hypertension, 18, 1360-1363. 
RHENEY, C. C. & KIRK, J. K. 2000. Performance of three blood glucose meters. 
Annals of Pharmacotherapy, 34, 317-321. 
RICHELLE, M., PRIDMORE-MERTEN, S., BODENSTAB, S., ENSLEN, M. & 
OFFORD, E. A. 2002. Hydrolysis of isoflavone glycosides to aglycones by 
β-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in 
postmenopausal women. The Journal of nutrition, 132, 2587-2592. 
RIZZA, S., MUNIYAPPA, R., IANTORNO, M., KIM, J. A., CHEN, H., 
PULLIKOTIL, P., SENESE, N., TESAURO, M., LAURO, D., CARDILLO, 
C. & QUON, M. J. 2011. Citrus polyphenol hesperidin stimulates production 
of nitric oxide in endothelial cells while improving endothelial function and 
 241 
 
reducing inflammatory markers in patients with metabolic syndrome. The 
Journal of Clinical Endocrinology and Metabolism, 96, E782-92. 
ROOWI, S., MULLEN, W., EDWARDS, C. A. & CROZIER, A. 2009. Yoghurt 
impacts on the excretion of phenolic acids derived from colonic breakdown 
of orange juice flavanones in humans. Molecular Nutrition & Food Research, 
53, S68-S75. 
ROTHWELL, J. A., PEREZ-JIMENEZ, J., NEVEU, V., MEDINA-REMON, A., 
M'HIRI, N., GARCÍA-LOBATO, P., MANACH, C., KNOX, C., EISNER, R. 
& WISHART, D. S. 2013. Phenol-Explorer 3.0: a major update of the 
Phenol-Explorer database to incorporate data on the effects of food 
processing on polyphenol content. Database, 2013, bat070. 
ROTHWELL, J. A., URPI-SARDA, M., BOTO-ORDONEZ, M., KNOX, C., 
LLORACH, R., EISNER, R., CRUZ, J., NEVEU, V., WISHART, D. & 
MANACH, C. 2012. Phenol-Explorer 2.0: a major update of the Phenol-
Explorer database integrating data on polyphenol metabolism and 
pharmacokinetics in humans and experimental animals. Database, 2012, 
bas031. 
RÜFER, C. E., BUB, A., MÖSENEDER, J., WINTERHALTER, P., STÜRTZ, M. & 
KULLING, S. E. 2008. Pharmacokinetics of the soybean isoflavone daidzein 
in its aglycone and glucoside form: a randomized, double-blind, crossover 
study. The American Journal of Clinical Nutrition, 87, 1314-1323. 
RUSH, J. W., DENNISS, S. G. & GRAHAM, D. A. 2005. Vascular nitric oxide and 
oxidative stress: determinants of endothelial adaptations to cardiovascular 
disease and to physical activity. Canadian Journal of Applied Physiology, 30, 
442-474. 
S. KARON, B., GRIESMANN, L., SCOTT, R., BRYANT, S. C., DUBOIS, J. A., 
SHIREY, T. L., PRESTI, S. & SANTRACH, P. J. 2008. Evaluation of the 
impact of hematocrit and other interference on the accuracy of hospital-based 
glucose meters. Diabetes Technology & Therapeutics, 10, 111-120. 
SAHA, S., HOLLANDS, W., NEEDS, P., OSTERTAG, L., DE ROOS, B., 
DUTHIE, G ., KROON, P. 2012. Human O-sulfated metabolites of (−)-
epicatechin and methyl-(−)-epicatechin are poor substrates for commercial 
aryl-sulfatases: Implications for studies concerned with quantifying 
epicatechin bioavailability. Pharmacological Research, 65, 592-602. 
SAPONARA, S., TESTAI, L., IOZZI, D., MARTINOTTI, E., MARTELLI, A., 
CHERICONI, S  & CALDERONE, V. 2006. (+/−)‐Naringenin as large conductance 
Ca2+‐activated K+ (BKCa) channel opener in vascular smooth muscle cells. British 
Journal of Pharmacology, 149, 1013-1021. 
SAVICA, V., BELLINGHIERI, G. & KOPPLE, J. D. 2010. The effect of nutrition 
on blood pressure. Annual Review of Nutrition, 30, 365-401. 
SBARRA, V., RISTORCELLI, E., PETIT-THÉVENIN, J. L., TEISSEDRE, P.-L., 
LOMBARDO, D. & VÉRINE, A. 2005. In vitro polyphenol effects on 
activity, expression and secretion of pancreatic bile salt-dependent lipase. 
 242 
 
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 
1736, 67-76. 
SCALBERT, A. & WILLIAMSON, G. 2000. Dietary Intake and Bioavailability of 
Polyphenols. The Journal of Nutrition, 130, 2073S-2085S. 
SELMA, M. V., ESPIN, J. C. & TOMAS-BARBERAN, F. A. 2009. Interaction 
between phenolics and gut microbiota: role in human health. Journal of 
Agricultural and Food Chemistry, 57, 6485-6501. 
SETCHELL, K. D., BROWN, N. M. & LYDEKING-OLSEN, E. 2002. The clinical 
importance of the metabolite equol—a clue to the effectiveness of soy and its 
isoflavones. The Journal of Nutrition, 132, 3577-3584. 
SETCHELL, K. D., BROWN, N. M., DESAI, P. B., ZIMMER-NECHIMIAS, L., 
WOLFE, B., JAKATE, A. S., CREUTZINGER, V. & HEUBI, J. E. 2003a. 
Bioavailability, disposition, and dose-response effects of soy isoflavones 
when consumed by healthy women at physiologically typical dietary intakes. 
The Journal of Nutrition, 133, 1027-1035. 
SETCHELL, K. D., BROWN, N. M., DESAI, P., ZIMMER-NECHEMIAS, L., 
WOLFE, B. E., BRASHEAR, W. T., KIRSCHNER, A. S., CASSIDY, A. & 
HEUBI, J. E. 2001. Bioavailability of pure isoflavones in healthy humans and 
analysis of commercial soy isoflavone supplements. The Journal of Nutrition, 
131, 1362S-1375S. 
SETCHELL, K. D., FAUGHNAN, M. S., AVADES, T., ZIMMER-NECHEMIAS, 
L., BROWN, N. M., WOLFE, B. E., BRASHEAR, W. T., DESAI, P., 
OLDFIELD, M. F. & BOTTING, N. P. 2003b. Comparing the 
pharmacokinetics of daidzein and genistein with the use of 13C-labeled 
tracers in premenopausal women. The American Journal of Clinical 
Nutrition, 77, 411-419. 
SHENOUDA, S. M. & VITA, J. A. 2007. Effects of flavonoid-containing beverages 
and EGCG on endothelial function. Journal of the American College of 
Nutrition, 26, 366S-372S. 
SHEPHERD, A. 2010. Current management strategies in the treatment of obesity. 
Nursing Standard, 25, 49-56. 
SHIN, J. H., SHIN, J., KIM, B., LIM, Y.-H., PARK, H., CHOI, S. I., KIM, S. & 
KIM, J. 2012. Within-visit blood pressure variability: relevant factors in the 
general population. Journal of Human Hypertension, 27, 328-334. 
SHISHIKURA, Y., KHOKHAR, S. & MURRAY, B. S. 2006. Effects of tea 
polyphenols on emulsification of olive oil in a small intestine model system. 
Journal of Agricultural and Food Chemistry, 54, 1906-1913. 
SHRIVASTAVA, A. & GUPTA, V. B. 2011. Methods for the determination of limit 
of detection and limit of quantitation of the analytical methods. Chronicles of 
Young Scientists, 2, 21. 
SILVEIRA, J. Q., CESAR, T. B., MANTHEY, J. A., BALDWIN, E. A., BAI, J. & 
RAITHORE, S. 2014. Pharmacokinetics of Flavanone Glycosides after 
Ingestion of Single Doses of Fresh-Squeezed Orange Juice versus 
 243 
 
Commercially Processed Orange Juice in Healthy Humans. Journal of 
agricultural and food chemistry. 62, 12576–12584. 
SIMONS, A. L., RENOUF, M., MURPHY, P. A. & HENDRICH, S. 2009. Greater 
apparent absorption of flavonoids is associated with lesser human fecal 
flavonoid disappearance rates. Journal of Agricultural and Food Chemistry, 
58, 141-147. 
SOHRAB, G., HOSSEINPOUR-NIAZI, S., HEJAZI, J., YUZBASHIAN, E., 
MIRMIRAN, P. & AZIZI, F. 2013. Dietary polyphenols and metabolic 
syndrome among Iranian adults. International Journal of food Sciences and 
Nutrition, 64, 661-667. 
SPENCER, J. P., ABD EL MOHSEN, M. M., MINIHANE, A.-M. & MATHERS, J. 
C. 2008. Biomarkers of the intake of dietary polyphenols: strengths, 
limitations and application in nutrition research. British Journal of Nutrition, 
99, 12-22. 
SPIEKER, L., FLAMMER, A. & LÜSCHER, T. 2006. The vascular endothelium in 
hypertension. The Vascular Endothelium II. Springer. 
SPRAGUE, A. H. & KHALIL, R. A. 2009. Inflammatory cytokines in vascular 
dysfunction and vascular disease. Biochemical pharmacology, 78, 539-552. 
STANFORTH, P. R., GAGNON, J., RICE, T., BOUCHARD, C., LEON, A. S., 
RAO, D., SKINNER, J. S. & WILMORE, J. H. 2000. Reproducibility of 
resting blood pressure and heart rate measurements: the HERITAGE Family 
Study. Annals of Epidemiology, 10, 271-277. 
STERGIOU, G. S., SKEVA, I. I., ZOURBAKI, A. S. & MOUNTOKALAKIS, T. D. 
1998. Self-monitoring of blood pressure at home: how many measurements 
are needed? Journal of hypertension, 16, 725-731. 
STUEHR, D. J. & GRIFFITH, O. W. 2006. Mammalian nitric oxide synthases. 
Advances in Enzymology and Related Areas of Molecular Biology, Volume 
65, 287-346. 
TADDEI, S., VIRDIS, A., GHIADONI, L., SALVETTI, G., BERNINI, G., 
MAGAGNA, A., & SALVETTI, A. 2001. Age-related reduction of NO 
availability and oxidative stress in humans. Hypertension, 38, 274-279. 
TAILOR, A. M., PEETERS, P. H., NORAT, T., VINEIS, P. & ROMAGUERA, D. 
2010. An update on the prevalence of the metabolic syndrome in children and 
adolescents. International Journal of Pediatric Obesity, 5, 202-213. 
TAMURA, M., NAKAGAWA, H., TSUSHIDA, T., HIRAYAMA, K. & ITOH, K. 
2007. Effect of Pectin Enhancement on Plasma Quercetin and Fecal Flora in 
Rutin‐Supplemented Mice. Journal of Food Science, 72, S648-S651. 
TERAO, J., KAWAI, Y. & MUROTA, K. 2008. Vegetable flavonoids and 
cardiovascular disease. Asia Pacific Journal of Clinical Nutrition, 17, 291-
293. 
THILAKARATHNA, S. H. & RUPASINGHE, H. 2013. Flavonoid Bioavailability 
and Attempts for Bioavailability Enhancement. Nutrients, 5, 3367-3387. 
 244 
 
THOMAS, M. V., BRANSCUM, A., MILLER, C. S., EBERSOLE, J., AL-
SABBAGH, M. & SCHUSTER, J. L. 2009. Within-subject variability in 
repeated measures of salivary analytes in healthy adults. Journal of 
Periodontology, 80, 1146-1153. 
TIERNEY, E. S. S., NEWBURGER, J. W., GAUVREAU, K., GEVA, J., COOGAN, 
E., COLAN, S. D., & DE FERRANTI, S. D. 2009. Endothelial pulse amplitude 
testing: feasibility and reproducibility in adolescents. The Journal of 
Pediatrics, 154, 901-905. 
TOMÁS‐BARBERÁN, F. A. & CLIFFORD, M. N. 2000. Flavanones, chalcones and 
dihydrochalcones–nature, occurrence and dietary burden. Journal of the 
Science of Food and Agriculture, 80, 1073-1080. 
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Appendices  
Appendix 1: Ethics approval study I 
Research Support  
University of Leeds 
Leeds   LS2 9JT  Tel:  0113 343 4873 
e-mail:  j.m.blaikie@adm.leeds.ac.uk 
 
 
MEEC Faculty Research Ethics Committee 
University of Leeds 
Abdurrahman Sweidan 
PhD Research Student 
School of Food Science and Nutrition 
Leeds LS2 9JT 
Dear Abdurrahman 
Title of study: Effect of acute and chronic co-ingestion of flavonoids on 
absorption 
Ethics Reference Number: MEEC 10-001 
The above project was reviewed by the MEEC Faculty Research Ethics Committee 
at its virtual meeting of 16
th
 August 2010. 
The following documentation was considered: 
Document    Version Date 
MEEC 10-001 ethical review form.docx 1 02/08/10 
MEEC 10-001 study flyer FINAL.docx 1 02/08/10 
MEEC 10-001 saliva protocol 6.docx 1 02/08/10 
MEEC 10-001 Participant information sheet FINAL.docx 1 02/08/10 
MEEC 10-001 consent form.docx 1 02/08/10 
MEEC 10-001 Food record  QUES.docx 1 02/08/10 
MEEC 10-001 Appendix 5.doc 1 02/08/10 
MEEC 10-001 Intervention study final chart.docx 1 02/08/10 
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On the basis of the information provided, the Committee is happy to approve the 
project, but would like to offer the following comments and advice: 
1. You said that participants would be recruited by e-mail using “appropriate 
university distribution lists” – could you specify which distribution lists you 
mean?  
2. You should have a protocol for dealing with any adverse events that might 
arise during the research.  
3. Could you clarify whether only hard copies of personal data will be obtained 
and no personal data will be stored electronically, or if it is to be stored 
electronically will you take measures to ensure the data is encrypted?  
4. On the flyer you mention that participants will collect “all of your urine”, do 
you mean “samples of your urine”? The £10 gift voucher could be mentioned 
on the flyer.  
5. On the consent form you do not really need to make reference to not 
answering particular questions as the participants are not going to be 
interviewed, but given that they need them to fill in the questions about their 
health/lifestyle etc accurately this could be confusing.  
6. The saliva samples need to be labelled with their participant code rather than 
their own name. Alternatively you could pre-label the samples with the 
participant codes and then distribute them to the relevant participants.  
Yours sincerely 
Jennifer Blaikie 
Research Ethics Administrator/ Research Support  
On Behalf of  
Professor Richard Hall 
Chair, MEEC FREC. 
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Appendix 2: Participant information sheet study I 
Dear participants, 
          There are many links between diet and health, a high intake of vegetables and 
fruits are associated with reduced risk of many cancers and coronary heart disease. In 
addition, a high intake of flavonoids or flavonoid rich foods has been inversely 
correlated with heart disease and cancer. Flavonoids (naturally-occurring 
antioxidants) are widespread in the human diet and samples such as urine and blood 
will allow us to measure the intake of fruit and vegetables. However, to the best of 
our knowledge, secretion of flavonoids into saliva after ingestion from food has 
rarely been investigated. Saliva will therefore be collected concurrent with urine 
samples when orange juice and soya nuts are co-ingested by volunteers. 
       I am writing to ask you to take part in this University of Leeds research project 
to assess the normal concentration of urinary flavonoids excreted after consumption 
of orange juice and soya nuts, ingested separately or together. 
      The decision to take part and participate in this study is yours and you can 
withdraw at any time without having to give a reason and without penalty. Please 
take your time to read and understand the study protocol before making your 
decision. Moreover, to help you make your decision, a short explanation of the study 
is given and you have one week to decide whether to participate or not. 
What is the purpose of this study? 
        The purpose of this study is to investigate the effect of co-ingestion of 
flavonoids on their absorption, as most studies only look at a single food source 
when measuring bioavailability. Some studies have shown differences in absorption 
in model systems when flavonoids are given in combination and we would like to see 
if there is any change in absorption in people. The concentration of flavonoids in 
urine and saliva among subjects after eating soya and orange juice will be monitored. 
Who is doing the study? 
        The study is being carried out by Mr Abdurrahman Sweidan, a research student 
at the School of Food Science and Nutrition, University of Leeds, towards the award 
of a PhD. 
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What will be involved if I take part in this study?  
       The study consists of 3 separate days; each will have a minimum of 24 hrs 
between them. Volunteers who have responded to the posted flyers/circular email 
will be invited to read the study information sheet, and the study protocol in full will 
be explained to each subject prior to the start of the study. Having given their verbal 
and written informed consent, participants will be asked to fill in: 
 basic health questionnaire recording age, gender, height, weight, medical and 
surgical history, medications taken, life style (e.g. smoking and drinking 
habits and physical activity) to ensure the suitability of the volunteers for 
study.  
 A urine and saliva samples collection record, a sample provision form will be 
asked to be completed after provision of each urine and saliva samples.  
What are the advantages and disadvantages of taking part? 
 There are no direct benefits for taking part. But you will receive a £10 voucher as a 
thank you for taking part. The information obtained from this study and future 
studies will allow a better understanding of the role of flavonoids in the prevention of 
nutrition-related diseases, and in the inter and intra individual variation in the 
absorption and metabolism of these compounds. 
Can I withdraw from the study at anytime? 
       Participants are free to withdraw at anytime they like. It is voluntary 
participation and you can stop at any stage of the study without giving any reasons. 
Will the information I give be kept confidential? 
       Yes, all the information obtained will be kept confidential and handled in 
accordance with the data protection Act 1998. Participant’s names will be number 
coded. In addition, all data will be kept in secure locked cabinet at the School of 
Food Science and Nutrition, University of Leeds. 
What will happen to the results of study? 
        The result achieved will help to plan a large-scale dietary study on fruit and 
vegetables and health. 
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Who has reviewed this study? 
      This study has been reviewed by the University of Leeds Research Ethics 
Committee and ethical approval granted. 
If you agree to take part, and would like more information and explanation please do 
not hesitate to contact: 
Mr. Abdurrahman Sweidan 
PhD Research student 
School of Food Science and Nutrition 
University of Leeds, Woodhouse Lane, Leeds, LS2 9JT 
E-mail: fsasw@leeds.ac.uk               Tel: 07882019642 
You can contact the academic project supervisor Dr. Andrea Day or Prof Gary 
Williamson: 
Tel: 01133432965 
E-mail:   a.j.day@leeds.ac.uk , G.Williamson@leeds.ac.uk  
 
       If you have no more questions and you feel confident and agree to take part in 
this study, could you please complete the participant consent form and hand it to the 
researcher. 
 
Thank you so much for your time to read this information and for your 
cooperation and help. 
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Appendix 3: Consent form 
 
Name of researcher:    Mr. Abdurrahman Sweidan              fsasw@leeds.ac.u  
AcademicSupervisors: Dr. Andrea Day                                  a.j.Day@leeds.ac.uk 
                                       Prof. Gary Williamson              g.williamson@leeds.ac.uk 
  Yes/No 
1 Have you read participant information sheet?  
2 Have you understood the information sheet which describes the above 
research? 
 
3 Have you had the opportunity to consider the information and ask 
questions about the study? 
 
4 Do you understand that participation is voluntary and you are free to 
withdraw from the study at anytime without giving any reasons? 
 
5 I understand that my responses will be kept strictly confidential. I give 
permission for members of the research team to have access to my 
anonymised responses. I understand that my name will not be linked 
with the research materials, and I will not be identified or identifiable 
in the report or reports that result from the research. 
 
6 Do you agree for the data collected from you to be used in future 
studies? 
 
7 Do you agree to take part in the above study?  
 
________________________           __________________  
_____________________ 
        Name of participant                                      Date                              Signature 
__________________________           __________________  
_____________________ 
            Lead Researcher                                       Date                            Signature 
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Appendix 4: Health Questionnaire 
 
Please complete this form and answer all the questions. 
Section 1: Background 
Date   ID   
Name   Marital status   
Gender    Educational level  
Age   Occupation  
 
Section 2: anthropometry measurements  
Parameter Measurement 
Height (cm)  
Weight (kg)  
 
Did you consume any dietary or health supplements?   Yes  No 
If yes, which type ...................................................................................................... 
Did you have any antibiotic in the last two months?   Yes     No 
Do you consider yourself as healthy person?             Yes     No 
Are you allergic to orange juice or soya products?          Yes     No 
Are you currently taking any medication?                     Yes     No 
 
Thank you for your time, 
Abdurrahman Sweidan 
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Appendix 5: Food record (3 days) 
Complete the table below for the food and drink that you eaten last 2 days and 
during the day of the study.  
Date  Day 1 2 3  
Subject 
code 
 
 
time Meal type  Where? 
What kind of 
food eaten 
Amount 
eaten 
Brand 
name  
6 am to 8am 
 
 
 
 
 
 
 
 
 
   
 
8am to 12 noon 
 
 
 
 
 
 
 
 
 
 
   
 
12 noon to 3 pm 
 
 
 
 
 
 
 
 
 
 
   
 
3 pm to 5 pm 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
5 pm to 8 pm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
8pm to 12 am 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
12 am to 6 am 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
- Meal type: snack, breakfast...etc. 
- Where? Home, bar, restaurant...etc. 
- What kind of food eaten? Bread, orange juice, tea ...etc.  
- Amount eaten: description of portion size of item eaten, example (small 
slice, white bread, tea spoon, glass of water, bowl of soup...etc. 
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Appendix 6: Protocol for a cellular urine 
 
Protocol for cellular urine 
Urine preparation:   
Urine samples of healthy volunteers will be transported to the lab within 12 hours of 
the collection where they will be processed within 24 hr before being frozen at -
20°C.  
 Upon arrival, the volume of sample will be measured and 2X 50-ml aliquots are 
taken.  
 Urine aliquots are then centrifuged at 2000 g, 4°C for 10 min to remove insoluble 
materials and cellular debris.  
 Being careful not to disturb the sediment and cell pellet, the supernatant is removed 
to within approximately 1-2 ml of the cell pellet. 
 The supernatant is then filtered through a syringe filter (0.45 µm pore size).  
 The samples will then be stored at -20°C until analyzed. 
Waste disposal: 
 The sediment will be decontaminated before disposal by adding Vikron (a 
disinfectant) (1% solution, 2X 5-g tablet /1 L) to the sediment and leaving over 
night.  
 The sediment can then be discarded in the clinical waste. 
General Safe operation: 
 The urine samples are only processed on a designated bench area highlighted by 
biohazard labels.  
 The centrifuge is disinfected before and after centrifugation by spraying 70% EtOH 
inside the chamber and wiping. 
Reference: 
Magistroni R. et al.; 2009; “ Proteomic analysis of urine from proteinuric patients 
shows a proteolitic activity directed against albumin”; Nephrol Dial Transplant; 24; 
pp. 1672-1681. 
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Appendix 7:  Protocol for saliva collection using salivette collection container 
Please follow the instruction and steps below before you collect your saliva 
sample: 
 
 Do not drink or eat for 30 minutes prior to collection of saliva sample. 
 Do not brush or floss your teeth before the collection. Also, remove lipstick, 
lip balms and any creams prior to collection. 
 Do not collect the sample if your mouth is bleeding. 
 Saliva sample should be collected at the time specified by the researcher. 
Please collect saliva samples as follows: 
1- Remove the top cap of the tube to expose the round sponge, taking care not to 
remove the holder that the sponge is sitting in. 
 
2- Place the cotton tube into your mouth by tipping the tube so the sponge falls 
into your mouth. Do not touch the sponge with your fingers. 
 
3- Keep the sponge in your mouth and place the cotton tube under your tongue. 
Very gently roll the cotton in the mouth and chew it for 10 minutes to start a 
flow of saliva until it is saturated. 
 
4- Spit the saturated cotton tube back into the plastic salivette container. Do not 
touch the sponge with your fingers.  
5- Close the cap firmly and make sure cap is on tightly. 
6-  Label the salivette collection container; write your name, date and time of 
collection. 
7- Store the sample in the cool place and then take it to the laboratory next day. 
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Appendix 8: Ethical approval (Impact of oranges on cardiovascular health) 
Performance, Governance and Operations 
Research & Innovation Service 
Charles Thackrah Building 
101 Clarendon Road 
Leeds LS2 9LJ  Tel: 0113 343 4873 
Email: ResearchEthics@leeds.ac.uk 
 
 
Abdurrahman Sweidan 
Food Science and Nutrition 
University of Leeds 
Leeds, LS2 9JT 
MEEC Faculty Research Ethics Committee/ University of Leeds 
Dear Abdurrahman 
Title of study Impact of oranges on cardiovascular health 
Ethics reference MEEC 12-025 
The above project was reviewed by the MEEC Faculty Research Ethics Committee 
at its meeting of 14
th
 March 2013. The following documentation was considered: 
Document    Version Date 
MEEC 12-025 Orange juice and CVD - ethical 
review form.docx 
1 28/02/13 
MEEC 12-025 Orange juice and CVD - Study 
Appendices.docx 
1 28/02/13 
MEEC 12-025 signed page ethics.JPG 1 28/02/13 
On the basis of the information provided, the Committee requested further 
information/ clarification on the following matters: 
1. A4: This project is for a research qualification.  
2. A8: The short summary of the research does use quite complicated concepts, 
technical terms and acronyms that may not be understandable. Later on there 
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is a succinct and plain description of the research aims.  The summary should 
be similarly written. 
3. A9: main ethical issues – reviewers felt this was too lengthy and some points 
not relevant to the question. Please review this. The information for 
participants is very good; perhaps some of the text could be used in the form 
to ensure simplified language. 
4. C8: Why is the project restricted to recruiting from the University population, 
which is not very inclusive? 
5. C24: Having read the Participant Information Sheet, this project appears to be 
externally funded and if so details of this should be included on the 
application form. 
6. Have you considered telling the participants how they as a group responded 
to the tests?  
A response, in summary form, should be sent to the Committee which addresses each 
of these points. Consideration will be given to your response and we will write to 
you with a further opinion.  
Please note that the Committee is not able to approve your application at this stage so 
you are unable to begin the parts of your research requiring ethical approval.  
Yours sincerely 
Jennifer Blaikie 
Senior Research Ethics Administrator, Research & Innovation Service 
On behalf of Professor Gary Williamson, Chair, MEEC FREC 
CC: Student’s supervisor(s) 
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Appendix 9: Participant information sheet study II 
 
Dear Participants, 
       I am writing to ask you to take part in this University of Leeds research project 
to assess the effects of compounds (flavonoids) found in oranges on cardiovascular 
health. There is limited information on the effects of orange flavonoids, but so far the 
information published is very positive, indicating that these compounds are able to 
improve cardiovascular health in some individuals. With your help we would like to 
investigate this further. 
      The decision to take part and participate in this study is yours and you can 
withdraw at any time without having to give a reason and without penalty. Please 
take your time to read and understand the study protocol before making your 
decision and feel free to ask any questions to the study researchers. 
What is the purpose of this study? 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the 
Western world. Measuring the health of blood vessels is now considered a predictor 
of future CVD risk; moreover blood vessel health can be improved and this will 
reduce the risk of CVD in the future. Flavonoids are found in all plant-based foods 
and beverages, and are associated with a reduced risk in CVD. There is accumulating 
evidence that flavonoids from oranges and orange juice can improve blood vessel 
health, but further studies are required to establish this relationship, especially given 
the fact that different people will absorb more or less of these flavonoids into their 
blood stream. 
We will measure every volunteer’s ability to absorb the flavonoids from an orange 
juice supplement by analyzing a 24 hour urine sample. We will also determine 
whether blood vessel health changes during two 4-week periods when different 
supplements are given to the volunteers. 
Who is doing the study? 
The study is being carried out by Mr. Abdurrahman Sweidan, a research student at 
the School of Food Science and Nutrition, University of Leeds; towards the award of 
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a PhD. Dr Andrea Day and Prof Gary Williamson are the PhD supervisors for this 
study. 
What will be involved if I take part in this study?  
Volunteers who have responded to the posted flyers/circular email will be invited to 
read the study information sheet, and the study protocol in full will be explained to 
each subject prior to the start of the study. Having given their verbal and written 
informed consent, participants will be asked to: 
 Fill in basic health questionnaire recording age, gender, height, weight, 
medical and surgical history, medications taken, life style (e.g. smoking) to 
ensure the suitability of the volunteers for study.  
 have a slightly restricted diet for 48 hours prior to each study session (see 
table below) 
 Undergo a complete fast (water allowed) from 9 pm on the day before each 
study day. 
 Take an orange juice supplement with water and collect urine for 24 hr on 
each of the study days.  
 Take the provided supplements daily for two sets of 4 weeks. 
 Attend 4 sessions on 4 separate study days, every 4 weeks for 12 weeks. 
On each study day we will: 
 Measure your weight, height and waist circumference. 
 Measure your blood pressure 
 Measure your fasting blood glucose level by taking a finger-prick blood 
sample using a single-use lancet (Accu-Chek Aviva), 
 Measure the blood flow in your fingertips before and after reducing blood 
flow in your forearm using a blood pressure cuff (called an Endo-PAT – see 
later for more details)  
 Each study day will take approximately 1.5 hours 
 4 study days in total, 1 every 4 weeks 
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 Total duration of study is 12 weeks 
Restricted diet: 
For 48 hours prior to each experimental session: 
 All citrus foods and drinks need to be avoided. 
ITEMS NOT ALLOWED 
Food items to avoid 
Citrus fruit in any form (fresh, canned or dried):  
e.g. oranges, tangerine, clementine, satsuma, grapefruit, lemon, lime 
Fruit juices, fruit squashes (cordials) and jam or marmalade containing citrus fruit 
 
Please eat your normal evening meal the day prior to each experimental session 
before 9 pm. Do not consume any food or drink, except water, after 9 pm. 
Do not consume any food or drink, except water, on the morning of the experimental 
session.  
Experimental session days: 
We would like to measure the effects of orange juice compounds on the 
cardiovascular system, by using an Endo-PAT measurement which is non-invasive, 
completely safe and risk free. Firstly, however, we need to know how well the 
orange juice compounds are absorbed in you, as there is a large variation between 
individuals. Therefore, all participant need to have a restricted citrus diet for 48 hours 
prior to all experimental sessions, and also fast overnight starting the evening before 
all four experimental days from 9:00 pm. 
When you arrive at the study room in the School of Food Science and Nutrition, we 
will:  
(1) ask you to complete a short questionnaire on your normal citrus intake over 
the past month(s)  
(2) take a finger prick blood sample, in which we can measure your blood 
glucose level 
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(3) ask you to provide us with a urine sample 
(4) measure your height, weight and waist circumference 
(5) take your blood pressure, using a standard inflatable cuff on your upper arm 
(6) measure your finger-tip blood flow using a non-invasive technique called 
Endo-PAT 
 You will be asked to lie down on a bed and relax for about 30-40 
minutes total 
 We will place a thimble-like probe on the end of each index finger as 
shown in diagram A below. 
  
Diagram: Endo-PAT fingertip and inflatable cuff. Reproduced 
from Hamburg, N., & Benjamin, E. (2009) 
 We will take a repeat blood pressure measurement after 5 and 10 
minutes 
 After 15 minutes we will inflate the finger tip probe with air (diagram 
B) and start to measure the blood flowing through your finger tip 
 When you have a stable blood flow (about 20-25 minutes) we will 
inflatable a blood pressure cuff (diagram C) around your forearm to 
interrupt blood flow to your lower arm and fingers. This procedure is 
completely safe and without any risk or danger, but you may 
experience a discomforting, throbbing sensation in your arms and 
fingers as the cuff is slightly tighter than for a blood pressure 
measurement. The cuff will be released after exactly 5 minutes, and 
blood flow resumes. Any discomfort you felt will immediately cease. 
A 
B 
C 
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 You will need to remain in a relaxed state for a further 5-10 minutes 
while the measurement reading is completed. 
(7) We will then ask you to take an orange juice supplement with water, and 
provide you with a light breakfast of toast and/or cereal. 
(8) We will provide you with a urine collection bottle in which you need to 
collect all your urine for the following 24 hours. You will need to return this 
to the University or arrange for it to be collected. 
(9) We will provide you with supplements to take home to consume with water 
on a daily basis for the following 4 weeks. We would like you to bring back 
the supplement bottle at the end of the 4 week period and to note down any 
days you forgot to take the supplement on. 
 
You are then free to leave. The experimental procedure should take about 1 hr 
(1.5 hr maximum), plus time for breakfast. 
What are the advantages and disadvantages of taking part? 
There are no direct benefits for taking part, however information obtained 
from the study will allow a better understanding of the role of flavonoids from citrus 
fruits in the prevention of cardiovascular diseases. You will receive £30 as a thank 
you for completing the study. 
There may be a slight discomfort in the overnight fast from 9 pm prior to 
each study day (water is allowed), but you will be given breakfast as soon as all 
measurements have been taken at approx 10 am. The supplements are commercially 
available, and should not cause any discomfort. We recommend you consume them 
with your regular breakfast. 
The experimental procedure involves using a blood pressure cuff on the 
forearm to restrict blood flow for 5 minutes. This may cause some slight discomfort 
and a tingling sensation in the fingers. The procedure is not associated with any risk, 
and feelings of discomfort cease immediately with the release of the pressure cuff 
after 5 minutes. There is the possibility of slight bruising of the forearm, but this is 
unlikely in most people.  
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Can I withdraw from the study at anytime? 
Participants are free to withdraw at anytime they like. It is voluntary participation 
and you can stop at any stage of the study without giving any reasons.  
Will the information I give be kept confidential? 
Yes, all the information obtained will be kept confidential and handled in 
accordance with the data protection Act 1998. Participants will be number coded and 
all data obtained will not be identifiable to you. In addition, all data will be kept in 
secure locked cabinet at the School of Food Science and Nutrition, and will be 
destroyed after 5 years, in accordance with University of Leeds regulations. 
What will happen to the results of study? 
The results achieved may be published in academic journals or presented at 
research conferences or meetings. The results will also be used for Abdurrahman 
Sweidan’s PhD thesis. Participant will not be identified in any publication/thesis.       
Who has reviewed this study? 
This study has been reviewed by the University of Leeds Research Ethics Committee 
and ethical approval granted.  
Who is funding this study? 
Mr Abdurrahman Sweidan is an international PhD student funded by Ministry of 
Higher Education in Libya. 
Contact for further information: 
If you agree to take part, and would like more information and explanation please do 
not hesitate to contact: 
Mr. Abdurrahman Sweidan 
PhD Research student 
School of Food Science and Nutrition 
University of Leeds, Leeds, LS2 9JT 
E-mail: cvd2013@leeds.ac.uk         Tel: 0784 849 8746 
Alternatively you can contact the academic project supervisors: 
Dr. Andrea Day  
E-mail:   a.j.day@leeds.ac.uk , 
If you have no more questions and agree to take part in this study, could you please 
complete the participant consent form and hand it to the researcher. 
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Appendix 10:  24-hour urine instruction form 
 
Subject code:                                                                          Date                
 
- collect all urine into the labeled bottles provided 
- write down the day, time and date you finish the collection. 
Day ( ...................), date (....../......../................), time (......: ........). 
- keep the urine sample bottles in dark and cool place if possible, until you 
bring them back to the University. 
- if you lose any specimens or have any problems during the whole period of 
the study please report that in the following table: 
 
Day/Time:  
Sample Collection Irregularity (eg. loss of all 
sample/ some sample): 
 
Comments: 
 
 
Day/Time:  
Sample Collection Irregularity (eg. loss of all 
sample/ some sample): 
 
Comments: 
 
 
 
 
 
        /           / 
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Appendix 11: Supplement instruction form 
 
Subject code:                                                                          Date                
- Take 2 tablets of the supplements provided every morning with breakfast, or 
before 11am. 
- If you forget to take the tablets, then please take them as soon as you 
remember but not past 6 pm. 
- If you do not take a tablet on a day, please make a note of this on the form 
below. 
- Please return this form and any remaining supplements to the study 
investigators when you return after 4 weeks. 
- Please make a note of the last day for taking the supplement: 
Day ( ...................), date (....../....../.........), time (.........:.). 
Supplement Irregularities: 
Date on which supplements taken later than 11 am Time taken (if after 11 
am) 
  
  
Date on which supplements were completely missed: 
 
 
Number of supplements remaining  
 
/          / 
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Appendix 12: Food frequency questionnaire for citrus fruits and juices 
Fresh fruit: portion size = 1 whole 
 Daily Weekly Monthly  
 1 2 3 1 2-3 4-5 <1 1 2 3 Never 
Orange            
Grapefruit            
Lemon            
Lime            
Tangerine            
Clementine            
Satsuma            
Other citrus fruit; 
please specify: 
 
           
Fruit Juice: portion size = 100 ml (small) glass 
Orange  juice (fresh or  from 
concentrate) 
           
Grapefruit juice (fresh or from 
concentrate) 
           
Other (please specify): 
 
           
Dried citrus fruit: portion size = handful 
Type (please specify): 
 
           
Canned fruit: portion size = 1/3 regular sized can, or 1 small can 
Type (please specify): 
 
           
Marmalade: portion size = cafe packet (i.e. amount thinly spread on 1 piece of toast) 
Orange marmalade            
Grapefruit marmalade            
Other marmalade 
(please specify): 
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Appendix 13: Pain assessment questionnaire  
 
Participan code:                                                                                                                   
Date:       /         / 
 
 Please tell us how do you feel? You may feel happy because you have no 
pain (hurt), or you may feel sad because you have some or a lot of pain. 
 
Wong-Baker Faces Pain Rating Scale 
 
 Face 0 is very happy because he or she doesn't hurt at all. 
 Face 1 hurts just a little bit. 
 Face 2 hurts a little more. 
 Face 3 hurts even more. 
 Face 4 hurts a whole lot. 
 Face 5 hurts as much as you can imagine, although you don't have to be 
crying to feel this bad. 
 You should point to each face using the words to describe the pain intensity. 
You should then choose the face that best describes how you feel. 
 
Thank you for your participation, 
 
Abdurrahman Sweidan 
Main study investigator 
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Appendix 14: Protocol for adverse events during intervention 
 Orange juice and soya nuts are normal foods; anyone with a suspected allergy 
to these foods will not be allowed to participate in study. 
 Water will be offered during food consumption and participants will be 
advised to drink water during the study day (bottled water will be provided). 
 Participants will be supervised during intervention and advised to eat and 
drink slowly. 
 Participants will be asked to collect their urine in labelled containers. If a 
spillage occurs they must inform researcher investigator immediately who 
will take measures to clean and decontaminate the relevant area. 
 People who are allergic to orange juice and soya will not be allowed to 
participate in this study. However, if allergic symptoms appear, food which 
causing the symptoms will be eliminated and then a doctor and dietician who 
is expert must be consulted.  
 If there are any adverse events, actions will be taken if necessary: 
- First aid will be used by administered by a trained person within the 
school. 
- Call University security number (32222) to call 999 if ambulance is 
required. 
 
 
 
 
 
